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Abstract 
NMR spectroscopy is an important tool in chemical analysis and for structural studies in 
various research areas. The subject of this thesis is liquid state NMR spectroscopy for 
structural analysis of small molecules, both regarding method development and structure 
elucidation by NMR spectroscopy. 
HMBC+ is a new pseudo-3D NMR experiment for measurement of long-range homonuclear 
JHH coupling constants in small molecules. Based on two existing experiments, multiplicity 
edited HMBC and HAT HMBC by Benie, Nyberg, and Sørensen, the new HMBC+ 
experiment takes advantage of a π phase difference with respect to n+1JHH between these two
experiments, observed in the 
n
JCH HMBC cross peak. Through a double editing procedure
this enables straightforward determination of both sign and magnitude of 
n+1
JHH, including
for very small coupling constants. Excellent results were obtained for the natural product 
strychnine, and 28 
n+1
JHH coupling constants were determined, of which 10 had not 
previously been measured due to their small sizes. By comparing to calculated coupling 
constants, an RMSD of 0.28 Hz was obtained, all coupling constant signs fit with the 
calculations, and all errors were below 1 Hz, also when comparing the absolute values to 
experimental coupling constants measured by Carter et al. using 1D 
1
H NMR on deuterated
strychnine analogues. Providing an excellent tool for measurement of long-range JHH with 
the extra convenience of labeling the coupling constant information to the 
13
C chemical shift
through the 
n
JCH correlation, this experiment has exciting applications for configurational
assignment of e.g. carbohydrates and for residual dipolar couplings.
Identification of known molecules and discovery of novel molecules are other important 
applications of NMR spectroscopy. Bacteria and fungi produce secondary metabolites for 
signaling and competing against other organisms, and these molecules are important in drug 
discovery due to their inherent biological activities. From a marine Photobacterium (P. 
halotolerans) we isolated the solonamides and the ngercheumicins, two families of cyclic 
depsipeptides capable of attenuating virulence in S. aureus by quorum sensing inhibition 
through the accessory gene regulator agr. This is likely due to their structural similarities 
with the auto-inducing peptides of S. aureus, controlling quorum sensing in bacterial 
populations. A filamentous fungus, A. fijiensis, was also investigated for production of novel 
secondary metabolites, and a new pyranonigrin (E) was isolated and structure elucidated by 
v 
NMR spectroscopy along with JBIR-74 and decumbenone A, two known metabolites 
previously isolated from Aspergillus and Penicillium species. 
Oligosaccharides found in human milk are important for infant nutrition, and a collaborative 
effort of university and industry partners was aimed at establishing methods for production 
of human milk oligosaccharides. Two different bioenzymatic methods for production of 
3’-sialyllactose were investigated, and a screening of trans-fucosidases enabled the NMR 
spectroscopic identification of three pNP-fucosylfucopyranosides as major reaction products.  
vi 
Resumé 
NMR spektroskopi er et af de vigtigste værktøjer til analyse og strukturopklaring af kemiske 
stoffer og bruges inden for mange forskellige forskningsområder. Denne afhandling 
omhandler NMR-spektroskopisk strukturanalyse af små molekyler i vandig eller organisk 
opløsning, både i forhold til metodeudvikling og strukturopklaring vha. NMR spektroskopi. 
HMBC+ er et nyudviklet pseudo-3D NMR eksperiment til måling af 
n+1
JHH homonukleare
koblingskonstanter over 3-4 bindinger i små molekyler, observeret gennem 
n
JCH 
korrelationer, hvor n typisk er 2-3 bindinger. Baseret på to eksisterende NMR eksperimenter, 
editeret HMBC og HAT HMBC af Benie, Nyberg og Sørensen, benytter HMBC+ 
eksperimentet sig af en π faseforskel ifht. n+1JHH mellem editeret HMBC og HAT HMBC. En
dobbelt editeringsprocedure muliggør dermed direkte aflæsning af både fortegn og størrelse 
af de homonukleare koblingskonstanter, så både små og store koblingskonstanter kan måles 
med høj nøjagtighed. Dette vises for naturproduktet stryknin, hvor 28 
n+1
JHH 
koblingskonstanter bestemmes med fortegn, deraf 10 som ikke før er målt. Sammenlignet 
med beregnede koblingskonstanter fås middelværdien af kvadratafvigelsessummen (RMSD) 
til 0,28 Hz, alle fortegn stemmer overens med beregningerne, og alle målte 
koblingskonstanter ligger indenfor 1 Hz af både beregnede og eksperimentelle værdier. De 
målte koblingskonstanter kombineres desuden med 
n
JCH HMBC korrelationer så 
koblingskonstanten forbindes med et tilhørende 
13
C kemisk skift, som gør strukturopklaring
og tilordning af relativ konfiguration lettere i fx kulhydrater, og HMBC+ eksperimentet vil 
kunne bruges til måling af residuale dipolære koblinger, hvorved man derved kan opnå 
yderligere strukturel information. 
Identifikation af kendte kemiske stoffer og opdagelse af nye molekyler er også vigtige 
discipliner indenfor NMR spektroskopi. Bakterier og svampe danner sekundær metabolitter 
til kommunikation med og konkurrence imod andre organismer, og disse molekyler har 
biologiske aktiviteter som er vigtige i udviklingen af nye lægemidler. To familier af cykliske 
depsipeptider blev isoleret fra en marin fotobakterie, P. halotolerans: solonamiderne og 
ngercheumicinerne. Disse peptider kan hæmme virulens-mekanismer i multi-resistente S. 
aureus gennem agr, som i stafylokokker styrer den fælles kommunikation (quorum sensing) 
i bakteriekolonier når tilstrækkeligt høje populationer opnås. Fundet af denne aktivitet i en 
fotobakterie skyldes højst sandsynligt depsipeptidernes strukturelle ligheder med de naturlige 
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signalstoffer (AIP) for agr. Skimmelsvampen A. fijiensis blev ligeledes undersøgt i håb om 
at opdage andre nye sekundære metabolitter, og en ny pyranonigrin (E) blev isoleret og 
strukturopklaret ved brug af NMR spektroskopi, sammen med JBIR-74 og decumbenone A, 
to kendte stoffer tidligere isoleret fra stammer af Apergillus og Penicillium.  
Oligosakkarider i modermælk er vigtige for spædbørns sundhed og velfærd, og et større 
projekt med universitets- og industripartnere havde til mål at finde nye metoder til at 
producere disse vigtige sukkerstoffer. To bioenzymatiske metoder til produktion af 
3’-sialyllaktose blev udviklet, og en undersøgelse af trans-fucosidase enzymer ledte til 
NMR-skeptroskopisk identifikation af tre pNP-fucosylfucopyranosider, som viste sig at være 
de primære oligosakkarider dannet ved reaktionen.  
viii 
Abbreviations 
1D One dimensional 
2D Two dimensional 
3D Three dimensional 
AA Amino acid 
Ac Acetyl  
ACCA Automatic coupling constants analyzer 
ADEQUATE Adequate double quantum transfer experiment 
agr Accessory gene regulator 
AIP Autoinducing peptide 
Ala Alanine 
AP Anti-phase 
AU Automation 
ax Axial 
BBO Broadband observe 
bs broad singlet 
HETSERF Heteronuclear selective refocusing 
CA Community associated (or acquired) 
CD Circular dichroism 
CGMP Caseinoglycomacropeptide 
CLIP Clean in-phase 
CMP Cytidine-5’-monophosphate 
COSY Correlation spectroscopy 
CYA Czapek yeast autolysate 
d Doublet 
DAD Diode array detector 
dd Doublet of doublets 
ddd Doublet of doublets of doublets 
DFT Density functional theory 
DMSO Dimethylsulfoxide 
DNP Dynamic nuclear polarization 
dq Doublet of quartets 
DQ Double quantum 
DQF Double quantum filtered 
dt Doublet of triplets 
DTU Technical University of Denmark 
E.COSY Exclusive correlation spectroscopy 
eq Equatorial 
ESI Electrospray ionization 
E-SPE Explorative solid-phase extraction 
EtOAc Ethyl acetate 
FC Fermi contact  
FDA Food and drug administration 
ix 
FDAA 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide (Marfey’s reagent) 
FID Free induction decay 
FL Fucosyllactose 
FOS Fructooligosaccharides 
Fuc Fucose 
g gradient-selected (e.g. gHSQC) 
Gal Galactose 
GalNAc N-acetylgalactosamine 
Glc Glucose 
GlcNAc N-acetylglucosamine 
GOS Galactooligosaccharides 
H2BC Heteronuclear 2-bond correlation 
HAT Homonuclear J-attenuated 
HECADE  Heteronuclear couplings from aSSCI-domain experiments with E.COSY-type 
cross peaks 
HETLOC Heteronuclear long-range coupling 
hla α-hemolysin (encoding gene) 
HMBC Heteronuclear multiple bond correlation 
HMO Human milk oligosaccharide  
HMQC Heteronuclear multiple quantum correlation 
HPAEC High performance anion exchange chromatography 
HPLC High performance liquid chromatography 
HR High resolution 
HSQC Heteronuclear single quantum coherence 
HSQMBC Heteronuclear single quantum multiple-bond connectivity 
HTS High-throughput screening 
Ile Isoleucine 
INADEQUATE Incredible natural abundance double quantum transition experiment 
INEPT Insensitive nuclei enhanced by polarization transfer 
IP In-phase 
IPAP In-phase/anti-phase 
JM J-modulated 
LC Liquid chromatography 
Leu Leucine 
LNFP-V Lacto-N-fucopentaose V 
LNnFP-V Lacto-N-neofucopentaose V 
LNnT Lacto-N-neotetraose 
LNT Lacto-N-tetraose 
m Multiplet 
MALDI Matrix-assisted laser desorption ionization 
MAX Mixed-mode anion exchange 
MEA Malt extract agar 
MeOH Methanol 
MRI Magnetic resonance imaging 
MRSA Methicillin-resistant S. aureus 
MS Mass spectrometry 
MTPA α-Methoxy-α-trifluoromethylphenylacetic acid 
 x 
 
NeuAc   N-acetylneuraminic acid (IUPAC: 5-acetamido-3,5-dideoxy-D-glycero-α-D-
galacto-non-2-ulopyranosonic acid) 
NMR Nuclear magnetic resonance 
NOE Nuclear Overhauser effect 
NOESY  Nuclear Overhauser effect spectroscopy 
NP Natural product 
NUS Non-uniform sampling 
PAD Pulsed amperometric detector 
P.E. Primitive exclusion 
Phe Phenylalanine 
PHIP Parahydrogen-induced polarization 
pNP p-nitrophenyl or p-nitrophenol 
ppm Parts per million  
PTFE Polytetrafluoroethylene 
QS Quorum sensing 
QSI Quorum sensing inhibitor 
qTOF quadrupole time of flight 
RDC Residual dipolar coupling 
RMSD Root-mean-square deviation 
ROESY  Rotating frame nuclear Overhauser effect spectroscopy 
RP Reverse phase 
S/N Signal-to-noise ratio 
s Singlet 
SAX Strong anion exchange 
SCX Strong cation exchange 
SDU University of Southern Denmark 
Ser Serine 
SJS Selective J-scaled 
SL Sialyllactose 
spa  Staphylococcal Protein A  
SPE Solid-phase extraction 
spp. Species 
t Triplet 
Thr Threonine 
TLC Thin layer chromatography 
TOCSY Total correlation spectroscopy 
UHPLC  Ultra high pressure liquid chromatography 
UV Ultraviolet 
VCD Vibrational circular dichroism 
WP Work package 
XLOC X nucleus for long-range couplings 
YES Yeast extract sucrose 
 
xi 
Publications 
I Mansson, M.; Nielsen, A.; Kjærulff, L.; Gotfredsen, C. H.; Wietz, M.; Ingmer, 
H.; Gram, L.; Larsen, T. O. Inhibition of Virulence Gene Expression in 
Staphylococcus aureus by Novel Depsipeptides from a Marine 
Photobacterium.Mar. Drugs 2011, 9, 2537–2552. 
II Kjaerulff, L.; Nielsen, A.; Mansson, M.; Gram, L.; Larsen, T. O.; Ingmer, H.; 
Gotfredsen, C. H. Identification of four new agr quorum sensing-interfering 
cyclodepsipeptides from a marine Photobacterium. Marine Drugs 2013, 11, 
5051–5062. 
III Holck, J.; Larsen, D. M.; Michalak, M.; Li, H.; Kjærulff, L.; Kirpekar, F.; 
Gotfredsen, C. H.; Forssten, S.; Ouwehand, A. C.; Mikkelsen, J. D.; Meyer, A. 
S. Enzyme catalysed production of sialylated human milk oligosaccharides and 
galactooligosaccharides by Trypanosoma cruzi trans-sialidase. New 
Biotechnology 2014, 31, 156–165. 
IV Michalak, M.; Larsen, D. M.; Jers, C.; Almeida, J. R. M.; Willer, M.; Li, H.; 
Kirpekar, F.; Kjærulff, L.; Gotfredsen, C. H.; Nordvang, R. T.; Meyer, A. S.; 
Mikkelsen, J. D. Biocatalytic production of 3′-sialyllactose by use of a 
modified sialidase with superior trans-sialidase activity. Process Biochemistry 
2014, 49, 265–270. 
V Lezyk, M.; Jers, C.; Kjaerulff, L.; Gotfredsen, C. H.; Mikkelsen, M. D.; 
Mikkelsen, J. D. Novel α-L-fucosidases from a soil metagenome – 
identification and characterization of their hydrolytic and transglycosylation 
abilities. Applied and Environmental Microbiology, 2014, in preparation 
Kjaerulff, L.; Benie, A. J.; Hoeck, C.; Gotfredsen, C. H.; Sørensen, O. W. 
HMBC+, a new NMR experiment for accurate and sign-selective measurement 
of homonuclear long-range coupling constants, in preparation, working title 
xii 
The publications I-V are included in this thesis and can be found in the Appendix, with 
supplementary information when relevant. 
xiii 
Contents 
1 Introduction ......................................................................................................................2 
1.1 70 years of nuclear magnetic resonance ......................................................................2 
2 New NMR experiments ....................................................................................................5 
2.1 Structure and function - stereochemistry and absolute configuration .........................5 
2.2 Residual dipolar couplings ..........................................................................................6 
2.3 Measurement of one-bond heteronuclear coupling constants ...................................10 
2.4 Measurement of long-range coupling constants........................................................11 
2.5 HMBC+, a new NMR experiment for measurement of n+1JHH .................................13 
2.5.1 The editing procedure ........................................................................................17 
2.5.2 Determination of coupling constants .................................................................22 
2.5.3 Application in oligosaccharide analysis.............................................................28 
2.6 Experiments for measurement of 2JCH ......................................................................29 
2.7 Conclusions and perspectives....................................................................................36 
3 Microbial natural products............................................................................................39 
3.1 Drug discovery today ................................................................................................39 
3.2 Sources of natural products .......................................................................................40 
3.3 Analysis of natural products ......................................................................................41 
3.3.1 The supply problem and dereplication ...............................................................41 
3.3.2 NMR spectroscopy of small amounts ................................................................42 
3.3.3 Determination of absolute stereochemistry .......................................................42 
3.4 Natural products from a marine Photobacterium ......................................................46 
3.5 Results and discussion ...............................................................................................46 
3.5.1 Small biologically active peptides from a marine Photobacterium ...................46 
3.5.2 Quorum sensing and autoinducing peptides ......................................................50 
3.5.3 Fungal metabolites from A. fijiensis ..................................................................53 
3.6 Conclusions and perspectives....................................................................................56 
3.7 Experimental .............................................................................................................58 
3.7.1 Fungal extracts ...................................................................................................58 
3.7.2 Fractionation and purification ............................................................................58 
3.7.3 Bioactivity testing ..............................................................................................59 
xiv 
 
3.7.4  LC-MS and NMR analyses ............................................................................... 59 
4  Human milk oligosaccharides ....................................................................................... 61 
4.1  Introduction .............................................................................................................. 61 
4.2  The HMO project ..................................................................................................... 62 
4.3  Biological role of HMOs .......................................................................................... 63 
4.4  Sources of fucose and sialic acid .............................................................................. 64 
4.4.1  Perspectives on the production of HMOs ......................................................... 65 
4.5  Characterization of HMOs ....................................................................................... 66 
4.5.1  HMO analysis by NMR .................................................................................... 67 
4.5.2  NMR structural assignment of HMO molecules............................................... 68 
4.5.3  Purity assessment .............................................................................................. 70 
4.5.4  CGMP as sialic acid donor ............................................................................... 72 
4.5.5  Sialyl-oligosaccharides from trans-sialidases ................................................... 74 
4.5.6  Trans-fucosylations ........................................................................................... 77 
4.5.7  Enzymes in reaction monitoring ....................................................................... 79 
4.6  Conclusions and perspectives ................................................................................... 83 
4.7  Experimentals ........................................................................................................... 85 
4.7.1  Reaction monitoring with CGMP ..................................................................... 85 
4.7.2  Reaction monitoring with 3’-SL ....................................................................... 85 
5  Overall conclusions and perspectives .......................................................................... 86 
6  References ....................................................................................................................... 88 
Appendix A-1 
Paper I A-39 
Paper II A-67 
Paper III A-103 
Paper IV A-119 
Paper V A-127 
 
1 Introduction 
1 
 
 
  
 2 
 
 
1 Introduction 
The subjects within this thesis range from design of new experiments for measurement of 
coupling constants, over discovery of bacterial and fungal natural products, to NMR 
structural studies of human milk oligosaccharides. However, the link connecting all these 
projects is nuclear magnetic resonance (NMR) spectroscopy. This chapter gives a brief 
introduction to NMR spectroscopy and some of the discoveries within the field. 
1.1 70 years of nuclear magnetic resonance 
Much has changed since Purcell and Bloch earned the Nobel Prize in 1952 for their early 
discoveries and developments within nuclear magnetic resonance (NMR) spectroscopy. The 
respective research groups at Massachusetts Institute of Technology and Stanford University 
observed the first NMR spectra of paraffin and water in 1945,
1,2
 and today NMR is one of 
the most important and informative analytical methods of all. NMR is used in many diverse 
areas of research and science; in chemistry, biology, medicine, physics, material science, and 
on the interfaces (Figure 1.1). In these areas NMR has become an important tool to probe 
structure and interactions, including dynamics. Experiments are performed in the liquid, 
solid, and gas phases as well as in biological systems. Magnetic resonance imaging (MRI) is 
a whole world of its own, and in essence one can examine almost any kind of material using 
a powerful magnet and radio waves.  
The first NMR spectrum of water by Bloch et al. had a 
1
H larmor frequency of 7.76 MHz 
with a signal-to-noise ratio (S/N) of about 6.
3,4
 The first spectrometers used a continuous 
wave to sweep the magnetic field, but with the introduction of Fourier transform 
spectroscopy in 1966, NMR spectroscopy took a great leap forward.
5
 With this 
improvement, the NMR spectrum was calculated mathematically by Fourier transforming the 
ringing caused by a single pulse. A few years later Jeener introduced 2D NMR spectroscopy 
which was later published in the form of 2D correlation spectroscopy (COSY) by Aue, 
Bartholdi and Ernst in 1976.
6,7
  
Today, spectrometers operate at up to 1 GHz with ultra-shielded, sub-cooled, 
superconducting magnets and specialized probes for optimum resolution and sensitivity, 
running advanced experiments on sub-mg samples.
8
 During the years a major objective in 
1 Introduction 
3 
 
NMR has been the race for the highest field magnets, as higher field means better S/N ratio 
and higher resolution, e.g. doubling field strength almost triples S/N and doubles sensitivity.
9
 
Nowadays there is a slight shift in the paradigm as we cannot continue increasing the field 
strength much further, and the spiraling cost of cryogens cause spectrometer vendors to look 
in other directions, vide infra. New systems are increasingly built for minimizing cryogen 
refills and pleasing the general costumer rather than pushing frontiers in field strength, 
however current advances in probe design increase spectrometer sensitivity, and e.g. 
cryoprobes enhance S/N fourfold.
10
 
 
Figure 1.1. Some of the different research areas and types of samples analysed by NMR.  
One of the later great achievements in NMR is the use of dynamic nuclear polarization 
(DNP), which is a technique where electron spin-polarization is transferred to nuclear 
polarization in a sample of interest resulting in an extreme gain in sensitivity.
11
 DNP is 
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gaining a lot of interest both in liquid and solid state NMR and particularly for imaging 
purposes and for investigating metabolic pathways in vivo.
12–14
 Unfortunately the 
polarization decays rapidly, and it is therefore not applicable to time consuming experiments 
with the current technology. A related and very promising new technique is zero-field NMR 
– the measurement of NMR spectra without magnets.15 The method uses parahydrogen-
induced polarization (PHIP) and makes a fingerprint of a molecule’s J couplings with no 
chemical shift information. A recent development to increase resolution or decrease 
experiment time is non-uniform sampling (NUS), which is applied to multidimensional 
NMR experiments with great advantage.
16,17
 Here, the idea is to sample the time domain data 
non-uniformly in nD experiments with an experiment time decreasing by 3
n-1
, which can 
alternatively be traded off for increased resolution.
18
  
In NMR spectroscopy today, there are two major groups of research: One group is concerned 
with small molecule NMR in the liquid state, where natural isotopic abundance allows the 
acquisition and interpretation of various nD experiments for structure elucidation and 
investigating molecular interactions. The other group focuses primarily on protein NMR in 
the solid state, usually requiring isotopic labelling and using a variety of other nD 
experiments, most often specifically tailored for proteins. Without doubt NMR has had a 
tremendous impact on many areas of science, and for a technology only about 70 years old 
we can expect to see many more exciting applications and improvements in the future. 
 
The work described in this thesis is concerned with structure elucidation of small molecules 
through the identification of known and unknown molecules in solution, both in pure form 
and in mixtures, but also through the investigation of molecular structure and conformation 
by the use of NMR coupling constants.  
The thesis is divided into three major chapters. Following this introduction, chapter 2 
describes new NMR experiments for measurement of long-range coupling constants in small 
molecules, chapter 3 describes the isolation of new natural products from bacteria and fungi 
with a discussion of their bioactivities (including Paper I and II), and chapter 4 covers NMR 
spectroscopic studies of human milk oligosaccharides (including Paper III, IV, and V). 
2 New NMR experiments 
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2 New NMR experiments  
This chapter is related to the development of new NMR experiments for measurement of 
coupling constants with the aim of creating new tools for structural studies by NMR 
spectroscopy. An introduction to methods for studying absolute and relative configuration is 
given, along with a brief description of the background for the experimental work and 
related applications. Finally, the new NMR experiments for measurement of coupling 
constants are described and discussed, with emphasis on the applications rather than the 
underlying theory. A publication related to the work described in this chapter is in 
preparation, but not included. For technical details, assignments, program codes, and more, 
see the Appendix. 
2.1 Structure and function - stereochemistry and absolute configuration 
Nature is chiral. Like the right and left hands are different from each other and cannot be 
superimposed, nature uses right- and left-handedness in many aspects. The world is three 
dimensional and so are our bodies and the molecules which make it function. This chirality is 
reflected in the configuration and conformation of molecules. E.g. proteins and 
carbohydrates require specific configurations to be recognized in the body, and especially for 
proteins conformation is crucial. If a protein is folded incorrectly the biological function 
disappears. In the structure elucidation of new molecules it is also very important to find the 
absolute structure – to know the configuration of all stereocenters in the molecule. 
In 1951 Bijvoet et al. solved the absolute configuration of (+)-tartrate as (2R,3R) by the use 
of X-ray crystallography.
19
 This was the first time chirality was linked to molecular 
structure, and X-ray crystallography remains superior for elucidating absolute configuration 
in crystalline materials. However, the method requires a well-defined crystal lattice and it 
can be very difficult, sometimes impossible, to obtain a crystal of sufficient quality. Absolute 
configuration can be measured by other methods, but they all require a basis for comparison, 
usually from previous measurements and/or other methods of analysis. These methods 
include optical rotation and circular dichroism (CD).
20
 Chiral molecules interact with 
polarized light, and measurement of a solution’s optical activity is a measure of its ability to 
rotate plane polarized light of a specific wavelength. In CD, the light (or more correctly 
electromagnetic radiation) is circularly polarized, and the difference in absorption of right 
 6 
 
and left polarized light as a function of wavelength yields a CD spectrum. However these 
methods require prior knowledge from analogues or similar scaffolds to yield proof of a 
certain configuration. Novel compounds with several stereocenters are not easily analysed by 
these methods and meso-compounds, although containing several stereocenters, are optically 
inactive. Vibrational CD (VCD) uses infrared radiation and enables determination of 
absolute configuration by comparison to calculated spectra, as enantiomers will have exact 
opposite VCD spectra.
21,22
 
Chemical methods with chiral derivatizing agents have been widely used to determine 
absolute configuration for certain types of molecules. For example secondary alcohols and 
amines can be derivatized to form Mosher’s esters which are subsequently analysed by NMR 
spectroscopy,
23
 and the absolute configuration in peptides and alkaloids can be determined 
using Marfey’s method.24 In natural products chemistry, total synthesis is also used to prove 
absolute structure, although it is a slow and costly method in most instances. 
NMR spectroscopy also offers more direct ways to examine stereochemistry. Chiral 
Solvating agents create a diastereomeric environment in enantiomers and thus results in 
changes in the chemical shifts.
25
 But like the optical methods there is no clear correlation 
between a spectrum and the absolute configuration of a molecule, and thus the method has 
little use without something to compare to. More widespread ways to use NMR spectroscopy 
for obtaining stereochemical and conformational relationships is the use of scalar (J) 
coupling constants and nuclear Overhauser effect (NOE) spectroscopy. The direct 
relationship between dihedral angles and J coupling constants
26,27
 together with the distance 
information from NOEs
28
 have long been important tools to obtain structural information 
from NMR spectroscopy, however NMR methods usually only yield relative configuration 
rather than absolute structures. During the last 20 years a third method has gained increasing 
interest, particularly in combination with the J couplings and NOEs: Residual dipolar 
couplings (RDC).  
2.2 Residual dipolar couplings 
In 1963 Saupe and Englert were the first to observe dipolar couplings when they acquired 
“high resolution” 1H NMR spectra of a small molecule in liquid crystals.29 One year later 
Saupe had established the theoretical foundations
30
 but it should take many years before the 
NMR community realized the full potential of these discoveries. Dipolar couplings have long 
been known as a nuisance from solid state NMR, but it took 30 years before Tolman and 
Prestegard realized that RDCs could be used together with long-range NOEs for the study of 
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field-oriented proteins in the liquid state.
31
 Two years later Tjandra and Bax had shown how 
RDCs could be controlled and used in structure calculations of proteins in aqueous 
solution
32,33
 and since then RDCs have gained increasing interest for structural studies of 
proteins and small molecules in solution. 
Dipolar couplings are observed in the liquid state upon introduction of anisotropy by an 
alignment medium, as opposed to the conventional liquid state NMR spectra acquired in 
isotropic solution. Dipolar couplings as known from solid state NMR are in the order of 20 
kHz, however observing coupling constants of this magnitude is not desirable and the dipolar 
couplings are conveniently scaled with the degree of alignment, explaining the term 
“residual”.34,35 Partial alignment in the order of 1‰ is said to be optimal, and with rapid 
averaging between aligned and unaligned molecules the RDCs in a weakly aligned sample 
are usually in the order of ±0-20 Hz.
36
 The dipolar coupling D is observed together with the 
scalar coupling as the total coupling constant T, which is the sum of J and D. 
T = J + D    (Eq. 2.1) 
There is however some researchers who instead define T as J + 2D due to conventions from 
solid state NMR.
37–39
 Most research groups as well as the software PALES for structure 
refinement uses J + D.
34,36,40–44
 If D is viewed in a manner similar to J, it makes most sense 
to use the definition in Eq. 2.1 with D as the contribution to the line splitting, and as long as 
it is used consistently, no errors will result from either. 
Residual dipolar couplings result from dipole-dipole interactions through space and are thus 
related to NOEs via the nuclear Overhauser effect.
45,46
 The mathematical expression for D 
between two spins I and S is 
2
1cos3
π)2(
2
3
IS
3
0SI
IS



r
h
D  (Eq. 2.2) 
Where γ is the gyromagnetic ratio for the individual nuclei, μ0 is the vacuum permeability, h 
is Planck’s constant, r
IS
 is the internuclear distance, and θ is the angle between the 
interatomic vector and the magnetic field, B0 (Figure 2.2).
37
 The brackets around the right 
hand part of the equation denote the averaging of observed molecules as they tumble in 
solution. As seen from Eq. 2.2, the RDC between two spins varies solely with internuclear 
distance and orientation.  
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Figure 2.2. Two-dimensional vector representation of the angle θ between the B0 field and the internuclear vector 
between spins I and S. 
Whereas the NOE depends on internuclear distance by a factor of r
-6
, the RDC is not only 
longer ranging, by r
-3
, but yields valuable orientational information. The angular relationship 
makes it possible to relate configurational relationships and determine conformations for 
mainly rigid structures. Whereas X-ray diffraction is limited to the crystalline state, RDCs 
opens up the possibility to study configuration and conformation in the liquid state and take 
on a more dynamic approach with e.g. protein-drug interactions. About a decade after the 
paper by Tolman and Prestegard
31
 researchers began to see the potential of RDCs in relation 
to small molecules.
47–49
 A search in SciFinder shows that the number of publications per year 
on residual dipolar couplings (both in relation to proteins and small molecules) have been 
more or less constant for the last decade with a slight decline after it peaked in 2004 (Figure 
2.3). Today there are more than 2,500 publications on the subject of RDCs.  
The first alignment media were for biomolecules and therefore these media were mostly 
compatible with aqueous samples. Today’s alignment media for small molecules are 
conveniently compatible with organic solvents such as dimethylsulfoxide (DMSO) or 
chloroform,
35
 and the predominant alignment media for small molecules are strain-induced 
polymers and liquid crystals. 
RDCs generally yield only relative stereochemical information, which is a considerable 
disadvantage when it comes to small molecules. It is debated whether the use of chiral 
alignment media makes it possible to determine absolute configuration, and a few papers 
describe initial attempts.
50–53
 It will however be difficult to find one chiral alignment medium 
suitable for a wide range of samples, and understanding the specific interactions involved 
will be even more difficult. Therefore enantiomeric discrimination in aligned samples is not 
yet attainable as a general method,
54
 but the possibility to elucidate stereochemical 
2 New NMR experiments 
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relationships in rigid molecules over larger distances than NOEs nevertheless makes dipolar 
couplings very interesting, and in rigid molecules with one known stereocenter the relative 
structural relationships can be determined more reliably with RDCs than by using J coupling 
and NOE analysis alone.
55,56
 
 
 
Figure 2.3. Stick plots of SciFinder hits on “Residual dipolar coupling” as entered and the concept (top) and a 
cumulative plot of the hits on the concept (bottom). This search covers both proteins and small molecules. “The 
concept” includes the entered term, synonymous terms and similar terms when searching within the records.  
RDCs are used in calculations to either confirm a given structure or calculate one that fits 
restraints from the experimental data. Restrained molecular dynamics are used to simulate a 
structure consistent with the data available, e.g. J couplings, NOEs and RDCs. A simple 
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example of how RDCs can be used is for the discrimination of axial and equatorial bonds in 
six-membered rings (incl. carbohydrates) by 
1
DCH couplings, as bonds pointing in the same 
direction will display one-bond RDCs of the same magnitude.
38,57
 Analysis of more 
complicated molecules requires the construction of an alignment tensor; a symmetric 3×3 
matrix with five independent parameters, which basically describes the molecule’s 
orientation in relation to the magnetic field.
58
 Specific software for use of RDCs in 
calculations exists, e.g. PALES
40,59
 and REDCAT
60
 primarily designed for macromolecular 
applications, and MSpin-RDC
61
 for small molecules. One of the limitations of RDCs for 
small molecule structure calculations is the need for minimum five RDCs in order to create 
the local alignment tensor, and additional RDCs are used to validate it.
62
 Each flexible 
element in a structure requires a minimum of five non-parallel RDCs
63
 and therefore a 
calculation quickly becomes complicated for molecules with high degrees of torsional 
freedom. In these cases the structural ensemble cannot be embodied by just one structure, 
and as there is only one set of NMR data for each molecule, the output is always an average 
solution structure.
64
 
2.3 Measurement of one-bond heteronuclear coupling constants 
The most commonly used RDCs are one-bond HSQC-type 
1
DCH couplings. Unlike for long-
range RDCs, there is only one 
1
DCH for each proton, and in some cases it is not possible to 
obtain five independent RDCs to create the alignment tensor, making it necessary to 
calculate the missing information by extrapolation.
62
 The one-bond heteronuclear RDC 
(
1
DCH) is a popular choice for several reasons. The data interpretation and setup of the 
experiment is straightforward for anyone acquainted with the HSQC experiment and a 
typical 
1
JCH coupling constant is about 145 Hz and always positive in sign.
38
 This is 
convenient as the RDC creates an additional splitting of the J coupling upon alignment, and 
with a relatively small degree of alignment (D << J) it is straightforward to estimate both 
magnitude and sign of 
1
DCH. A range of HSQC-type experiments have been designed over 
the years for the purpose of measuring 
1
JCH and 
1
DCH. The simplest version is the t2-coupled 
HSQC, where 
1
JCH/
1
TCH couplings are determined in the direct dimension, but it suffers from 
distorted peak shapes and interferences from long-range homonuclear couplings, which can 
make accurate measurement difficult.
42,48
 The t1-coupled HSQC has interferences from long-
range heteronuclear couplings and it requires many t1-increments and thus longer acquisition 
time to afford accurate measurement of the couplings.
17
 Several other HSQC/HMQC-type 
experiments have been developed for measuring one-bond J/D coupling constants.
42,48,65–68
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2.4 Measurement of long-range coupling constants 
It is highly desirable to supplement the 
1
DCH with homo- and heteronuclear long-range RDCs 
to extend the number of available dipolar couplings and thereby improve the structural 
determination. The long-range J coupling constants are however smaller in magnitude 
compared to 
1
JCH and they may be negative, although many of the experiments for 
measurement of long-range couplings are not sign selective, which complicates the structural 
analysis. These small J coupling constants are difficult to measure accurately, and opposed 
to the large 
1
JCH, an error of a few Hz can have great impact on the long-range coupling and 
its interpretation. Any experiment for measurement of J couplings can be used to measure 
RDCs, and therefore the term “coupling constant” refers to both J and residual dipolar 
couplings. If J is however not determined sign sensitively, the determination of D becomes 
very difficult due to the many possible combinations to give T. 
Basically there are currently two ways to obtain long-range 
n
JCH couplings: Either by 
13
C-
edited TOCSY correlation-type experiments or by long-range 
1
H-
13
C correlations in HMBC-
type experiments. The key to measuring long-range coupling constants (both J and RDCs) is 
to minimize spectral overlap and resonance cancellation, which is attempted in different 
ways. Most often the coupling constant is measured as a line-splitting between the α- and β-
spin states which can be in-phase (IP), anti-phase (AP) or using both to edit the multiplet 
components into individual subspectra (IPAP) (Figure 2.4).
69,70
  
 
Figure 2.4. Principle of IPAP-based experiments, where addition and subtraction of IP and AP data yields separate α 
(top) and β (bottom) spin state components. The two lines in the stick plots are separated by J or T. Modified from 71. 
For analysis of small coupling constants an IP cross peak often yields an underestimated 
coupling constant while the AP cross peak has a tendency to make the coupling constant 
seem larger due to cancellation of resonances in the cross peak center (Figure 2.5). These 
methods are therefore best suited in combination with fitting procedures which complicates 
data analysis.
71
 The IPAP separates the individual cross peak components and overlay of the 
spectra affords easy and accurate data interpretation, and is more suitable for measurement of 
small (< 2-3 Hz) coupling constants (Figure 2.4).Another general method is J-resolved 
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spectroscopy, where the desired (in this case long-range) coupling constants are developed 
independent of the heteronuclear chemical shift, yielding a splitting of J in the indirect 
dimension (F1) (Figure 2.5). This has the inherent drawback of long experiment time as it 
requires many t1 increments for sufficient resolution. Several experiments for long-range 
coupling constants build on the exclusive correlation spectroscopy (E.COSY) principle, 
where passive JHH coupling constants are suppressed to in stead displace the active coupling 
pattern in the respective dimensions in the size of the passive coupling constants.
72–75
 This 
allows accurate measurement of small coupling constants, as long as at least one of the 
passive coupling constants is large enough so the cross peak fine structure is resolved. All 
experiments for sign-selective measurement of JHH have so far been based on this principle, 
and the XLOC (X-nucleus for long-range couplings) experiment
76–79
 for measurement of 
1
JXH and 
n+1
JHH is very robust and yields valuable information.
38,80
  
 
Figure 2.5. Simple cross peak patterns for IP, AP, IPAP, J-resolved and E.COSY type experiments. Blue is positive 
resonance intensity and grey is negative. Modified from 71. 
The E.COSY-type multiplet pattern enables the measurement of two coupling constants from 
one cross peak as well as obtaining the relative sign of the coupling constants from the 
direction of the displacement vector of the cross peaks, and for the experiments where 
1
JCH 
or 
1
JNH are involved, the long-range coupling constants are thus measured sign-selectively as 
the signs of these coupling constants are always positive or negative, respectively.
38
 These 
experiments include the P.E.HSQC (primitive exclusion HSQC)
66
 yielding 
1
JCH and 
2
JHH, as 
well as XLOC for measurement of 
1
JXH and 
n+1
JHH (mentioned above) and HETLOC 
(heteronuclear long-range couplings)
81
 for 
1
JCH and 
n
JCH. The HETLOC experiment was the 
first experiment for sign-sensitive measurement of long-range heteronuclear coupling 
constants, however due to a TOCSY (total correlation spectroscopy) coherence transfer, no 
correlations to or across quaternary carbons or heteroatoms are observed and resonances may 
disappear when JHH vanishes. A modification of the HETLOC experiment is called 
HECADE.
82
 This reduces resonance overlap in F1, but the slightly longer pulse sequence 
2 New NMR experiments 
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also results in reduced sensitivity.
83
 In 1993 Zhu et al. developed a J-quantitative experiment 
to extract coupling constants from the cross peak intensities.
84,85
 The literature reveals a wide 
range of HMBC-type experiments which may allow the determination of coupling constants 
to and across quaternary carbon atoms.
71,83,86
 However they all seem to have shortcomings of 
different kinds: Many of them are not sign-selective, some have long sequences and 
consequently low sensitivity and some have very complex crosspeaks or antiphase 
peakshapes that require peak-fitting procedures for extraction of the coupling constants. In 
any case, the use of experiments for measurement of long-range RDCs is limited and there is 
a demand for better experiments developed for this purpose, especially experiments yielding 
correlations to quaternary carbons.
87
 Table 2.1 provides a rough overview of some of the 
many 2D NMR experiments for measurement of 
n
JCH and other long-range coupling 
constants in small molecules.  
Table 2.1. Overview of some of the most important NMR experiments for measurement of long-range homo- and 
heteronuclear J coupling constants (and RDCs). Cq: quaternary carbon atoms. Inspired by 
71. 
Coupling 
constants* 
Experiment 
name/type 
Principle for coupling constant 
determination, with comments References 
1
JCH, 
n
JHH
 
XLOC E.COSY 76–78 
1
JCH, 
n
JCH
 
HETLOC E.COSY 81,88 
n
JCH, 
n
JHH HECADE E.COSY. Can measure 
n
JCH to Cq 82,89 
1
JCH, 
n
JCH, 
n+1
JHH
 
C-HETSERF E.COSY. Complicated cross peaks 
53,90 
2
JCH, 
3
JCH
 
SJS-HSQC E.COSY 91 
1
JCH, 
n
JCH, 
n+1
JHH
 
P.E.HSQMBC E.COSY 
92 
n
JCC
 
JM-ADEQUATE IP, read in F1 93 
*For experiments where determination of more than one coupling is possible, F1 is mentioned before F2. 
n
JCH 
Phase sensitive 
HMBC AP (fitting needed) 
94–98 
n
JCH
 
HSQC-TOCSY IP or IPAP. No 
n
JCH to Cq 99–104 
n
JCH
 
J-HMBC  J-resolved 78,86,105–110 
n
JCH HSQMBC 
IP, AP (fitting needed),  IPAP, J-
resolved or E.COSY 
92,111–122 
n
JCH
 
HSQMBC-
COSY/TOCSY 
IPAP. Sign-sensitive. Can measure 
n
JCH to Cq 
123,124 
2.5 HMBC+, a new NMR experiment for measurement of n+1JHH 
A new NMR experiment was developed for measurement of long-range homonuclear 
coupling constants. It is based on two existing HMBC-type experiments from the Carlsberg 
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Laboratory (Valby, Denmark), the multiplicity-edited HMBC and the homonuclear J 
attenuated (HAT) HMBC by Benie, Nyberg and Sørensen.
125–127
 The pulse sequences for the 
two experiments are shown in Figure 2.6 and Figure 2.7, respectively.  
 
Figure 2.6. Multiplicity edited HMBC pulse sequence with a third-order low-pass J filter. Filled and open bars refer 
to π/2 and π pulses, respectively. The dashed open boxes represent 13C decoupling. τ = (2 1JCH)
-1, δ corresponds to a 
gradient delay, ε = 2 t1/2,min+t(πH), ε’ = ε + t(πC), τ1 = ½[
1Jmin + 0.07 (
1Jmax - 
1Jmin)]
-1, τ2 = (
1Jmax + 
1Jmin)
-1, τ3 = ½[
1Jmax - 
0.07 (1Jmax - 
1Jmin)]
-1. φ1 = {x, -x, -x, x}, φ2 = {x, x, 4(-x), x, x}, φ3 = {4(x), 4(y), 4(-x), 4(-y)}. Δ = (2 
nJCH)
-1 is the delay 
for evolution of long-range couplings.   
 
a) Improved edited HMBC standard 
 
 
 
 
 
 
 
b) Improved edited HMBC - 
 
 
 
 
 
 
 
c) Improved edited HMBC + 
 
 
 
 
 
 
 
 
φ3 φ1 φ2 
φ3 φ1 φ2 
x 
x 
x 
φ2 φ3 φ1 
τ1 τ2 τ3 
+7 
-2 -1 -4 
-4G -3G/-5G 
H 
C 
Gz 
δ 
x 
H 
C 
Gz 
δ 
x 
τ1 τ2 τ3 
+7 
-2 -1 -4 
+5G/+3G 
-4G -5G/-3G 
+4G 
H 
C 
Gz 
x 
τ1 τ2 τ3 
+7 
-2 -1 -4 
+3G/+5G +4G 
-3G 
+5G 
2
'

2
'



22

2
t1
2
t1
2
'

2
'

2
t1
2
t1
'
2
'


2
t1
2
t1' 
2 New NMR experiments 
15 
 
 
Figure 2.7. HAT HMBC pulse sequence with a third-order low-pass J filter. Filled and open bars refer to π/2 and π 
pulses, respectively. τ = (2 1JCH)
-1, δ corresponds to a gradient delay, ε = 2 t1/2,min+t(πH), ε’ = ε + t(πC), τ1 = ½[
1Jmin + 
0.07 (1Jmax - 
1Jmin)]
-1, τ2 = (
1Jmax + 
1Jmin)
-1, τ3 = ½[
1Jmax - 0.07 (
1Jmax - 
1Jmin)]
-1. φ1 = {x, -x, -x, x}, φ2 = {x, x, 4(-x), x, x}, 
φ3 = {4(x), 4(y), 4(-x), 4(-y)}. Δ = (2 
nJCH)
-1 is the delay for evolution of long-range couplings.   
One of the differences between the two experiments is a π phase difference in the multiplet 
structure with respect to 
n+1
JHH.
127
 The idea of the new HMBC+ experiment is to utilize this 
difference by adding and subtracting the multiplicity-edited subspectra from the HMBC and 
the HAT HMBC and thus separate the multiplet structure into different subspectra to afford 
accurate measurement of J and D. This principle is illustrated in Figure 2.8, which shows the 
multiplet structures for the multiplicity-edited HMBC and the HAT HMBC (top left corner). 
Upon addition and subtraction of the data, the multiplet is split in two, so that (in this case) 
the addition spectrum shows the left-hand JCH splitting and the subtracted spectrum shows 
the right-hand side. This is processed as magnitude data and when the add and subtract 
spectra are overlaid (right-hand side of Figure 2.8) both homo- and heteronuclear long-range 
couplings can in theory be extracted. As a result of the editing, the JHH couplings can be 
determined very accurately, but for the heteronuclear coupling, in practice only large 
n
JCH are 
obtainable due to an IP coupling pattern (Figure 2.9). The individual multiplet structures in 
the original spectra would often become fused when the cross peak fine structures are IP and 
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in close proximity, and these experiments were not suitable for measurement of small 
coupling constants. But because of the π phase difference with respect to n+1JHH, this 
coupling constant is antiphase in the HAT HMBC, compared to the edited HMBC, as drawn 
in Figure 2.8 for a three-spin system of one proton observing a CH group.  
 
Figure 2.8. Schematic representation of structure and phases of a three-spin CH…H multiplet in HMBC, HAT 
HMBC and HMBC+. Addition and subtraction (left side) of the HMBC and HAT subspectra yields complimentary 
phases that when combined (right side) will afford accurate measurement of scalar and dipolar couplings in 
HMBC+. 
The figure assumes that |JCH| > |JHH|, however these long-range couplings are comparable in 
size and therefore the opposite situation also occurs. In cases where JHH is larger than JCH the 
splitting from JCH will often not be observed as the two lines become one for small coupling 
constants (they are IP in HMBC+), but the JHH is still measured accurately by the IPAP 
principle. Stick plot representations of theoretical multiplicity patterns for other spin systems 
in the case of |JCH| > |JHH| are shown in Figure 2.9. Other alternatives can be analysed by 
drawing tree diagrams of the coupling patterns. The figure is read one row at a time from left 
to right, showing first the edited HMBC and HAT HMBC theoretical cross peak pattern 
2 New NMR experiments 
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(stick plots, in blue), then the add (+) and subtract (-) subspectra created by linear 
combination of the first two spectra. Here it can be seen that 
n
JCH gives rise to a splitting in 
the add/subtract subspectra. The last column represents the overlaid add/subtract spectra in 
magnitude mode, where it is possible to extract 
n+1
JHH as the distance between individual 
lines in the two subspectra. Especially for diastereotopic protons, the coupling constant 
determination can be difficult when the two 
n+1
JHH are similar in size, as the two middle lines 
may not be separated. In this situation, the coupling constants cannot directly be determined 
accurately (fourth row, Figure 2.9). 
 
 
Figure 2.9. Stick plot examples of multiplet structures in HMBC (HMBCED), HAT HMBC and HMBC+ when |JCH| 
> |JHH|. Green represents the add subspectrum, while black represents the subtract subspectrum. By calculating the 
absolute value spectra (magnitude) and overlaying the add and subtract spectra, long-range homonuclear couplings 
can be extracted. Direct extraction of n+1JHH (and D) for diastereotopic methylene protons (second last row) may be 
difficult in HMBC+ when the JHH coupling constants are of similar size. 
2.5.1 The editing procedure 
The add and subtract subspectra are created by linear combinations of the datasets from the 
HMBC and the HAT HMBC. This procedure is in principle similar to the multiplicity editing 
procedure used in the original experiments where updown- and updown+ (the sign indicates 
if the 
13C π pulse is before or after the 1H π pulse) spectra are combined to produce 
subspectra according to even/uneven number of protons.
125,128
 To minimize spectral overlap 
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the HMBC+ is created from the multiplicity-edited spectra, thus creating four new 
subspectra from the four initial spectra (Figure 2.10).  
  
  
Figure 2.10. Overview of the eight spectra resulting from HMBC+. HMBC and HAT HMBC each result in two 
subspectra due to the multiplicity editing (expnos 1-4). These are further combined to give add and subtract (sub) 
subspectra (expnos 5-8). 
For this kind of editing to be successful the pulse sequences must undergo a few changes. In 
order to obtain comparable resonance intensity and correct multiplet structures, four 
conditions must be met: 
1. The 13C chemical shift must be refocused for t1,min between the two 
13C π/2 pulses 
2. Any sample heating must be similar for all sequences 
3. The sequences must have the same evolution time for 1H chemical shifts as well as JHH 
and JCH 
4. The sequences must have the same total length and must also have the same timing 
between the initial 
1H π/2 pulse and acquisition of the FID. 
Fulfilling these requirements can only be done by taking them all into account at the same 
time, as the solution to one condition is strongly interlinked with the rest. The first condition 
(1) is already met in the original experiments due to the ε delay in the sequences, which 
ensures that the 
13C π pulse for t1,min is placed exactly between the two 
13C π/2 pulses. 
Regarding the timing between the 
1H π/2 pulse and the end of the sequence (4), there is a 
difference of τ, which is what generates the π phase difference between the experiments. 
Decoupling periods can cause sample heating (2), and therefore the decoupling of length τ + 
ε’/2 in the beginning of the HMBC should be added to the HAT sequence as well. HAT 
HMBC is τ shorter than the multiplicity edited HMBC (4), and this must therefore be added 
to HAT HMBC some time after the first 
1
H pulse (4). Prior to this pulse the HMBC +/- 
HMBC HAT HMBC
C/CH2        CH/CH3
Multiplicity 
editing
HMBC+
C/CH2        CH/CH3
Add C/CH2 Sub C/CH2 Add CH/CH3 Sub CH/CH3
1 2 3 4
5 6 7 8
2 New NMR experiments 
19 
 
sequences have the τ + ε’/2 long decoupling period, and therefore this delay must be added to 
the HAT HMBC as well, this time in front of the 
1H π/2 pulse (3 and 4). Ensuring the exact 
same pulse sequence lengths also includes counting and adjusting for all the small 
correctional delays which ensure that the hardware has time to switch between e.g. gradients 
and pulses. The resulting pulse sequences for the HMBC+ experiment are shown in Figure 
2.11. The HMBC sequences are unchanged, whereas the HAT HMBC +/- have undergone 
some changes compared to the original sequences.  
The decoupling period of τ + ε’/2 is inserted around the 1H π/2 pulse. After the first pulse a 
decoupling period of τ/2 is used, as we need to add τ/2 in both ends of the HAT experiment 
to lengthen it by τ, and 13C decoupling in the first τ/2 period ensures that evolution of JCH is 
not affected. Another τ/2 period is added in the end of the HAT sequences, ensuring that JHH 
is refocused and the total time for all the sequences are exactly the same. The HMBC 
experiment contains three pulse sequences, the standard, minus (-) and plus (+). This was an 
implementation by Benie and Sørensen to enhance the editing procedure from the first 
multiplicity-edited HMBC experiment.
125,126
 Processing of these complex datasets is usually 
done with a program containing a list of user defined processing commands. In Topspin 
(Bruker Biospin) they are called AU programs and may contain standard commands and C 
statements, functions and variables.
129
  
In the improved multiplicity edited HMBC by Benie and Sørensen the updown+/- sequences 
(Figure 2.6 b and c) were acquired in an interleaved fashion with the standard HMBC 
experiment (Figure 2.6 a).
126
 The editing procedure was achieved by linear combination 
corresponding to 2*standard ± [(updown-) + (updown+)]. In the case of five sequences and 
four (directly) resulting spectra in HMBC+, the solution was to ensure that the data is 
recorded in an interleaved fashion where the HMBC updown+/- are cycled half as much as 
the HMBC standard sequence and the HAT +/- sequences. In practice this was done by 
acquiring the experiment as a pseudo-3D experiment with four planes from the four pulse 
sequences recorded in the experiment, where plane #1 is HMBC std., plane #2 is interleaved 
HMBC+ and HMBC-, plane #3 is HAT-, and plane #4 is HAT+. This distribution ensures 
that the five sequences are distributed into four slices, two for HMBC and two for HAT 
HMBC.  
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a) Improved edited HMBC standard 
 
 
 
 
 
 
 
 
 
b) Improved edited HMBC - 
 
 
 
 
 
 
 
 
 
c) Improved edited HMBC + 
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Figure 2.11. HMBC+ pulse sequence containing the modified sequences from the multiplicity-edited HMBC and the 
HAT HMBC (includes previous page). The experiment uses a third-order low-pass J filter. Filled and open bars 
refer to π/2 and π pulses, respectively. The dashed open boxes represent 13C decoupling.  τ = (2 1JCH)
-1, δ corresponds 
to a gradient delay, ε = 2 t1/2,min+t(πH), ε’ = ε + t(πC), τ1 = ½[
1Jmin + 0.07 (
1Jmax - 
1Jmin)]
-1, τ2 = (
1Jmax + 
1Jmin)
-1, τ3 = 
½[1Jmax - 0.07 (
1Jmax - 
1Jmin)]
-1. φ1 = {x, -x, -x, x}, φ2 = {x, x, 4(-x), x, x}, φ3 = {4(x), 4(y), 4(-x), 4(-y)}. Δ = (2 
nJCH)
-1 is the 
delay for evolution of long-range couplings.  See the corresponding pulse program in the Appendix. 
Instead of running all five sequences interleaved in 2D and then adjusting for the resonance 
intensity by dividing the HMBC+/- by 2, this both saves experiment time and minimizes 
artefacts. A small correctional factor of 1.05 (also used in the edited HMBC) is however 
needed as the resonance intensity of the standard HMBC is slightly higher than for the 
HMBC+/- due to the value of |cos(ϕ)| being slightly smaller for the +/- experiments, because 
the angle ϕ is close to π, but slightly smaller or larger for HMBC+/-.126 The pseudo-3D 
scheme furthermore enables easy processing of each of the four slices. To create HMBC+ 
the AU program is however necessary. One of the main challenges for the AU program was 
caused by the fact that the HAT HMBC subspectrum #2 required a π/2 phase correction in 
F1 to give absorption lineshapes. This meant that just adding and subtracting the raw HMBC 
and HAT HMBC data would be done with a phase mismatch and therefore not give the 
d) HAT HMBC - 
 
 
 
 
 
 
 
 
 
e) HAT HMBC + 
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correct result. Therefore a π/2 phase correction in t1 of HAT prior to Fourier transformation 
was required to add and subtract the data properly. This was done by taking advantage of the 
fact that both real and imaginary data are recorded, and while the real data is in absorption 
the imaginary data is in dispersion, due to a π/2 phase difference caused by the two detectors 
being placed orthogonally in the probe. This is what conventionally allows phase corrections 
on the frequency domain data, and by swapping the real and imaginary data as well as 
changing the sign of the new imaginary data as described by Palmer III et al.,
130
 the desired 
phase shift was achieved in the time domain data of the mentioned subspectrum, allowing 
the editing procedure to run without phase mismatch (for pulse program and AU program, 
see the Appendix). 
2.5.2 Determination of coupling constants  
Then linear combination of the data as presented in Figure 2.10 yields the HMBC+ 
subspectra which are processed by the AU program to give the subspectra in magnitude 
mode in the F2-dimension. Overlays of the add and subtract spectra enables determination of 
n+1
JHH from the displacement of the two spectra as it was illustrated in Figure 2.9. Because 
the coupling constants are determined using this editing procedure, there is no lower 
boundary for the size of the JHH coupling constant to be determined. In practice the coupling 
constant is measured by taking slices through the spectral rows (F2) in a multiplet and 
displacing the subtract spectrum onto the add subspectrum. In this order the sign of the 
coupling is measured correctly.  
The small organic molecule vinyl acetate was used to test the experiment (Figure 2.12), as it 
is a simple molecule with the large 
3
JHH couplings of the vinyl group appearing in both the 
even (C/CH2) and uneven (CH/CH3) subspectra, and in addition the 
2
JCH couplings are 
known.
131,132
 Four HMBC+ cross peaks of vinyl acetate are shown in Figure 2.12 along with 
the respective 1D slices. The blue lines correspond to the add subspectrum and the red lines 
are the subtract subspectrum (cf. Figure 2.10). The subtract spectra have been shifted slightly 
upfield in F1 for purely visual reasons, due to the complicated coupling pattern of the H3-C4 
cross peak. The NMR assignment of vinyl acetate is shown in Table 2.2, along with the 
coupling constants measured from the HMBC+ crosspeaks, which are in excellent agreement 
with the coupling constants from the 
1
H 1D spectrum (Figure 2.12).  
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Figure 2.12. Structure of vinyl acetate with atom numbering in grey (top) and cross peaks with F1-slices from 
HMBC+ on vinyl acetate (DMSO-d6, 400 MHz, 16 scans, 4096 data points, 128 increments, zero filled to 1024 in F1). 
Each subspectrum was scaled separately and the subtract subspectrum (red) was shifted upfield to make it easier to 
see the individual components. 
Table 2.2. NMR assignment table for vinyl acetate, including coupling constants measured with HMBC+, in a 
coupled 13C spectrum (400 MHz, 0.185 Hz FID resolution) and by Crecely et al. in 1971.131  
# 
1
H chemical shift 
[ppm], JHH 
13
C-chemical 
shift [ppm] 
3
JHH [Hz] 
HMBC+ 
2
JCH [Hz] 
HMBC+
 
2
JCH [Hz] 
coupl. 
13
C 
2
JCH [Hz] 
Ref.
131
 
1 2.11, 3, s 20.4 - 6.8 7.0 - 
2 - 167.8 - - - - 
3 7.19, 1, dd, 14.0, 6.3 141.2 +14.04, +6.28 9.4 9.6 +9.65 
4a 4.63, 1, dd, 6.3, 1.5 97.9 +6.25 6.8 7.7 -7.9 
4b 4.88, 1, dd, 14.0, 1.5 97.9 +14.06 7.4 7.7 +7.6 
 
The measurement of 
n+1
JHH couplings for spin systems with one active JHH is 
straightforward, as the coupling constant is determined from the splitting in F2 between the 
components of the add and subtract subspectra (mid section of Figure 2.12). With no active 
JHH couplings as seen for quaternary carbons, there is no HMBC+ editing and the entire 
cross peak ends up in the add subspectrum as a HMBC correlation. For the H3-C4 cross peak 
in vinyl acetate, two active 
3
JHH to H4a and H4b are involved, and the coupling pattern 
becomes slightly more complicated. For spin systems with large coupling constants where 
the individual peaks are well resolved this is not a problem, and the couplings can be 
analysed, e.g. by drawing tree diagrams (Figure 2.13).
133
 The couplings in the H3-C4 
multiplet are most accurately determined by displacing the rightmost red line (#8) onto the 
ppm
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rightmost blue line (#7) to give the small coupling constant, and the other is found by 
continuing the displacement so that the left blue line (#2) intercepts the third red line from 
left (#6). If the two middle lines #4-5 were separated in the 2D spectrum, the lines #5 and #8 
could have been used to give the same result. In addition to the homonuclear coupling 
constants, the size of four 
2
JCH were determined, however since the 
n
JCH can only be 
measured in-phase, this is not suitable for small heteronuclear couplings. Interference from 
passive JHH couplings should also be taken into consideration, e.g. a HMBC correlation 
between H3 and C2 shows a dd shape (data not shown) originating from the 
3
JHH couplings 
to H4a-b while the 
3
JCH is not resolved. The 
2
JCH couplings measured in vinyl acetate by 
HMBC+ are slightly smaller than those measured from 
1
H-coupled 
13
C spectra.
131
 Even these 
large couplings in vinyl acetate are estimated too small, which shows why the IP method 
generally does not yield accurate results for small coupling constants. 
 
Figure 2.13. Tree diagrams for the HMBC+ cross peaks from Figure 2.12 of vinyl acetate (with approximate values 
of J in Hz). The editing happens by the action of the active long-range JHH coupling constant, as highlighted by the 
coloring of the bottom lines. Because the H3-C4 cross peak contains two active homonuclear couplings, the coupling 
pattern becomes symmetric. The geminal coupling H4a-H4b is a passive coupling in the HMBC experiment, making 
it IP like the nJCH couplings and it is therefore not measured.  
Of the coupling constants shown in the tree diagrams, only the geminal coupling between 
H4a and H4b could not be determined. Because this is a HMBC-type experiment it cannot be 
used to measure geminal coupling constants, but is more suitable for long-range JHH coupling 
constants. To test the HMBC+ experiment on a complex molecule with coupling constants in 
all ranges, including negative values of
 
JHH, the plant alkaloid strychnine was used. 
Strychnine has undergone extensive investigation by NMR spectroscopy and a number of 
2 New NMR experiments 
25 
 
coupling constants have been measured and calculated.
134–136
 Figure 2.14 shows three 
examples of HMBC+ cross peaks with two positive 
3
JHH and one small and negative 
4
JHH 
(see the full spectra and NMR assignment in the Appendix).  
 
Figure 2.14. Examples of HMBC+ H…CH multiplets in strychnine (CDCl3, 400 MHz, 16 scans, 4096 data points, 128 
increments, zero filled to 8192x1024, standard HMBC delays) showing 4JH20βH16 = -0.35 Hz, 
3JH11βH12 = +3.24 Hz, and 
3JH15αH16 = +3.94 Hz (from left). The coupling constants were measured by displacing the 1D traces (rows) to fit. The 
correct sign is obtained by displacing the subtract subspectrum onto the add subspectrum (red onto the blue). The 
1D traces are scaled arbitrarily. For the full spectrum, see the Appendix. 
Using HMBC+, 28 
n+1
JHH coupling constants in strychnine were determined sign-selectively 
and compared to couplings from the literature
134,136
 as well as coupling constants from DFT 
calculations. Starting from the crystal structure of strychnine
137
 (PDB entry SY9) the 
structure was energy minimized using B3LYP/6-31G(d) in chloroform. J coupling constants 
were calculated through gas-phase single point calculations in accordance with 
recommendations by Bally and Rablen.
138
 This was done in Gaussian
139
 with the B3LYP 
functional and a 6-31G(d,p)u+1s basis set (Table 2.3, calculations by Casper Hoeck, DTU 
Chemistry). Two other basis sets were examined for the single point calculation (6-311+G 
and cc-pVDZ), but 6-31G showed the best correlation with experimental data (data not 
ppm
2.32.42.52.62.72.8 ppm
60
65
70
75
80
85
20β 11β 15α 
C16 
C12 
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shown). The u+1s extension is short for “uncontracting and augmenting by extra compact 1s 
functions”.138 Interestingly, the best correlation between experiment and calculations was 
obtained when using Fermi contact (FC) terms only, giving a root mean square deviation 
(RMSD) of 0.40 Hz, while the full coupling constant term gave an RMSD of 0.47 Hz (data 
not shown). Completely in line with recommendations by Bally and Rablen, a linear scaling 
factor of 0.9117 gave the best fit with an RMSD of 0.28 Hz (Table 2.3).
138
  
The FC term is the dominating contribution to the coupling constant, taking into account the 
magnetic interactions of the nucleus with electrons at the site of the nucleus. The other terms 
are the diamagnetic and paramagnetic spin-orbit and spin-dipole terms, which partly cancel 
each other out and thereby have smaller contributions to the 
1
H-
1
H scalar couplings.
140
 
Calculation of J coupling constants were performed in gas-phase, as adding implicit 
chloroform had no significance for the result and RMSD in accordance with Bally and 
Rablen.
138
 The correction factor is a linear fitting that scales the values by a fixed factor, 
found by linear regression analysis on a large training set of small molecules.
138
 This is a 
cheap and easy way to obtain high accuracy results with minimal cost in computational 
power. The scaling factor is specific for a basis set and evens out systematic errors in 
calculations. Cobas et al. reported JHH coupling constants using several methods to extract 
couplings from 1D data
133,141,142
 while developing an automatic coupling constants analyzer 
(ACCA) for MestReC.
134,143
 Using these extracted couplings as a supplement to the 
extensive work by Carter et al. from 1974, some of the HMBC+ coupling constants could be 
compared to experimental reference values.
136
 Ten of the measured coupling constants had 
not previously been determined experimentally, and could therefore only be compared to 
calculations. Carter et al. used incorporation of deuterium to facilitate the measurement of 
JHH coupling constants in complicated 1D 
1
H multiplets. The coupling constants measured 
by HMBC+ are in excellent agreement with both references values and calculations, and all 
sizes of coupling constants correlate very well with predicted values (Figure 2.15). H17ab is 
a second order multiplet system in the 
1
H NMR spectrum, however a coupling between 
H17ab and H16 was measured. Since the chemical shift of H17a and H17b could not be 
discriminated and only one correlation was observed, it was assumed to be an average 
coupling constant, keeping in mind that special care must be taken when second order effects 
are at play. However it turned out that the measured coupling constant fit exactly to the 
combined values of JH16-H17a and JH16-H17b and therefore it seemed correct. Further work will 
clarify if this is a correct assumption. Another coupling constant between H20b and H22 was 
measured to 1.20 Hz by Carter et al., but HMBC+, ACCA, and calculations all agreed on a 
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coupling constant of approximately -0.6 Hz (although for ACCA, the sign was of course not 
determined), and therefore this seems to have been a mistake in the original reference.
136
  
Table 2.3. Experimental and calculated n+1JHH coupling constants of strychnine, where experimental HMBC+ 
coupling constants were measured and compared to reference coupling constants.134,136 Calculations were performed 
with FC only using B3LYP/6-31G(d,p)u+1s and then linearly scaled by a factor of 0.9117. *H17ab was seen as a 
broad singlet and the measured coupling was assumed average. ** Carter et al.136 determined this coupling to 1.20 
Hz, however this seems like a mistake and therefore the ACCA coupling was used for comparison. For more 
calculated coupling constants, see an expanded table in the Appendix. 
#H1 #H2 
Experimental 
HMBC+ 
Experimental 
1
H NMR
136, b: 134 
Calculated 
FC only, scaled 
1 3 1.17 1.18 1.13 
1 4 0.50 0.45 0.55 
2 4 1.09 1.12 0.97 
8 12 -0.19 - -0.10 
8 13 10.49 10.47 9.96 
8 16 -0.70 - -0.27 
11a 12 8.34 8.44 8.43 
11a 13 -0.42 - -0.31 
11b 12 3.24 3.28 3.75 
12 13 3.20 3.12 3.58 
12 15b 0.40 - 0.02 
12 23a -0.08 - -0.02 
13 14 2.97 3.10 3.27 
13 15a 0.34 0.49-0.59
b
 0.38 
13 15b -0.30 - -0.28 
14 15a 5.42 4.58 4.60 
14 15b 2.03 1.98 1.93 
14 16 0.76 - 0.54 
14 20b -0.58 - -0.50 
14 22 -2.89 2.82
b
 -3.03 
15a 16 3.97 4.11 3.89 
15b 16 2.29 1.82 2.02 
16 17a   - 0.04 
16 17b   - -0.18 
16 17ab* -0.14 - -0.14 
16 20b -0.35 - -0.33 
20a 22 -1.37 1.47
b
 -1.82 
20b 22 -0.63 0.63
b
** -0.58 
22 23a 6.08 5.74 6.14 
22 23b 7.00 6.88 6.86 
 
Only the full term calculation (see the Appendix) gave rise to coupling constant errors of 
more than 1 Hz, and the signs of the coupling constants are also in perfect agreement with 
the calculations. 
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Figure 2.15. Plot of coupling constants in strychnine measured by HMBC+ against FC only calculated couplings with 
linear scaling factor 0.9117 using B3LYP/6-31G(d,p)u+1s (▲, black line is linear regression with R2 = 0.992) and 
against the experimental reference coupling constants in Table 2.3 (●, compared as absolute values, therefore only 
showing positive coupling constants). The grey lines define an area of perfect fit ± 1 Hz between HMBC+ and 
experimental/calculated coupling constants, which all data points fall within. 
2.5.3 Application in oligosaccharide analysis 
HMBC+ has many prospective applications for coupling constant analysis and use thereof. 
In the last section it was shown how the experiment can be used to measure very accurate 
coupling constants sign-selectively in vinyl acetate and in the plant alkaloid strychnine, 
showing the potential of HMBC+ for investigation of relative configuration in small 
molecules. In oligosaccharide analysis, the experiment has two convenient applications: The 
n+1
JHH splitting in the HMBC cross peak supports the assignment of the stereochemical 
relationship between the protons, due to the fact that the vicinal coupling 
3
JHH in pyranose 
rings is largest for axial-axial protons and smallest when both protons are equatorial.
144,145
 
For complex oligosaccharides it can be difficult to elucidate neighboring CH pairs when 
resonance overlap makes the COSY spectrum practically useless. In HMBC+ the 
n
JCH 
correlations are combined with the 
n+1
JHH coupling constants to help assign the correct 
stereochemical relationship and thus the monomer identity. This is in a way analogous to the 
advantage of the HSQC-TOCSY experiment over TOCSY, as the spectral dispersion of 
13
C 
is highly advantageous and especially 
3
JHH is vital for determination of monomer identity. 
The combination of 
1
H-
13
C long-range 
n
JCH correlations with the measurement of 
n+1
JHH is 
y = 0.9804x + 0.0011 
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therefore believed to facilitate easier oligosaccharide analysis. Furthermore, the experiment 
can be used to measure 
4
JHH across glycosidic bonds, which may aid in conformational 
studies. These coupling constants are very small in size and often negative, and therefore 
have so far not been reported for structural studies of carbohydrates, although Otter and 
Bundle reported long-range interglycosidic homonuclear correlations over 4 and 5 bonds via 
a gCOSY experiment.
146
 Currently, most often a combination of distance calculations with 
NOESY/ROESY-type experiments and other coupling constants are used, e.g. JCH or JCC, 
also in combination with alignment for measurement of RDCs.
147–149
 
 A high degree of resonance overlap is often seen in oligosaccharides and therefore it is 
necessary for at least one of the 
3
JCH correlations to be non-overlapped and unique to 
measure the correct coupling constant, and here it is advantageous that the 
4
JHH coupling 
constant can be found by observing either of the two proton resonances. E.g. the trans-
glycosidic 
4
JHH in LNT between GlcNAc H3 and Gal2 H1 can be determined (-0.3 Hz) from 
H3 to H1, however in the opposite direction there is an ambiguity between the trans-
glycosidic 
4
JHH and an intra-residual 
4
JHH in Gal1 (Figure 2.16). 
 
Figure 2.16. Partial assignment of LNT, where resonance overlaps for two protons at 4.42 ppm and two carbon 
atoms at 82.8-82.9 ppm make it difficult to differentiate the 4JHHs (red chemical shifts). The coupling constant of -0.3 
Hz across the glycosidic bond between GlcNAc and Gal2 can however be measured from H3 to H1 (green chemical 
shifts) using the new HMBC+ experiment. See the CH/CH3 subspectrum in the Appendix. 
Further studies will show the usefulness of HMBC+ in its various applications; however 
experiments so far demonstrate a very robust experiment with good sensitivity for very 
accurate determination of long-range JHH coupling constants in small molecules. Initial 
results have shown that HMBC+ can be used to measure RDCs in aligned samples, but these 
results will be treated elsewhere.  
2.6 Experiments for measurement of 2JCH 
Long-range heteronuclear coupling constants are also highly desired in structural studies, and 
especially 
2
JCH couplings to quaternary carbon atoms yields important structural information. 
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In collaboration with Ole W. Sørensen we wanted to pursue the sign-selective measurement 
of 
2
JCH, using double-quantum (DQ) coherence ADEQUATE-type experiments to gain 
access to this coupling constant. This experiment could find use both for isotropic and 
aligned samples, and measurement of the sign of 
2
JCH was important, as this type of coupling 
constant is often negative, but it is not always the case.
132
 
Several 
1
H-detected 
13
C-
13
C DQ experiments could form the basis of the new experiment.
75
 
Weigelt and Otting’s 1H-detected INEPT-INADEQUATE experiment uses proton 
magnetization both for excitation and detection,
150
 giving it an advantage over the original 
INADEQUATE experiment which suffered from very low sensitivity since only 
13
C-
13
C 
pairs were detected.
151
 In natural abundance this meant that only one in 8,000 molecules 
gave rise to measurable magnetization.
152
  
With the 
1
H-detected INEPT-INADEQUATE (Figure 2.17), later known as 1,1-
ADEQUATE due to the use of 
1
JCH and 
1
JCC, the S/N ratio was improved about 13-fold 
compared to the 2D INADEQUATE experiment.  
 
Figure 2.17. Original 1,1-ADEQUATE pulse sequence by Weigelt and Otting.150 Filled and open bars refer to π/2 
and π pulses, respectively. The dashed open box represents 13C decoupling. τ1 = (4 
1JCH)
-1 and τ2 = (4 
1JCC)
-1, Δ 
corresponds to a gradient delay and φ1 = {x, y, -x, -y}. A slightly better phase cycle can be employed with φ1 = {x, y, -
x, -y, y, -x, -y, x, -x, -y, x, y, -y, x, y, -x} and cycling the 13C π pulse immediately after t1 with φ2 = {4(x), 4(y), 4(-x), 4(-
y)}. The gradient ratios are 1:-1:1.004.  
While the INADEQUATE experiment enabled direct connectivities between neighbouring 
13
C nuclei, the 1,1-ADEQUATE yielded cross peaks between a proton and a 
13
C DQ 
coherence corresponding to δC1 + δC2, where C1 is the directly bonded 
13
C atom and C2 is 
any neighbouring 
13
C (Figure 2.18). This allowed determination of the chemical shift of a 
neighbor 
13C atom (δC2). The experiment starts from 
1
H magnetization which through an 
INEPT sequence (the first two τ1 delays) is transferred to 
13
C (Figure 2.17). 
 
 
 
 
 
 
 
 
x x x y x 
φ1 φ1 φ1 φ1 x 
τ2 
H 
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τ1 τ1 
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Figure 2.18. The J couplings involved in the INADEQUATE, 1,1-ADEQUATE and the new experiment for 
measurement of 2JCH. The new experiment is also based on the couplings shown for 1,1-ADEQUATE, but the 
2JCH is 
the aim of the experiment. The red rectangular area symbolizes the DQ coherence which is manifested in a DQ 
frequency axis in the 13C dimension, F1, with cross peaks between δH and δC1 + δC2. 
This is followed by generation of DQ coherence which evolves during t1 and in the end 
magnetization is transferred back to 
1
H for detection. 
The general idea for the new experiment was to remove the 
1H π pulse in the middle of t1 
(Figure 2.17) to prevent the refocusing of JCH and JHH. At the same time an improvement to 
the phase cycle was made, with φ2 running a 32-step cycle in steps of 45° or π/4 (Figure 
2.19).  
 
Figure 2.19. New pulse sequence based on INEPT-INADEQUATE. Filled and open bars refer to π/2 and π pulses, 
respectively. The dashed open box represents 13C decoupling. τ1 = (4 
1JCH)
-1 and τ2 = (4 
1JCC)
-1, Δ corresponds to a 
gradient delay and φ1 = {x, y, -x, -y, y, -x, -y, x, -x, -y, x, y, -y, x, y, -x} and φ2 (8) = {0, 4, 2, 6, 3, 7, 1, 5, 6, 2, 4, 0, 5, 1, 
7, 3, 2, 6, 0, 4, 1, 5, 3, 7, 4, 0, 6, 2, 7, 3, 5, 1}, where the numbers correspond to π/4*n. The gradient ratios are 1:-
1:1.004. See the pulse program (ADEQ11ETGPLR_LKJ3) in the Appendix. 
The new phase cycle makes the experiment less sensitive to adjustment of correct pulse 
lengths and thereby reduces spectral artefacts, however with a tradeoff of a lower S/N ratio. 
Because the experiment uses DQ coherence during the evolution period, a coupling between 
a proton and two adjacent 
13
C atoms was expected, with J = 
1
JCH + 
2
JCH appearing along F1. 
In case of a CH-CH system, the cross peak should appear as a doublet of doublets with JA = 
1
JC1H1 + 
2
JC2H1 and JB = 
1
JC2H2 + 
2
JC1H2. Because 
1
JCH is easily measured and always positive 
in sign, the magnitude and sign of 
2
JCH could be determined.  
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Compared to the INEPT-INADEQUATE experiment, the S/N ratio is expected to be lower, 
due to the fact that the resonance is dispersed by multiplicity rather than a single peak, in 
addition to some loss in resonance intensity resulting from the 45° phase cycle. However, the 
splittings observed were much larger than 
1
JCH + 
2
JCH, possibly due to multiplication by the 
number of protons on each carbon atom. A CH-CH3 spin system in N-methyl ephedrine 
resulted in a dd-like pattern (observing the CH proton) with splittings of 370 and 124 Hz, 
and with respective 
1
JCH of 133.2 and 125.8 Hz determined from a 
1
H-coupled 
13
C spectrum, 
this pointed towards a connection with the number of protons attached to the neighboring 
13
C 
atom. Unfortunately it was difficult to find suitable molecules with known 
2
JCH to test the 
exact correlation and the extra splitting created unexpected problems for higher 
multiplicities, possibly due to interference from unwanted coherence transfer pathways. 
Splittings in the expected size range were however seen for three spin systems with no JHH 
coupling, as e.g. H12 in brazilin, where couplings to three different quaternary carbons 
showed couplings in the correct size range of J = 
1
JCH + 
2
JCH (Figure 2.20 and Figure 2.21). 
For DQ CH-CH pairs (C1-C2) and for C-CH2 pairs (C6-C7), the splitting was about doubled, 
which suggested that not only protons on the neighbor 
13
C atom were responsible for the 
extra splitting. Passive couplings to other neighboring 
13
CH pairs were however not at play, 
as e.g. H1 has one small DQ-coupling (to C1a) and one large DQ-coupling (to C2). 
  
Figure 2.20. Structure of brazilin with numbering.153,154 The NMR assignment can be found in the Appendix. 
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Figure 2.21. Aromatic (left) and aliphatic (right) regions of the spectrum of brazilin using the ADEQUATE-based 
experiment (shown in Figure 2.19) (400 MHz, DMSO-d6, 32 scans, 2048 data points, 1024 increments, zero filled to 
4096x2048 and forward linear predicted with 32 coefficients).  
It seemed that the center line in the CH-CH multiplet cancelled out, possibly resulting in J = 
1
JC1H1 + 
2
JC2H1 + 
1
JC2H2 + 
2
JC1H2. This was not an optimal situation, as this type of splitting 
could not be used to determine either of the 
2
JCH coupling constants. To try to overcome this 
problem, a change to the pulse sequence was made, from INEPT to DEPT magnetization 
transfer (Figure 2.22 and Figure 2.23).
75
  
 
Figure 2.22. DEPT2LR pulse sequence, where the polarization transfer happens through DEPT instead of INEPT 
(Figure 2.19). Filled and open bars refer to π/2 and π pulses, respectively. The dashed open box represents 13C 
decoupling. τ1 = (4 
1JCH)
-1 and τ2 = (4 
1JCC)
-1, Δ corresponds to a gradient delay and φ1 = {x, y, -x, -y, y, -x, -y, x, -x, -y, 
x, y, -y, x, y, -x}, φ2 = {y, -x, -y, x, -x, -y, x, y, -y, x, y, -x, x, y, -x, -y} (shifted 90° from φ1) and φ3 (8) = {0, 4, 2, 6, 3, 7, 1, 
5, 6, 2, 4, 0, 5, 1, 7, 3, 2, 6, 0, 4, 1, 5, 3, 7, 4, 0, 6, 2, 7, 3, 5, 1}, where the numbers correspond to π/4*n. The gradient 
ratios are 1:-1:1.004. Θ is the flip angle in DEPT that controls the selection of different multiplicities. Here, Θ = 60° 
was used for optimal resonance intensity of CH with some intensity for CH2. See the pulse program in the Appendix 
(DEPT2LR_LKJ). 
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Figure 2.23. Aromatic (left) and aliphatic (right) regions of the spectrum of brazilin using the DEPT2LR experiment 
(shown in Figure 2.22) (400 MHz, DMSO-d6, 32 scans, 2048 data points, 1024 increments, zero filled to 4096x2048 
and forward linear predicted with 32 coefficients).  
The DEPT2LR experiment, as it was tentatively named, now showed the center lines in e.g. 
the H1-C2 cross peak, although it created a separation between the α- and β-spin states of the 
observed proton as if the high energy proton could only couple to the low energy carbon 
states and vice versa (Figure 2.24). Some of these cross peak patterns somewhat resembles 
that of the P.E.HSQMBC.
92
 This type of cross peak however showed different splittings in 
the upper and lower part. Experimental and calculated coupling constants were compared for 
menthol and brazilin, but this proved problematic. The 
2
JCH couplings are usually negative 
and in the order of 0-10 Hz, and calculated and experimental values therefore had a high 
chance of being of the same size, however this was not the case for all couplings, and 
whether the convergence for some couplings was coincidence rather than correct 
determination was so far not possible to decide. Without experimental data to compare to, it 
was difficult to say whether the poor fit was due to the basis set not being suitable for 
calculation of 
2
JCH, and therefore gave a poor correlation, or the experimentally determined 
coupling constants were simply not correct. Some 
2
JCH coupling constants have been 
reported in the literature,
132
 but mostly for proton-rich systems, and a suitable model system 
with known coupling constants was not found. Furthermore, the cross peak patterns were not 
fully understood, and with a low S/N experiment demanding much NMR time for a thorough 
investigation, the project seemed difficult to finish with the current tools available. A few 
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further attempts of pulse sequence modifications were attempted, but no further conclusions 
were reached at this point. 
 
Figure 2.24. Expansions from Figure 2.23, with new multiplet structures. The 13C DQ frequencies are for C1+C2 
239.7 ppm and for C6+C6a 145.9 ppm. 
Verdier et al. measured 
2
JCH coupling constants in menthol,
96
 however only three such 
coupling constants could be compared between the experiments, and H1-C2 was determined 
by DEPT2LR to +1.7 Hz (vs. 1.8 Hz) and H2eq-C1 was determined to -3.5 Hz (vs. 3.6 Hz), 
however the last coupling H8-C4 was far off, determined to -4.4 or -1.3 Hz (vs 7.6 Hz). 
Numbering was adopted from the reference.
96
 There are other examples of experiments for 
measurement of 
2
JCH, however more data needs to be acquired using both experiments before 
further comparisons can be made.
91,98
   
The DEPT2LR experiment in its current form has a narrow applicability for the 
determination of 
2
JCH coupling constants to quaternary carbon atoms; perhaps also for CH-
CH spin systems. It is inherently insensitive and the fact that coupling constants need to be 
extracted from the indirect dimension makes the experiment quite demanding regarding 
NMR time. ADEQUATE-type experiments are therefore most suitable to small molecules in 
rather high concentration, and therefore it will probably never be an experiment of choice for 
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the typical natural products sample. Non-uniform sampling (NUS) could be an advantage for 
these experiments, making them slightly less time demanding. Nevertheless it seems the 
minimum requirement for putting the experiment to use would be to fully understand the 
coupling patterns and be able to extract more coupling constants, not only from CH-Cq spin 
systems. 
2.7 Conclusions and perspectives 
The new HMBC+ experiment was shown to give excellent results for vinyl acetate and 
strychnine, especially regarding the sign-selective measurement of 
n+1
JHH, and in some cases 
n
JCH coupling constants may be estimated. Interferences from passive JHH couplings as well 
as the IP character of the JCH coupling constants are expected to limit the use of HMBC+ for 
measurement of heteronuclear coupling constants. HMBC+ however facilitates easy and 
accurate measurement of long-range 
n+1
JHH homonuclear coupling constants of any size and 
sign, based on HMBC and HAT HMBC experiments by Benie, Sørensen, and Nyberg.
125–127
 
Acquisition of one single 3D experiment and processing using our new AU program creates 
eight subspectra, of which the first four are edited HMBC and HAT HMBC, for optional use 
in structure elucidation, and the last four subspectra form the multiplicity edited HMBC+. 
Both pulse program and AU program can be found in the Appendix. Like e.g. the XLOC 
experiment
77
 the determination of JHH coupling constants is independent of the 
1
H linewidth 
due to the editing procedure developed, facilitating IPAP-type measurement in the direct 
dimension with high resolution. Compared to existing experiments where measurement of 
JHH is possible, this is the first to directly determine both magnitude and sign of small long-
range coupling constants. Simple IPAP-type editing eliminates problems with resolution 
preventing the extraction of coupling constants, and the possibility to find the same coupling 
constant in two different cross peaks maximizes the number of obtainable coupling constants 
in samples with spectral overlap. Ten new 
n+1
JHH coupling constants were determined for 
strychnine and shown to correlate very well with calculated values. Because molecular 
configuration and coupling constants are tightly connected, this is believed to improve future 
structural studies markedly, supplying a high number of 
n+1
JHH coupling constants combined 
with HMBC correlations, and with the sign determination this is a very useful experiment.  
The measurement of JHH couplings from CHx to CH and CH3 groups is straightforward, 
however for couplings to CH2, overlap in the multiplet lines can be an issue and 
understanding the multiplet patterns is more important. Often it is however easier to 
determine the same coupling constant in the other direction from e.g. CH2 to CH, as opposed 
2 New NMR experiments 
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to from CH to CH2. It would also be possible to implement another level of editing of the 
CH2 subspectrum by changing the τ delay and thereby obtain a further separation of the 
multiplet pattern. In the cases shown so far, most of the coupling constants have been 
determined from the CH/CH3 subspectra, although it was shown for vinyl acetate that it 
works for CH2 as well. The coupling constant determination just requires a bit more of the 
user, and for small coupling constants to CH2, it seems a fitting procedure would be 
necessary if the coupling constant cannot be determined elsewhere in the spectrum.  
Since HMBC+ is a long-range HMBC-type experiment, there are some limitations to the JHH 
that can be determined. Geminal 
2
JHH coupling constants cannot be measured from HMBC 
correlations. These couplings are however often large and negative, and therefore easily 
determined from e.g. a standard 
1
H spectrum.  
The HMBC+ experiment can be used for measurement of RDCs; however having only 
started to unravel the potential of the experiment, treatment of aligned samples is next in 
line, and the experimental measurement of RDCs is not elaborated in this thesis. It should 
however be noted that samples with rapid T2 relaxation will need a high number of scans to 
obtain a sufficient S/N ratio, as the resonance dephases during the pulse sequence due to 
spin-spin relaxation. This unfortunately seems to be an issue for polymer gels, and therefore 
long experiment time and high sample stability is needed to obtain sufficient data quality. 
In order to supplement the homonuclear coupling constants from HMBC+ with 
heteronuclear coupling constants, it was attempted to develop an experiment for sign-
sensitive measurement of 
2
JCH coupling constants. The ADEQUATE-based experiments 
described have however not been fully developed, and problems with “exotic” multiplet 
structures remain, possibly due to interference from unwanted coherence transfer pathways. 
So far it seems the experiment can be used for measurement of 
2
JCH coupling constants to 
quaternary carbon atoms, but with few 
2
JCH experimental couplings to compare to, the 
accuracy of the method has not yet been determined. As an example, 
2
JCH values in the 
natural product brazilin were measured, yet calculated values differed several Hz from the 
measured coupling constants. Whether this was caused by problems with the experiment or 
with the calculation of 
2
JCH coupling constants in brazilin is difficult to say. It could be that 
the strained structure in brazilin is not comparable to the training set of the calculation 
method, and thus pointing towards a problem in the parameterization. Two-bond 
heteronuclear 
1
H-
13
C coupling constants have furthermore not gained much attention, except 
in the SJS-HSQC experiment a few years back,
91
 but the experiment was tested on a natural 
product not commercially available. We did not test the SJS-HSQC experiment on our 
 38 
 
spectrometers yet, nevertheless it is important to obtain experimental 
2
JCH for comparison. 
The experiment under development here will need further work as well as a validation to be 
of general use, and in its current state the S/N ratio of the ADEQUATE-type experiment is 
low for measurement of RDCs, however at high concentration and with the most sensitive 
equipment available the potential of the experiment in that direction should also be 
evaluated. Generally, for both HMBC+ and ADEQUATE-type experiments, going to higher 
field strength will increase the spectral intensity for both isotropic and aligned samples. 
In this chapter, the experimental work was dedicated to developing new experiments for 
measurement of J couplings and RDCs, showing examples for isotropic samples measuring J 
from HMBC+. This naturally only provides relative configurational information over short 
ranges. However, the number of coupling constants which can now be determined accurately 
and sign-selectively, especially in combination with other experiments for measurement of 
n
JCH, naturally leads to a discussion of whether the J couplings alone, for many small 
molecules, provides adequate stereochemical discrimination to obtain relative configurations. 
The best option is without doubt to combine J coupling constants, NOEs, and RDCs. Any of 
these methods can only be used to obtain relative configuration, and generally require a 
somewhat locked conformation to be able to use the relative information on the molecular 
scale. RDCs have so far not found widespread application in research groups not specialized 
in the area, most likely due to the technical barrier of obtaining aligned samples, and it would 
be interesting to compare the use of J coupling constants alone to the combination of Js and 
RDCs for an assortment of small molecules, including diastereoisomers. In many cases 
RDCs will however be necessary, due to the added global angular restraints. Future studies 
will show the full potential of the new experiment, and by making the program code 
available to others online, we hope to see it in use by other research groups as well. 
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3 Microbial natural products 
This chapter evolves around the discovery of natural products and begins with an 
introduction to natural products and some of the tools and challenges in the identification 
and analysis of new natural products. The experimental work on the isolation and 
characterization of secondary metabolites from a marine bacterium and a filamentous 
fungus is described in Section 3.5.1-3.5.2 and 3.5.3, respectively. Finally, the potential of 
these sources in today’s drug discovery is discussed. 
Two journal articles on bacterial metabolites from a marine bacterium have been published 
(Paper I and II, see Appendix), and the reader is referred to the respective supplementary 
materials for experimental details. NMR assignment tables for the fungal metabolites 
described can be found in the Appendix for chapter 3 and experimental details can be found 
in the end of the chapter. 
3.1 Drug discovery today 
Nature has been an important source of medicine for thousands of years, and today natural 
products (NPs) remain the primary inspiration in drug discovery. In traditional medicine, 
especially plants have been used for extraction of active principles, and since the discovery 
of the penicillins and the golden era of antibiotics, microorganisms have been an important 
source of bioactive molecules.
155
  
All living organisms produce secondary metabolites for intra- and interspecies 
communication and competition, and the molecules, which also help differentiate between 
species, are by design optimized in a natural selection process over many years of 
evolution.
156
 It is said that NPs have so-called privileged structures, meaning that one natural 
scaffold can give rise to various biological activities with just minor changes to the 
structure.
157
 Consequently there is a great chance of finding biological activity in a natural 
extract (a lead molecule), and further modifications on the structure can result in highly 
specific biological activities with good pharmacological properties and low toxicity.
158
 On 
the downside, both the discovery of new NPs and the synthesis of analogues in search of a 
hit molecule are slow processes which are not very desirable for pharmaceutical companies 
today.
159
 During the last two decades, focus has been turned towards high-throughput 
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screening (HTS) of combinatorial chemistry libraries, made to resemble NPs but with fewer 
stereocenters and simpler structural scaffolds to facilitate easy synthesis. Despite this method 
being prevalent for some years, only one new chemical entity (NCE) has reached market 
from combinatorial chemistry: The antitumor agent sorafenib approved by the U.S. Food and 
Drug Administration (FDA) in 2005.
160
 The chemical space covered by combinatorial 
chemistry is somewhat limited compared to the enormous diversity within NPs, and it is 
likely for a library synthesized by a given range of reactions to fall outside the drug space.
157
 
36 % of NCEs (1981-2010) are purely synthetic, having no inspiration from NPs, the other 
64 % are NPs, NP derivatives, or inspired by NPs (Figure 3.25).
160,161
 It seems that drug 
discovery and development will continue to require inspiration from nature.
162,163
 
 
Figure 3.25. Source of all small molecule drugs approved in 1981-2010. ND: NP derived (28 %), NP (6 %), S*: 
Synthetic NP mimic or with NP pharmacophore (30 %), S: Purely synthetic (36 %). Modified from 160. 
3.2 Sources of natural products 
The isolation and purification of NPs often demand large amounts of the producing 
organisms to yield minute amounts of the active substances. One example is the anticancer 
drug paclitaxel (Figure 3.26), which was originally produced by isolation from the Pacific 
yew tree Taxus brevifolia.
164
 One course of treatment (~2 g paclitaxel) required the bark 
extracts from six full-grown yew trees, and as it takes more than a century for the trees to 
mature, it posed a great stress on the natural source and an ethical dilemma on society. 
During the late stage clinical trials and launch of paclitaxel as the drug Taxol (Bristol-Myers 
Squibb) in the early nineties, it was produced semi-synthetically by modifications of 
10-deacetylbaccatin III (Figure 3.26), extracted from leaves and twigs of a faster growing 
and better yielding yew species. Today paclitaxel is produced in plant cell cultures of T. 
brevifolia, a more sustainable process with no risk of extinction for the natural source.
165,166
 
Several synthetic routes to paclitaxel were developed, but none were suitable for large scale 
production.
167,168
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Figure 3.26. Structure of paclitaxel (left) and the precursor 10-deacetylbaccatin III (right). 
This is a good example of some of the difficulties faced in drug development from NPs, 
especially for complicated structures in low yields and with limited supply of the producing 
species. Microbial sources such as fungi and bacteria have the benefits of fast growth and 
reproduction making them easier to sample and grow. The environmental stress of taking 
small microbial samples for cultivation is also limited, compared to the collection of larger 
organisms for direct use in the laboratory.  
3.3 Analysis of natural products 
3.3.1 The supply problem and dereplication 
A common problem for microbial NPs is that the secondary metabolites are often isolated in 
very low yields. The production of a target compound may be improved by testing different 
growth conditions, e.g. growth medium or by co-culturing with another species, which may 
even induce expression of silent gene clusters to produce other exciting metabolites.
169–171
 
Furthermore it necessitates that the isolated material is used in the most sensible way 
possible regarding structure elucidation and biological assays. 
In the initial work with a specific fungal or bacterial species, a small culture (agar plate or 
liquid culture) is grown to assess the potential of finding novel compounds. This 
investigation is known as dereplication - the efforts to not replicate previous findings.
172
 It is 
highly undesirable to spend time in the laboratory working on the isolation and structure 
elucidation of a molecule that later turns out to be known, and therefore often not particularly 
interesting. The search of biologically active molecules is often coupled to one or more 
bioassays in bio-guided dereplication,
173
 but the order can be reversed to assessment of the 
bioactivity after purification and structure elucidation has taken place. In the case of highly 
active molecules, the first method can sometimes be difficult if the analysis methods are less 
sensitive than the bioassay, whereas the second method may not result in coupling a 
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bioactivity to a new molecule due to the often small amounts isolated and essentially 
unlimited number of bioassays available for testing against different diseases.  
3.3.2 NMR spectroscopy of small amounts 
NMR spectroscopy is a rather insensitive analysis method compared to e.g. LC-MS and most 
initial biological screens, but because NMR is nondestructive this is mainly an issue in case 
of limited sample amounts. Over the years, various technological improvements have 
increased the sensitivity of NMR spectrometers. One obvious improvement is the increase in 
field strength, but especially the development of cryoprobe technology has had a large 
impact on sensitivity, compared to conventional room temperature probes.
159,174
 A state-of-
the-art helium-cooled cryoprobe improves the signal-to-noise (S/N) ratio up to four times,
10
 
whereas a nitrogen-cooled cryoprobe improves the S/N ratio about two times, though the 
exact improvement is sample dependent.
175
 Alternatively the gain in sensitivity for high-field 
instruments and cryoprobes may enable the use of 
13
C-
13
C correlated experiments such as 
INADEQUATE, which are inherently insensitive.
176
 For NPs and other samples where only 
limited amounts are available, it is advantageous to decrease the sample volume in the NMR 
tube. This can be achieved with e.g. 3 mm probes, 1.7 mm probes, or nanoprobes, where the 
sub-mg sample is spun at the magic angle of 54.7°.
174,177,178
 Solvent susceptibility-matched 
Shigemi tubes are also a good choice when only limited amounts are available, although 
some extra effort may be needed to ensure optimal sample positioning and shimming.
179
 
Ideally, as much of the sample as possible should reside within the observe volume of the 
probe to increase the resonance intensity as much as possible for samples of limited amounts.  
Hyphenation is another option which optimizes information output and the time spent in the 
laboratory to obtain an NMR spectrum.
180
 Hyphenation in NMR is the coupling of NMR 
spectroscopy with UV, HPLC, MS and other detectors and can be done with a flow-probe or 
with SPE cartridges trapping the constituents and enabling longer NMR experiments, often 
with a high degree of automation.
180–183
 Coupling to biological assays makes hyphenation in 
NMR a valuable tool in fast screening of NP extracts.
184,185
 
3.3.3 Determination of absolute stereochemistry 
NMR spectroscopy is an excellent tool in determination of 2D structural relationships; 
however in the third dimension it is not optimal. Enantiomers cannot be differentiated by 
NMR spectroscopy, and assigning absolute configuration to a molecule is an important part 
of structure determination. Some of the other analytical methods used in this context were 
described in Chapter 2, including X-ray crystallography and two chemical derivatization 
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techniques which were used to structure elucidate some of the new molecules: Marfey’s 
method and Mosher’s esters, vide infra. 
Marfey’s method was first reported in 1984 for determination of enantiomeric purity.24 For 
NPs containing amino acids, it is often used to determine absolute stereochemistry.
186–188
 In 
short, it involves acid hydrolysis of the peptide into amino acids which are then derivatized 
using a chiral auxiliary called Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine 
amide, FDAA) via a nucleophilic aromatic substitution to yield diastereoisomers, which can 
be separated by RP-HPLC and analyzed by UV or MS detection (Figure 3.27). By parallel 
analysis of FDAA derivatives of pure L- and D- amino acids, the amino acid composition of 
the NP can be elucidated. About 100 μg of peptide is typically used, but the procedure can 
easily be scaled down for the method to become even more sensitive and thereby attractive 
to natural products chemists with very little material available. The postreaction mixture is 
diluted about five times to a volume of 1 ml and only a few μl of this solution is usually 
needed for analysis by e.g. UHPLC. By using HPLC vials with inserts, a volume of about 
100 μl is sufficient, and consequently only 10 μg of peptide would be required. 
 
Figure 3.27. Reaction of Marfey’s reagent with L- and D-amino acids (AA) to yield two diastereoisomers. 
Mosher’s ester analysis is another derivatization method which can be used to determine the 
absolute stereochemistry of secondary alcohols (or amines, forming amides).
23,189
 In this case 
S- and R-enantiomers of e.g. Mosher’s acid chloride (α-methoxy-α-
trifluoromethylphenylacetyl chloride, MTPA-Cl) are used to create two diastereoisomers 
where the phenyl group induces anisotropic effects on the protons near the stereocenter, 
respectively shielding and deshielding the substituents.
190
 Acquiring 
1
H NMR spectra of both 
esters and calculating the chemical shift changes between the S- and R-MTPA analogues, the 
stereocenter can be assigned (Figure 3.28). Due to the presence of a trifluoromethyl group in 
MTPA, 
19
F NMR provides another option to analyze the stereochemistry, in this case only if 
one substituent of the secondary alcohol (or amine) is notably more bulky than the other.
191
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This is because the conformation of the Mosher’s ester has a significant impact on the 
shielding effects imposed by the carbonyl in MTPA on the trifluoromethyl group (Figure 
3.28), and unless one substituent is markedly more bulky than the other this conformation 
may not be predominant. When the large substituent (L1) eclipses the large phenyl group it 
causes a conformational change due to a steric clash. The structure is shifted slightly further 
towards a staggered conformation, and the CF3 group is rotated away from the anisotropic 
deshielding effect caused by the carbonyl, in turn moving the 
19
F resonance upfield (Figure 
3.28). A problem with using the 
19
F NMR method is that the bulkiness of the substituents 
does not always differ markedly, and in such cases the method should be used with great 
care. When using MTPA esters it is therefore highly advantageous to use both 
1
H and 
19
F 
NMR in the analysis. Another issue is the possibility of misassignments caused by 
stereochemical confusion: Due to a change in the priority of the substituents of the 
stereogenic center in MTPA when the chloride is substituted for an ester, the S-MTPA-Cl 
yields the R-MTPA Mosher’s ester.192 The absolute configuration of the stereocenter changes 
without any inversion or direct bonds being broken, and care should be taken to assign the 
stereochemistry correctly. In the literature there are however several examples failing to 
consistently stick to the ΔδSR convention, and in stead using ΔδRS, without doubt adding to 
the confusion.
193–195
 Even though other similar auxiliaries have been suggested, MTPA is the 
one most commonly used.  
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Figure 3.28. Assignment key for Mosher’s ester analysis using MTPA. Top: S- and R-MTPA esters and 
corresponding Newman projections, showing the steric clash with the benzene ring. Bottom: The chemical shift 
difference between the S- and R-MTPA esters ΔδSR determine the stereochemistry of the secondary alcohol using 1H, 
19F NMR, or both.196 
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3.4 Natural products from a marine Photobacterium 
Covering more than 70 % of the earth’s surface, the ocean is a vastly underexplored 
resource.
197
 In the hunt for bioactive molecules, marine microorganisms have potential for 
discovery of new molecules, considering the average cell densities of 10
5
-10
6
 ml
-1
 in sea 
water.
198
 Unfortunately, less than 1 % of the marine bacteria are culturable by current 
methods, but if the range of culturable bacteria can be broadened, the scope of potential 
bioactive molecules from this resource would be immensely expanded. Marine bacteria are 
often symbionts of e.g. molluscs or sponges,
199,200
 and many bioactive molecules isolated 
from these sources were eventually found to be produced by an endosymbiont 
microorganism. Microorganisms in the aquatic environment are highly exposed to threats 
and competition from the surroundings and the bioactive potential of their secondary 
metabolites may thus be greater than for terrestrial species.
201
  
Marine bacteria are essentially bacteria found in the marine environment. Differing only at 
the species level from the terrestrial species, the majority of bacterial orders and families also 
contain marine species. E.g. Photobacterium halotolerans (genus, species) belongs to the 
family of Vibrionaceae in the order Vibrionales. Vibrionaceae are widespread in the aquatic 
environment, but not limited to marine habitats.
202
 Marine bacteria must tolerate (and some 
require) high salinity, known as halotolerance, but bacteria generally adapt well to their 
environment, which may be the main reason for the relatively vague definition of marine 
bacteria.
203
 
3.5 Results and discussion 
3.5.1 Small biologically active peptides from a marine Photobacterium 
In the work described here, we have focused on isolation and structure elucidation of new 
bioactive metabolites from a marine Photobacterium halotolerans, collected from a mussel 
surface near the Solomon Islands during the Galathea 3 expedition.
198,204
 The bacterium was 
chosen due to a two-pronged inhibitory effect of bacterial growth and quorum sensing 
(QS).
205
 The known antibiotic holomycin was responsible for the antibacterial activity,
204
 
and solonamide A and B were responsible for the QS inhibition in S. aureus (Paper I). 
Various other small peptide-like compounds were isolated from the same species, counting 
diketopiperazines and cyclotetrapeptides (unpublished results), as well as a series of larger 
depsipeptides belonging to an existing family called ngercheumicins. The four new 
ngercheumicins (F, G, H, and I) were tested in the same S. aureus QS assay as the 
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solonamides due to the structural resemblance with a 16-membered macrocyclic peptide ring 
and a hydrophobic alkyl chain. Here it was shown that the ngercheumicins, like the 
solonamides, inhibited QS in S. aureus, although higher concentrations were needed to 
obtain the inhibitory effect (Paper II) (Figure 3.29). 
 
Figure 3.29. Structures of the ngercheumicins (top) and the solonamides (bottom) with assigned stereochemistry and 
amino acid constituents shown. 
In the initial screening of a bacterial extract, the metabolite profile is usually investigated 
using HPLC-UV-MS. Crude fractionation on small scale enables early dereplication, and 
working with the Photobacterium we used 
1
H NMR for dereplication in addition to the MS-
based approach. This was done on the EtOAc extract of a one liter liquid batch after 
fractionation on a diol column yielding ten fractions. One fraction revealed solonamide B as 
the major compound, which enabled comparison of the NMR data with known compounds 
found in the UV-MS dereplication, without the need for further purification. Solonamide B 
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exhibited no distinct UV spectrum and the exact mass was found to be consistent with the 
small peptide sansalvamide.
206
 The NMR dereplication could however firmly rule out the 
hits found in the NP database Antibase 2010.
207
 Especially for small peptides with no distinct 
UV chromophore, early NMR data can help establish the basic structural features in a 
fraction. Specific NMR resonances can often be used discriminatively to prevent spending 
valuable time on purification of known compounds or discarding an unknown because the 
molecular formula matches that of a known molecule. Horizontal gene transfer within the 
bacterial world is relatively common, and therefore new, exciting molecules like the 
solonamides could easily be discarded if the choice to identify a compound depends only on 
the exact mass and UV chromophore being unique.
208
 
The ngercheumicins were isolated from the cell-associated fraction of a 20 liter culture from 
a desire to characterize the chemical fingerprint of Photobacterium halotolerans, which 
seemed to produce a wide variety of non-ribosomal peptides. Dereplication of this fraction 
revealed a series of analogs with relative mass-jumps of 28 and 2 Da, consistent with C2H4 
and a double bond equivalent, respectively. Due to the extensive resonance overlap in the 
fatty acid chain, there was some ambiguity in especially the assignment of the double bond 
position of ngercheumicin H (Table 3.4). 
Table 3.4. Experimental 1H and 13C NMR data and assignments of the fatty acid chains in the ngercheumicins 
(complete NMR data in Paper II). Chemical shift values are in ppm. 
Atom # 
Ngercheumicin F Ngercheumicin G Ngercheumicin H Ngercheumicin I 
δ 1H  δ 13C  δ 1H  δ 13C  δ 1H  δ 13C  δ 1H  δ 13C  
Fatty acid         
36 - CO - 171.8 - 171.9 - 171.9 - 171.9 
37 ~2.24 43.3 2.24, 2.22 43.4 2.25, 2.22 43.4 2.25, 2.22 43.4 
38 3.78 67.4 3.77 67.5 3.78 67.5 3.78 67.5 
38 - OH 4.62 - 4.60 - 4.60 - 4.59 - 
39 1.34, 1.30 36.2 1.31 36.6 1.32 36.6 1.32 36.6 
40 1.42, 1.28 25.1 1.34, 1.22 24.8 1.36, 1.23 24.8 1.35, 1.22 24.8 
41 1.96 26.6 1.23 ~29 ~1.2 ~29 1.23 29.1 
42 5.31 129.6 ~1.2 ~29 1.28 ~29 ~1.2 ~29 
43 5.31 129.6 ~1.2 ~29 1.97 26.6 ~1.2 ~29 
44 1.96 26.5 ~1.2 ~29 5.31 129.6 ~1.2 ~29 
45 1.28 29.0 ~1.2 ~29 5.31 129.6 ~1.2 ~29 
46 1.24 28.3 1.21 29.1 1.97 26.6 ~1.2 ~29 
47 1.22 31.1 1.22 31.3 1.28 ~29 ~1.2 ~29 
48 1.25 22.1 1.25 22.1 1.25 28.2 ~1.2 ~29 
49 0.84 13.9 0.84 13.9 1.22 31.1 1.22 31.3 
50     1.25 22.0 1.25 22.1 
51     0.84 13.9 0.84 13.9 
 
 
In the hope of supporting the structural assignments it was attempted to calculate the 
13
C 
chemical shifts of the fatty acid chains (Table 3.4) by density functional theory (DFT). 
Minimizations in MacroModel (Maestro, OPLS-2005, H2O, standard settings) were followed 
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by DFT calculations with Jaguar to predict NMR shielding constants in DMSO using the 
B3LYP functional and the 6-31G** basis set. The structures were simplified to N-methyl 
amides of the fatty acids to make the calculations faster. With this structural modification it 
was believed that the chemical shifts in the fatty acid chain would resemble those in the 
natural product. By calculating chemical shifts for the different structures with variations in 
cis and trans configurations and moving the double bond up to two carbons in each direction 
compared to the original assignment, we hoped there would be differences in the calculated 
chemical shift values that would enable the confirmation or correction of the assignment. 
The differences in chemical shifts were however very small, and the only unbiased way to 
compare the values was to sort them by size. Unfortunately this method was not sufficiently 
discriminative to provide a more reliable assignment (Figure 3.30 and Figure 3.31). Due to 
time restrictions and realizing that these small differences would be difficult to model in 
sufficient accuracy, no further studies were conducted. 
 
Figure 3.30. Comparison of calculated and experimental 13C chemical shifts for the cis-fatty acid chain in 
ngercheumicin F. The black line corresponds to a perfect fit between experimental and calculated values. 
It should however be noted that the assignments were supported by an n-7 fatty acid pattern 
in the double bond position within the three unsaturated ngercheumicins (n-7 is fatty acid 
nomenclature for an unsaturation seven carbon atoms from the chain end). The absolute 
stereochemistry of the ngercheumicins was not fully determined, in part due to the small 
amounts isolated, and in part due to the presence of three leucine residues of both L- and D-
configuration, which hampered the analysis by Marfey’s method. 
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Figure 3.31. Comparison of calculated and experimental 13C chemical shifts for the trans-fatty acid chain in 
ngercheumicin F. The black line corresponds to a perfect fit between experimental and calculated values. 
It was attempted to assess the stereochemistry of the amino acids in the ring by use of NOEs 
and backbone J coupling constants, primarily between the amide protons and Hα. Comparing 
these experimental data to energy-minimized structures it was possible to distinguish 
between L-Thr and L-allo-Thr, as L-allo-Thr showed the best correlation with experimental 
data – and it was known from the Marfey’s analysis that the Thr residues had the same 
stereochemistry. There were small differences in fits between the structures but with four 
unknown stereocenters further conclusions could not be made. The NOESY data was only 
acquired at 800 ms, which is good for optimizing correlations but difficult to rely on for 
quantitation of NOEs to calculate distance information due to the susceptibility to spin 
diffusion. Unfortunately no further spectra could be acquired, as it had been judged that it 
would not be possible to complete the stereochemical assignment with the amounts 
available, and therefore the rest was used to screen for biological activity.  
3.5.2 Quorum sensing and autoinducing peptides 
Both the solonamides and the ngercheumicins were found to inhibit QS in S. aureus, 
including the community associated methicillin-resistant S. aureus (CA-MRSA) strain 
USA300 (Paper I and II).
209
 The inhibition occurs via the accessory gene regulator (agr) QS 
system which controls the onset of virulence in S. aureus. Dr. Anita Nielsen and Prof. Hanne 
Ingmer (Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, 
University of Copenhagen) showed that these cyclic peptides affect the expression of agr by 
down-regulation of rnaIII and hla, encoding extracellular toxins, and up-regulation of spa, 
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encoding surface proteins needed in the growth phase before the onset of QS and 
virulence.
205
 Without the presence of a QS inhibitor, the onset of virulence is controlled by 
autoinducing peptides (AIPs), which induce agr expression at sufficiently high cell densities 
to initiate production of e.g. extracellular toxins.
210
 Different S. aureus strains express 
different AIP variants, with QS cross inhibition between the types producing other AIPs.
211
 
Structurally, AIPs are 16-membered peptide thiolactones, ring-closed between a cysteine 
residue and the peptide C-terminus (Figure 3.32).
212
 The solonamides and the 
ngercheumicins are all depsipeptides with the same lactone ring size and they all have an 
exocyclic chain, although the AIPs have peptide chains whereas the solonamides and 
ngercheumicins have (mainly) fatty acid chains. The amino acids in the C-terminus ends are 
generally hydrophobic for all the peptides and there are no positively charged amino acids in 
any of the peptides (Figure 3.32).  
 
Figure 3.32. Amino acid sequences and ring closures of S. aureus AIP I-III, solonamide B and ngercheumicin G. 
Amino acids with hydrophobic side chains are colored green, polar uncharged side chains are red, and polar 
charged sidechains are bright red. AIP structures were reproduced from 213.  
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Altogether these structural similarities contribute to explaining the observed bioactivities, 
and it is likely that the solonamides and the ngercheumicins are competitive inhibitors of the 
agr QS system in S. aureus. Of the new QS inhibitors identified, Solonamide B showed the 
highest activity, and Nielsen et al.
214
 recently showed that solonamide B binds to the agr 
signal receptor histidine kinase AgrC,
210
 confirming the hypothesis of solonamide B as a 
competitive inhibitor. Furthermore, it was shown that solonamide B causes a remarkable 
reduction in CA-MRSA USA300 toxicity towards human neutrophils (white blood cells in 
response to inflammation) and rabbit erythrocytes (red blood cells).
214
  
Solonamide B was produced in remarkably large amounts by the Photobacterium, as the 
most abundant secondary metabolite of this bacterium. From a 20 liter liquid culture, 201 mg 
of solonamide B was isolated, compared to 17 mg solonamide A and 0.5-1.1 mg of the 
ngercheumicins. This suggests that solonamide B has an important function for this marine 
bacterium or that there may be another biological role of this depsipeptide for the 
Photobacterium itself, perhaps an intraspecies communication system as seen within the 
AIPs of the staphylococci; however without further studies this is purely speculations. It is 
ventured that these depsipeptides are not made for QS inhibition in S. aureus, and therefore 
some sort of communication or regulation in a different species (or the Photobacterium) 
seems a more likely evolutionary reason for their production. 
For further information see Paper I and II on the solonamides and the ngercheumicins, 
respectively. 
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3.5.3 Fungal metabolites from A. fijiensis 
Filamentous fungi are historically some of the most prolific producers of various drugs, such 
as antibiotics and anticancer agents. In the search for novel secondary metabolites we 
investigated two species of the black aspergilli, namely A. carbonarius and A. fijiensis, both 
found in the fungal collection at DTU Systems Biology. A. carbonarius is a known producer 
of ochratoxin A, a foodborne carcinogenic mycotoxin known to be up-concentrated in the 
food chain.
215,216
 The species A. fijiensis was only recently described, and had therefore not 
been extensively investigated for novel metabolites before.
217
 Dereplication of the plug 
extracts (see Experimental section 3.7) resulted in the decision to make a large-scale 
extraction of A. fijiensis since this seemed to produce more possibly unknown molecules.  
Dereplication primarily based on chromatographic retention time, masses and explorative 
solid-phase extraction (E-SPE)
173
 revealed the known hits in Antibase for A. fijiensis to be 
asperparaline A, preparaherquamide, marcfortine A and C, oxaline, calbistrins and secalonic 
acids (Figure 3.33). These were all previously isolated from either Aspergillus or Penicillium 
spp.
207
 which makes them likely to be produced by this fungus. Both the asperparalines, the 
secalonic acids, and the marcfortines have several analogues which could be present in the 
extract, but only a representative selection is shown. 
After dereplication the three major compounds believed to be unknown were targeted for 
isolation and identification. It turned out that one of these ([M+H]
+
 m/z 417.2, 9.0 min) had 
recently been identified by a colleague from A. aculeatus (Lene M. Petersen, DTU Systems 
Biology, paper submitted for publication) and another was supposedly up-concentrated 
plastic remnants from the stomacher bags ([M+H]
+
 m/z 338.3, 11.8 min). This turned out to 
be an increasing problem, and identifying the source and reason for these changes is 
something that often takes long time to unravel. The work with the extract however 
continued, as there was still one unknown secondary metabolite ([M+H]
+
 m/z 266.1, 4.5 
min). Even though a hit in Antibase suggested the molecule Nigerloxin as a possible 
candidate, the UV data were different. The fractionation and purification resulted in 
identification of four secondary metabolites from A. fijiensis (see Experimental section 3.7). 
 
54 
Figure 3.33. Top: Structures from dereplication of the A. fijiensis extract. Bottom: Base peak chromatogram (m/z 50-
1000 ESI+) of the A. fijiensis raw extract in methanol. With annotations of [M+H]+ exact mass (observed or 
calculated from other adducts) and possible known compounds. See section 3.7.1 for experimental procedures. 
The unknown molecule was identified as a new pyranonigrin and tentatively named 
pyranonigrin E (Figure 3.34, see NMR assignment in the Appendix). This family constituted 
pyranonigrin A, B, C, D, and S, all known from A. niger.
218,219
 Pyranonigrin A, the closest
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analogue, was known as a radical scavenger found in molds on rice and for a moderate 
insecticidal activity.
218,220
 The new pyranonigrin E was O-methylated, which had not been 
seen before, and contained a longer alkenyl chain than the existing pyranonigrins. The 
specific rotation of pyranonigrin E was measured and found comparable to that of 
pyranonigrin A,
219
 and therefore the absolute configuration of the hydroxyl group is likely to 
be R for pyranonigrin E as well (see details in section 3.7.2). 
 
Figure 3.34. Structures of pyranonigrin A (closest resembling) and the new pyranonigrin E. 
The extract also contained the two known diketopiperazines JBIR-74 and JBIR-75 (Figure 
3.35) which were purified from the same fraction as pyranonigrin E,
221
 however only 0.2 mg 
of JBIR-75 was isolated, and therefore it was not subjected to NMR analysis. The NMR 
assignment for JBIR-74 is in the Appendix. The MS data for the purified compound believed 
to be JBIR-75 were in agreement with a loss of a CH2 moiety (14 Da) and the UV 
chromatogram was equivalent to that of JBIR-74 with UVmax at 300 and 226 nm for both. 
JBIR-75 and pyranonigrin E were subjected to antifungal and anticancer assays (Peter B. 
Knudsen, DTU Systems Biology), however no activity was found.  
 
Figure 3.35. Structures of JBIR-75 and JBIR-74. The known compounds contain D-Val and D-allo-Ile, and the 
optical rotation of JBIR-74 shows positive values similar to those found in the literature.221 Therefore the metabolites 
most likely have the same configurations. 
Pyranonigrin E was present in another fraction that also contained a metabolite from the 
extract eluting at 4.2 min (Figure 3.33) with a base peak at m/z 263.1644. This corresponded 
to water loss from a molecule with [M+H]
+
 of 281.1748 as seen from the presence of [M+H-
2H2O]
+
, [M+Na]
+
, [2M+Na]
+
. This low molecular mass gave 30 Antibase hits with the same 
molecular formula and a nondiscriminative UV spectrum (λmax 230-240 nm) made it difficult 
to dereplicate. Since it was possible to purify more of the new pyranonigrin as well as 
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identify this unknown molecule, it was purified by RP-HPLC (see Experimental section 
3.7.2) and identified by 1D and 2D NMR spectroscopy as decumbenone A (NMR 
assignment in the Appendix), a melanin biosynthesis inhibitor previously isolated from a 
Penicillium decumbens.
222
 
In collaboration with bachelor student Zeliha Basaran and Assoc. Prof. Thomas O. Larsen 
the antifungal activity in the A. fijiensis extract against Candida albicans was investigated. 
Initially it was found that plug extracts showed high antifungal activity, and testing of a 
series of fractions led to the identification of the calbistrins and secalonic acids as 
responsible for the activity. This was inferred from testing E-SPE fractions,
173
 where all the 
active fractions contained either calbistrins or secalonic acids. The calbistrins had known 
antifungal activity against C. albicans,
223
 and the secalonic acids are mycotoxins found in 
Penicillium and Aspergillus species.
224,225
 Testing secalonic acid F (purified from A. 
homomorphus by Casper Hoeck, DTU Chemistry) confirmed the antifungal activity against 
C. albicans. 
In summary, the chemistry of A. fijiensis was investigated for novel metabolites and one new 
molecule from A. fijiensis was identified and named pyranonigrin E. Two known secondary 
metabolites from Aspergillus spp., JBIR-74 and -75 were identified along with decumbenone 
A, known from P. decumbens.  
3.6 Conclusions and perspectives 
Despite the high technological state of our society, disease continues to be a major challenge 
in the 21
st
 century. Cancer is a major cause of death in the developed world, and also 
bacterial infections are today not only a threat to the frail individuals of our society, but 
community-associated infections of healthy adults by multidrug resistant pathogens are 
becoming more and more common. While antibiotic resistance is increasing, the number of 
new drugs to combat these pests decreases. Many actions can be taken to try to stop the 
development, and probably the optimal strategy is multifaceted. While the use of antibiotics 
against non-threatening infections both in humans and animals must be restricted, it seems 
naive to not keep developing new molecular “weapons” against multidrug resistant 
pathogens. The choice of methods for drug development may be a matter of belief or 
opinion, however in retrospect nature has been the major supply of drug leads, and 
neglecting to utilize this superior resource while we try to establish other methods for drug 
discovery could turn out to be fatal. It is not hard to imagine that nature already has the 
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solutions to our problems; we “just” have to discover them, and the microbial world seems 
like the perfect place to search.  
Filamentous fungi are being and have been extensively investigated by natural product 
chemists, and the same secondary metabolites are often found in phylogenetically distant 
species due to horizontal gene transfer.
226
 This highlights the importance of early-stage 
dereplication and careful strain selection, using continuously updated metabolite databases in 
the process. Metabolites from A. fijiensis were isolated in relatively small amounts and initial 
attempts of linking a biological activity to the structures were unsuccessful. Our findings 
from a marine bacterium, on the other hand, indicate that by looking in untraditional niches 
of the world, there is interesting chemical biology to be found. Despite the isolated 
metabolites being biosynthetically simple compared to the complex polyketides found in 
other sources, the biological activity and high yields (at least for the solonamides) proved the 
search worthwhile. Solonamide B was shown to strongly inhibit the agr QS system of S. 
aureus, including the hypervirulent strain USA300. This type of anti-infectious therapy is a 
hot topic, and while the in vitro activity is in the micromolar range and this is not a molecule 
ready for clinical trials, solonamide B shows very promising results by reducing the killing 
of human neutrophils in the presence of S. aureus USA300.
214
  
By optimizing the selection of strains, the dereplication process, and the biological screening 
of secondary metabolites, the hit rate increases. Whether future natural products based drug 
discovery will be in a purely academic setting is probably too early to tell. There is however 
a controversy between the requirement to publish as an academic researcher and the need to 
monopolize drugs in pharmaceutical companies. In the current state, no private company can 
be expected to develop a drug spun out of a research publication. Even a highly efficacious 
bioactive molecule, proven able to solve one of the world’s major problems, is unlikely to 
become a drug if a pharmaceutical company cannot get return of investments. It seems 
however that drug discovery and development of new antibiotics must receive imminent 
attention to stop the current trend within multi-drug resistance from spiraling out of control. 
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3.7 Experimental 
3.7.1 Fungal extracts 
A. carbonarius (IBT 21089) and A. fijiensis (IBT 4580, 13989, 14441, and 14442) from the 
IBT culture collection at the Department of Systems Biology were inoculated on agar plates 
with CYA (Czapek Yeast Autolysate), OAT (Oatmeal agar), YES (Yeast Extract Sucrose), 
and MEA (Malt Extract Agar) and grown in the dark at 25 °C for 7 days. Nine plugs across 
the colonies
227
 from the CYA and YES plates were extracted with 1 ml ethyl acetate
containing 1 % (v/v) formic acid and ultrasonicated for one hour. In addition 20 plugs from a 
CYA plate were deposited at 0 °C for the preparation of a large extract later. The plug 
extracts from CYA and YES were transferred to HPLC vials and evaporated under N2 at 33 
°C until dryness, then redissolved in acetonitrile (1 ml) and ultrasonicated for 10 min 
following filtration (0.45 μm PTFE filter) to remove solid particles. 50 μl was transferred to 
another HPLC vial and diluted with 100 μl acetonitrile for LC-DAD-HRMS and 
dereplication. 
For a large-scale extract of A. fijiensis (IBT 14442) 200 plates of CYA were inoculated and 
incubated in the dark at 25 °C for 7 days. The agar plates were extracted after 1 min in a 
Colworth 400 stomacher with ethyl acetate containing 1 % (v/v) formic acid, and then left to 
extract for 1 hour following a second round of biomass extraction overnight. Filtration on a 
Büchner funnel and concentrated to dryness on a rotary evaporator yielded about 4.4 g of 
pooled extracts (sample for HRMS) ready for desugaring and degreasing. The extract was 
dissolved in methanol/MilliQ water (9:1, 250 ml) and extracted with heptane (250 ml) and 
then 200 ml of MilliQ water was added to the aqueous phase and extracted with 200 ml 
dichloromethane. From each of the three fractions a sample was taken for HRMS (filtrated). 
After freeze drying the heptane extract yielded 0.2 g fats, the methanol/water phase yielded 
2.4 g of polar substances, and the dichloromethane phase yielded 1.0 g containing secondary 
metabolites. 
3.7.2 Fractionation and purification 
Both the methanol-water and the dichloromethane extracts of A. fijiensis were subjected to 
E-SPE following the procedure by Månsson et al. using SAX, MAX, SCX and diol SPE 
cartridges.
173
 The E-SPE fractions were subjected to LC-MS and bioguided dereplication via
the C. albicans assay described below. 
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The dichloromethane extract was fractionated on an Isolera One automated flash 
chromatography system (Biotage, Uppsala, Sweden) using a 25 g SNAP Isolute diol column 
(Biotage, Uppsala, Sweden) with solvents ranging from heptane to dichloromethane to ethyl 
acetate to methanol yielding 18 fractions. Fraction #12 (148 mg) was further purified by 
reversed phase flash chromatography using a 10 g SNAP column with ZepraZT C18 material 
at a flow of acetonitrile-MilliQ water at 10 ml min
-1
 from 15 to 75 % acetonitrile over 22 min 
and from 75 to 100 % over 4 min yielding 11 fractions. Fraction #3 (19 mg) from this run 
was subjected to final purification on a Waters 600 chromatograph (Milford, MA, USA) with 
a Waters 600 DAD with a Luna II C18 column (5 μm, 10 x 250 mm, Phenomenex, Torrance, 
CA, USA) running at 5 ml min
-1
 acetonitrile-MilliQ water from 20 to 60 % acetonitrile over 
20 min, yielding 11.0 mg of JBIR-74 (6.5 min, 33 % acetonitrile, white solid, HRMS m/z 
248.1172, M
+
 calculated for C12H16N4O2 m/z 248.1273, [α]D in methanol at 20°C, 11 mg 
ml
-1
: +122.2°) and 2.7 mg of pyranonigrin E (12 min, 44 % acetonitrile, white solid, HRMS 
m/z 265.0953, M
+
 calculated for C13H15NO5 m/z 265.0950, [α]D in methanol at 20°C, 2.7 mg 
ml
-1
: +29.6°). 
Fraction #11 from the diol fractionation (62 mg) was purified on the same Waters 
chromatograph with a Gemini C6-Phenyl column (5 μm, 10 x 250 mm, Phenomenex, 
Torrance, CA, USA) from 15 to 45 % acetonitrile in 17 min and from 45 to 100 % in 5 min 
yielding 0.8 mg of decumbenone A (13 min, yellow oil, HRMS m/z 280.1712, M
+
 calculated 
for C16H24O4 m/z 280.1675) and an additional 0.9 mg of pyranonigrin E (15 min). 
3.7.3 Bioactivity testing 
Major diol fractions (#6-13) were subjected to antifungal activity testing using C. albicans 
(IBT #654 and IBT #656) (with Zeliha Basaran and Assoc. Prof. Thomas O. Larsen) using 
20 μl at 20 mg ml-1 in an agar well diffusion assay with inoculations of 24 and 48 hours, 
using DMSO as negative control and the antifungal drug griseofulvin as positive control.  
IBT 654 however showed very weak susceptibility towards griseofulvin, whereas IBT #656 
displayed clearing zones of up to 11 mm when subjected to griseofulvin. A. fijiensis 
fractions showed clearing zones up to 31 mm in diameter, whereas pure secalonic acid D 
(MFP147 from local metabolite collection, not pure) and F (supplied by Casper Hoeck) gave 
clearing zones of 22 and 11 mm, respectively.  
3.7.4 LC-MS and NMR analyses 
LC-HRMS analyses were performed on a MaXis quadrupole time of flight (qTOF) 
electrospray ionization (ESI) mass spectrometer (Bruker Daltonics, Bremen, Germany) with 
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an Ultimate 3000 UHPLC system and a DAD detector (Dionex, Sunnyvale, CA, USA) and 
separation by a Kinetex C18 (2.6 μm, 2.1 x 200 mm, Phenomenex, Torrance, CA, USA) at 40 
°C with a 0.4 ml min
-1
 flow of acetonitrile-water (MilliQ) containing 20 μM formic acid 
from 10 to 100 % acetonitrile in 10 min. 
NMR analyses were performed on a Bruker Ascend 400 MHz with a 5 mm BBO Prodigy 
cryoprobe, a Varian 500 MHz Unity Inova with a 5 mm HCP probe, and a Bruker Avance 
800 MHz spectrometer with a TCI cryoprobe. 
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4 Human milk oligosaccharides 
This chapter describes structural studies of oligosaccharides, and begins with a background 
introduction, followed by a description of the experimental work on NMR structural studies 
of biologically important oligosaccharides in relation to this thesis. Relevant NMR 
assignments are in the Appendix for chapter 4, and three publications related to the work 
described in this chapter can be found in the back of the thesis, Paper III, IV, and V (in 
preparation). 
4.1 Introduction 
Breast milk is the perfect food source for an infant in the first period of life.
228
 It contains all 
the things needed for the baby to grow healthy and strong. If for some reason breast milk is 
not an option, the usual alternative is infant formula, a cow’s milk-based product made to 
mimic human milk. However data suggests that there are differences in the health and well-
being of breastfed vs. bottle-fed infants.
229
 Comparing human milk to cow’s milk there is one 
particular group of molecules found in human milk which commercially produced cow’s 
milk is virtually devoid of: Human milk oligosaccharides (HMOs).
230
  
 
Figure 4.36. General branching structure for a HMO backbone with lactose at the reducing end and Gal-GlcNac-
based propagations. The backbone can be decorated with L-Fuc and Neu5Ac at the various positions shown.231 
HMOs are a large group of lactose-based oligosaccharides with backbones of primarily D-
glucose (Glc), D-galactose (Gal) and N-acetylglucosamine (GlcNAc), often decorated with 
L-fucose (Fuc) and Neu5Ac (N-acetylneuraminic acid also known as sialic acid) (Figure 
4.36). The simplest structures are lactose decorated with Neu5Ac, usually in the 3’- and 6’-
positions on Gal, or with Fuc, usually in the 3- and 2’-positions on Glc and Gal, respectively 
(Figure 4.37).  
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Figure 4.37. Structures of two HMOs, 3’-sialyllactose (3’-SL, top) and 3-fucosyllactose (3-FL, bottom). 
4.2 The HMO project 
In 2010 a range of industry and university partners began a collaboration aimed at 
developing enzymatic processes to produce HMOs. The partners (Arla Foods, DuPont, DTU, 
University of Southern Denmark (SDU), University of Copenhagen (KU-Life), and 
University of Reading) realized that large-scale production of HMOs resulting from a four 
year research project was an ambitious aim; however the immediate goal was production of 
HMOs in laboratory scale and assessing the structural and biological properties. The project 
started in April 2010 led by Prof. Jørn D. Mikkelsen (DTU Chemical Engineering) and the 
35-40 researchers were divided into five work packages (WP) with responsibilities of 1) 
generating enzymes, 2) bioresource utilization and process development, 3) chemical 
structure and analysis, 4) functional properties and proof of concept, and 5) project 
management and intellectual property rights (IPR). One of the end goals was production of 
10 HMOs to be analyzed and screened in various assays for biological activity. NMR and 
MALDI-TOF analyses (by groups at DTU Chemistry and SDU, respectively) should be used 
to characterize the final ten HMOs and collaborate with WP1 and WP2 in the ongoing 
analysis of reaction products. 
Approximately one year into the project I entered as a PhD student, and the initial work was 
to prepare for future analyses of potentially small amounts and/or mixtures, by structure 
elucidating commercially available HMO samples, which were also used by the different 
WPs until scale-up the various HMOs could be achieved. These analyses were often 
combined with purity assessment as the biological assays in WP4 are sensitive to 
contaminants and assessing the purity of a reactant is important to be able to characterize the 
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process. Carbosynth (Berkshire, UK) and Elicityl (Crolles, France) are major commercial 
distributors of HMOs for research purposes with mainly chemical synthesis and biomass 
extraction/fermentation as respective production methods. Different impurities can thus be 
expected from the products, depending on the production method and purification, which in 
turn may influence the response of a biological assay. 
4.3 Biological role of HMOs 
The average lactose content in human milk and cow’s milk is 55-70 g/l and 40-50 g/l 
respectively, and human milk is estimated to contain 5-15 g/l of HMOs whereas cow’s milk 
contains only trace amounts of these oligosaccharides,
231–234
 although the composition varies 
during the different phases of lactation.
232
 More than 180 different HMOs have been 
identified in human milk samples
235
 and the biological role of these oligosaccharides is 
surprisingly manifold, although some of the effects are not fully elucidated:  
 HMOs are prebiotic, which defines a non-viable food component not digested by the host 
organism, but which benefits the gut microbiota, e.g. bifidobacteria and lactobacilli.
236–
238
  
 HMOs function as soluble receptor analogues for a wide range of pathogens, preventing 
their binding to the intestinal epithelium and thereby inhibit infection.
233,239,240
 These 
pathogens include influenza virus, HIV-1, V. cholera, E. coli, and many more.
231,239
 
 It is believed that HMOs have beneficial immunomodulatory properties by activating the 
immune system upon exposure and perhaps even prevent allergies.
234
 
 As fucose and sialic acid are abundant constituents of brain gangliosides, HMOs appear 
to be important factors in infant brain development.
241,242
  
In fact, the brain gangliosides are structurally very similar to gangliosides in the intestinal 
epithelium where e.g. cholera toxin binds. Gangliosides are ceramide-bound HMO-like 
molecules found on cell membranes eliciting interaction and communication with the 
environment.
243
 The only other mammal found to have a milk oligosaccharide composition 
as complex as humans is the elephant.
244
 It may not be a coincidence that both humans and 
elephants are slow-growing species with highly developed neural systems. Other mammals 
are found to have different building blocks, other ratios of known oligosaccharides or a 
simpler oligosaccharide composition, but the origins and conclusions to these relationships 
remain unsettled.
245–249
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4.4 Sources of fucose and sialic acid 
Fuc- and Neu5Ac-containing molecules are very valuable constituents in research, in 
medicine, and as food supplements due to their biological properties. Unfortunately it is not 
straightforward to obtain these monomers in pure form, neither from natural sources nor by 
chemical synthesis. L-fucose is equivalent to 6-deoxy-L-galactose, however L-galactose is 
neither available as a suitable substrate for large-scale synthesis. Several chemical syntheses 
converting other monosaccharides into L-fucose are described in the literature, but common 
disadvantages are low yields and many synthetic steps.
241,250–252
 Wong et al. produced L-
Fucose enzymatically in 55 % yield from dihydroxyacetone phosphate and lactaldehyde.
253
 
Pinto et al. synthesized a Fuc analogue in 40 % yield, however further deprotection steps 
would be required to make any use of it.
254
 A patent application from 2013 by Glycom A/S 
(Kgs. Lyngby, Denmark) also describes new ways of synthesizing L-Fuc.
255
 
There are some examples of attempts to synthesize Neu5Ac in the literature,
256–258
 however 
many syntheses focus on different analogues
259
 or use complicated or expensive starting 
materials.
260,261
 In general the difficulties in extracting or synthesizing L-fucose and sialic 
acid are reflected in the cost of the monomers. Carbosynth currently sells 100 g L-Fucose for 
608 €, and Neu5Ac for 266 €.262  
Natural sources abundant in L-fucose or Neu5Ac are not easy to find. Plant polysaccharides 
contain L-fucose and especially seaweeds have a high content of sulfated L-fucose polymers 
called fucoidan.
241
 Fucoidan is primarily made up of L-fucose and sulphate groups. It is used 
as a dietary supplement and has received much attention due to its manifold biological 
activities.
263,264
 The best source for enzymatic utilization of Neu5Ac seems to be 
caseinoglycomacropeptide (CGMP). CGMP is a constituent in whey, which is a byproduct in 
cheese production. It is not to be confused with the secondary messenger cyclic guanosine 
monophosphate (cGMP) or CMP-Neu5Ac which is the sialic acid donor for 
sialyltransferases in mammals (Figure 4.38). CGMP is a 64 amino acid peptide containing 5-
13 % (w/w) Neu5Ac and dairy companies such as Arla Foods produce CGMP isolates for 
functional food ingredients.
265,266
 Due to the bulk production, low cost and relatively high 
sialic acid content it seems to be a good source of Neu5Ac, which is difficult to obtain from 
other natural sources. Sialic acid can be cleaved from CGMP by acid hydrolysis or by the 
use of enzymes (Figure 4.38). 
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Figure 4.38. Examples of enzymes able to transform sialic acid motifs. a) Neuraminidases and sialidases cleave off 
Neu5Ac from carbohydrate moieties, b) sialyltransferases move Neu5Ac between nucleotide-sugars and 
carbohydrate moieties, c) trans-sialidases transfer Neu5Ac between carbohydrate chains while retaining 
stereochemistry, and d) the structure of CMP-β-Neu5Ac, cytidine-5’-monophospho-N-acetylneuraminic acid sodium 
salt. 
Neuraminidases or sialidases are sialyl hydrolases that cleave the glycosidic linkages of 
Neu5Ac-glycan structures. Two different types of enzymes can catalyze the transfer of 
Neu5Ac between residues: Sialyltransferases, which use nucleotide-sugar donors in an SN2-
like inversion mechanism to form α-Neu5Ac-glycan bonds, and trans-sialidases, which move 
Neu5Ac residues between glycan chains (or to water, functioning as sialidases) via a double 
displacement or retaining mechanism.
267
  
4.4.1 Perspectives on the production of HMOs 
Enzymes with the ability to transfer Neu5Ac are also used to synthesize and manipulate 
sialic acid-containing compounds in chemoenzymatic reactions.
268
 Another option to make 
sialylated oligosaccharides is the use of cell factories.
269
 The method requires some genetic 
engineering to optimize the biosynthesis, but 3’-sialyllactose yields as high as 25 g/l has 
been obtained from cultures using lactose as acceptor and glycerol as the only carbon and 
energy source.
270
 The strain of E. coli used in the production of 3’-sialyllactose is also used 
in the pharmaceutical industry for e.g. large-scale production of human insulin. Restrictions 
on the production of food supplements (especially for infant formula) are however expected 
to be harder, and the recombinant genes come from pathogenic bacteria, which produce 
Neu5Ac as a way to evade the host immune system.
271
 It is also very doubtful whether 
parents would allow feeding large amounts of oligosaccharides produced by recombinant E. 
66 
coli to their children, especially after the Chinese scandal in 2008 where melamine added to 
milk caused serious kidney disease in thousands of children.
272
A group of Chinese researchers have cloned a herd of cattle to produce human lysozyme, 
which protects infants from infections and supposedly this “humanized the bovine milk”.273
The milk oligosaccharide content is however unchanged, but one could speculate on the 
possibility of cloning genes necessary for HMO production in a similar future project, and 
thus further enhance the health benefits of cow’s milk.  
Chemical synthesis of HMOs is a complicated process, and reaching high molecular weights 
in solution is a challenge with the many protection and deprotection steps required, 
decreasing the synthetic yield.  Another issue is the chemistry of Neu5Ac, with the lack of a 
3-hydroxy group and the carboxyl group at the anomeric position making glycoside 
formation difficult.
274,275
 The HMO backbone tetrasaccharide lacto-N-tetraose (LNT) was
synthesized by Noro et al.
276
 in 1979 and since then a wide range of HMOs have been
synthesized.
277–281
 Recently, Jennum et al. synthesized LNT, lacto-N-neotetraose (LNnT –
see Table 4.5 on page 69) and developed one-pot procedures for these rather complex 
oligosaccharides. Fucosylated LNT and LNnT were also synthesized, yielding LNFP-I and 
LNnFP-I.
282
A combination of chemical and enzymatic reactions seems to be the best route to sialic acid-
containing HMO-like molecules, either by chemical modification of enzymatically 
synthesized Neu5Ac-containing molecules or by final decoration of synthetic HMO 
backbone structures with Neu5Ac.
280,283
Due to the current inaccessibility of HMOs in large scale, other oligosaccharides are used as 
food additives and in some infant formulas today.
234,284
 Galactooligosaccharides (GOS) are
oligomers of D-galactose with a D-glucose moiety in the reducing end and 
fructooligosaccharides (FOS) are oligomers of D-fructose with D-glucose in the reducing 
end.
285
 These oligosaccharides are not found in human milk but they have prebiotic
properties mimicking some of the highly desired effects of HMOs.
234,284
4.5 Characterization of HMOs 
Analysis and detection of oligosaccharide mixtures is difficult due to the structural 
similarities and the high number of possible isomers. HPLC, MS, and NMR spectroscopy are 
probably the best methods to characterize HMOs, preferably used together either directly 
coupled or one by one.
286
 HMO molecules are very hydrophilic and therefore the most
suitable separation method is anion exchange chromatography.
287
 Capillary electrophoresis
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has also been used for separation of either sialylated or neutral HMOs, but as the separation 
is based on electrophoretic mobility, which is different for charged and uncharged molecules, 
this method is not applicable to HMOs in general.
288,289
Mass spectrometric methods (especially if initial separation of mixtures is achieved) are very 
important tools to examine HMOs due to the exact mass determination. Matrix-assisted laser 
desorption ionization (MALDI) and electrospray ionization (ESI) techniques are especially 
suitable for carbohydrates which can be difficult to ionize.
290,291
 The MALDI technique
cannot be coupled to chromatography and is therefore most suitable for small amounts and 
relatively uncomplicated samples, whereas ESI is coupled to a liquid stream and therefore 
finds its strength in the analysis of mixtures by coupling to HPLC. Tandem MS can be used 
to obtain monomer sequences in simple oligosaccharide samples, and in combination with 
specific enzyme digestion it is possible to elucidate branching points.
235,286
 Although a bit
cumbersome, this method provides a very sensitive method for analysis of HMOs in minute 
amounts, down to the low femtomole range. 
4.5.1 HMO analysis by NMR 
Compared to MS, NMR spectroscopy is a relatively insensitive technique; however NMR 
yields important structural information. The primary strength of NMR spectroscopy in 
oligosaccharide analysis is within structural studies in the distinction of isomers and 
conformations of HMOs in solution. Even in mixtures of compounds it is possible to 
elucidate monomer structures and branching points. So-called structural reporter groups have 
been used to identify specific monomers due to NMR resonances outside the crowded region 
of the 
1
H NMR spectrum (3-4 ppm);
292,293
 e.g. the 6-Me group of Fuc or the unique
resonances from the equatorial and axial H3s of Neu5Ac. Anomeric resonances in both 
1
H
and 
13
C NMR contain information that can be used in the structure elucidation. The anomeric
chemical shifts are different for α- and β-anomers and are therefore often used 
discriminatively, e.g. the differences in 
1
H and 
13C chemical shifts between α- and β-Glc in
3’-sialyllactose is about 0.5 ppm and 4 ppm, respectively. Also the anomeric 1JCH coupling
constants are known to differ about 10 Hz between α- and β-anomers.294 For Neu5Ac, which
has a quaternary anomeric carbon, assignment of the anomeric configuration is difficult. The 
2
JC2,H3ax and 
3
JC1,H3ax coupling constants are believed to offer the best discrimination, 
however the measurement is not straightforward, especially in cases of overlapping 
resonances.
295–297
 Other coupling constants (especially 
3
JHH) are used in the assignment of
axial and equatorial substituents to differentiate especially the hexopyranoses. The 
13
C 
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chemical shifts are also fairly monomer-specific, and chain elongation or branching causes 
systematic changes in the chemical shifts of surrounding atoms, depending on the type and 
stereochemistry of the glycosylation. This is something that automatic assignment 
procedures and carbohydrate databases take advantage of.
298,299
 Chemical shifts of reference 
compounds are thus used to great advantage in assignment of carbohydrates, and therefore it 
is important to have the same spectral reference. Most unprotected carbohydrate samples are 
acquired in D2O, as it simplifies the spectra by removing any resonances from hydroxyl 
groups. However, D2O is not an ideal solvent for spectral referencing. There is no 
13
C 
resonance and the HDO residual solvent resonance around 4.79 ppm at room temperature is 
highly temperature dependent.
300
 In addition, the residual solvent resonance is often removed 
by presaturation of the resonance frequency if the sample contains larger amounts of water. 
This makes it even harder to use as a spectral reference in 
1
H NMR. There are two ways to 
solve this problem: Either adding a reference compound to all samples and reference in 
accordance with literature values or using external referencing. External referencing is done 
by acquiring a spectrum of a reference compound in the given solvent, and then using the 
spectrum reference frequency obtained to calibrate spectra run in the same solvent at the 
same temperature, without addition of reference compound and thus avoiding sample 
contamination.
301
 This method however does not take salt and pH effects into account, which 
may change the chemical shift values. A reference compound often used for carbohydrates is 
1,4-dioxane adjusted to 3.75 ppm and 67.4 ppm at 25 °C for 
1
H and 
13
C, respectively.
300,302
 
4.5.2 NMR structural assignment of HMO molecules 
The experimental work within this project began with the construction of a small NMR 
library of assigned HMOs. Structure elucidation of commercial samples involved the tri-, 
tetra- and pentasaccharides shown below (Table 4.5, see NMR assignments with HMBC 
correlations in the Appendix). Reference 
1
H and 
13
C NMR assignments are available for 
many of the HMOs, however in many cases in incomplete form or based on structural 
reporter groups.
245,246,303–306
 Various reference spectra of lactose, selected monomers and 
possible contaminants were acquired and analyzed when necessary. 
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Table 4.5. Commercial HMOs characterized by NMR spectroscopy. NMR assignments are in the Appendix. 
Trivial name (abbreviation) Condensed structure 
3’-sialyllactose (3’-SL) Neu5Acα2-3Galβ1-4Glc 
6’-sialyllactose (6’-SL) Neu5Acα2-6Galβ1-4Glc 
2’-fucosyllactose (2’-FL) Fucα1-2Galβ1-4Glc 
3-fucosyllactose (3-FL) Galβ1-4(Fucα1-3)Glc 
Lacto-N-tetraose (LNT) Galβ1-3GlcNAcβ1-3Galβ1-4Glc 
Lacto-N-neotetraose (LNnT) Galβ1-4GlcNAcβ1-3Galβ1-4Glc 
Lacto-N-fucopentaose V (LNFP-V) Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 
Lacto-N-neofucopentaose V (LNnFP-V) Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 
There are a few differences between the structure elucidation of oligosaccharides compared 
to natural products, and a general assignment protocol is therefore described here. Since 
spectra are usually acquired in D2O and small chemical shift differences are often important 
for the outcome of analysis, careful spectral referencing must be ensured. In this work 1,4-
dioxane was used as external reference (δH 3.75 ppm, δC 67.4 ppm, 25°C). The majority of 
carbohydrate resonances in 
1
H NMR are observed in a narrow spectral region between 3.5
and 4 ppm with severe resonance overlap. The less crowded regions of the 
1
H spectrum
contains the structural reporter groups
293
 which are more easily used in analysis and includes
the anomeric protons between 4 and 6 ppm and any other more or less monomer-specific 
resonances from e.g. N-acetyl groups and deoxy-sugars (Figure 4.39).  
Figure 4.39. Comparison of 1H NMR spectra (500 MHz, D2O) for LNT, 2’-FL, 3-FL, 6’-SL, and 3’-SL (from the top)
showing the differences between their structural reporter groups and anomeric regions. 
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Even though compounds like the fucosyl- and sialyllactoses contain the same respective 
monomers and thus have identical molecular masses, there are distinguishable features in the 
less crowded areas of the NMR spectra which aid in the differentiation and detection of these 
isomers. For 
13
C NMR, the majority of the carbohydrate resonances of pyranoses are found
between 60 and 80 ppm, and the anomeric resonances are around 90-105 ppm. 
Consequently, protons in the crowded region of the 
1
H spectrum of about 0.5 ppm have their
respective (directly bonded) carbon chemical shifts distributed over a 20 ppm range. This 
helps to unravel resonance overlap and distinguish 
13
CH-pairs by using 2D heteronuclear
experiments. For an oligosaccharide, little information can be extracted from the 3.5-4 ppm 
region of a DQF-COSY spectrum, but with sufficient resolution in the second dimension 
these protons are more easily identified by use of gHSQC, gHMBC, gHSQC-TOCSY and 
other heteronuclear experiments (Figure 4.40). Especially the gHSQC-TOCSY is highly 
useful for oligosaccharide samples. Most of the 
13
C resonances in each monosaccharide can
be assigned from the HSQC-TOCSY correlations to the anomeric proton. HSQC-type 
correlations are used to identify protons directly correlated to the 
13
C resonances in the spin
system identified from the gHSQC-TOCSY. Missing resonances within the monosaccharide 
building blocks are identified by concurrent use of gHMBC, gH2BC and the homonuclear 
DQF-COSY and TOCSY, depending on the extent of resonance overlap. Monosaccharide 
building blocks are connected using HMBC- and NOESY/ROESY-correlations across the 
glycosidic bonds. In cases where this type of HMBC-correlation is absent, one must rely on 
through-space couplings from NOESY and ROESY spectra. The chemical shifts should 
however also present clues to the linkage position by comparison to similar molecules. To 
illustrate some of the points regarding spectral overlap for a pure HMO, selected 1D and 2D 
NMR spectra for synthetic LNT are shown in Figure 4.40. The spectral overlap seen in the 
1
H and DQF-COSY spectra is markedly reduced in the heteronuclear experiments. 
4.5.3 Purity assessment 
Purity assessment by NMR is not straightforward. Inorganic impurities are rarely detected 
and NMR resonances of macromolecules such as polymers or proteins often disappear due to 
fast (T2) relaxation compared to small molecules. This leads to extensive broadening of the 
resonances which in some cases are only seen as an elevated baseline. Chemical shifts easily 
change with differences in temperature, ionic strength and pH, and the optimal parameters 
(e.g. pulse width and relaxation delay) for one molecule may cause resonances of other 
molecules to vanish.  
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Figure 4.40. NMR spectra of synthetic LNT (800 MHz, DQF-COSY at 500 MHz, D2O, 20 mg, generously supplied by 
Dr. Thomas Fenger and Prof. Robert Madsen). From top left: 1D 1H, 1D 13C, 2D DQF-COSY, gHSQC, gHMBC, and 
gHSQC-TOCSY. 
Most methods of analysis however have their drawbacks when it comes to mixture analysis, 
and NMR has its strengths within organic molecules and structural isomers. Examples of 
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impurities often observed in HMO samples were various reactants, solvents, and buffers, 
usually resulting from side reactions or inadequate purification, e.g. glycerol was found in 
many samples from enzymatic reactions due to its use as stabilizer for frozen proteins. 
Changes in chemical shifts compared to the pure reference samples were often observed. 
For analysis of mixtures where the constituents had a high degree of resonance overlap in 1D 
as well as 2D spectra it could be difficult to establish whether this was simply pH effects or 
whether a structural modification had occurred. This highlights the importance of combining 
several methods of analysis, why we should use a combination of NMR and MS for most 
purposes.Finding a good source of fucose for enzymatic synthesis proved difficult, and in 
2012 a large order of LNFP-V and LNnFP-V (Table 4.5) was placed with one of the HMO-
producing companies. The two HMOs were intended for development of the biological 
assays of WP4, and two samples were submitted to NMR analysis prior to use. The 
compounds were assigned by 1D and 2D NMR spectroscopy and it was found that the 
samples contained substantial carbohydrate impurities of which some were the 
corresponding non-fucosylated tetrasaccharides (Figure 4.41).  
Figure 4.41. 1H NMR spectra (500 MHz, D2O) of LNnFP-V (top, blue) and LNnT (bottom, green) showing the
anomeric region. In LNnFP-V the β-Gal resonances are found at 4.40 and 4.47 ppm, the β-GlcNAc at 4.69 ppm and 
the α-Fuc around 5.4 ppm (splits due to the anomers of Glc), and the β- and α-Glc at 4.64 and 5.19 ppm, respectively. 
The major impurities were not identified, although the presence of LNnT was confirmed by comparison with the 2D 
NMR spectra. Integrals belong to the upper spectrum. 
Other impurities were not fully structure elucidated, however one abundant impurity with 
anomeric resonances at 5.12 ppm and 5.00 ppm displayed strong NOE correlations between 
the two anomeric protons mentioned. This suggested some resemblance to trehalose (two α-
D-Glc connected by an α,α-1,1-glycosidic bond), although the asymmetry in the chemical 
shift means the two monomers were not identical.
307
 Nevertheless, it meant that these
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samples were not suitable for biological assays as it would be difficult to know if a certain 
response was caused by the pentasaccharides or any of the impurities. 
4.5.4 CGMP as sialic acid donor 
CGMP is a relatively small hydrophilic peptide which is released from κ-casein by the 
enzyme chymosin during cheese production.
266,308
 The κ-casein is cleaved between Phe105
and Met106 yielding this 64 amino acid peptide from the C-terminal end of  κ-casein, with 
phosphorylation and glycosylation sites at various Thr and Ser residues.
266
 Five different
oligosaccharide structures are found in bovine CGMP, of which two are neutral in charge (no 
Neu5Ac), two are monosialylated and one is disialylated. As a Neu5Ac-containing dairy 
byproduct, CGMP was widely used in the HMO project as a sialic acid donor for enzymatic 
reactions, and as sialic acid is difficult to obtain from natural sources, this seemed to be the 
optimal donor. In the oligosaccharides bound to the protein backbone, Neu5Ac is known to 
bind to the 3-position of Gal and the 6-position of GalNAc.
309
 The glycosylation of CGMP is
non-uniform both regarding the glycosylation sites and the size of the oligosaccharides, and 
some CGMP contains no Neu5Ac at all.
310,311
 There is evidence suggesting that CGMP
forms aggregates in solution and it is unclear how much of the sialic acid in CGMP is 
actually accessible to enzymes,
308
 and thus what the true sialic acid utilization potential of
CGMP is. Many enzymes are specific for certain Neu5Ac linkage types and therefore it is 
important to know the relative amounts of the different Neu5Ac species. We therefore 
decided to investigate CGMP by NMR spectroscopy and in particular the ratio of 3- and 6-
bound Neu5Ac. We used Lacprodan CGMP-20 (Arla Foods Ingredients, VibyJ, Denmark), 
which is a food grade protein powder product. The CGMP-20 contains 5.7 % (w/w) Neu5Ac 
as determined by our collaborators (Paper III).
312
 As expected, both α2-3- and α2-6-linked
Neu5Ac variants were found in CGMP-20, however from visual inspection of the NMR data 
it appeared that the α2-3-linked Neu5Ac was slightly more abundant in this product (Figure 
4.42). Assuming that the NMR parameters for these Neu5Ac-species in CGMP are similar, 
integration of the 2D NOESY (600 ms mixing) and DQF-COSY cross peaks between H3eq 
and H3ax indicated about 15-20 % less Neu5Ac bound to the 6-position than to the 3-position 
of GalNAc/Gal. Judging by the DQF-COSY cross peak shape, especially the α2-6-linked 
Neu5Ac seems to be present in more than one structural environment reflected by the 
diagonal elongation of the H3eq-H3ax cross peak structure. This is likely due to the α2-3-
linked Neu5Ac being bound to the nonreducing end of the oligosaccharide, whereas the α2-
6-linked Neu5Ac is found as a branching point closer to the peptide backbone.
309
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Figure 4.42. Region of DQF-COSY spectrum of CGMP (D2O, 500 MHz, 1.5 seconds relaxation time) showing the 
cross peaks between H3eq, H3ax, and H4 of Neu5Ac.  
The molecular weight of CGMP is about 8 kDa whereas the aglyco-CGMP weighs 6.8 
kDa.
266,313
 This means that the average CGMP has glycosylations corresponding to a total of
1.2 kDa, however the extent of glycosylation varies.
310,311
 The five common oligosaccharide
fragments on CGMP each contribute between 203 and 948 Da to the molecular weight, 
however the larger sialylated tri- and tetrasaccharides (657-948 Da) are most abundant.
309,314
Roughly estimated, this means that about two Neu5Ac units can be found in the average 
CGMP molecule, and judging by the ratio of α2-3- and α2-6-linked Neu5Ac, an α2-3-trans-
sialidase may thus be able to utilize one Neu5Ac per CGMP molecule. This is in reasonable 
agreement with the 5.7 % (w/w) Neu5Ac in CGMP-20 which for an 8 kDa CGMP 
corresponds to 1.5 Neu5Ac units per molecule (both 3- and 6-bound). Although this seems 
like a small amount, it has to be taken into account that there are not many cheap and easily 
accessible Neu5Ac sources available, and transglycosylation enzymes cannot utilize free 
Neu5Ac. Therefore binding of Neu5Ac to a donor molecule is advantageous for enzymatic 
utilization. 
4.5.5 Sialyl-oligosaccharides from trans-sialidases 
At the start of the HMO project the first target compound was 3’-SL, and about a year after 
joining the project, Dr. Jesper Holck and Dr. Malwina Michalak had developed procedures 
ppm
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for production of 3’-SL of high purity by use of native and mutated trans-sialidases from 
Trypanosoma spp. expressed in Pichia pastoris (Paper III and IV). Trypanosoma spp. are 
protozoan parasites or single-celled animal-like protists known to cause tropical infections 
such as Chaga’s disease.315 As this is therefore not an ideal production host, the enzymes
were expressed in P. pastoris, which is also used for expression of recombinant proteins in 
the biotechnological industry. The 3’-SL was structure elucidated by MS and NMR 
spectroscopy and two research papers were published on the results, which will therefore not 
be further elaborated here (Paper III and IV). It was also attempted to sialylate GOS, with 
enzyme and purification work by Dr. Jesper Holck and Yao Guo. It was speculated that this 
might improve the prebiotic properties and afford an easy route to a relatively simple 
mixture, mimicking the biological roles of HMOs. Structure elucidation of the different 
constituents of GOS was not attempted by 2D NMR due to the high homogeneity.  However, 
treatment of GOS with a trans-sialidase in the presence of CGMP, and following 
fractionation by ion exchange chromatography to remove unreacted GOS, yielded a fraction 
assumed to contain sialyl-GOS. By comparing the NMR spectra with spectra of GOS and 
sialyllactoses this assumption was confirmed. Several resonances were indicative of the 
Neu5Acα2-3Galβ motif as shown in Figure 4.43. The grey boxes highlight the Gal 
resonances in close proximity with Neu5Ac as well as the H3 resonances of Neu5Ac. The 
acetyl (Ac) group of Neu5Ac is also present in the less crowded region of the spectra, 
however singlet resonances at this position are common in other molecules and therefore not 
discriminative (e.g. acetic acid and GlcNAc). By examining and comparing 1D 
1
H and 2D
DQF-COSY spectra it was clear that not only lactose had reacted to form 3’-SL but other 
Neu5Ac-containing oligosaccharides were present, as seen from the group of resonances 
slightly shifted from the 3’-SL resonances (Figure 4.44). Especially the resonances indicated 
by grey rectangles are clearly related to the sialylation. Due to the limited amount of material 
(low S/N ratio) and the resonance overlap, it was not possible to investigate the structures 
further by use of other 2D homonuclear and heteronuclear NMR methods.  
The strength of NMR in this case is the unambiguous assignment of all Neu5Ac as being 
bound to the 3-position of Gal. In case of a α2-6-linked Neu5Ac, the H3 resonances around 
1.80 ppm (axial) and 2.75 ppm (equatorial) would be shifted further upfield similar to what 
is seen in 6’-SL. Other linkage types would also be expected to result in chemical shift 
changes for the two H3 protons of Neu5Ac.  
NMR spectroscopy was used to investigate the linkages formed from sialylation of GOS and 
lactose, and it was shown that the purified products contained exclusively α2-3 linked 
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Neu5Ac.  To determine the number, relative amounts, and sizes of different sialyl-GOS 
molecules, LC-MS would be superior.  
 
 
Figure 4.43. Partly annotated 1H NMR spectra (500 MHz, D2O) of sialyl-GOS (Dr. Jesper Holck), 3’-SL, GOS, and 
lactose (from the top). Grey rectangles indicate distinct resonances for molecules containing Neu5Acα2-3Gal.   
 
Figure 4.44. Overlay of DQF-COSY spectra for sialyl-GOS (red), GOS (blue) and 3’-SL (grey). The relative 
resonance intensity and contour levels were individually optimized for visual inspection. 
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4.5.6 Trans-fucosylations 
A HMO-related project (with Mateusz Lezyk, DTU Chemical Engineering) involved the 
search for trans-fucosidases for production of fucose-HMOs using lactose and p-nitrophenyl 
α-L-fucose (pNP-Fuc) as substrates. After screening for enzymes in a soil metagenomic 
library, a small group of enzymes were selected for characterization and assaying of their 
trans-fucosidase activity. However, the yields were very low and it was not possible to 
identify reaction products by high performance anion exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD) for which no standards were available. We therefore 
started a collaboration to use NMR spectroscopy to identify products observed in higher 
yields than the fucosyllactoses (2’-FL and 3-FL) which were the primary targets. It was 
believed that the major constituents could be difucosyllactoses, however by using NMR 
spectroscopy it was quickly established that the lactose was not the optimal acceptor 
molecule for the nine enzymes investigated. In fact the fucosyllactoses (2’-FL and 3-FL) 
were present in too low amounts to confirm their presence by 1D and 2D NMR 
spectroscopy. The major reaction taking place was hydrolysis of pNP-Fuc, as seen by the 
presence of free fucose in the postreaction mixture. In analogy with the trans-sialidases, the 
trans-fucosidases also act as fucosidases, and therefore hydrolyze pNP-Fuc.
316
 The major
trans-fucosylation products were identified and structure elucidated by 2D NMR 
spectroscopy, revealing that pNP-Fuc or Fuc acts as the glycosyl acceptor to form the pNP-
Fuc-Fuc glycosides p-nitrophenyl α-L-fucopyranosyl-(1-2)-α-L-fucopyranoside as well as the 
1-3- and 1-4-linked pNP-Fuc-Fuc glycosides (Figure 4.45).  
Figure 4.45. Structures of p-nitrophenyl α-L-fucopyranosyl-(1-2)-α-L-fucopyranoside, p-nitrophenyl α-L-
fucopyranosyl-(1-3)-α-L-fucopyranoside, and p-nitrophenyl α-L-fucopyranosyl-(1-4)-α-L-fucopyranoside (from left). 
The products were identified and structure elucidated in postreaction mixtures after removal 
of the enzyme by ultrafiltration (5 kDa cutoff). The results were confirmed by 
1
H NMR
 78 
 
analysis of purified products in minute amounts (Figure 4.46), which enabled linking the 
chromatographic peaks to the different pNP-Fuc-Fuc glycosides.  
 
 
Figure 4.46. Anomeric regions of the 1H NMR spectra in D2O (400 and 500 MHz) for pNP-αFucα1-4Fuc, pNP-
αFucα1-3Fuc, pNP-αFucα1-2Fuc (See NMR data in the Appendix), reaction products of Mfuc7, and reaction 
products of Mfuc6 (from the top). The water resonance around 4.8 ppm was partially removed by presaturation. 
Since no commercial standards were available for these products, it was initially attempted to 
relate 
1
H NMR integral values to integrals from the PAD response (Figure 4.47). This was 
done by calibrating the β-Gal H1 resonance of lactose to an integral value of 1 and then 
using the known anomeric resonances of the products as well as pNP-Fuc to compare the 
relative amounts of trans-fucosylation and hydrolysis products. Besides the fucosyllactoses 
there were other minor resonances not accounted for in Figure 4.47. Comparing amounts 
between the different enzymes should be done with caution as this requires exactly equal 
amounts of lactose and solvent in the samples as well as comparable relaxation properties. 
Although this can be assumed to some extent to be fulfilled, it is still best to use the results to 
compare enzyme regioselectivity qualitatively. By using NMR spectroscopy it was shown 
that these enzymes primarily act as fucosidases, hydrolyzing the donor, but analyzing 
reaction mixtures it was possible to investigate the product specificity of the enzymes and 
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showing that the primary reaction products were self condensation pNP-Fuc-Fuc glycosides. 
For experimental details and NMR data see Paper V.   
Figure 4.47. Diagram of 1H NMR integral values of pNP-Fuc and reaction products relative to lactose in postreaction 
mixtures from 9 different trans-fucosidases. WT=wildtype, MUT=mutant. 
4.5.7 Enzymes in reaction monitoring 
Studying enzymatic reactions over time while monitoring the disappearance and build-up of 
reactants and products can yield information of the kinetics of an enzymatic reaction. In 
collaboration with Dr. Jesper Holck from DTU Chemical Engineering we wanted to monitor 
the reaction of a trans-sialidase with CGMP and lactose as glycosyl donor and acceptor, 
respectively. The reactions were run as described in the experimental section 4.7. 
We hoped to see a change in the spectrum over time, however it turned out any reaction 
product was formed in so small amounts that it was indiscernible due to the large resonances 
of CGMP. The trans-sialidase resonances were broad and almost not visible in the spectra, 
but the CGMP, being a relatively small peptide in high concentration, made it impossible to 
discern the sialyllactose formed in minute amounts. There was no baseline separation at 
places where resonances of 3’-SL were expected and even comparison to a spectrum of 
CGMP on its own did not help to simplify matters. Buffer was not added to the CGMP 
sample, which would have facilitated an easier comparison between the spectra. However it 
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would not have changed the conclusion that this low yielding enzymatic reaction in the 
presence of the large CGMP resonances was not optimal for reaction monitoring by 1D 
1
H 
NMR.  
Later in the project we were asked to examine another trans-sialidase in a similar fashion. In 
this case our collaborators (Rui Xue and Yao Guo from DTU Chemical Engineering) were 
interested in determining the identity of some byproducts they could observe by thin layer 
chromatography (TLC), and if possible study the kinetics of the reaction. Using lactose and 
pNP-Neu5Ac as substrates they could observe the formation of 3’-SL and after one hour it 
disappeared while other products formed. They also attempted to use 3’-SL and lactose as 
substrates (in a 2:1 ratio), and it appeared that the 3’-SL was converted into free Neu5Ac and 
6’-SL, judging by TLC and comparing to the pure standards. 1H NMR spectra of the 
different carbohydrates in the sample (Figure 4.48) were acquired, along with spectra of the 
citric acid/disodiumphosphate buffer and the enzyme solution (data not shown). The enzyme 
sample showed mainly resonances from the buffer and glycerol. A negative control and a 
postreaction sample were freeze dried and redissolved in D2O to assess the resonance 
overlap at start and finish (Figure 4.48).  
 
Figure 4.48. 1H NMR spectra (500 MHz, D2O, 25 °C) of carbohydrates found in the reaction mixture. NC is a 
negative control without enzyme, and R is the reaction after completion (then freeze dried and redissolved in D2O, 
although not all H2O was removed). Regions chosen for integration are highlighted in the NC and R by grey boxes. 
From the left, the six boxes represent 3’-SL Gal H1; Lactose and 6’-SL Gal H1; 3’-SL Gal H3; α-Neu5Ac H3eq both 
free and in sialyllactoses; free β-Neu5Ac H3eq; 6’-SL Neu5Ac H3ax. Glycerol resonances are labelled with * in the R 
spectrum. 
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The spectra of the negative control (NC) and the postreaction mixture (R) displayed distinct 
differences. There were no resonances from the enzyme which had been broadened so much 
that they completely disappeared. There were easily recognizable resonances from 3’-SL, 6’-
SL, and Neu5Ac, although the Neu5Ac chemical shifts appeared to be shifted upfield due to 
the effect of the buffer. The second order spin system at 2.6 ppm came from citric acid, just 
downfield from the equatorial H3 resonances, which for 6’-SL was shifted slightly upfield 
compared to 3’-SL. The reaction mixture contained large resonances from glycerol, which 
came from the enzyme solution (marked with * in Figure 4.48). The Neu5Ac H3ax 
resonances appear between 1.6 and 1.9 ppm, and they are different for the three Neu5Ac-
containing samples, although the free β-Neu5Ac resonance is found closer to the 3’-SL H3ax 
in the buffered solution. The free α-Neu5Ac H3 resonances are found at 1.7 and 2.7 ppm, 
more or less overlapping with those of 6’-SL, however the α-anomer constitutes only about 5 
% of the total free Neu5Ac in solution. The Gal H1 resonance at 4.5 ppm for 3’-SL is 
completely separated from those of lactose and 6’-SL which are overlapping, however the 
water resonance turned out to add to the integral and therefore the Gal H3 resonance at 4.1 
ppm yielded a more accurate measurement. The H3ax at 1.7 ppm for the 6’-SL is separated 
from those of 3’-SL and β-Neu5Ac. For Neu5Ac the H3eq of the β-anomer at 2.2 ppm was 
isolated. All this together formed a good basis for reaction monitoring by NMR as there were 
separated resonances for the 3’-SL, the 6’-SL, and the β-Neu5Ac (Figure 4.48). The 
reactions were run in H2O to prevent the heavier D2O from having an effect on the reaction 
kinetics.
317,318
 This was done by inserting a glass capillary containing D2O into the NMR 
tube, which ensured sufficient deuterium resonance for the lock. We could not stir the 
solution inside the NMR tube and we did not spin the samples, so therefore the free diffusion 
in the sample as opposed to magnetic stirring may have had an effect. In the case of a slow 
reaction, the diffusion would however have limited influence on the kinetics. See 
experimental details in section 4.7. 
The integrals were converted to concentrations by calibrating the integral at 2.7 ppm (Figure 
4.48) to the starting concentration of 3’-SL (20 mM). This integral also covered the 6’-SL 
and the free α-Neu5Ac (but not the β-Neu5Ac), however the hydrolysis reaction was slow 
and this calibration was therefore expected to be an acceptable approximation in comparison 
to the uncertainty of integration in general. At t = 3 min the concentrations of β-Neu5Ac and 
6’-SL were measured to 0.06 mM and 0.54 mM, and therefore the error resulting from this 
approximation was negligible. The integral of the 3’-SL Gal H3 also confirmed this by 
starting from 20 mM (Figure 4.49).  
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Figure 4.49. Graph of concentrations over time and test of the reproducibility for enzyme kinetics experiments 
measured by 1H NMR. Integrals were measured by 1H NMR and calibrated to the starting concentration of 3’-SL. 
Starting conditions were 20 mM 3’-SL, 10 mM lactose, 50 mM phosphate buffer, and 50 μl enzyme (37 °C, H2O, 500 
MHz). 
 
Figure 4.50. Enzymatic reactions of a trans-sialidase with 20 mM 3’-SL and 10 mM lactose (2, ▲), no lactose (6, ♦), 
or 100 mM lactose (7, ●). 
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The Gal H1 integrals had systematic errors as they were closest to the water resonance and 
the 6’-SL and lactose resonances were combined; however the slopes of these curves 
followed those of the corresponding sialyllactoses, and nevertheless the two curves were 
redundant. The reaction was repeated three times under the same conditions to test the 
reproducibility of the method. There were small deviations in the concentrations of 
substrates and products within a 2 mM window for the final concentrations (Figure 4.49). 
The reaction was repeated without lactose and with a ten times higher lactose concentration, 
and surprisingly lactose slowed down the reaction, most likely as a competitive inhibitor 
(Figure 4.50). It was believed that the enzyme could not use 6’-SL as a substrate. To test this 
hypothesis the reaction was run with 6’-SL and lactose which resulted in hydrolysis of 6’-
SL, but to lesser extent than for 3’-SL. After 19 hours, 3 mM of β-Neu5Ac had been formed 
in this reaction (data not shown). The project came to a halt when priorities changed and lack 
of enzyme prevented further analyses.  
4.6 Conclusions and perspectives 
The initial goal of production and analysis of 10 HMOs was not achieved and we took part in 
parallel identification of 3’-sialyllactose products from different trans-sialidases. Various 
commercial HMOs were analyzed by NMR spectroscopy to create a small HMO NMR 
database. This was believed to afford easier mixture analysis when necessary; however it 
was sometimes problematic to compare spectral data for pure substances in D2O to buffered 
systems in H2O with different ionic strengths and pH. Nevertheless we identified various 
impurities and oligosaccharides, usually in complex mixtures, which resulted in 
contributions to Paper III, IV and V. 
Reaction monitoring of enzymatic processes was achieved by 
1
H NMR in H2O, and it was 
possible to correlate integral values to concentration. Even though the accuracy of the 
integrations can be questioned, the slope of the curves should not be, and the results with this 
reaction show good potential for kinetic investigations of trans-sialidases by 
1
H NMR. 
CGMP works well as a sialic acid donor in enzymatic reactions; however kinetics studies of 
low-yielding reactions in the presence of CGMP proved difficult as the 
1
H NMR resonances 
of CGMP dominated in the high concentrations necessary for adequate Neu5Ac availability. 
An attempt to investigate the reaction kinetics using smaller Neu5Ac donors such as 3’-SL 
were initiated, which afforded adequate resonance separation to monitor the changes in 
reactants and products overnight. 
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It was revealed that lactose seems to acts as a competitive inhibitor for the substrate binding 
site of the trans-sialidase enzyme, shown by the deceleration of the reaction with higher 
lactose concentration and acceleration at lower concentration and without lactose present. 
The reaction is slow for an enzymatic reaction, and altogether this suggests that the enzyme’s 
interactions with donor and acceptor could be optimized further. Despite the anticipations 
that 6’-SL was not a substrate for this enzyme, it was shown that 6’-SL was slowly 
hydrolyzed to form Neu5Ac and lactose. 
In a related project, a variety of enzymes were assessed for their trans-fucosidase activities, 
and by analyzing postreaction mixtures by 1D and 2D NMR spectroscopy it was shown that 
the enzymes’ major activities were as fucosidases, hydrolyzing the pNP-Fuc substrate. The 
desired trans-fucosylation reaction would be to use lactose as a glycosyl acceptor and pNP-
Fuc as donor to form fucosyllactoses, however the major products besides free Fuc were 
identified as pNP-α-L-Fuc-(1-n)-α-L-Fuc, where n is 2, 3, and 4. Fucosyllactoses were not 
detected by NMR spectroscopy but by HPAEC chromatography in small amounts, and 
therefore further screening of trans-fucosidases for production of fucosyllactoses is 
necessary. 
A general conclusion drawn from this project is that production of HMOs in large scale for 
human consumption is still a goal that is difficult to reach. Discovering appropriate methods, 
and in particular finding the right enzymes, has been more difficult than expected. Enzymes 
able to sialylate and (to limited extent) fucosylate lactose and higher oligosaccharides have 
been obtained, even though the yields are very low. The HMO backbone was not synthesized 
enzymatically, and therefore it seems that production of HMOs by current technologies 
would be best undertaken by joint efforts of biotechnology and synthetic chemistry. Several 
HMO backbone structures were synthesized within the HMO project by Dr. Camilla Jennum, 
Dr. Thomas Fenger and Prof. Robert Madsen (DTU Chemistry) and enzymatic decoration 
with fucose and sialic acid could potentially form a basis for HMO production, however both 
synthetic and enzymatic approaches must be further improved before this can become 
reality. 
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4.7 Experimentals 
4.7.1 Reaction monitoring with CGMP 
CGMP (10.5 mM), lactose (30.0 mM), and citric acid/disodiumphosphate buffer (50 mM) 
were mixed in 500 μl D2O and heated to 30 °C (Holck 2013). The NMR magnet was 
shimmed, tuned and matched and a 
1
H spectrum was acquired. The enzyme was added (20 
μl, 1.1 g/l final concentration), the time was noted and the magnet was again quickly 
shimmed manually. Then a 
1
H spectrum was acquired approx. every 9 minutes overnight. 
4.7.2 Reaction monitoring with 3’-SL 
When starting a reaction in the 500 MHz NMR spectrometer (see spectrometer details in the 
Appendix) the magnet was prepared (shimming, tuning and matching) with the sample inside 
at 37 °C (before enzyme addition) and a t0 reference spectrum was acquired. Addition of 50 
μl enzyme solution changed the concentrations in the samples, and therefore the first usable 
data points were after addition of enzyme and initial shimming (approx. 3 min). The first few 
measurements (8 scans each) were acquired manually while shimming between the 
measurements and then after 10-15 min the spectrometer was set up to acquire a spectrum 
every 10 min with automatic shimming on the z1 and z2 coils for about 60 seconds between 
acquisitions. The data was saved as a 2D experiment and processed in Topspin 3.0 with the 
‘multicmd’ and ‘multi_integ’ AU programs. The initial manual measurements were included 
and used as the first data points by ensuring that the time for each measurement was noted 
along with the exact start and finish time of the automatic acquisition, which could then be 
divided by the number of 1Ds to give the exact time between each measurement. 
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5 Overall conclusions and perspectives 
This thesis contains the parallel results of three different projects. Chapter 2 describes the 
development of new NMR experiments for measurement of coupling constants; chapter 3 
was on identification of secondary metabolites from microbial sources, with the hope of 
finding new bioactive molecules; and chapter 4 gave a description of the work undertaken 
for the common goal of producing human milk oligosaccharides, also with biological 
activities in mind. The experiments developed in chapter 2 can be used for studies of the 
molecules described in chapter 3 and 4, and in this way the thesis is held together by the 
general topic: Structural studies of human milk oligosaccharides and other natural products. 
A new NMR experiment, named HMBC+, was developed for measurement of J coupling 
constants in small molecules, and it was demonstrated on vinyl acetate and strychnine – a 
small organic molecule and a natural product. The strength of this experiment lies in the sign 
sensitive measurement of long-range homonuclear JHH coupling constants, and the results so 
far point towards a very accurate determination. Further work will show the full potential of 
this new experiment, but its robustness and ability to sign sensitively determine very small 
coupling constants makes it superior to existing methods. It is believed that the HMBC+ 
experiment has potential applications both in oligosaccharide analysis and for determination 
of relative configuration in small molecules, e.g. by measurement of RDCs. 
Chapter 2 also describes work on NMR experiments for sign sensitive measurement of 
2
JCH 
in small molecules, however this is work in progress and the experiment in its current state 
has narrow applications for determination of coupling constants to quaternary carbon atoms. 
For proton-rich spin systems, interference from undesired coherences seems to obscure the 
multiplet patterns and so far the principles behind it have not been understood. Measurement 
of suitable 
2
JCH coupling constants by other methods and comparison of results from the 
different methods would be the next step in the ongoing work with these experiments. 
Changes to the pulse sequences may also help elucidate and eventually solve the current 
problems with this experiment. 
A range of new molecules were discovered and described in this thesis. This includes the 
solonamides and the ngercheumicins: Two families of cyclic depsipeptides isolated from a 
marine bacterium with the ability to prevent virulence in the pathogenic S. aureus (Paper I 
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and II). These peptides share some structural traits with the natural quorum sensing inducing 
AIPs in S. aureus, and the ability to inhibit QS in three of four subclasses of agr provides 
important knowledge of the structure-activity relationships of such QS inhibitors.
214
 Future
work on this project could involve synthesis of solonamide analogues in attempts to 
elucidate the pharmacophore as well as improve the activity, and studies of the interaction 
between solonamide B and its supposed target, the sensor histidine kinase AgrC, would 
provide important information on the mechanism of action.  
Aspergillus fijiensis, a relatively unknown fungal species, was also investigated in the hope 
of isolating novel secondary metabolites. Regrettably only one new molecule was isolated, 
an analogue of the pyranonigrins, therefore named pyranonigrin E. Dereplication is an 
important tool in this research area, and quick update as well as thorough use of metabolite 
databases is very important when several people are working with the same fungal genera, as 
it is quite common to find the same secondary metabolites in different species. It turned out 
that one of the pursued metabolites had recently been isolated by Lene Maj Petersen from A. 
aculeatus. Another supposedly unknown molecule had been labeled as such in the local 
metabolite database, when in fact the molecule was a contamination from stomacher bags 
during the extraction, suddenly appearing as a very large peak in all extracts, possibly due to 
a new production method at the stomacher bag supplier. 
Finally, participation in a larger project with the goal of producing human milk 
oligosaccharides led to the joint efforts of producing 3’-SL by enzymatic methods (Paper III 
and IV). In a related collaboration, a range of enzymes were screened for their trans-
fucosylation abilities, and three “auto”-fucosylation products were identified, both in 
reaction mixtures and as purified compounds in small amounts (Paper V). This shows the 
importance of collaborations across various fields of research, and how joint efforts, using 
several methods of analysis, leads to a clearer interpretation of the results. A great deal of 
work is still needed before industrial production of complex HMOs is achievable, and work 
on both enzymes and synthetic procedures seems necessary to reach this ambitious but noble 
goal. 
The HMBC+ experiment is without doubt the most significant contribution of this thesis to 
the NMR society. With both the experiment and the subsequent processing running 
smoothly, it is the hope that less experienced NMR users will also make use of this 
experiment for easier structural analysis of complex molecules in the future.  
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Spectrometers and acquisition 
 Varian Mercury 300 MHz with a 5 mm 4 nucleus probe (HCFP)  
 
 Bruker Ascend 400 MHz with a with a 5 mm H – Broadband Dual Channel z-gradient 
Prodigy cryoprobe 
 
 Varian Inova 500 MHz with a 5 mm HCP probe 
 
 Bruker Avance 800 MHz with a 5 mm TCI cryoprobe (at the Danish Instrument Centre for 
NMR Spectroscopy of Biological Macromolecules at the Carlsberg Laboratory, Valby, 
Denmark). 
 
Unless otherwise noted, experiments were acquired using standard pulse sequences at 25 °C, 
referenced to solvent residual resonances (see below). Zero filling in F2 was done once and zero 
filling in F1 was done once or to 1024 points to enhance the digital resolution. Linear prediction was 
only used for ADEQUATE-type experiments. 
 
DMSO-d6: 2.49 ppm, δC 39.50 ppm 
CDCl3 δH: 7.26 ppm, δC 77.16 ppm 
In D2O and H2O, using external 1,4-dioxane: δH 3.75 ppm, δC 67.4 ppm 
 
Chapter 2 
HMBC+ pulse program 
; HMBCplus.c 
; pulse program by 
; LOKJA, AWBN, CHG, and OWS (May 2014) 
; for measurement of magnitude and sign of long-range J(HH) 
; Echo/antiecho gradient selection 
; With third order low-pass J-filter to suppress one-bond correlations 
 
#include <Avance.incl> 
#include <Grad.incl> 
#include <Delay.incl> 
 
; NB: set TD1 to 4 or the program will NOT work 
 
; compacted pulseprogram with minor modifications. 
; uses NBL so that we can acquire the HMBC+/- to the 
; same location with only 50% of the time + and 50% 
; -.  
 
;SER file: HMBC, HMBC+/-, HAT-, HAT+ 
 
; the pulseprogram can be thought of as three pulseprograms with different delays 
; which we can define "on the fly" in the pulseprogram 
define delay AB_delay1 
define delay AB_delay2 
define delay AB_delay3 
define delay AB_delay4 
Appendix 
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define delay AB_delay5 
define delay AB_delay6 
define delay AB_delay7 
 
; this loopcounter specifies which experiment type will be run:  
; 0 (std) , 1 (-) or 2 (+) 
define loopcounter updown 
 
; this loopcounter is used to control when the decoupler is turned off after the 
first proton 90  
; 1 (HMBC -/+) or 0 (std and HAT) 
define loopcounter HMBCED 
 
define delay EPS 
define delay EPSA 
define delay LP1 
define delay LP2 
define delay LP3 
 
; gH=26.752196, gC=6.72828 
; EA = gH+gC : gH-gC (approx.: 5:3) 
define list<gradient> EA1 = {1.0000 -0.5981} 
define list<gradient> EA2 = {1.0000 0.5981} 
define list<gradient> EA3 = {0.5981 1.0000} 
 
"d10=3u" 
"d11=30m" 
"d12=20u" 
"p2=p1*2" 
"p4=p3*2" 
 
"TAU  =  (1s/(2*cnst9))" ; Tau, probably best to set this according to the modal 
average 
"TAU1  = (1s/((cnst6 + 0.07*(cnst8 - cnst6))*2))"  
"TAU2  = (1s/(cnst6 + cnst8))"     
"TAU3  = (1s/((cnst8 - 0.07*(cnst8 - cnst6))*2))" 
"DELTA = 50u + p16 + d16"   ; gradient duration 
"EPS=p2+d10*2" 
"EPSA=EPS+p4" 
 
"LP1   = TAU1 - DELTA - 2*d12"   ; LPJF 
"LP2   = TAU2 - DELTA - p3"   ; LPJF 
"LP3   = TAU3 - DELTA - p3"   ; LPJF 
 
"l0=0" 
"updown=0" 
"HMBCED=0" 
"in10=inf2/2" 
 
aqseq 312 
 
1 ze 
  10u 
2 3m 
3 3m 
  30u 
4 d11 
  d1 BLKGRAD 
; handle the HMBC +/- experiments using nsdone 
  if "nsdone %2  == 1" 
  { 
  "AB_delay1=d12" 
  "AB_delay2=TAU+0.5*EPSA" 
  "AB_delay3=d12" 
  "AB_delay4=d6-2*DELTA" 
  "AB_delay5=TAU+EPS-DELTA" 
  "AB_delay6=TAU-DELTA" 
  "AB_delay7=EPSA" 
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  "updown=1" 
  "HMBCED=1" 
  } 
  else 
  { 
  "AB_delay1=d12" 
  "AB_delay2=TAU+0.5*EPSA" 
  "AB_delay3=d12" 
  "AB_delay4=d6-2*DELTA+EPSA" 
  "AB_delay5=TAU-DELTA" 
  "AB_delay6=TAU-DELTA+EPS" 
  "AB_delay7=d16" 
  "updown=2" 
  "HMBCED=1" 
  } 
 
; if l0 != 1 then do one of the other experiments 
; (this would be more elegant if "else if" was allowed) 
 
; standard HMBC   
  if "l0==0" 
  { 
  "AB_delay1=TAU+0.5*EPSA" 
  "AB_delay2=d12" 
  "AB_delay3=TAU+0.5*EPSA" 
  "AB_delay4=d6-DELTA+0.5*EPSA" 
  "AB_delay5=0.5*TAU-DELTA" 
  "AB_delay6=0.5*TAU-DELTA+EPS" 
  "AB_delay7=DELTA" 
  "updown=0" 
  "HMBCED=0" 
  }   
 
; HAT - 
  if "l0==2" 
  { 
  "AB_delay1=0.5*TAU+d12" 
  "AB_delay2=0.5*TAU+0.5*EPSA" 
  "AB_delay3=0.5*TAU" 
  "AB_delay4=d6-2*DELTA" 
  "AB_delay5=0.5*TAU+EPS-DELTA" 
  "AB_delay6=0.5*TAU-DELTA" 
  "AB_delay7=0.5*TAU+EPSA" 
  "updown=1" 
  "HMBCED=0" 
  } 
 
; HAT + 
  if "l0==3" 
  { 
  "AB_delay1=0.5*TAU+d12" 
  "AB_delay2=0.5*TAU+0.5*EPSA" 
  "AB_delay3=0.5*TAU" 
  "AB_delay4=d6-2*DELTA+EPSA" 
  "AB_delay5=0.5*TAU-DELTA" 
  "AB_delay6=0.5*TAU+EPS-DELTA" 
  "AB_delay7=d16+0.5*TAU" 
  "updown=2" 
  "HMBCED=0" 
  } 
 
  AB_delay1 pl12:f2 
  AB_delay2 cpd2:f2   
  (p1 ph10):f1 
  if "HMBCED==1"  
  { 
  AB_delay3 do:f2 
  } 
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  else 
  { 
  AB_delay3  
  d12 do:f2  
  } 
  d12 pl2:f2 
  LP1 
  50u UNBLKGRAD 
  p16:gp1 
  d16 
  (p3 ph4):f2 
  50u 
  p16:gp1*-0.5714 
  d16 
  LP2 
  (p3 ph5):f2 
  50u 
  p16:gp1*-0.2857 
  d16 
  LP3 
  (p3 ph6):f2 
  50u 
  p16:gp1*-0.1429 
  d16 
   
  AB_delay4 
   
  if "updown==0" 
  { 
  (p3 ph2):f2 
  d10 
  (p2 ph10):f1 
  d10 
   
  AB_delay5 
   
  50u 
  p16:gp5*EA1 
  d16 igrad EA1   
  (p4 ph3):f2 
  50u 
  p16:gp5*EA1 
  d16 igrad EA1 
 
  AB_delay6 
   
  (p3 ph1):f2 
  
  AB_delay7 
  } 
     
  if "updown==1" 
  { 
  50u 
  p16:gp5*EA3*-1 
  d16 
  (p3 ph2):f2 
  50u 
  p16:gp5*0.7990 
  d16 
 
  AB_delay5 
   
  (p4 ph3):f2 
  d10 
  (p2 ph10):f1 
  d10 
 
 A-6 
 
  AB_delay6 
   
  50u 
  p16:gp5*-0.7990 
  d16 
  (p3 ph1):f2 
  50u 
  p16:gp5*EA3 
  d16 
 
  AB_delay7   
  } 
  if "updown==2" 
  { 
  50u 
  p16:gp5*EA2*-1 
  d16 
  (p3 ph2):f2 
  50u 
  p16:gp5*0.7990 
  d16 
 
  AB_delay5 
 
  d10 
  (p2 ph10):f1 
  d10 
  (p4 ph3):f2 
 
  AB_delay6 
   
  50u 
  p16:gp5*-0.7990 
  d16 
  (p3 ph1):f2 
  50u 
  p16:gp5*EA2 
  ; no d16 here as we include it in AB_delay7 to prevent it from becoming zero 
  AB_delay7 
  } 
  
  goscnp ph31 
  10u st 
  10u iu0 
  lo to 2 times nbl ; do the four experiments (HMBC switches between +/- on 
alternate scans) 
  3m ipp1 ipp2 ipp3 ipp31 ru0; do phases and ns scans 
  lo to 3 times ns  
  d11 mc #0 to 4 
     F1QF() 
     F2EA(igrad EA1 & igrad EA2 & igrad EA3 rpp1 rpp2 rpp3 rpp31, id10) 
   d11 BLKGRAD 
exit 
 
;phase cycle 
ph1=0 0 2 2 2 2 0 0 
ph2=0 0 0 0 2 2 2 2 2 2 2 2 0 0 0 0 
ph3=0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 
ph4=0 
ph5=0 
ph6=0 
ph10=0 
ph31=0 0 2 2 
 
 
;plw1    :f1 power level for pulse (default) 
;plw2    :f2 power level for pulse (default) 
;plw12   :f2 power level for CPD/BB decoupling 
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;p1      :f1 90 degree high power pulse 
;p2      :f1 180 degree high power pulse 
;p3      :f2 90 degree high power pulse 
;p4      :f2 180 degree high power pulse 
;p16     :gradient pulse 
; 
;d0      :increment delay (3usec) 
;d1      :relaxation delay: 1-5*T1 
;d6      :delay for evolution of long range couplings 
;d11     :delay for disk I/O                    [ 30 msec] 
;d12     :delay for power switching             [ 20 usec] 
;d16     :delay for homospoil/gradient recovery [200 usec] 
; 
;TAU     :1/(J(min) + J(max)) 
;TAU1    :1/2(J(min)+0.07(J(max)-J(min)) 
;TAU2    :1/(J(min) + J(max)) 
;TAU3    :1/2(J(max)-0.07(J(max)-J(min)) 
;DELTA   :Gradient duration, p16 + d16 + 50u 
; 
;cnst6   :1J(min), ~125 Hz 
;cnst8   :1J(max), ~165 Hz 
;cnst9   :1J optimal for editing ~145 Hz 
;MC2     :Echo-Antiecho 
;EA1     :Echo-Antiecho gradient program, [+5 -3] 
;EA2     :Echo-Antiecho gradient program, [+5 +3] 
;EA3     :Echo-Antiecho gradient program, [+3 +5] 
; 
;pcpd2   :Pulse length for cpd on f2 [65 usec] 
;cpdprg2 :Cpd-program                [garp4] 
; 
;gpnam1  :Gradient pulse 1 file name [SMSQ10.100] 
;gpnam5  :Gradient pulse 5 file name [SMSQ10.100] 
;gpz1    :Gradient strength 1, +7        [+12%] 
;gpz5    :Gradient strength 5            [+80%] 
; 
;ns: 16*n 
;ds: 32 
; 
;Processing: 
; F2     : SSB = 4, WDW = QSINE, PH_mod = pk 
; F1     : SSB = 2, WDW = QSINE, PH_mod = no 
; Au-pgm : Use HMBCplus AU program 
; FT     : xfb; xf2m; abs2; abs1; 
 
 
  
 A-8 
 
HMBC+ AU program 
; HMBCplus AU program  
; for processing of HMBCplus datasets in Topspin 3.0 
; by LOKJA, AWBN, CHG, and OWS (May 2014) 
; It creates 8 expnos: 
;   1-2: Edited HMBC (1: C/CH2, 2: CH/CH3) 
;   3-4: HAT HMBC (3: C/CH2, 4: CH/CH3) 
;   5-6: HMBCplus C/CH2 (5: add, 6: subtract) 
;   7-8: HMBCplus CH/CH3 (7: add, 8: subtract) 
 
 #define MAXSIZE 32768 
 #define RSER2DAB(direction, num, eno) \ 
 {SETCURDATA; (void)sprintf(Hilfs_string,"rser2d s%d %d %d y n", 
direction,num,eno); \ 
  AUERR=CPR_exec(Hilfs_string,WAIT_TERM);} 
 
AUERR = hmbcplus(curdat); 
QUIT 
 
 int hmbcplus(const char* curdat) 
{ 
  
 char infile1[PATH_MAX], infile2[PATH_MAX],stattext[PATH_MAX]; 
 char outfile1[PATH_MAX],outfile2[PATH_MAX]; 
 char path[PATH_MAX + 64]; 
 
 int row1[MAXSIZE], row2[MAXSIZE]; 
 int rowout1[MAXSIZE], rowout2[MAXSIZE]; 
 int td1s, td2s, td1,td2,tds,td; 
 int i, j; 
 int oexpno,nexpno, byteorder, parmode,zexpno; 
   
 FILE *fpin1, *fpin2, *fpout1,*fpout2; 
 
 float scaleed=1.05, scalehat=1.0, scaleplus=1.0; 
 
  /***** get dataset and parameters *****/ 
 
  FETCHPAR("PARMODE", &parmode) 
 
  if (parmode != 2) 
    STOPMSG("Program is only suitable for pseudo 3D data") 
 
 
 
  /***** get input *****/ 
 
  oexpno=expno; 
  nexpno = expno*100 + 1; 
  GETINT("Enter first EXPNO to store new dataset:", nexpno) 
  if (nexpno <= 0) 
    STOPMSG("invalid expno value") 
 
  
 GETFLOAT("Enter scaling factor for HMBCed (0.8-1.2)", scaleed); 
 if((scaleed < 0.8) || (scaleed > 1.2)) STOPMSG("Scaling factor must be between 0.8 
and 1.2"); 
/* GETFLOAT("Enter scaling factor for HAT HMBC (0.8-1.2)", scalehat); 
 if((scalehat < 0.8) || (scalehat > 1.2)) STOPMSG("Scaling factor must be between 
0.8 and 1.2"); 
 GETFLOAT("Enter scaling factor for Plus spectra (0.8-1.2)", scaleplus); 
 if((scaleplus < 0.8) || (scaleplus > 1.2)) STOPMSG("Scaling factor must be between 
0.8 and 1.2"); */ 
  
/* create the output datasets as 2D dataset */ 
/* contains bug fixes needed for some computers */ 
  RSER2DAB(23,1,nexpno);    /* std HMBC */ 
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  RSER2DAB(23,2,nexpno+1);   /* HMBC-/+ */ 
  RSER2DAB(23,3,nexpno+2);   /* HAT- */ 
  RSER2DAB(23,4,nexpno+3);   /* HAT+ */ 
/* create datasets for the PLUS experiment */ 
/* we also use them as temp datasets */ 
  RSER2DAB(23,1,nexpno+4); 
  RSER2DAB(23,2,nexpno+5); 
  RSER2DAB(23,1,nexpno+6); 
  RSER2DAB(23,2,nexpno+7); 
/* create the HMBCed spectra */ 
  expno = nexpno+4; 
  (void)strcpy(infile1, ACQUPATH("ser")); 
  fpin1 = fopen(infile1, "rb"); 
  if (fpin1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+5; 
  (void)strcpy(infile2, ACQUPATH("ser")); 
  fpin2 = fopen(infile2, "rb"); 
  if (fpin2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile2); 
    STOPMSG(path) 
  }  
  expno = nexpno; 
  (void)strcpy(outfile1, ACQUPATH("ser")); 
  fpout1 = fopen(outfile1, "wb"); 
  if (fpout1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  } 
  expno = nexpno + 1; 
  /* we write to ser2 as we want to remove E/AE later ! */ 
  (void)strcpy(outfile2, ACQUPATH("ser2")); 
  fpout2 = fopen(outfile2, "wb"); 
  if (fpout2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile2); 
    STOPMSG(path) 
  } 
  SETCURDATA; 
  FETCHPARS("BYTORDA", &byteorder) 
  FETCHPARS("TD",&tds) 
  tds = ( (tds + 255) / 256 ) * 256; 
/* here we get the data from the 2D not the 3D */ 
  FETCHPAR1("TD",&td1) 
  FETCHPAR1S("TD",&td1s) 
  for (i=0; i < td1s; i++) 
  { 
    fread(row1,sizeof(int),tds,fpin1); 
    local_swap4(row1,sizeof(int)*tds,byteorder); 
    fread(row2,sizeof(int),tds,fpin2); 
    local_swap4(row2,sizeof(int)*tds,byteorder); 
    for (j=0; j < tds ; j++) 
{ 
int row1u = row1[j]; 
int row2s = (int)(scaleed * row2[j]); 
rowout1[j] = row1u + row2s; 
rowout2[j] = row1u - row2s; 
} 
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    local_swap4(rowout1,sizeof(int)*tds,byteorder); 
    fwrite(rowout1,sizeof(int),tds,fpout1); 
    local_swap4(rowout2,sizeof(int)*tds,byteorder); 
    fwrite(rowout2,sizeof(int),tds,fpout2); 
    }  
  fclose(fpin1); 
  fclose(fpin2); 
  fclose(fpout1); 
  fclose(fpout2); 
   
  /* remove E/AE from second HMBCed experiment. Because we need to get rid of 90 
degree phase error in second HAT subspectrum */ 
  expno = nexpno+1; 
  (void)strcpy(infile1, ACQUPATH("ser2")); 
  fpin1 = fopen(infile1, "rb"); 
  if (fpin1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
    STOPMSG(path) 
  } 
  (void)strcpy(outfile1, ACQUPATH("ser")); 
  fpout2 = fopen(outfile1, "wb"); 
  if (fpout2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  }  
   
  for (i=0; i < td1s; i+=2) 
  { 
    fread(row1,sizeof(int),tds,fpin1); 
    local_swap4(row1,sizeof(int)*tds,byteorder); 
    fread(row2,sizeof(int),tds,fpin1); 
    local_swap4(row2,sizeof(int)*tds,byteorder); 
  
      for (j=0; j < tds ; j+=2) 
        {  
  int row_r1 = row1[j]; 
  int row_r2 = row2[j]; 
  int row_i1 = row1[j+1]; 
  int row_i2 = row2[j+1]; 
 
 /* see Palmer III, JMagnReson 93(1991), 151-170 */ 
 /* the second fid has the signs swapped due to the way */ 
  /* Bruker's FT works */ 
 
                rowout1[j] = row_r1 + row_r2; 
                rowout1[j+1] = row_i1 + row_i2; 
                rowout2[j+1] = (row_r1 - row_r2);                 
                rowout2[j] = -(row_i1 - row_i2);                 
        } 
    local_swap4(rowout1,sizeof(int)*tds,byteorder); 
    fwrite(rowout1,sizeof(int),tds,fpout2); 
    local_swap4(rowout2,sizeof(int)*tds,byteorder); 
    fwrite(rowout2,sizeof(int),tds,fpout2); 
    }  
  fclose(fpin1); 
  fclose(fpout2); 
  SETCURDATA; 
  STOREPARNS(1, "FnMODE", 4) 
  STOREPARN(1, "FnMODE", 4) 
  unlink(ACQUPATH("ser2")); /* delete tmp ser file */ 
    
/* now create the HAT spectra */ 
  expno=oexpno; 
  SETCURDATA 
  RSER2DAB(23,3,nexpno+4); 
  RSER2DAB(23,4,nexpno+5); 
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  expno = nexpno+4; 
  (void)strcpy(infile1, ACQUPATH("ser")); 
  fpin1 = fopen(infile1, "rb"); 
  if (fpin1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+5; 
  (void)strcpy(infile2, ACQUPATH("ser")); 
  fpin2 = fopen(infile2, "rb"); 
  if (fpin2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile2); 
    STOPMSG(path) 
  }  
  expno = nexpno+2; 
  (void)strcpy(outfile1, ACQUPATH("ser")); 
  fpout1 = fopen(outfile1, "wb"); 
  if (fpout1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+3; 
  (void)strcpy(outfile2, ACQUPATH("ser2")); /* as for HMBCed */ 
  fpout2 = fopen(outfile2, "wb"); 
  if (fpout2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile2); 
    STOPMSG(path) 
  } 
  SETCURDATA; 
  FETCHPARS("BYTORDA", &byteorder) 
  FETCHPARS("TD",&tds) 
  tds = ( (tds + 255) / 256 ) * 256; 
  FETCHPAR1("TD",&td1) 
  FETCHPAR1S("TD",&td1s) 
  for (i=0; i < td1s; i++) 
  { 
    fread(row1,sizeof(int),tds,fpin1); 
    local_swap4(row1,sizeof(int)*tds,byteorder); 
    fread(row2,sizeof(int),tds,fpin2); 
    local_swap4(row2,sizeof(int)*tds,byteorder); 
    for (j=0; j < tds ; j++) 
{ 
int row1u = row1[j]; 
int row2s = (int)(scalehat * row2[j]); 
rowout1[j] = row1u + row2s; 
rowout2[j] = row1u - row2s; 
} 
    local_swap4(rowout1,sizeof(int)*tds,byteorder); 
    fwrite(rowout1,sizeof(int),tds,fpout1); 
    local_swap4(rowout2,sizeof(int)*tds,byteorder); 
    fwrite(rowout2,sizeof(int),tds,fpout2);  
    }  
  fclose(fpin1); 
  fclose(fpin2); 
  fclose(fpout1); 
  fclose(fpout2); 
  /* remove E/AE from second HAT HMBC experiment */ 
  expno = nexpno+3; 
  SETCURDATA; 
  (void)strcpy(infile1, ACQUPATH("ser2")); 
  fpin1 = fopen(infile1, "rb"); 
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  if (fpin1 == 0) 
  { 
(void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
STOPMSG(path) 
  } 
  (void)strcpy(outfile1, ACQUPATH("ser3")); /* as we need to phase correct the data 
afterwards */ 
  fpout2 = fopen(outfile1, "wb"); 
  if (fpout2 == 0) 
  { 
(void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
STOPMSG(path) 
  }  
  for (i=0; i < td1s; i+=2) 
  { 
fread(row1,sizeof(int),tds,fpin1); 
local_swap4(row1,sizeof(int)*tds,byteorder); 
fread(row2,sizeof(int),tds,fpin1); 
local_swap4(row2,sizeof(int)*tds,byteorder); 
for (j=0; j < tds ; j+=2) 
{ 
int row_r1 = row1[j]; 
int row_r2 = row2[j]; 
int row_i1 = row1[j+1]; 
int row_i2 = row2[j+1]; 
/* see Palmer III, JMagnReson 93(1991), 151-170 */ 
/* the second fid has the signs swapped due to the way */ 
/* Bruker's FT works */ 
rowout1[j] = row_r1 + row_r2; 
rowout1[j+1] = row_i1 + row_i2; 
rowout2[j+1] = (row_r1 - row_r2);
rowout2[j] = -(row_i1 - row_i2);
} 
local_swap4(rowout1,sizeof(int)*tds,byteorder); 
fwrite(rowout1,sizeof(int),tds,fpout2); 
local_swap4(rowout2,sizeof(int)*tds,byteorder); 
fwrite(rowout2,sizeof(int),tds,fpout2); 
}  
  fclose(fpin1); 
  fclose(fpout2); 
  SETCURDATA; 
  STOREPARNS(1, "FnMODE", 4) 
  STOREPARN(1, "FnMODE", 4) 
  unlink(ACQUPATH("ser2")); /* delete tmp ser file */ 
/* now remove the phase error from this dataset */ 
   expno = nexpno+3; 
   SETCURDATA; 
  (void)strcpy(infile1, ACQUPATH("ser3")); 
  fpin1 = fopen(infile1, "rb"); 
  if (fpin1 == 0) 
  { 
(void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
STOPMSG(path) 
  } 
  (void)strcpy(outfile1, ACQUPATH("ser")); 
  fpout2 = fopen(outfile1, "wb"); 
  if (fpout2 == 0) 
  { 
(void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
STOPMSG(path) 
  }  
  for (i=0; i < td1s; i+=2) 
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  { 
   /* read in rows pairwise so as to allow for phase correction  */ 
    fread(row1,sizeof(int),tds,fpin1); 
    local_swap4(row1,sizeof(int)*tds,byteorder); 
    fread(row2,sizeof(int),tds,fpin1); 
    local_swap4(row2,sizeof(int)*tds,byteorder);  
    for (j=0; j < tds ; j+=2) 
        { 
     int row_1 = row1[j]; 
  int row_2 = row2[j]; 
  int row_3 = row1[j+1]; 
  int row_4 = row2[j+1]; 
   
         /* this gives a 90 degree phase correction in F1 */ 
 
                rowout1[j] = row_2;   
                rowout1[j+1] = row_4; 
                 
                rowout2[j] = -row_1; 
                rowout2[j+1] = -row_3;          
        } 
                 
    local_swap4(rowout1,sizeof(int)*tds,byteorder); 
    fwrite(rowout1,sizeof(int),tds,fpout2); 
    local_swap4(rowout2,sizeof(int)*tds,byteorder); 
    fwrite(rowout2,sizeof(int),tds,fpout2); 
    }    
  fclose(fpin1); 
  fclose(fpout2); 
  unlink(ACQUPATH("ser3")); /* delete tmp ser file */ 
  
/* now make the HMBC PLUS spectra */ 
  expno = nexpno; 
  (void)strcpy(infile1, ACQUPATH("ser")); 
  fpin1 = fopen(infile1, "rb"); 
  if (fpin1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+2; 
  (void)strcpy(infile2, ACQUPATH("ser")); 
  fpin2 = fopen(infile2, "rb"); 
  if (fpin2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile2); 
    STOPMSG(path) 
  }   
  expno = nexpno+4; 
  (void)strcpy(outfile1, ACQUPATH("ser")); 
  fpout1 = fopen(outfile1, "wb"); 
  if (fpout1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+5; 
  (void)strcpy(outfile2, ACQUPATH("ser")); 
  fpout2 = fopen(outfile2, "wb"); 
  if (fpout2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  } 
 
  for (i=0; i < td1s; i++) 
  { 
    fread(row1,sizeof(int),tds,fpin1); 
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    local_swap4(row1,sizeof(int)*tds,byteorder); 
    fread(row2,sizeof(int),tds,fpin2); 
    local_swap4(row2,sizeof(int)*tds,byteorder); 
  
      for (j=0; j < tds ; j++) 
        { 
         int row1u = row1[j]; 
         int row2s = (int)(scaleplus * row2[j]); 
          rowout1[j] = row1u + row2s; 
          rowout2[j] = row1u - row2s; 
        } 
    local_swap4(rowout1,sizeof(int)*tds,byteorder); 
    fwrite(rowout1,sizeof(int),tds,fpout1); 
    local_swap4(rowout2,sizeof(int)*tds,byteorder); 
    fwrite(rowout2,sizeof(int),tds,fpout2); 
    }  
  fclose(fpin1); 
  fclose(fpin2); 
  fclose(fpout1); 
  fclose(fpout2); 
   
  expno = nexpno+1; 
  (void)strcpy(infile1, ACQUPATH("ser")); 
  fpin1 = fopen(infile1, "rb"); 
  if (fpin1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+3; 
  (void)strcpy(infile2, ACQUPATH("ser")); 
  fpin2 = fopen(infile2, "rb"); 
  if (fpin2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file for reading", infile2); 
    STOPMSG(path) 
  }   
  expno = nexpno+6; 
  (void)strcpy(outfile1, ACQUPATH("ser")); 
  fpout1 = fopen(outfile1, "wb"); 
  if (fpout1 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  } 
  expno = nexpno+7; 
  (void)strcpy(outfile2, ACQUPATH("ser")); 
  fpout2 = fopen(outfile2, "wb"); 
  if (fpout2 == 0) 
  { 
    (void)sprintf(path, "%s:\n%s", "cannot open file", outfile1); 
    STOPMSG(path) 
  } 
  for (i=0; i < td1s; i++) 
  { 
    fread(row1,sizeof(int),tds,fpin1); 
    local_swap4(row1,sizeof(int)*tds,byteorder); 
    fread(row2,sizeof(int),tds,fpin2); 
    local_swap4(row2,sizeof(int)*tds,byteorder); 
  
    for (j=0; j < tds ; j++) 
        { 
         int row1u = row1[j]; 
         int row2s = (int)(scaleplus * row2[j]); 
          rowout1[j] = row1u + row2s; 
          rowout2[j] = row1u - row2s; 
        } 
    local_swap4(rowout1,sizeof(int)*tds,byteorder); 
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    fwrite(rowout1,sizeof(int),tds,fpout1); 
    local_swap4(rowout2,sizeof(int)*tds,byteorder); 
    fwrite(rowout2,sizeof(int),tds,fpout2); 
    }  
  fclose(fpin1); 
  fclose(fpin2); 
  fclose(fpout1); 
  fclose(fpout2); 
  expno=nexpno+6; 
  SETCURDATA; 
  STOREPARNS(1, "FnMODE", 4) 
  STOREPARN(1, "FnMODE", 4) 
  expno=nexpno+7; 
  SETCURDATA; 
  STOREPARNS(1, "FnMODE", 4) 
  STOREPARN(1, "FnMODE", 4) 
  expno=oexpno; 
  SETCURDATA; 
  for(i=0; i < 4; i++) 
  {  
  expno=nexpno+i; 
  STOREPARN(1,"PH_mod",0); 
  SETCURDATA; 
  XF2; 
  XF1; 
  XF2M; 
  } 
  for(i=4; i < 8; i++) 
  {  
  expno=nexpno+i; 
  STOREPARN(1,"PH_mod",0); 
  SETCURDATA; 
  XF2; 
  XF1; 
  XF2M; 
  } 
  return; 
 } 
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ADEQ11ETGPLR_LKJ3 pulse program 
;adeq11etgplr_LKJ3 
;avance version (May 2014) 
;Modified 1,1-ADEQUATE 
;for longrange 2JCH couplings in F1 dimension 
;phase sensitive using Echo/Antiecho gradient selection 
;with decoupling during acquisition 
;and new improved phase cycling scheme with 45 degree steps 
; 
; Program by LOKJA-CHG-OWS 
; 
; Based on the pulse sequence by  
;J. Weigelt & G. Otting, J. Magn. Reson, A113, 1995, 128-130. 
; 
; 
;$CLASS=HighRes 
;$DIM=2D 
;$TYPE= 
;$SUBTYPE= 
;$COMMENT= 
 
 
#include <Avance.incl> 
#include <Delay.incl> 
#include <Grad.incl> 
 
"p2=p1*2" 
"d0=3u" 
"p4=p3*2" 
"d11=30m" 
 
"d4=1s/(cnst2*4)" 
"d23=1s/(cnst3*4)" 
 
"in0=inf1/2" 
 
"DELTA=d4-p16-d16-6u" 
 
1 ze 
  d11 pl12:f2 
2 d1 do:f2 
3 (p1 ph2) 
  d4 pl2:f2 
  (center (p2 ph1) (p4 ph1):f2 ) 
  d4 
  (p1 ph1) (p3 ph3):f2 
  d23 
  (p4 ph3):f2 
  d23 UNBLKGRAD 
  (p3 ph3):f2 
  d0 
  ; 180x pulse removed to obtain multiplicity patterns in F1 
  d0  
  3u 
  p16:gp1*EA 
  d16 
  (p4 ph4):f2 
  3u 
  p16:gp2*EA 
  d16 
  6u   ; compensate initial d0 to refocus 13C for t1=0 
  (p3 ph1):f2 
  d23 
  (p4 ph1):f2 
  d23 
  (center (p1 ph1) (p3 ph1):f2 ) 
  d4 
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  (center (p2 ph1) (p4 ph1):f2 ) 
  DELTA 
  3u 
  p16:gp3 
  d16 pl12:f2 
  4u  BLKGRAD 
  go=2 ph31 cpd2:f2 
  d1 do:f2 mc #0 to 2 F1EA(igrad EA, id0) 
exit 
    
 
ph1=0  
ph2=1 
ph3=0 1 2 3 1 2 3 0 2 3 0 1 3 0 1 2  
ph4=(8) 0 4 2 6 3 7 1 5 6 2 4 0 5 1 7 3 2 6 0 4 1 5 3 7 4 0 6 2 7 3 5 1 
ph31=0 2   
 
 
;pl1 : f1 channel - power level for pulse (default) 
;pl2 : f2 channel - power level for pulse (default) 
;pl12: f2 channel - power level for CPD/BB decoupling 
;p1 : f1 channel -  90 degree high power pulse 
;p2 : f1 channel - 180 degree high power pulse 
;p3 : f2 channel -  90 degree high power pulse 
;p4: f2 channel - 180 degree high power pulse 
;p16: homospoil/gradient pulse 
;d0 : incremented delay (2D)                         [3 usec] 
;d1 : relaxation delay; 1-5 * T1 
;d4 : 1/4J(CH) 
;d11: delay for disk I/O                             [30 msec] 
;d16: delay for homospoil/gradient recovery 
;d23: 1/(4J(CC)) 
;cnst2 : J(CH) = 127 .. 160 Hz 
;cnst3 : J(CC) = 35 .. 55 Hz 
;inf1: 1/SW(C) = 2 * DW(C) 
;in0: 1/(2 * SW(C)) = DW(C) 
;nd0: 2 
;NS: 4 * n (optimal is 32, minimum is 4) 
;DS: 4 * n 
;td1: number of experiments 
;FnMODE: echo-antiecho 
;cpd2: decoupling according to sequence defined by cpdprg2 
;pcpd2: f2 channel - 90 degree pulse for decoupling sequence 
 
 
;use gradient ratio:    gp 1 :  gp 2 : gp 3 
;                      +49.8 : -49.8 : +50    for C-13 
 
;for z-only gradients: 
;gpz1: +49.8% 
;gpz2: -49.8% 
;gpz3: +50% 
; which equals 1:-1:1.004 (Weigelt & Otting) 
 
;use gradient files: 
;gpnam1: SMSQ10.100 
;gpnam2: SMSQ10.100 
;gpnam3: SMSQ10.100 
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DEPT2LR_LKJ pulse program 
;dept2lr_lkj 
;avance version 
;proton detected 13C-DQ experiment for measurement of 2JCH ;coupling constants, 
with splitting in F1 as  
;1J(C1H1) + 2J(C2H1) 
; 
;based on dept2 proton detected inadequate by OWS,  
;J. Magn. Reson. 124, 1997, 245-249. 
; 
; by LKJ-CHG-OWS May 2014 
; modified from version by AXME-OWS 
#include <Avance.incl> 
#include <Delay.incl> 
#include <Grad.incl> 
"d0=3u" 
"d2=1s/(cnst2*2)"    ;1/2J(CH) 
"d4=1s/(cnst3*4)"    ;(1/2J(CC))/2 
"d11=30m" 
"p2=p1*2" 
"p4=p3*2" 
"p8=p1*(cnst8/90)"    ;Theta1 
"p9=p1*(cnst9/90)"   ;Theta2 
"l3=(td1/2)"  
"d24=(1s/(cnst3*4))-(1s/(cnst2*2))-p9"    ; d4-d2-p9 
"d29=d2-50u-p16-d16" ; d2-50u-p16-d16 
"d20=6u"    
"in0=inf1/2" 
1   ze 
d11 pl12:f2 
2   d1 do:f2 ; decoupler off during d1 
3   d11 
4  (p1 ph1) 
d2 pl2:f2  
   (center (p2 ph1) (p3 ph7):f2) 
d2 
   (p8 ph3)    ;1H Theta 1 pulse 
d24 
   (p4 ph7):f2 
d4          ;tau_c/2 
   (p3 ph8):f2 
d0 
d0 
50u UNBLKGRAD 
p16:gp1*EA 
d16 
   (p4 ph10):f2 
50u 
p16:gp2*EA 
d16 
d20 ; compensate initial d0 
;(refocus 13C completely for t1=0) 
   (p3 ph11):f2 
d4 
   (p4 ph12):f2 
d24         ;d4-d2-p9 
   (p9 ph5)     ;1H Theta 2 pulse 
d2 
   (center (p2 ph6) (p3 ph12):f2)   
50u 
p16:gp3 
d16 pl12:f2 
d29 BLKGRAD ;d29=d2-(50u+p16+d16) 
go=2 ph31 cpd2:f2 
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    d1 do:f2 wr #0 if #0 zd      ;decoupler off during d1    
    d11 igrad EA 
    lo to 3 times 2                
    d11 id0 
    lo to 4 times l3 
exit 
 
 
ph1 = 0        
ph3 = 1         
ph5 = 0 
ph6 = 0 
ph7 = 0 1 2 3 1 2 3 0 2 3 0 1 3 0 1 2 
ph8 = 1 2 3 0 2 3 0 1 3 0 1 2 0 1 2 3             
ph10 =(8) 0 4 2 6 3 7 1 5 6 2 4 0 5 1 7 3 2 6 0 4 1 5 3 7 4 0 6 2 7 3 5 1 
ph11 = 1 
ph12 = 0 
ph31 = 0 2 
 
 
;pl1 : f1 channel - power level for pulse (default) 
;pl2 : f2 channel - power level for pulse (default) 
;pl12: f2 channel - power level for CPD/BB decoupling 
;p1 : f1 channel -  90 degree high power pulse 
;p2 : f1 channel - 180 degree high power pulse 
;p3 : f2 channel -  90 degree high power pulse 
;p4 : f2 channel - 180 degree high power pulse 
;p8: Theta1 1H pulse 
;p9: Theta2 1H pulse 
;p16: homospoil/gradient pulse 
;d0 : incremented delay (2D)                         [3 usec] 
;d1 : relaxation delay; 1-5 * T1 
;d2:  1/2J(CH) or 2*Tau1 
;d4 : 1/4J(CC) or Tau2 
;d11: delay for disk I/O                             [30 msec] 
;d16: delay for homospoil/gradient recovery 
;d20: compensate initial d0 and p2 
;d23: 1/(4J(CC)) 
;d24: d4-d2-p9 
;d29: d2-50u-p16-d16 
;cnst2 : J(CH) = 127 .. 160 Hz 
;cnst3 : J(CC) = 35 .. 55 Hz 
;cnst8: Theta1 (degrees) 
;cnst9: Theta2 (degrees) 
;inf1: 1/SW(C) = 2 * DW(C) 
;in0: 1/(2 * SW(C)) = DW(C) 
;nd0: 2 
;l3: td1/2 
;NS: 4 * n (optimal is 32, minimum is 4) 
;DS: 4 * n 
;td1: number of experiments 
;FnMODE: echo-antiecho 
;cpd2: decoupling according to sequence defined by cpdprg2 
;pcpd2: f2 channel 90 degree pulse for decoupling sequence 
 
;use gradient ratio:    gp 1 :  gp 2 : gp 3 
;                      +49.8 : -49.8 : +50.1    for C-13 
 
;for z-only gradients: 
;gpz1: +49.8% 
;gpz2: -49.8% 
;gpz3: +50.1% 
;which equals 1:-1:1.006 
 
;use gradient files: 
;gpnam1: SMSQ10.100 
;gpnam2: SMSQ10.100 
;gpnam3: SMSQ10.100 
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Strychnine 
Journal Number: LKJ020067a 
Amount: 20 mg 
Solvent: CDCl3 
Atom 
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
1 7.20, 1H, d, 7.4 122.4 
2 7.10, 1H, t, 7.4 124.4 
3 7.26, 1H, m 128.8 
4 8.09, 1H, d, 8.0 116.2 
5 - 142.1 
6 - 131.7 
7 - 51.9 
8 3.88, 1H, d, 10.5 59.9 
9-N - - 
10 - 169.2 
11α 3.13, 1H, dd, 17.5, 8.5 42.4 
11β 2.67, 1H, dd, 17.4, 3.0 42.4 
12 4.29, 1H, m 77.5 
13 1.29, 1H, dt, 10.4, 2.8 48.0 
14 3.17, 1H, bs 31.4 
15α 2.40, 1H, dt, 14.6, 4.1 26.6 
15β 1.49, 1H, d, 14.4 26.6 
16 4.07, 1H, m 60.1 
17α 1.94, 1H, m 42.5 
17β 1.92, 1H, m 42.5 
18α 3.32, 1H, m 50.2 
18β 2.91, 1H, m 50.2 
19-N - - 
20α 3.78, 1H, d, 14.6 52.4 
20β 2.81, 1H, d, 14.7 52.4 
21 - 139.2 
22 5.98, 1H, m 128.7 
23α 4.16, 1H, dd, 13.8, 7.0 64.5 
23β 4.07, 1H, m 64.5 
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Extended table of calculated 
n+1
JHH coupling constants in strychnine
#H1 #H2 Exp. Ref.  6-31G(d,p) 6-31G(d,p) 6-31G(d,p) 6-311+G(d,p) 
HMBC+ FC only corr. FC only Full corr. FC only 
1 3 1.17 1.18 1.24 1.13 1.11 1.11 
1 4 0.50 0.45 0.60 0.55 0.60 0.52 
2 4 1.09 1.12 1.06 0.97 0.94 0.93 
8 12 -0.19 - -0.11 -0.10 -0.18 -0.10 
8 13 10.49 10.47 10.93 9.96 10.91 10.14 
8 16 -0.70 - -0.29 -0.27 -0.33 -0.33 
11a 12 8.34 8.44 9.24 8.43 9.48 8.78 
11a 13 -0.42 - -0.34 -0.31 -0.38 -0.31 
11b 12 3.24 3.28 4.12 3.75 4.00 3.58 
12 13 3.20 3.12 3.92 3.58 4.21 3.82 
12 15b 0.40 - 0.02 0.02 0.03 0.02 
12 23a -0.08 - -0.02 -0.02 0.23 -0.11 
13 14 2.97 3.10 3.59 3.27 3.76 3.44 
13 15a 0.34 0.49-0.59
b
 0.42 0.38 0.39 0.46 
13 15b -0.30 - -0.31 -0.28 -0.04 -0.25 
14 15a 5.42 4.58 5.05 4.60 5.15 4.77 
14 15b 2.03 1.98 2.11 1.93 2.16 2.05 
14 16 0.76 - 0.60 0.54 0.59 0.52 
14 20b -0.58 - -0.55 -0.50 -0.64 -0.59 
14 22 -2.89 2.82
b
 -3.32 -3.03 -3.43 -3.00 
15a 16 3.97 4.11 4.26 3.89 4.36 4.11 
15b 16 2.29 1.82 2.21 2.02 2.32 2.20 
16 17a - 0.05 0.04 0.16 0.06 
16 17b - -0.20 -0.18 -0.27 -0.15 
16 17ab* -0.14 - -0.15 -0.14 -0.11 -0.10 
16 20b -0.35 - -0.36 -0.33 -0.42 -0.35 
20a 22 -1.37 1.47
b
 -1.99 -1.82 -2.10 -1.83 
20b 22 -0.63 0.63
b
 -0.63 -0.58 -0.42 -0.59 
22 23a 6.08 5.74 6.74 6.14 6.54 5.97 
22 23b 7.00 6.88 7.53 6.86 7.77 7.38 
RMSD = 0.40 0.28 0.47 0.29 
All calculations are at the B3LYP level. Linear correction factor 0.9117. *17ab is assumed to be an 
average. 
Ref: Carter, J. C.; Luther, G. W.; Long, T. C. J. Magn. Reson. 1974, 15, 122–131. b: Cobas, J. C.; 
Constantino-Castillo, V.; Martín-Pastor, M.; del Río-Portilla, F. Magn. Reson. Chem. 2005, 43, 843–
848. 
HMBC+ spectra for strychnine and LNT 
(following pages)
HMBC+ CH/CH3. The subtract subspectrum (red) has been shifted slightly upwards, to make it easier to see the splitting. When the red curve (subtract) is on the left side, J is negative. 
ppm
1.52.02.53.03.54.04.55.05.56.06.57.07.58.0 ppm
20
30
40
50
60
70
80
90
100
110
120
130
4 
3 
1 
2 22 
23β 
23α 12 
16 
8 
20β 1315α 
17 
15β 
11β 
20α 
18β 18α 
11α 
14 
HMBC+ C/CH2 (region with couplings to CH2). The subtract subspectrum (red) has been shifted slightly upwards, to make it easier to see the splitting. 
ppm
1.52.02.53.03.54.04.55.05.56.0 ppm
20
25
30
35
40
45
50
55
60
65
70
13 15α 17 15β 
11β 
20α 
18β 
18α 
11α 
14 
23β 23α 
12 16 
8 
20β 22 
HMBC+ CH/CH3 subspectrum for LNT. The subtract subspectrum (red) has been shifted slightly upwards, to make it easier to see the splitting. 
ppm
3.23.43.63.84.04.24.44.64.85.05.2 ppm
55
60
65
70
75
80
85
90
95
100
105
H3 GlcNAc – H1 Gal2 = -0.3 Hz 
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Brazilin 
Journal Number: LKJ020060a 
Amount: 20 mg 
Solvent: DMSO-d6 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
1 7.14, 1H, d, 8.3 131.0 
1a - 114.4 
2 6.42, 1H, dd, 8.3, 2.4 108.7 
3 - 156.5 
4 6.21, 1H, d, 2.4 102.8 
4a - 154.1 
6 3.85, 1H, m 
3.57, 1H, d, 11.3 
69.6 
6a - 76.3 
7 2.88, 1H, d, 15.7 
2.70, 1H, d, 15.7 
42.0 
7a - 129.8 
8 6.54, 1H, s 112.1 
9 - 144.3 
10 - 144.0 
11 6.64, 1H, s 111.7 
11a - 135.6 
12 3.85, 1H, m 49.5 
Broad singlets are observed at 9.24, 8.61, 5.26 and 3.5 ppm. 
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Chapter 3 
Pyranonigrin E 
Journal Number: LKJ032404 
Amount: 2.7 mg 
Solvent: DMSO-d6 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
Key NOE  
correlations 
1 - -   
2 - 154.1   
3 - 143.7   
4 - 169.9   
4a - 164.6   
5 - 174.8   
6 8.63, 1H, bs - 5, 7, 7a, (4a), (4) 7-OH 
7 5.73, 1H, dd, 9; 1.3 74.9 4a, 5, (7a)  
7-OH 6.80, 1H, d, 9.1 - 5, 7 6 
7a - 113.9   
8 3.76, 3H, s 60.3 3 2’, 3’  
1’ 6.59, 1H, m 117.2 2, 2’, 3’  
2’ 6.59, 1H, m 139.7 2, 1’, 3’ 8 
3’ 2.27, 2H, m 34.5 1’, 2’, 4’, 5’ 8 
4’ 1.48, 2H, sextet, 7.2 21.4 2’, 3’, 5’  
5’ 0.91, 3H, t, 7.5 13.6 3’, 4’  
 
  
Appendix 
 
A-27 
 
JBIR-74 
Journal Number: LKJ032403  
Amount: 11.0 mg 
Solvent: DMSO-d6 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
NOE  
correlations 
1 - 165.0   
2 4.03, 1H, bd, 2.4 58.2 1, 3, 4, 5, 1’  
2-NH 8.20, 1H, bs - 1, 2’ 3, 4 
3 1.90, 1H, m 39.6 1, 2, 4, 5, 6 2-NH 
4 1.42, 1H, m 
1.22, 1H, m 
24.4 2, 3, 5, 6 2-NH 
5 0.78, 3H, d, 6.7 13.5 2, 3, 4 3’ 
6 0.87, 3H, m 11.6 3, 4  
1’ - 159.1   
2’ - 124.4   
2’-NH  -   
3’ 6.51, 1H, s 103.2 1’, 4’, 5’, (1) 5’, 5 
4’ - 136.2   
4’-NH  -   
5’ 7.43, 1H, s 118.6 (2’), 3’, 6’ 3’, 6’ 
6’ 7.89, 1H, s 137.8 4’, 5’ 5’ 
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Decumbenone A 
Journal Number: LKJ032608  
Amount: 0.8 mg 
Solvent: DMSO-d6 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
NOE  
correlations 
1 3.60, 2H, m 56.7 (3)  
1-OH 4.39, 1H, t, 5.3 - 1, 2  
2 2.69, 1H, m 
2.90, 1H, ddd, 17.6, 7.6, 
6.5 
44.3 3, 4  
3 - 213.3 -  
4 - 56.7 -  
5 2.68, 1H, m 41.6 (10), (15) 14, 6, 7’ 
6 4.05, 1H, m 64.3 (5) 5, 7’ 
6-OH 4.12, 1H, d, 4.8 - 5, 6 15 
7’ 
7’’ 
1.09, 1H, ddd, 13, 11, 1 
1.71, 1H, m 
39.3 5, 6, 8, 9, 16 5, 6, 16 
 
8 2.44, 1H, m 25.1   
9 5.50, 1H, bs 132.8 5, 7, 11, 16  
10 - 131.8 -  
11 5.83, 1H, d, 9.8 127.4 5, 9, 13  
12 5.29, 1H, d, 9.8 134.0 4, 10  
13 - 73.4 - 15 
13-OH 4.90, 1H, s - 4, 12, 13, 14  
14 0.99, 3H, s 26.4 4, 12, 13 5 
15 1.31, 3H, s 14.0 3, 4, 5, 13 6-OH, 13-OH 
16 0.94, 3H, d, 7.2  21.1 7, 8, 9 7’ 
Chapter 4 
All spectral data have been referenced to external 1,4-dioxane with δH 3.75 ppm and δC 67.4 
ppm. 
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3’-sialyllactose (3’-SL) 
Journal Number: LKJ020001a 
Amount:  
Solvent: D2O 
Atom 
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC 
correlations 
α-Glc 
1α 5.21, 1H, d, 3.6 92.7 2α, 4α 
2α 3.58, 1H, m 72.0 
3α 3.82, 1H, m 72.2 
4α 3.67, 1H, m 79.1 
5α 3.95, 1H, m 70.9 3α 
6α 3.87, 1H, m 60.7 
6α 3.92, 1H, m 60.7 
β-Glc 
1β 4.65, 1H, d, 8.1 96.6 
2β 3.27, 1H, dd, 8.1, 9.0 74.6 1β, 3β 
3β 3.64, 1H, m 75.2 5β 
4β 3.65, 1H, m 79.0 
5β 3.59, 1H, m 75.6 4β 
6β 3.82, 1H, m 60.9 5β 
6β 3.97, 1H, m 60.9 
β-Gal 
1’ 4.52, 1H, d, 7.9 103.5 5α/5β 
2’ 3.57, 1H, m 70.2 1’, 3’ 
3’ 4.10, 1H, bd, 9.8 76.3 2”, 2’ 
4’ 3.95, 1H, m 68.3 2’, 3’ 
5’ 3.70, 1H, m 76.0 6’ 
6’ 3.71, 1H, m 61.9 
6’ 3.76, 1H, m 61.9 5’ 
α-NAcNeu 
1” - 174.7 - 
2” - 100.6 - 
3” 1.79, 1H, dd, 12.5, 11.7 40.5 1”, 2”, 4”, 5” 
3” 2.75, 1H, dd, 12.5, 4.5 40.5 2”, 4”, 5” 
4” 3.68, 1H, m 69.2 
5” 3.84, 1H, m 52.5 CO, 4”, 6” 
CO - 175.8 - 
CH3 2.02, 3H, s 22.9 CO 
6” 3.62, 1H, m 73.7 2”, 4”, 8” 
7” 3.59, 1H, m 68.9 8”, 9” 
8” 3.88, 1H, m 72.6 7” 
9” 3.64, 1H, m 63.4 
9” 3.86, 1H, m 63.4 
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6’-sialyllactose (6’-SL) 
Journal Number: LKJ020003a  
Amount: 6.0 mg 
Solvent: D2O 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.20, 1H, d, 3.7 92.2 3α, 4α 
2α 3.58, 1H, m 71.4 3α 
3α 3.82, 1H, m 72.0 2α, 5α 
4α 3.60, 1H, m 80.1 3α, 5α, 6α  
5α 3.93, 1H, m 70.3 4α 
6α 3.83, 1H, m 60.5  
6α 3.86, 1H, m 60.5 5α 
β-Glc    
1β 4.65, 1H, d, 8.1 96.0 2β, 3β/4β 
2β 3.29, 1H, m 74.1 1β, 3β/4β 
3β 3.63, 1H, m 75.0 2β, 5β 
4β 3.61, 1H, m  80.0 1’, 3β/5β  
5β 3.59, 1H, m 75.0 4β 
6β 3.78, 1H, m 60.6 4β, 5β 
6β 3.93, 1H, m 60.6 4β, 5β 
β-Gal    
1’ 4.41, 1H, d, 7.8 103.6 5α/5β, 3’, 5’ 
2’ 3.51, 1H, m 71.2 1’, 3’ 
3’ 3.64, 1H, m 72.7 2’, 4’ 
4’ 3.91, 1H, m 68.9 2’, 3’, 5’, 6’  
5’ 3.79, 1H, m 74.1 1’, 4’, 6’ 
6’ 3.58, 1H, m 64.0 2”, 4’ 
6’ 3.96, 1H, m 64.0 2”, 4’, 5’ 
α-NAcNeu    
1” - 173.9 - 
2” - 100.6 - 
3” 1.72, 1H, dd, 12.5, 11.7 40.5 1”, 2”, 4”, 5” 
3” 2.69, 1H, dd, 12.5, 4.7 40.5 2”, 4”, 5” 
4” 3.63, 1H, m 68.7 3”, 5” 
5” 3.84, 1H, m 52.1 3”, 4”, CO, 6” 
CO - 175.3 - 
CH3 2.01, 3H, s 22.4 CO, 5”, 6” 
6” 3.70, 1H, m 72.9 2”, 5”, 7” 
7” 3.54, 1H, m 68.7 6”, 8”, 9” 
8” 3.87, 1H, m 72.2 6”, 7”, 9” 
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9” 3.62, 1H, m 63.0 7”, 8” 
9” 3.86, 1H, m 63.0 7” 
2’-fucosyllactose (2’-FL) 
Journal Number: LKJ020006a  
Amount: 2.0 mg 
Solvent: D2O 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.21, 1H, d, 3.7 92.6 2α 
2α 3.57, 1H, m 72.1  
3α 3.78, 1H, m 76.1 5α 
4α 3.71, 1H, m 76.7 3α, 6α 
5α 3.89, 1H, m 71.2  
6α 3.79, 1H, m 60.9 5α 
6α 3.89, 1H, m 60.9  
β-Glc    
1β 4.62, 1H, d, 8.0 96.6  
2β 3.28, 1H, dd, 9.4, 8.0 74.7 1β, 3β 
3β 3.57, 1H, m 75.1 1β, 2β, 4β 
4β 3.71, 1H, m 76.6 3β, 5β 
5β 3.46, 1H, ddd, 9.8, 5.5, 1.7 76.1 1β, 3β 
6β 3.76, 1H, m 61.0  
6β 3.94, 1H, dd, 12.0, 1.7 61.0  
β-Gal    
1’ 4.51, 1H, d, 7.7 101.0 5’ 
2’ 3.66, 1H, dd, 9.3, 8.0 77.0 3’, 6’ 
3’ 3.86, 1H, m 74.4 2’ 
4’ 3.88, 1H, m 69.9 2’, 3’, 5’  
5’ 3.70, 1H, m 76.3  
6’ 3.73, 1H, m 61.9  
6’ 3.80, 1H, m 61.9 5’ 
α-Fuc    
1’’ 5.29, 1H, m 100.1 2’, 2’’, 3’’, 5’’ 
2’’ 3.78, 1H, m 68.9 3’’ 
3’’ 3.77, 1H, m 70.4 2’’ 
4’’ 3.80, 1H, m 72.4 2’’, 3’’ 
5’’ 4.22, 1H, m 67.7 4’’, 6’’ 
6’’ 1.21, 3H, bd, 6.6 16.1 4’’, 5’’ 
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3-fucosyllactose (3-FL) 
Journal Number: LKJ020005a 
Amount: 2.0 mg 
Solvent: D2O 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.16, 1H, d, 3.7 92.9 3α, 4α 
2α 3.75, 1H, m 73.4  
3α 3.93, 1H, m 75.5 1’’, 4α, 5α 
4α 3.85, 1H, m 73.48  1’, 2α, 5α, 6α 
5α 3.95, 1H, m 71.7 4α 
6α 3.86, 1H, m 60.5  
6α 3.89, 1H, m 60.5  
β-Glc    
1β 4.63, 1H, d, 8.0 96.6 3β, 5β 
2β 3.45, 1H, m 76.3 1β, 3β 
3β 3.76, 1H, m 77.8 1’’, 2β, 4β 
4β 3.85, 1H, m 73.50 1’, 3β, 5β, 6β 
5β 3.57, 1H, m 76.2 1β, 3β 
6β 3.80, 1H, m 60.6  
6β 3.95, 1H, m 60.6 4β, 5β 
β-Gal    
1’ 4.41, 1H, d, 7.8 102.6 4α, 4β, 5’ 
2’ 3.47, 1H, m 72.0 1’, 3’ 
3’ 3.63, 1H, ddd, 9.9, 3.2, 1.5 73.2 1’, 2’, 4’ 
4’ 3.89, 1H, m 69.1 2’, 3’, 5’  
5’ 3.58, 1H, m 75.8 1’, 3’, 4’, 6’ 
6’ 3.71, 1H, m 62.3 5’ 
6’ 3.74, 1H, m 62.3 4’, 5’ 
α-Fuc    
1’’ 5.36+5.42, 1H, 2*d,  4.0 99.2+99.3 3β, 2’’, 3’’, 5’’ 
2’’ 3.77-3.78, 1H, m 68.8+68.9 3’’ 
3’’ 3.95, 1H, m 70.0+70.1 2’’, 4’’ 
4’’ 3.79, 1H, m 72.8 2’’, 3’’, 5’’, 6’’ 
5’’ 4.81, 1H, dq, 6.6 67.3 1’’, 3’’, 4’’, 6’’ 
6’’ 1.17, 3H, dd, 6.6, 2.6 16.0 4’’, 5’’ 
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Lacto-N-tetraose (LNT) 
Journal Number: LKJ020004a 
Amount: 20 mg 
Solvent: D2O 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.20, 1H, d, 3.8 92.7 2α, 3α, 4α 
2α 3.56, 1H, m 72.0 3α 
3α 3.81, 1H, m 72.3 2α, 5α 
4α 3.62, 1H, m 79.2 3α, 5α 
5α 3.93, 1H, m  71.0  
6α 3.81, 1H, m 60.8 5α 
6α 3.86, 1H, m 60.8 5α 
β-Glc    
1β 4.64, 1H, d, 7.9 96.9 2β, 3β, 4β 
2β 3.26, 1H, m 74.6 1β, 3β 
3β 3.62, 1H, m 75.2 5β 
4β 3.63, 1H, m 79.1  
5β 3.58, 1H, m 75.7  4β 
6β 3.77, 1H, m 60.9  
6β 3.93, 1H, m 60.9 4β, 5β 
β-Gal 1    
1’ 4.42, 1H, d, 7.8 103.8 3’, 4α, 5α, 5β 
2’ 3.57, 1H, m 70.9 3’ 
3’ 3.72, 1H, m 82.8 2’, 4’ 
4’ 4.13, 1H, d, 3.1 69.2 2’, 3’, 5’, 6’ 
5’ 3.69, 1H, m 75.8 4’ 
6’ 3.73, 1H, m 61.8 5’ 
6’ 3.76, 1H, m 61.8 5’ 
β-GlcNAc    
1* 4.71, 1H, m 103.4 2*, 3*, 4* 
2* 3.88, 1H, m 55.6 1*, 3*, CO 
CO - 175.8 - 
CH3 2.01, 3H, s 23.1 CO, 1*, 2*, 3* 
3* 3.79, 1H, m 82.9 2*, 4*, 5* 
4* 3.55, 1H, m 69.3 2*, 3*, 5*, 6* 
5* 3.46, 1H, ddd, 9.2, 5, 2  76.0 3*, 4*, 6* 
6* 3.76, 1H, m 61.3 4*, 5* 
6* 3.88, 1H, m 61.3 5* 
β-Gal 2    
1” 4.42, 1H, d, 7.8 104.4 2”, 3”, 3* 
2” 3.51, 1H, m 71.5 1”, 3” 
3” 3.62, 1H, ddd, 9.9, 3.2, 1.5 73.3 2”, 4” 
4” 3.89, 1H, m 69.4 2”, 3” 
5” 3.69, 1H, m 76.1 1”, 4”, 6” 
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6” 3.74-3.78, 1H, m 61.9 5” 
6” 3.74-3.78, 1H, m 61.9 5” 
Lacto-N-neotetraose (LNnT) 
Journal Number: LKJ020026  
Amount: 10 mg 
Solvent: D2O 
 
 
  Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.21, 1H, d, 3.8 92.6 3α, 5α 
2α 3.56, 1H, m 72.0  
3α 3.81, 1H, m 72.2 4α 
4α 3.60, 1H, m 79.2  
5α 3.93, 1H, m  70.9 4α 
6α 3.88, 1H, m 60.8  
6α 3.82, 1H, m 60.8  
β-Glc    
1β 4.65, 1H, d, 8.0 96.6 2β, 5β 
2β 3.26, 1H, m 74.6 1β, 3β 
3β 3.63, 1H, m 75.2 1’ 
4β 3.67, 1H, m 79.1  
5β 3.58, 1H, m 75.6   
6β 3.80, 1H, m 60.9  
6β 3.91, 1H, m 60.9  
β-Gal 1    
1’ 4.42, 1H, d, 7.9 103.75 4α/β, 2’, 3’ 
2’ 3.58, 1H, m 70.8 1’, 3’, 6’ 
3’ 3.71, 1H, m 82.85  
4’ 4.14, 1H, d, 3.2 69.2 2’, 3’, (5’), (6’) 
5’ 3.70, 1H, m 75.7  
6’ 3.7-3.8, 1H, m 61.8  
6’ 3.7-3.8, 1H, m 61.8  
β-GlcNAc    
1* 4.69, 1H, d, 8.2 103.57 3’, 2*, 3*, 5* 
2* 3.79, 1H, m 56.0 CO, 1* 
CO - 175.7  
CH3 2.02, 3H, s 23.0 CO, 2* 
3* 3.72, 1H, m 73.0 2* 
4* 3.71, 1H, m 79.0 1*, 2* 
5* 3.58, 1H, m  75.4  
6* 3.85, 1H, m 60.7 4* 
6* 3.95, 1H, m 60.7 4*, 5* 
β-Gal 2    
1” 4.47, 1H, d, 7.8 103.68 4*, 2’’, 3’’, 5’’ 
2” 3.52, 1H, m 71.8 1’’, 3’’ 
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3” 3.66, 1H, m 73.3  
4” 3.91, 1H, m 69.4 2’’, 3’’, 6’’ 
5” 3.71, 1H, m 76.2 1’’ 
6” 3.7-3.8, 1H, m 61.9  
6” 3.7-3.8, 1H, m 61.9  
 
Lacto-N-fucopentaose V (LNFP-V) 
Journal Number: LKJ020032a  
Amount: 12.5 mg 
Solvent: D2O 
 
 
  Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.17, 1H, d, 3.8 92.9 3α, 5α 
2α 3.74, 1H, m 73.5 3α 
3α 3.92, 1H, m 75.5 1° 
4α 3.85, 1H, m 73.2 5α, 1’ 
5α 3.95, 1H, m  71.8  
6α 3.8-3.94, 1H, m 60.5  
6α 3.8-3.94, 1H, m 60.5  
β-Glc    
1β 4.64, 1H, d, 8.0 96.6 2β, 3β, 5β 
2β 3.45, 1H, m 76.3 1β, 3β 
3β 3.75, 1H, m 77.8 4β, 5β, 1° 
4β 3.85, 1H, m 73.2 3β, 1’ 
5β 3.57, 1H, m 76.2  
6β ~3.95, 1H, m 60.6  
6β ~3.80, 1H, m 60.6  
α-L-Fuc    
1° 5.36-5.42, 1H, d, 4.0 99.2-99.4 3°, 5°, 3α, 3β 
2° 3.78, 1H, m 68.8  
3° 3.94, 1H, m 70.0 2° 
4° 3.77, 1H, m 72.7  
5° 4.80, 1H, m 67.3 1°, (3°), 4°, 6° 
6° 1.15, 3H, d, 6.7 16.0 4°, 5° 
β-Gal 1    
1’ 4.41, 1H, d, 7.9 102.5 3’, 5’, 4α/β 
2’ 3.50, 1H, m 71.5 1’, 3’ 
3’ 3.71, 1H, m 82.3 2’, 1* 
4’ 4.08, 1H, d, 3.3 69.0 2’, 3’, 5’, 6’ 
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5’ 3.57, 1H, m 75.4 1’, 4’, 6’ 
6’ 3.73, 1H, m 62.3 5’ 
6’ 3.76, 1H, m 62.3 5’ 
β-GlcNAc    
1* 4.71, 1H, d, 8.4 103.3 2*, (5*), 3’ 
2* 3.88, 1H, m 55.5 1*, 3*, 4*, CO 
CO - 175.8 - 
CH3 2.01, 3H, s 23.0 CO, (1*), (2*), 
(3*) 
3* 3.79, 1H, m 82.8 2*, 4*, 1” 
4* 3.57, 1H, m 69.2 3*, 5*, 6* 
5* 3.47, 1H, m  76.0  
6* 3.76, 1H, m 61.3  
6* 3.88, 1H, m 61.3  
β-Gal 2    
1” 4.44, 1H, d, 7.7 104.2 2”, 3”, 5”, 3* 
2” 3.51, 1H, m 71.5 1”, 3” 
3” 3.62, 1H, m 73.3 2”, 4” 
4” 3.89, 1H, m 69.3 2”, 3” 
5” 3.69, 1H, m 76.0 1”, 4”, 6” 
6” 3.72-3.78, 1H, m 61.9  
6” 3.72-3.78, 1H, m 61.9  
 
Lacto-N-neofucopentaose V (LNnFP-V) 
Journal Number: LKJ020031a 
Amount: 11.5 mg 
Solvent: D2O 
 
 
Atom  
assignment 
1
H chemical shift [ppm], 
multiplicity, J [Hz] 
13
C chemical 
shift [ppm] 
HMBC  
correlations 
α-Glc    
1α 5.17, 1H, d, 3.8 93.0 3α, 5α 
2α 3.74, 1H, m 73.4 3α 
3α 3.93, 1H, m 75.5  
4α 3.85, 1H, m 73.2 3α, 5α, 6α, 1’ 
5α 3.95, 1H, m  71.8  
6α 3.8-3.94, 1H, m 60.5  
6α 3.8-3.94, 1H, m 60.5  
β-Glc    
1β 4.64, 1H, d, 8.0 96.7 2β, 3β, 5β 
2β 3.44, 1H, m 76.4 1β, 3β 
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3β 3.75, 1H, m 77.8 4β, 5β, 1° 
4β 3.85, 1H, m 73.3 3β, 5β, 1’ 
5β 3.58, 1H, m 76.2  
6β ~3.95, 1H, m 60.7  
6β ~3.80, 1H, m 60.7  
α-L-Fuc    
1° 5.37-5.42, 1H, d, 4.0 99.2-99.4 3°, 5°, 3α, 3β 
2° 3.78, 1H, m 68.8  
3° 3.93, 1H, m 70.1 1° 
4° 3.78, 1H, m 72.8  
5° 4.80, 1H, m 67.3 1°, (3°), 4°, 6° 
6° 1.15, 3H, d, 6.7 16.0 4°, 5° 
β-Gal 1    
1’ 4.41, 1H, d, 7.9 102.6 (3’), 5’, 4α/β 
2’ 3.49, 1H, m 71.5 1’, 3’ 
3’ 3.70, 1H, m 82.4 2’, 1* 
4’ 4.09, 1H, d, 3.3 69.1 2’, 3’, (5’), 6’ 
5’ 3.56, 1H, m 75.4 1’, 4’, 6’ 
6’ 3.73, 1H, m 62.3  
6’ 3.76, 1H, m 62.3  
β-GlcNAc    
1* 4.69, 1H, d, 8.2 103.5 3’, (2*), 3*, 5* 
2* 3.78, 1H, m 55.9 CO, 1* 
CO - 175.7  
CH3 2.02, 3H, s 23.0 CO, 2* 
3* 3.73, 1H, m 73.0 2*, 4*, 5* 
4* 3.74, 1H, m 79.1  
5* 3.57, 1H, m  75.4 3* 
6* 3.86, 1H, m 60.7 4* 
6* 3.94, 1H, m 60.7 4*, 5* 
β-Gal 2    
1” 4.47, 1H, d, 7.8 103.7 4*, 2”, 3”, (5”) 
2” 3.53, 1H, m 71.8 1”, 3” 
3” 3.66, 1H, m 73.3 2” 
4” 3.92, 1H, m 69.4 2”, 3” 
5” 3.72, 1H, m 76.2 1” 
6” 3.7-3.8, 1H, m 61.9  
6” 3.7-3.8, 1H, m 61.9  
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pNP-Fuc-Fuc glycosides 
 
 
p-nitrophenyl α-L-fucopyranosyl-(1-2)-α-L-fucopyranoside 
1H NMR: δ 8.26 (d, 2H, J = 8.8 Hz, H3’’), 7.28 (d, 2H, J = 8.8 Hz, H2’’), 5.84 (d, 1H, J = 2.8 Hz, 
H1), 5.11 (d, 1H, J = 3.9 Hz, H1’), 4.34 (br. q, 1H, J = 6.5 Hz, H5’), 4.14 (m, 1H, H2),4.13 (m, 1H, 
H5), 4.11 (m, 1H, H3), 4.08 (m, 1H, H4), 3.97 (dd, 1H, J = 3.5 Hz, 10.5 Hz, H3’), 3.83 (m, 1H, H4’), 
3.82 (m, 1H, H2’), 1.23 (d, 3H, J = 6.5 Hz, H6’), 1.15 (d, 3H, J = 6.7 Hz, H6). 13C NMR derived 
from gHSQC and gHMBC: δ 162.2 (C1’’), 143.0 (C4’’), 126.9 (C3’’), 117.6 (C2’’), 97.6 (C1), 96.3 
(C1’), 75.3 (C2), 72.7 (C4’), 70.3 (C3’), 68.7 (C4), 68.8 (C2’), 68.6 (C3), 67.9 (C5’), 66.7 (C5), 16.3 
(C6’), 16.2 (C6). 
p-nitrophenyl α-L-fucopyranosyl-(1-3)-α-L-fucopyranoside 
1H NMR: δ 8.26 (d, 2H, J = 9.0 Hz, H3’’), 7.28 (d, 2H, J = 9.0 Hz, H2’’), 5.98 (d, 1H, J = 3.5 Hz, 
H1), 5.05 (d, 1H, J = 4.0 Hz, H1’), 4.28 (br. q, 1H, J = 6.7 Hz, H5’), 4.21 (dd, 1H, J = 3.4 Hz, 10.4 
Hz, H3), 4.14 (br. q, 1H, J = 6.7 Hz, H5), 4.04 (dd, 1H, J = 3.5 Hz, 10.4 Hz, H2), 3.92 (m, 1H, H3’), 
3.91 (m, 1H, H4), 3.80 (br. d, 1H, J = 3.3 Hz, H4’), 3.72 (dd, 1H, J = 4.0 Hz, 10.2 Hz, H2’), 1.21 (d, 
3H, J = 6.7 Hz, H6’), 1.15 (d, 3H, J = 6.7 Hz, H6). 13C NMR derived from gHSQC and gHMBC: δ 
162.5 (C1’’), 143.2 (C4’’), 126.9 (C3’’), 117.7 (C2’’), 97.0 (C1’), 95.1 (C1), 72.7 (C2), 72.5 (C4), 
72.3 (C4’), 70.1 (C3’), 68.8 (C3), 68.6 (C2’), 67.9 (C5’), 66.7 (C5), 16.3 (C6’), 16.1 (C6). 
p-nitrophenyl α-L-fucopyranosyl-(1-4)-α-L-fucopyranoside 
1H NMR: δ 8.26 (d, 2H, J = 9.2 Hz, H3’’), 7.27 (d, 2H, J = 9.2 Hz, H2’’), 5.83 (d, 1H, J = 3.9 Hz, 
H1), 4.95 (d, 1H, J = 4.0 Hz, H1’), 4.54 (br. q, 1H, J = 6.6 Hz, H5), 4.20 (m, 1H, H3), 4.18 (m, 1H, 
H5’), 4.04 (dd, 1H, J = 3.9 Hz, 10.6 Hz, H2), 3.94 (dd, 1H, J = 3.0 Hz, 10.8 Hz, H3’), 3.90 (br. d, 1H, 
J = 3.0 Hz, H4’), 3.83 (br. d, 1H, J = 3.0 Hz, H4), 3.80 (dd, 1H, J = 4.0 Hz, 10.8 Hz, H2’), 1.23 (d, 
3H, J ~ 7 Hz, H6’), 1.17 (d, 3H, J = 6.6 Hz, H6). 13C NMR derived from gHSQC and gHMBC: δ 
162.3 (C1’’), 143.1 (C4’’), 126.8 (C3’’), 117.6 (C2’’), 101.3 (C1’), 97.7 (C1), 80.5 (C4’), 70.2 (C3’), 
69.7 (C3), 69.5 (C2’), 69.5 (C5’), 68.8 (C4), 68.4 (C2), 67.7 (C5), 16.2 (C6’), 16.2 (C6). 
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Abstract: During a global research expedition, more than five hundred marine bacterial 
strains capable of inhibiting the growth of pathogenic bacteria were collected. The purpose 
of the present study was to determine if these marine bacteria are also a source of 
compounds that interfere with the agr quorum sensing system that controls virulence gene 
expression in Staphylococcus aureus. Using a gene reporter fusion bioassay, we recorded agr 
interference as enhanced expression of spa, encoding Protein A, concomitantly with reduced 
expression of hla, encoding α-hemolysin, and rnaIII encoding RNAIII, the effector molecule 
of agr. A marine Photobacterium produced compounds interfering with agr in S. aureus 
strain 8325-4, and bioassay-guided fractionation of crude extracts led to the isolation of 
two novel cyclodepsipeptides, designated solonamide A and B. Northern blot analysis 
confirmed the agr interfering activity of pure solonamides in both S. aureus strain 8325-4 
and the highly virulent, community-acquired strain USA300 (CA-MRSA). To our 
knowledge, this is the first report of inhibitors of the agr system by a marine bacterium. 
  
OPEN ACCESS
Mar. Drugs 2011, 9  
 
 
2538
Keywords: Photobacterium; Vibrionaceae; antivirulence; quorum sensing inhibition; agr 
 
1. Introduction  
Microorganisms are an attractive source of new natural products with antimicrobial properties [1,2], 
and the marine environment constitutes a prolific resource of bioactive microorganisms [3–5]. Many 
marine microenvironments stimulate the production of specific metabolites as a response to environmental 
factors [6]. It is likely that some of these metabolites mediate both intra- and interspecies microbial 
interactions, and can be seen as potential new scaffolds for development of drug lead candidates [6,7]. 
The increasing problem of antibiotic resistance among human pathogens highlights the need for novel 
therapeutic strategies [8]. The search for new avenues in microbial control has therefore been extended 
from traditional bacteriostatic or bacteriolytic compounds to compounds that target, for example, 
quorum sensing (QS) pathways [9–11]. Quorum sensing inhibitors (QSI) do not necessarily kill or 
inhibit the growth of a pathogen but rather modulate microbial phenotypes, for example by attenuating 
virulence [12,13]. In vivo studies with QS inhibitory compounds demonstrated how these can be used 
to slow the spread of infection [14] or enhance the clearance of pathogens from infected tissue [10]. 
Staphylococcus aureus is one of the main causes of nosocomial infections, and methicillin-resistant 
S. aureus (MRSA) are emerging at an alarming rate [15,16]. The virulence of S. aureus is ascribed to a 
number of virulence factors, including extracellular toxins such as α-hemolysin encoded by hla, and 
cell surface adhesion factors such as Protein A encoded by spa [17]. Their expression is coordinated 
through several key regulators, of which the agr (accessory gene regulator) QS system is central [18]. 
This system is a classical two-component system with a sensor histidine kinase, AgrC, and a response 
regulator, AgrA, in addition to AgrB and AgrD which are responsible for the production of the quorum 
sensing signal [19,20]. agr-dependent QS is mediated via autoinducing peptides (AIP), 16-membered 
thiolactone macrocycles carrying a peptide tail that control virulence gene expression through the 
effector molecule RNAIII [21,22]. Structure-activity relationship studies (SAR) demonstrated that 
while the tail of the AIP is essential for agr activation [19,23], the macrocyclic ring is responsible for 
antagonistic activity [23]. This has led to the synthesis of global inhibitors based on truncated 
AIPs [23,24]; however, there are only few reports of natural antagonists of this system [24–27]. 
Nielsen et al. [28] recently developed a screening assay based on S. aureus lacZ reporter fusion strains, 
where the effect of compounds or extracts on expression of three key virulence genes (spa, hla, and 
rnaIII) and hence potential interference with the agr locus can be assessed. Subsequently, the assay 
was used to identify two xanthones as novel quorum sensing interfering compounds in S. aureus [28].  
We recently established a global collection of marine bacteria with antibacterial activity [29]. The 
purpose of the present study was to determine if this strain collection also harbored organisms that 
produced other types of bioactive compounds and we screened pure cultures, crude extracts, and purified 
secondary metabolites from the collection for potential inhibitors of the agr system. One of the bacterial 
families we investigated was the Vibrionaceae. These bacteria are ubiquitous in marine and brackish 
environments and often associated with marine organisms [30]. The Vibrionaceae consist of seven 
genera, with the majority of species belonging to the Vibrio and Photobacterium genera. Vibrio spp. can 
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be pathogenic to humans [31–33] or marine animals [30], but also occur in the commensal microflora of 
zooplankton [30] or live as bioluminescent symbionts with squid or fish [34–36]. The Photobacterium 
genus similarly comprises symbiotic [37,38] and pathogenic species [39–41]. Members of the 
Vibrionaceae produce broad-range inhibitory compounds [7,29]; however, only few of the antibacterial 
compounds have been isolated to date [42]. Antimicrobial compounds from Vibrio species include the 
pyrrolidinediones andrimid [43–45] and moiramide B [46] that inhibit fatty acid synthesis [47]. In 
addition, we recently reported the production of the potent pyrrothine antibiotic holomycin by a marine 
Photobacterium [45]. 
Herein, we report the isolation and chemical investigation of two novel depsipeptides produced by 
that same Photobacterium strain. The compounds, designated solonamides A and B, inhibit the agr QS 
system of S. aureus and therefore interfere with its virulence gene expression. This indicates that 
marine bacteria are a source of novel chemistry with potential use in antibacterial therapy. 
2. Results and Discussion  
2.1. Identification of QS Inhibitors from Photobacterium sp. 
In an initial search for antimicrobial compounds we isolated strain S2753 related to Photobacterium 
halotolerans [29]. Subsequently, the known antibiotic, holomycin, was identified as responsible for its 
growth inhibitory activity [45]. When investigating ethyl acetate extracts of S2753 in an agar diffusion 
assay monitoring expression of the S. aureus virulence genes hla, rnaIII, and spa [28], we observed an 
increased expression of spa and decreased expression of hla and rnaIII. The inverse effect of the extracts 
on spa and hla/rnaIII expression, respectively, indicates the presence of at least one compound that 
interferes with the S. aureus agr QS system [28]. Secondary screening of the extract by explorative 
solid-phase extraction (E-SPE) [48] detected the potential QSI activity in a fraction that did not inhibit 
growth of S. aureus or V. anguillarum (data not shown). Bioassay-guided fractionation by diol and  
C-18 columns resulted in the isolation of two compounds active in the S. aureus agar diffusion assay 
(Figure 1). The activity of the pure compounds matched the initial activity of the extract, confirming 
that these compounds are responsible for the observed changes in gene expression. 
Figure 1. Effect of solonamides (A and B) on hla, rnaIII and spa expression. Solonamides 
(5 mg mL−1) were added to wells in TSA plates containing the 8325-4 derived lacZ reporter 
strains PC322 (hla::lacZ), SH101F7 (rnaIII::lacZ), or PC203 (spa::lacZ). Incubation time 
was 15 h for plate I and II, and 35 h for plate III (plate numbering indicated with white 
letters). Solonamide B tested in two wells. 
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2.2. Structural Elucidation of the Solonamides 
The solonamides were isolated as white powder with respective molecular formulas C30H46N4O6 (A) 
and C32H50N4O6 (B) as determined by HRMS (1 ppm mass accuracy). Analysis of NMR data 
characterized the structures of the solonamides as cyclodepsipeptides consisting of four amino acids 
and a 3-hydroxy fatty acid (Figure 2). The amino acid composition was elucidated as alanine, 
phenylalanine, and two leucines for both peptides based on DQF-COSY and HSQC NMR data. 
Figure 2. Structures of solonamides A and B produced by Photobacterium sp. strain S2753 
and structure of natural group I AIP [21]. 
A B 
 
I 
The spin systems of the amino acids were confirmed through strong and unambiguous H2BC 
correlations [49] and the carbonyl signals assigned by HMBC correlations. Through careful inspection of 
the DQF-COSY and H2BC NMR data, solonamide A was found to contain a 3-hydroxyhexanoic acid 
(Hha), while solonamide B contained a 3-hydroxyoctanoic acid (Hoa). Long-range HMBC and NOESY 
correlation data allowed the sequence of amino acids to be established as fatty acid-Phe-Leu-Ala-Leu 
(Figure in Supplementary Information). This was corroborated by MS-MS experiments giving the 
exact molecular formula of the fragments (2 ppm mass accuracy, see Supplementary Information). The 
signal from one oxygen-bearing carbon with a high carbon shift indicated an ester linkage. The ring 
closure linkage was secured by HMBC correlations from H-3 in the fatty acid moiety to the carbonyl 
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in Leu and a weak NOESY correlation from H-3 to the Leu amide and Hα protons. In total, this 
accounted for the ten degrees of unsaturation resulting from the macrocyclic ring, five carbonyls, and 
the phenyl group. 
The absolute configurations of the individual amino acids were established by acid hydrolysis and 
Marfey’s method with UHPLC analysis. Both peptides were found to contain L-Phe, D-Ala, and an 
enantiomeric pair of L-Leu and D-Leu. Acid hydrolysis of the reduced linear peptides and subsequent 
Marfey’s derivatization specified the stereochemistry of the two Leu, exchanging the L-Leu peak  
(RT 3.77 min) with a new peak (RT 3.73 min), attributable to the corresponding alcohol. Thus, L- and  
D-stereochemistry was assigned as fatty acid-L-Phe-D-Leu-D-Ala-L-Leu in both solonamide A and B.  
The absolute configuration of the fatty acid was established by NMR spectroscopic analysis of the 
1H and 19F chemical shift differences (ΔδSR) in the (R)- and (S)-Mosher’s esters analysis of solonamide A 
and B. The absolute stereochemistry of C-3 in the 3-hydroxy fatty acid was established as (R) in both 
depsipeptides (Figure 3). 
Figure 3. Distribution of the Δδ values (ppm) calculated for the (a) 3-hydroxyhexanoic 
acid (Hha) and (b) 3-hydroxyoctanoic acid (Hoa) in the (R)- and (S)-Mosher’s esters. 
 
(a) 
 
(b) 
The yield of solonamides was up to 10 mg L−1, which is a high organic yield compared to that of 
other γ-proteobacteria [50,51]. This suggests that they could be storage compounds accumulated 
during growth. However, the solonamides were also produced on a chitin based minimal medium 
(Supplementary Information) which indicated that these compounds may be produced in the natural 
habitat of vibrios, such as chitinous zooplankton. In addition, D-alanine and L-leucine are incorporated 
in the structure; amino acids that are not present in the laboratory medium. Thus, the Photobacterium 
seems to produce these specific stereoforms rather than incorporating the available amino acids.  
2.3. Production of Solonamides by Related Photobacterium Strains 
To test whether the solonamides are also produced by strains related to our Photobacterium isolate, 
we compared strain S2753 with P. halotolerans LMG 22194T, P. rosenbergii LMG 22223T, and 
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P. angustum S14 [52]. None of these strains produced solonamides (as confirmed by LC-UV/MS), and 
none affected virulence gene expression in the gene-reporter agar diffusion assay. None of the three 
strains inhibited growth of V. anguillarum, and holomycin, the antibiotic of S2753 [45], was not detected.  
To the best of our knowledge, only two species of Photobacterium have been investigated for  
their secondary metabolites so far [51,53,54]. Oku et al. [51] isolated unnarmicin A and C from a 
marine Photobacterium strain MBIC06485 related to P. leiognathi. Like the solonamides, unnarmicin 
A and C consist of four amino acids (L-Phe, L-Leu, D-Phe, L-Leu) and a 3-hydroxyoctanoic and  
3-hydroxyhexanoic fatty acid, respectively. The finding of the unnarmicins in another marine 
Photobacterium sp. indicates that production of such peptides could be a common feature in this group 
of bacteria, despite the absence of solonamides in any related strains that we investigated.  
2.4. Solonamides Interfere with agr 
To verify that the purified solonamides do in fact cause transcriptional changes in virulence gene 
expression and to assess if the effect is strain specific, we isolated mRNA from S. aureus 8325-4 and 
the community-acquired strain, USA300 at different stages of growth following solonamide exposure 
and monitored gene expression by Northern blot analysis. Solonamide B dramatically reduced the 
expression of both hla and rnaIII while increasing expression of spa, strongly indicating that the 
compound interferes with agr regulation (Figure 4). The decreased expression of rnaIII was even more 
pronounced in the highly virulent USA300 strain where high agr activity is suspected to be a main 
contributor to the virulence of the strain [55,56]. The solonamides did not affect the growth rate of the 
liquid S. aureus cultures. Solonamide A was able to increase spa expression, but caused only a marginal 
reduction of hla and rnaIII expression in both 8325-4 and USA300. The discrepancy between the 
Northern blot analysis and the agar diffusion assay (mainly with regard to hla) may be rooted in the 
much higher concentrations of solonamides that are used in the agar diffusion assay as compared to the 
Northern blot analysis. Also, the Northern blot analysis directly monitors the amount of mRNA shortly 
after solonamide addition, whereas the agar diffusion assay relies on the accumulation of β-galactosidase 
enzyme over a period of 15 or 35 h.  
The structural similarity of the solonamides and the AIPs (Figure 2) suggest that they may  
be competitive inhibitors of the agr system. Unlike the AIPs, the solonamides are cyclized through a  
3-hydroxy fatty acid forming a lactone rather than a thiolactone. However, synthetic lactone and 
lactam variations of natural AIPs have been found to have antagonistic activity [19,23,57], which our 
study corroborates. While inhibition of agr by AIPs is more tolerant of sequence and structural 
diversity than is activation [23], Mayville et al. [14] found that the presence of the hydrophobic leucine 
and phenylalanine residues is important for the inhibition of the agr response. Both solonamides 
contain a leucine and phenylalanine; however, the reduced activity of solonamide A indicates that the 
overall hydrophobicity of the depsipeptides affected by the varying length of the fatty acid moiety 
might be an important factor influencing activity.  
The solonamides are the first reported antagonists produced by a natural source with a structure 
resembling that of native S. aureus AIPs. Kiran et al. (2008) [25] identified hamamelitannin from 
Hamamelis virginiana (witch hazel) as an inhibitor of RNAIII and δ-hemolysin production in S. aureus 
8325-4, USA300, and clinical S. epidermidis isolate MH. Also, ambuic acid from an unidentified fungal 
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strain was found to attenuate agr [26].Given the relatively low abundance of staphylococci in the 
marine environment, it seems unlikely that the Photobacterium sp. S2753 produces solonamides as 
part of a deliberate strategy to interfere with this specific type of bacteria. However, the solonamides 
might be targeted at other Gram-positive bacteria in the marine environment, such as bacilli and 
actinobacteria, though little is known about quorum sensing pathways in marine Gram-positive 
bacteria. A large number of different QS systems have been characterized from Gram-negative 
bacteria in the marine environment [57–62]. We speculate that the solonamides could also affect such 
systems despite sharing little structural similarity to agonists and antagonists of the systems identified 
to date [63]. Acylated homoserine lactones, the most widely researched type of QS molecules in  
Gram-negatives, can serve as both agonists and antagonists in different systems [27], and thus the 
solonamides may also serve as quorum sensing signals for the Photobacterium itself. However, we did 
not detect solonamides or compounds with similar QSI activity in any of the related strains. 
Figure 4. Effect of solonamide A and B on virulence gene expression in S. aureus strain 
8325-4 [18] and USA300 [55] examined by Northern blot analysis. Solonamides were added 
to exponentially growing cultures at OD600 = 0.4, and RNA was purified at OD600 = 0.7 and 
1.7. The RNA was reacted with probes recognizing hla, rnaIII, and spa, respectively. 
Solonamide B tested in duplicates. DMSO was used as negative control. 
 
Our findings suggest that quorum sensing inhibition could be an alternative therapeutic strategy for 
treatment of MRSA S. aureus infections; however, the effect in an in vivo infection model needs to be 
tested. Many genes are under QS control both in Gram-positive and Gram-negative bacteria, and thus 
it is not a simple drug target [64,65]. For example, biofilm formation in S. aureus has been linked to 
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low QS activity [66], and so there is a risk that the use of QS inhibitors could lead to decreased 
susceptibility of traditional antibiotics. Also, it is still unknown how QS inhibition will affect the 
overall fitness of a pathogen under in vivo conditions and thus pose a selective pressure for 
development of resistance [67] or enhanced virulence [68,69]. 
3. Experimental Section 
3.1. Isolation and Identification of Strain S2753 
Bacterial strain S2753 was isolated from a mussel surface collected in the tropical Pacific (9.1°S 
156.8°E) during the Danish Galathea 3 expedition [29]. S2753 was assigned to the Vibrionaceae by 
16S rRNA gene sequence similarity [29] and identified as being closely related to Photobacterium 
halotolerans based on recA and rpoA gene sequences, with homologies of 87% (recA) and 94% 
(rpoA) [45]. BLAST analyses showed that other closely related species were Photobacterium rosenbergii 
and Photobacterium angustum S14 [52].  
3.2. Initial Screening for Anti-Virulence Compounds 
S2753 was cultured in each 30 mL of (i) marine minimal medium (MMM) [70] containing 0.4% 
glucose and 0.3% casamino acids; (ii) Marine Broth 2216 (MB; Difco 2216); (iii) Sigma Sea Salts 
(SSS; Sigma S9883; 40 g L−1) containing 0.4% glucose and 0.3% casamino acids, and (iv) MMM 
containing 0.2% colloidal chitin [71,72] to investigate the best conditions for production of antibacterial 
compounds. All cultures were incubated aerated (200 rpm) for 72 h at 25 °C. All cultures were extracted 
with an equal volume of ethyl acetate (EtOAc). The extract was evaporated under nitrogen until 
dryness and redissolved in 300 μL 80% v/v ethanol (EtOH) in water. 20 μL of the extract was tested in 
an agar diffusion assay where expression from promoters of hla, rnaIII, and spa is monitored [28].  
For further screening, the culture broth of S2753 grown in MMM (1 L, 72 h, 25 °C, 100 rpm) was 
extracted directly with sterile Diaion HP20SS (12 g L−1, 24 h) (Sigma-Aldrich, St. Louis, MO). The 
resin was filtered off and washed with 80% (v/v) acetonitrile (MeCN)/water (300 mL) and the extract 
evaporated until dryness on a rotary evaporator. From this extract, 10 mg dry material was subjected to 
an explorative solid-phase extraction (E-SPE) protocol [48]. This yielded 15 fractions for re-testing in the 
agar diffusion assay as described above. The E-SPE fractions were also tested for antibacterial activity 
against Vibrio anguillarum strain 90-11-287 and S. aureus 8325 in a well diffusion agar assay [73].  
3.3. Isolation and Structural Elucidation of Solonamide A and B 
Using 10 L glass fermentors, S2753 was cultured in 5 × 4 L SSS (iii, above) containing 0.4% glucose 
and 0.3% casamino acids (25 °C, 72 h, 100 rpm) as this medium gave comparable yields to that of 
MMM (i) but at a lower cost. The broth was extracted directly with Diaion HP20SS (12 g L−1) as 
described above. The extract (3.4 g) was redissolved in EtOAc, absorbed onto 5 g Isolute diol 
(Biotage, Uppsala, Sweden), and added to a glass column with pure diol (95 g). A total of 12 fractions 
were collected from the diol column (100 g, 20 × 350 mm) ranging from heptane, dichlormethane 
(DCM), EtOAc, to pure methanol (MeOH), running under gravity. The fractions containing the QSI 
compounds (fraction 5, 20:80 (v/v) EtOAc/DCM and fraction 6, 40:60 (v/v) EtOAc/DCM) were 
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separated on Sepra ZT C18 (Phenomenex, Torrance, CA)(10 g SNAP) on an Isolera automated flash 
system (Biotage) using a MeCN/water gradient 25–75% over 20 min (12 mL min−1). Pure compounds 
were obtained directly: Solonamide A (17 mg) and B (201 mg). Activity of pure compounds was tested 
in the agar diffusion assay as described above (20 μL per well), with a final concentration of compounds 
of 5 mg mL−1 in dimethyl sulfoxide (DMSO).  
NMR spectra were recorded on a Varian Unity Inova 500 MHz spectrometer equipped with a 5 mm 
probe using standard pulse sequences. The signals of the solvent were used as internal references  
(δH 2.49 and δC 39.5 ppm for DMSO). Carbonyl shifts were confirmed with 13C 1D on a Bruker 
Avance 800 MHz spectrometer with a 5 mm TCI cryoprobe at the Danish Instrument Center for NMR 
Spectroscopy of Biological Macromolecules. 
LC-MS and LC-MS/MS analyses were performed on a maXis quadrupole time of flight mass 
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray (ESI) ion source. 
The MS was connected to an Ultimate 3000 UHPLC system (Dionex, Sunnyvale, CA) equipped with a 
diode-array detector. Separation was performed at 40 °C on a 150 mm × 2.1 mm ID, 2.6 µm Kinetex 
C18 column (Phenomenex) using a linear water/MeCN (both buffered with 20 mM formic acid) gradient 
starting from 15% MeCN and increased to 100% in 13 min at a flow of 0.4 mL min−1. The MS and 
MS/MS experiments were performed in ESI+ with a data acquisition range of m/z 100–1200 with 
collision energy of 27 V. The MS was calibrated using sodium formate automatically infused prior to 
each analytical run, providing a mass accuracy of below 1 ppm in MS mode and 2 ppm in MS/MS mode.  
The absolute configuration of the amino acids were found using acid hydrolysis (6 M HCl,  
110 °C, 20 h) [74] and derivatisation with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine  
amide, FDAA, Sigma-Aldrich) following the protocol by Bonnard et al. [75]. Ultra-high liquid 
chromatography-diode array (UHPLC-UV) analyses of the amino acids were done on a Dionex RSLC 
Ultimate 3000 (Dionex) equipped with a diode-array detector. Separation was obtained on a Kinetex 
C18 column (150 × 2.10 mm, 2.6 μm, Phenomenex) maintained at 60 °C using a linear gradient starting 
from 25% MeCN in water (both buffered with 50 ppm TFA) increasing to 27% MeCN over 6 min at a 
flow rate of 0.8 mL min−1. Retention times of the FDAA amino acid derivatives used as standards were 
as follows (maximum standard deviation ± 0.002 min): FDAA (1.50 min), L-Ala (1.14 min), D-Ala 
(1.61 min), L-Phe (3.58 min), D-Phe (5.04 min), L-Leu (3.77 min), D-Leu (5.49 min), comparable to the 
observed retention times from the solonamide-derived amino acids.  
To specify the stereochemistry of enantiomeric amino acids, the depsipeptides were reduced by 
LiBH4. The resulting linear peptides were subjected to the above mentioned acid hydrolysis and 
Marfey’s derivatisation. Details are given in the Supplementary Information.  
For the absolute configuration of the fatty acid residues, the (R)- and (S)-Mosher’s esters were 
prepared for both depsipeptides, and the stereocenters were assigned based on their 1H and 19F chemical 
shift differences (ΔδSR) [76,77]. Details are given in the Supplementary Information.  
Solonamide A: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for NMR data refer 
to Table 1; HRESIMS m/z 558.3486 (calcd for C30H46N4O6, 558.3496).  
Solonamide B: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for NMR data refer 
to Table 1; HRESIMS m/z 586.3725 (calcd for C32H50N4O6, 586.3730).  
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Table 1. NMR spectroscopic data (DMSO-d6) of solonamide A and B. 
 A B 
 Atom δC (ppm) δH (ppm)(multiplicity, J (Hz)) HMBC Atom δC (ppm) δH (ppm)(multiplicity, J (Hz)) HMBC 
Hha/Hoa 
1 170.6 -  1 170.4 - - 
2 40.7 2.67 (1H, dd, 13.5, 3.8) 
2.11 (1H, dd, 13.5, 10.1) 
1,3,4 2 40.5 2.69 (1H, dd, 13.5, 3.7) 
2.11 (1H, dd, 13.5, 10.3) 
1,3,4 
3 72.1 5.14 (1H, m) 1,5 3 72.0 5.13 (1H, m) 1,4,5,36 
4 36.2 1.62 (1H, m) 
1.45 (1H, m) 
2,3,6 4 33.8 1.65 (1H, m) 
1.45 (1H, m) 
5,6 
5 17.7 ~1.22 (1H, m) 3,4 5 23.8 ~1.20 (2H, m) 6,7 
6 13.8 0.85 (3H, t, 7) 4,5 6 30.8 ~1.22 (2H, m) ND 
    7 21.8 1.25 (2H, m) ND 
    8 13.6 0.84 (3H, m) 6 
L-Phe 
7-NH - 8.61 (1H, d, 3.2) 1 9-NH - 8.59 (1H, d, 3.0) 1,10,11,8 
8-CHα 55.9 4.26 (1H, ddd, 10, 6.1, 3.2) 9,10,14 10-CHα 55.6 4.26 (1H, ddd, 10, 6.1, 3.3) 11,18 
9-CHβ,1 36.4 2.94 (1H, dd, 13.3, 6.1) 
2.72 (1H, dd, 13.3, 10) 
8,10,11/15,14 11-CHβ,1 36.1 2.95 (1H, dd, 13.3, 6.1) 
2.73 (1H, dd, 13.3, 10) 
10,12,13/17,18 
10 135.8 - - 12 136.0 - - 
11,15 129.1 7.18 (2H, m) 9,13 13,17 128.7 7.20 (2H, m) 11,15 
12,14 128.4 7.25 (2H, m) 10 14,16 128.0 7.26 (2H, m) 12,14/16 
13 126.5 7.18 (1H, m) 11 15 126.2 7.20 (1H, m) 13/17 
16-CO 174.4 - - 18-CO 174.2 - - 
D-Leu 
17-NH - 8.63 (1H, d, 5.6) 16,18,19 19-NH - 8.64 (1H, d, 5.6) 18,20,21 
18-CHα 53.1 3.56 (1H, m) ND 20-CHα 52.7 3.57 (1H, m) 21,22,25 
19-CHβ,1 38.9 1.36 (1H, m) 
1.29 (1H, m) 
18,21,22 21-CHβ,1 38.6 1.31–1.37 (2H, m) 20,22,24 
20-CHγ 23.5 0.97 (1H, m) 21 22-CHγ 23.3 0.99 (1H, m) ND 
21-CHδ,1 23.2 0.69 (3H, d, 6.6) 19,20 23-CHδ,1 22.9 0.70 (3H, d, 6.6) 21,22,24 
22-CHδ,1 20.7 0.52 (3H, d, 6.5) 19,20 24-CHδ,1 20.4 0.53 (3H, d, 6.4) 21,23 
23-CO 171.8 - - 25-CO 171.6 - - 
D-Ala 
24-NH - 7.53 (1H, d, 8.9) 27,29 26-NH - 7.48 (1H, d, 8.9) 25,27,28 
25-CHα 48.2 4.18 (1H, m) 26,27 27-CHα 47.8 4.18 (1H, m) 28,29 
26-CHβ,1 16.6 1.32 (3H, d, 7.4) 27 28-CHβ,1 16.4 1.33 (3H, d, 7.3) 27,29 
27-CO 171.3 - - 29-CO 170.9 - - 
L-Leu 
28-NH - 7.08 (1H, d, 10) 27,29 30-NH - 7.05 (1H, d, 10) 29,31 
29-CHα 49.0 4.46 (1H, dt, 10, 4.4) 30,31,34 31-CHα 48.6 4.47 (1H, dt, 10, 4.3) 32,33,29/36 
30-CHβ,1 39.3 1.63 (1H, m) 
1.53 (1H, m) 
29,31,33,27/34 32-CHβ,1 39.0 1.64 (1H, m) 
1.52 (1H, m) 
31,33,35,29/36 
31-CHγ 23.9 1.50 (1H, m) 29,30,33 33-CHγ 23.8 1.50 (1H, m) 32,34,35 
32-CHδ,1 23.2 0.86 (3H, d, 6.5) 30,31,33 34-CHδ,1 23.0 0.86 (3H, d, 6.6) 32,33,35 
33-CHδ,1 21.3 0.81 (3H, d, 6.5) 30 35-CHδ,1 21.1 0.82 (3H, d, 6.4) 32,33 
34-CO 171.2 - - 36-CO 170.8 - - 
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3.4. LC-UV/MS Analyses of Related Photobacterium Strains 
To investigate the potential production of agr inhibitors in related Photobacterium strains, the 
metabolite profile of S2753 was compared by liquid chromatography-diode array/mass spectrometry 
(LC-UV/MS) to P. halotolerans (LMG 22194T), P. rosenbergii (LMG 22223T), and P. angustum (S14) 
described by de Nys et al. [52]. All strains were grown in 30 mL MMM containing 0.4% glucose and 
0.3% casamino acids (25 °C, 72 h, 200 rpm). Cultures were extracted with an equal volume of EtOAc 
and evaporated under nitrogen. Residues were redissolved in MeOH for LC-UV/MS analyses and in 
80% EtOH for bioassay testing. Inhibition of agr was tested as described above. Extracts were also 
tested against V. anguillarum strain 90-11-287 for growth inhibition. LC-UV/MS analyses were 
performed on an Agilent 1100 liquid chromatograph with a diode array detector (Agilent, Waldbronn, 
Germany) coupled to an LCT TOF mass spectrometer (Micromass, Manchester, UK) using a Z-spray 
ESI source. Separation was obtained on a Luna II C18 column (50 × 2 mm, 3 μm, Phenomenex) fitted 
with a security guard system using a linear gradient starting from 15% MeCN in water (both buffered 
with 20 mM formic acid) increasing to 100% MeCN over 20 min at a flow rate of 0.3 mL min−1. 
3.5. Northern Blot Analysis 
Northern blot analysis was performed as described previously [78]. The strains used were S. aureus 
FPR 3757 [55], a CA-MRSA USA300 obtained from ATCC (Boras, Sweden), and 8325-4 [17]. Samples 
for RNA purification were taken from cultures in Tryptone Soya Broth (TSB, Oxoid, Greve, Denmark) 
shaking at 185 rpm at 37 °C in a water bath (10 mL culture in 100 mL Erlenmeyer flask). Growth was 
monitored by measuring optical density at OD600. Start inoculum was OD600 = 0.03. Solonamides were 
added at OD600 = 0.4. Samples for RNA purification were taken at OD600 = 0.7 and 1.7. Probes 
targeting rnaIII, spa, and hla transcripts were amplified by PCR using primers hla forward (5′-GGG 
TTA GCC TGG CCT TCA GCC-3′), hla reverse (5′-GGG TGC CAT ATA CCG GGT TC-3′),  
spa forward (5′-GGG GGT GTA GGT ATT GCA TCT G-3′), spa reverse (5′-GGG GCT CCT GAA 
GGA TCG TC-3′), rnaIII forward (5′-GGG GAT CAC AGA GAT GTG ATG-3′), and rnaIII reverse 
(5′-GGG CAT AGC ACT GAG TCC AAG G-3′)(TAG Copenhagen A/S, Denmark). The resulting 
PCR fragments were 311 bp (hla), 719 bp (spa), and 316 bp (rnaIII), respectively.  
4. Conclusions  
The rapid, worldwide increase in antibiotic-resistant S. aureus [15] has led to an intense search for 
compounds with potential use in alternative therapeutic strategies [9]. Virulence of S. aureus involves 
a complex set of proteins, with the agr QS system controlling expression of several of the virulence 
genes. The investigation of crude extracts and fractions from a marine Photobacterium led to the 
identification of two novel depsipeptides, solonamides A and B, as potent inhibitors of this system. 
Interestingly, we found that solonamide B interfered with agr not only in S. aureus 8325-4 but also in 
strain USA300, which is a predominant community-acquired MRSA (CA-MRSA) strain in the US [79]. 
This finding suggests that quorum sensing inhibition could be an option for treatment of S. aureus 
USA300 infections. Future experiments will reveal the extent to which the solonamides are effective in 
treating S. aureus infections. In combination with other recent work from our laboratory [42,45,71]  
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the present study underlines that vibrios are a promising potential source of novel bioactive 
secondary metabolites.  
Acknowledgments 
We thank Anita Iversen for ultra high-resolution MS data and the Danish Center for NMR 
Spectroscopy of Biological Macromolecules for NMR time. Funding from the Programme Committee 
for Food, Health and Welfare under the Danish Strategic Research Council is acknowledged. The 
present work was carried out as part of the Galathea 3 expedition under the auspices of the Danish 
Expedition foundation. This is Galathea 3 contribution p85. 
References 
1. Berdy, J. Bioactive microbial metabolites—A personal view. J. Antibiot. 2005, 58, 1–26. 
2. Clardy, J.; Fischbach, M.A.; Walsh, C.T. New antibiotics from bacterial natural products. Nat. 
Biotechnol. 2006, 24, 1541–1550. 
3. Das, S.; Lyla, P.S.; Khan, S.A. Marine microbial diversity and ecology: Importance and future 
perspectives. Curr. Sci. 2006, 90, 1325–1335. 
4. Gulder, T.A.M.; Moore, B.S. Chasing the treasures of the sea—Bacterial marine natural products. 
Curr. Opin. Microbiol. 2009, 12, 252–260. 
5. Rahman, H.; Austin, B.; Mitchell, W.J.; Morris, P.C.; Jamieson, D.J.; Adams, D.R.; Spragg, A.M.; 
Schweizer, M. Novel anti-infective compounds from marine bacteria. Mar. Drugs 2010, 8, 498–518. 
6. de Carvalho, C.C.C.R.; Fernandes, P. Production of metabolites as bacterial responses to the 
marine environment. Mar. Drugs 2010, 8, 705–727. 
7. Long, R.A.; Azam, F. Antagonistic interactions among marine pelagic bacteria. Appl. Environ. 
Microbiol. 2001, 67, 4975–4983. 
8. Wright, G.D.; Sutherland, A.D. New strategies for combating multidrug-resistant bacteria. Trends 
Mol. Med. 2007, 13, 260–267. 
9. Clatworthy, A.E.; Pierson, E.; Hung, D.T. Targeting virulence: A new paradigm for antimicrobial 
therapy. Nat. Chem. Biol. 2007, 3, 541–548. 
10. Rasmussen, T.B.; Givskov, M. Quorum-sensing inhibitors as anti-pathogenic drugs. Int. J. Med. 
Microbiol. 2006, 296, 149–161. 
11. Sintim, H.O.; Al Smith, J.; Wang, J.X.; Nakayama, S.; Yan, L. Paradigm shift in discovering 
next-generation anti-infective agents: Targeting quorum sensing, c-di-gmp signaling and biofilm 
formation in bacteria with small molecules. Future Med. Chem. 2010, 2, 1005–1035. 
12. Bjarnsholt, T.; Givskov, M. Quorum-sensing blockade as a strategy for enhancing host defences 
against bacterial pathogens. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2007, 362, 1213–1222. 
13. Camara, M.; Williams, P.; Hardman, A. Controlling infection by tuning in and turning down the 
volume of bacterial small-talk. Lancet Infect. Dis. 2002, 2, 667–676. 
14. Mayville, P.; Ji, G.Y.; Beavis, R.; Yang, H.M.; Goger, M.; Novick, R.P.; Muir, T.W.  
Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus 
aureus responsible for virulence. Proc. Natl. Acad. Sci. USA 1999, 96, 1218–1223. 
Mar. Drugs 2011, 9  
 
 
2549
15. Grundmann, H.; Aires-De-Sousa, M.; Boyce, J.; Tiemersma, E. Emergence and resurgence of 
meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368, 874–885. 
16. Hiramatsu, K.; Cui, L.; Kuroda, M.; Ito, T. The emergence and evolution of methicillin-resistant 
Staphylococcus aureus. Trends Microbiol. 2001, 9, 486–493. 
17. Chan, W.C.; Coyle, B.J.; Williams, P. Virulence regulation and quorum sensing in staphylococcal 
infections: Competitive agrc antagonists as quorum sensing inhibitors. J. Med. Chem. 2004, 47, 
4633–4641. 
18. Novick, R.P.; Morse, S.I. In vivo transmission of drug resistance factors between strains of 
Staphylococcus aureus. J. Exp. Med. 1967, 125, 45–59. 
19. McDowell, P.; Affas, Z.; Reynolds, C.; Holden, M.T.G.; Wood, S.J.; Saint, S.; Cockayne, A.;  
Hill, P.J.; Dodd, C.E.R.; Bycroft, B.W.; Chan, W.C.; Williams, P. Structure, activity and 
evolution of the group i thiolactone peptide quorum-sensing system of Staphylococcus aureus. 
Mol. Microbiol. 2001, 41, 503–512. 
20. Novick, R.P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. 
Mol. Microbiol. 2003, 48, 1429–1449. 
21. Ji, G.Y.; Beavis, R.C.; Novick, R.P. Cell density control of staphylococcal virulence mediated by 
an octapeptide pheromone. Proc. Natl. Acad. Sci. USA 1995, 92, 12055–12059. 
22. Ji, G.Y.; Beavis, R.; Novick, R.P. Bacterial interference caused by autoinducing peptide variants. 
Science 1997, 276, 2027–2030. 
23. Lyon, G.J.; Wright, J.S.; Muir, T.W.; Novick, R.P. Key Determinants of Receptor Activation in 
the Agr Autoinducing Peptides of Staphylococcus aureus. Biochemistry 2002, 41, 10095–10104. 
24. Muir, T.W. Turning virulence on and off in staphylococci. J. Pept. Sci. 2003, 9, 612–619. 
25. Kiran, M.D.; Adikesavan, N.V.; Cirioni, O.; Giacometti, A.; Silvestri, C.; Scalise, G.; Ghiselli, R.; 
Saba, V.; Orlando, F.; Shoham, M.; Balaban, N. Discovery of a quorum-sensing inhibitor of  
drug-resistant staphylococcal infections by structure-based virtual screening. Mol. Pharmacol. 
2008, 73, 1578–1586. 
26. Nakayama, J.; Uemura, Y.; Nishiguchi, K.; Yoshimura, N.; Igarashi, Y.; Sonomoto, K. Ambuic 
acid inhibits the biosynthesis of cyclic peptide quormones in gram-positive bacteria. Antimicrob. 
Agents Chemother. 2009, 53, 580–586. 
27. Qazi, S.; Middleton, B.; Muharram, S.H.; Cockayne, A.; Hill, P.; O’Shea, P.; Chhabra, S.R.; 
Camara, M.; Williams, P. N-acylhomoserine lactones antagonize virulence gene expression and 
quorum sensing in Staphylococcus aureus. Infect. Immun. 2006, 74, 910–919. 
28. Nielsen, A.; Nielsen, K.F.; Frees, D.; Larsen, T.O.; Ingmer, H. Method for screening compounds 
that influence virulence gene expression in Staphylococcus aureus. Antimicrob. Agents Chemother. 
2010, 54, 509–512. 
29. Gram, L.; Melchiorsen, J.; Bruhn, J.B. Antibacterial activity of marine culturable bacteria 
collected from a global sampling of ocean surface waters and surface swabs of marine organisms. 
Mar. Biotechnol. 2010, 12, 439–451. 
30. Thompson, F.L.; Iida, T.; Swings, J. Biodiversity of vibrios. Microbiol. Mol. Biol. Rev. 2004, 68, 
403–435. 
31. Faruque, S.M.; Albert, M.J.; Mekalanos, J.J. Epidemiology, genetics, and ecology of toxigenic 
Vibrio cholerae. Microbiol. Mol. Biol. Rev. 1998, 62, 1301–1314. 
Mar. Drugs 2011, 9  
 
 
2550
32. Linkous, D.A.; Oliver, J.D. Pathogenesis of Vibrio vulnificus. FEMS Microbiol. Lett. 1999, 174, 
207–214. 
33. Su, Y.C.; Liu, C.C. Vibrio parahaemolyticus: A concern of seafood safety. Food Microbiol. 2007, 
24, 549–558. 
34. Fidopiastis, P.M.; von Boletzky, S.; Ruby, E.G. A new niche for Vibrio logei, the predominant 
light organ symbiont of squids in the genus Sepiola. J. Bacteriol. 1998, 180, 59–64. 
35. Haygood, M.G.; Distel, D.L. Bioluminescent symbionts of flashlight fishes and deep-sea 
anglerfishes form unique lineages related to the genus Vibrio. Nature 1993, 363, 154–156. 
36. Ruby, E.G. Lessons from a cooperative, bacterial-animal association: The Vibrio fischeri 
Euprymna scolopes light organ symbiosis. Annu. Rev. Microbiol. 1996, 50, 591–624. 
37. Ast, J.C.; Dunlap, P.V. Phylogenetic resolution and habitat specificity of members of the 
Photobacterium phosphoreum species group. Environ. Microbiol. 2005, 7, 1641–1654. 
38. Boisvert, H.; Chatelai, R.; Bassot, J.M. Studies on a Photobacterium isolated from light organ of 
fish Leiognathidae. Ann. Inst. Pasteur 1967, 112, 521–525. 
39. Magarinos, B.; Romalde, J.L.; Lopez-Romalde, S.; Morinigo, M.A.; Toranzo, A.E. Pathobiological 
characterisation of Photobacterium damselae subsp piscicida isolated from cultured sole (Solea 
senegalensis). Bull. Eur. Assoc. Fish Pathol. 2003, 23, 183–190. 
40. Thompson, F.L.; Thompson, C.C.; Naser, S.; Hoste, B.; Vandemeulebroecke, K.; Munn, C.; 
Bourne, D.; Swings, J. Photobacterium rosenbergii sp. nov. and Enterovibrio coralii sp. nov., 
vibrios associated with coral bleaching. Int. J. Syst. Evol. Microbiol. 2005, 55, 913–917. 
41. Richards, G.P.; Watson, M.A.; Crane, E.J., III; Burt, I.G.; Bushek, D. Shewanella and 
Photobacterium spp. in oysters and seawater from delaware bay. Appl. Environ. Microbiol. 2008, 
74, 3323–3327. 
42. Mansson, M.; Gram, L.; Larsen, T.O. Production of bioactive secondary metabolites by marine 
Vibrionaceae. Mar. Drugs 2011, 9, 1440–1468. 
43. Long, R.A.; Rowley, D.C.; Zamora, E.; Liu, J.Y.; Bartlett, D.H.; Azam, F. Antagonistic interactions 
among marine bacteria impede the proliferation of Vibrio cholerae. Appl. Environ. Microbiol. 
2005, 71, 8531–8536. 
44. Oclarit, J.M.; Okada, H.; Ohta, S.; Kaminura, K.; Yamaoka, Y.; Iizuka, T.; Miyashiro, S.;  
Ikegami, S. Anti-bacillus substance in the marine sponge, hyatella species, produced by an 
associated Vibrio species bacterium. Microbios 1994, 78, 7–16. 
45. Wietz, M.; Mansson, M.; Gotfredsen, C.H.; Larsen, T.O.; Gram, L. Antibacterial compounds 
from marine Vibrionaceae isolated on a global expedition. Mar. Drugs 2010, 8, 2946–2960. 
46. Needham, J.; Kelly, M.T.; Ishige, M.; Andersen, R.J. Andrimid and moiramides A–C, metabolites 
produced in culture by a marine isolate of the bacterium Pseudomonas fluorescens—Structure 
elucidation and biosynthesis. J. Org. Chem. 1994, 59, 2058–2063. 
47. Pohlmann, J.; Lampe, T.; Shimada, M.; Nell, P.G.; Pernerstorfer, J.; Svenstrup, N.; Brunner, N.A.; 
Schiffer, G.; Freiberg, C. Pyrrolidinedione derivatives as antibacterial agents with a novel mode 
of action. Bioorg. Med. Chem. Lett. 2005, 15, 1189–1192. 
48. Mansson, M.; Phipps, R.K.; Gram, L.; Munro, M.H.G.; Larsen, T.O.; Nielsen, K.F. Explorative 
Solid-Phase Extraction (E-SPE) for accelerated microbial natural product discovery, dereplication, 
and purification. J. Nat. Prod. 2010, 73, 1126–1132. 
Mar. Drugs 2011, 9  
 
 
2551
49. Nyberg, N.T.; Duus, J.O.; Sorensen, O.W. Heteronuclear two-bond correlation: Suppressing 
heteronuclear three-bond or higher nmr correlations while enhancing two-bond correlations even 
for vanishing (2)J(CH). J. Am. Chem. Soc. 2005, 127, 6154–6155. 
50. Fenical, W. Chemical studies of marine-bacteria—Developing a new resource. Chem. Rev. 1993, 
93, 1673–1683. 
51. Oku, N.; Kawabata, K.; Adachi, K.; Katsuta, A.; Shizuri, Y. Unnarmicins A and C, new 
antibacterial depsipeptides produced by marine bacterium Photobacterium sp. MBIC06485.  
J. Antibiot. 2008, 61, 11–17. 
52. de Nys, R.; Kumar, N.; Sharara, K.A.; Srinivasan, S.; Ball, G.; Kjelleberg, S. A new metabolite 
from the marine bacterium Vibrio angustum S14. J. Nat. Prod. 2001, 64, 531–532. 
53. Matsuura, S.; Odaka, M.; Sugimoto, T.; Goto, T. Structure of pteridines from Photobacterium 
phosphorium. Chem. Lett. 1973, 2, 343–346. 
54. Suzuki, A.; Goto, M. Photolumazines, new naturally occurring inhibitors of riboflavin synthetase. 
Biochim. Biophys. Acta 1973, 313, 229–234. 
55. Diep, B.A.; Gill, S.R.; Chang, R.F.; Phan, T.H.; Chen, J.H.; Davidson, M.G.; Lin, F.; Lin, J.; 
Carleton, H.A.; Mongodin, E.F.; Sensabaugh, G.F.; Perdreau-Remington, F. Complete genome 
sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus 
aureus. Lancet 2006, 367, 731–739. 
56. Li, M.; Diep, B.A.; Villaruz, A.E.; Braughton, K.R.; Jiang, X.F.; Deleo, F.R.; Chambers, H.F.;  
Lu, Y.; Otto, M. Evolution of virulence in epidemic community-associated methicillin-resistant 
Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2009, 106, 5883–5888. 
57. Cao, J.G.; Meighen, E.A. Purification and structural identification of an autoinducer for the 
luminescence system of Vibrio harveyi. J. Biol. Chem. 1989, 264, 21670–21676. 
58. Chen, X.; Schauder, S.; Potier, N.; Van Dorsselaer, A.; Pelczer, I.; Bassler, B.L.; Hughson, F.M. 
Structural identification of a bacterial quorum-sensing signal containing boron. Nature 2002, 415, 
545–549. 
59. Higgins, D.A.; Pomianek, M.E.; Kraml, C.M.; Taylor, R.K.; Semmelhack, M.F.; Bassler, B.L. 
The major vibrio cholerae autoinducer and its role in virulence factor production. Nature 2007, 
450, 883–886. 
60. Kuo, A.; Blough, N.V.; Dunlap, P.V. Multiple N-Acyl-L-homoserine lactone autoinducers of 
luminescence in the marine symbiotic bacterium Vibrio fischeri. J. Bacteriol. 1994, 176, 7558–7565. 
61. Milton, D.L.; Hardman, A.; Camara, M.; Chhabra, S.R.; Bycroft, B.W.; Stewart, G.S.A.B.; 
Williams, P. Quorum sensing in Vibrio anguillarum: Characterization of the VanI/VanR locus 
and identification of the autoinducer N-(3-Oxodecanoyl)-L-homoserine lactone. J. Bacteriol. 
1997, 179, 3004–3012. 
62. Schaefer, A.L.; Greenberg, E.P.; Oliver, C.M.; Oda, Y.; Huang, J.J.; Bittan-Banin, G.; Peres, C.M.; 
Schmidt, S.; Juhaszova, K.; Sufrin, J.R.; Harwood, C.S. A new class of homoserine lactone 
quorum-sensing signals. Nature 2008, 454, 595–599. 
63. Dobretsov, S.; Teplitski, M.; Paul, V. Mini-review: Quorum sensing in the marine environment 
and its relationship to biofouling. Biofouling 2009, 25, 413–427. 
64. Harraghy, N.; Kerdudou, S.; Herrmann, M. Quorum-sensing systems in staphylococci as 
therapeutic targets. Anal. Bioanal. Chem. 2007, 387, 437–444. 
Mar. Drugs 2011, 9  
 
 
2552
65. Otto, M. Quorum-sensing control in staphylococci—A target for antimicrobial drug therapy. 
FEMS Microbiol. Lett. 2004, 241, 135–141. 
66. Boles, B.R.; Horswill, A.R. agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS 
Pathog. 2008, 4, 1–13. 
67. Defoirdt, T.; Boon, N.; Bossier, P. Can bacteria evolve resistance to quorum sensing disruption. 
PLoS Pathog. 2010, 6, 1–6. 
68. Köhler, T.; Perron, G.G.; Buckling, A.; van Delden, C. Quorum sensing inhibition selects for 
virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 2010, 6, 1–6. 
69. Rumbaugh, K.P.; Diggle, S.P.; Watters, C.M.; Ross-Gillespie, A.; Griffin, A.S.; West, S.A. 
Quorum sensing and social evolution of bacterial virulence. Curr. Biol. 2009, 19, 341–345. 
70. Ostling, J.; Goodman, A.; Kjelleberg, S. Behavior of incp-1 plasmids and a minimu transposon in 
a marine Vibrio sp.—Isolation of starvation inducible lac operon fusions. FEMS Microbiol. Ecol. 
1991, 86, 83–94. 
71. Wietz, M.; Mansson, M.; Gram, L. Chitin stimulates production of the antibiotic andrimid in a 
Vibrio coralliilyticus strain. Environ. Microbiol. Rep. 2011, 3, 559–564. 
72. Weyland, H.; Ruger, H.-J.; Schwarz, H. Zur Isolierung und identifizierung mariner bakterien. Ein 
beitrag zur standardisierung und entwicklung adaequater methoden. Veroff. Inst. Meeresforsch. 
Bremerh. 1970, 12, 269–296. 
73. Hjelm, M.; Bergh, O.; Riaza, A.; Nielsen, J.; Melchiorsen, J.; Jensen, S.; Duncan, H.; Ahrens, P.; 
Birkbeck, H.; Gram, L. Selection and identification of autochthonous potential probiotic bacteria 
from turbot larvae (Scophthalmus maximus) rearing units. Syst. Appl. Microbiol. 2004, 27, 360–371. 
74. Fujii, K.; Ikai, Y.; Oka, H.; Suzuki, M.; Harada, K. A nonempirical method using LC/MS for 
determination of the absolute configuration of constituent amino acids in a peptide: Combination 
of marfey’s method with mass spectrometry and its practical application. Anal. Chem. 1997, 69, 
5146–5151. 
75. Bonnard, I.; Manzanares, I.; Rinehart, K.L. Stereochemistry of kahalalide F. J. Nat. Prod. 2003, 
66, 1466–1470. 
76. Dale, J.A.; Dull, D.L.; Mosher, H.S. Alpha-methoxy-alpha-trifluoromethylphenylacetic acid, a 
versatile reagent for determination of enantiomeric composition of alcohols and amines. J. Org. 
Chem. 1969, 34, 2543–2549. 
77. Sullivan, G.R.; Dale, J.A.; Mosher, H.S. Correlation of configuration and f-19 chemical-shifts of 
alpha-methoxy-alpha-trifluoromethylphenylacetate derivatives. J. Org. Chem. 1973, 38, 2143–2147. 
78. Jelsbak, L.; Ingmer, H.; Valihrach, L.; Cohn, M.T.; Christiansen, M.H.G.; Kallipolitis, B.H.; 
Frees, D. The chaperone clpx stimulates expression of Staphylococcus aureus protein a by rot 
dependent and independent pathways. PLoS One 2010, 5, e12752:1–e12752:11. 
79. Tenover, F.C.; Goering, R.V. Methicillin-resistant Staphylococcus aureus strain USA300: Origin 
and epidemiology. J. Antimicrob. Chemother. 2009, 64, 441–446. 
Samples Availability: Available from the authors. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
Supplementary Information 
 
A1: LC-MS selective ion-trace of solonamide A (m/z 558, RT = 11.43 min) and solonamide B (m/z 
586, RT = 13.25 min) production on different growth media, including marine minimal media with 
glucose (MMM), marine broth (MB), sigma sea salts (SSS), and marine minimal media with chitin 
(Chitin). Slight shift in retention times due to inter-batch variations on the LC-MS system. 
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Assignments of the depsipeptides were performed using a conventional assignment approach.  
HMBC correlations between  3-H/1-CO, 3-H/36-CO and NOEs between 3-H/31-Hα-Leu confirms 
the lactone closure of the structure. The figure (A3) below shows key correlation for the lactone 
ring closure. 
 
 
 
 
 
 
 
 
 
 
A4. 1D 
1
H spectrum of Solonamide A 
 
A5. 1D 
1
H spectrum of Solonamide B 
 MS/MS data  
A6: MS and MS/MS spectrum of solonamide A (C30H46N4O6, calcd. 558.3496, Δ m/z 0.8 ppm) with 
characteristic fragments and their molecular formulas (Δ m/z 0.2-0.6 ppm): 
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 A7: Characteristic fragments for solonamide A (left) and B (right): 
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Establishment of absolute configuration 
The absolute configuration of C3 at 3-hydroxyhexanoic acid (Hha) and 3-hydroxyoctanoic acid 
(Hoa) was determined using the Mosher’s method. Here with the Mosher’s method two enantiomers 
of an acid chloride (α-methoxy-α-trifluoromethylphenylacetic acid chloride, MTPA-Cl) are reacted 
with the secondary alcohol at the stereogenic center in order to reveal the configuration of this 
center. The reaction yields two diastereoisomers with known configuration around one of the 
stereogenic centers enabling the determination of the other stereogenic center.  
The sign of the ∆δ values can be seen in the figures below, all pointing toward the same 
configuration at the C3 stereocenter in Hha and Hoa. The values for ∆δ are positive for the alkane 
end of Hha/Hoa and negative towards the carbonyl end, which points towards an R-configration of 
the C3 stereocenter. The difference seen in the flourine NMR data supports this conclusion when 
the alkane chain of the molecule is regarded as least bulky compared to the remaining part of the 
molecule with a ∆δ(SR) ~ -0.68 ppm . 
 
 
 
 
 
 
 
A8. Distribution of the ∆δ values calculated for the 3-hydroxyhexanoic acid (Hha) of solonamide A 
 
 
 
 
 
 
 
A9. Distribution of the ∆δ values calculated for the 3-hydroxyoctanoic acid (Hoa) of solonamide B 
 
Experimental procedure used for Mosher’s:  
Methanolysis of solonamide A (and B) 
5 mg (8.52 μmol) of the depsipeptide (solonamide A) is dissolved in 1.5 mL of 0.5 M NaOMe in 
MeOH and stirred at room temperature for 1 h. The reaction mixture is neutralised by careful 
addition of 1M HCl (aq) and the pH is monitored with universal indicator paper. The reaction 
mixture is concentrated to dryness on a rotary evaporator, and partitioned in EtOAc and H2O. 
Methanolysis of solonamide B was performed using the same procedure. The organic phase is 
concentrated to dryness on a rotary evaporator and the methyl ester product verified by LC-MS 
([M+H]
+
 A: 591.3803 Da, B: 619.4053 Da) and purified by RP-HPLC on a Waters HPLC with a 
600 controller and a 996 photodiode array detector using a water/MeCN gradient elution from 40 to 
60 % MeCN over 20 min (5 mL/min) with a Luna C18 column (5 µm, 250x10 mm, Phenomenex). 
Pure methyl esters of solonamide A (1.1 mg) and B (2.7 mg). 
 
Preparation of the R-MTPA ester of solonamide A (and B) 
To a stirred solution of the purified methanolysis product (0.55 mg, 0.889 μmol) in dry pyridine 
(150 µL) is added 5 µL (catalytic amount, 0.1 eq) of a solution of dimethylaminopyridine (DMAP) 
in dry pyridine (0.4 mg, 50 µL). After 10 min 9.1 µL S-(+)-MTPA-Cl (48.6 μmol) is added and the 
reaction is left overnight at room temperature. The reaction mixture is dried on a speedvac, 
redissolved in MeOH and purified on a Waters HPLC with a 600 controller and a 996 photodiode 
array detector using a water/MeCN gradient elution from 45 to 100 % MeCN over 20 min (5 
mL/min) with a Luna C18 (5 µm, 250x10 mm, Phenomenex) column to give pure R-MTPA ester (A: 
0.5 mg, B: ~1.2 mg). 
 
Preparation of the S-MTPA ester of solonamide A (and B) 
Using the same procedure as for the R-MTPA ester, the S-MTPA ester is produced by reaction with 
R-(–)-MTPA-Cl. Pure R-MTPA esters (A: 0.4 mg, B: ~1.1 mg). 
 
 
 
 
 
Establishing stereochemistry of enantiomeric Leu by reduction and Marfey’s 
2 mg of solonamide B is reduced in 2 M LiBH4 in THF at 0°C for 30 min, then at rt overnight and 
lastly heated to 50˚C for 30 min. EtOAc is added and the reaction is quenched with sat. NH4Cl (aq) 
before the product is extracted with EtOAc, CH2Cl2  and Et2O concentrated and purified by RP-
HPLC on a Waters HPLC with a 600 controller and a 996 photodiode array detector using a 
water/MeCN gradient elution from 25 to 80% MeCN over 20 min (5 mL/min) with a Luna C18 
column (5 µm, 250x10 mm, Phenomenex). Yields 0.7 mg of reduced open-chain solonamide B. The 
same procedure is used for solonamide A, only with a gradient of 35-70 %, yielding 0.8 mg. 
300 µg of each peptide is hydrolysed with 300 µL 6 M HCl at 110°C for 20 h. To the hydrolysis 
products is added 75 µL water, 20 µL 1 M NaHCO3 solution and 100 µL 1% FDAA in acetone, 
followed by reaction at 40°C in 1 h. The vial is removed from the heat, neutralised with 10 µL 2 M 
HCl and the solution is diluted with 395 µL MeOH to a total volume of 0.5 mL. The FDAA 
derivatives are analysed by UPLC on a Dionex Ultimate 3000 with a diode array detector and a 
Kinetex C18 column (2.6 µm, 150x2.10 mm, Phenomenex). The analyses are run with a gradient 
elution of water/MeCN from 25 to 37 % MeCN over 6 min (60°C, 0.8 mL/min) and the FDAA 
derivatives of the hydrolysates are compared to retention times of the standard amino acid 
derivatives: D-Ala (1.61 min), L-Ala (1.14 min), D-Leu (5.49 min), L-Leu (3.77 min), D-Phe (5.04 
min), L-Phe (3.585 min). FDAA elutes at 1.50 min. 
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Abstract: During our search for new natural products from the marine environment, we 
discovered a wide range of cyclic peptides from a marine Photobacterium, closely related 
to P. halotolerans. The chemical fingerprint of the bacterium showed primarily  
non-ribosomal peptide synthetase (NRPS)-like compounds, including the known 
pyrrothine antibiotic holomycin and a wide range of peptides, from diketopiperazines to 
cyclodepsipeptides of 500–900 Da. Purification of components from the pellet fraction led 
to the isolation and structure elucidation of four new cyclodepsipeptides, ngercheumicin F, 
G, H, and I. The ngercheumicins interfered with expression of virulence genes known to be 
controlled by the agr quorum sensing system of Staphylococcus aureus, although to a 
lesser extent than the previously described solonamides from the same strain  
of Photobacterium. 
Keywords: Photobacterium; depsipeptide; structure elucidation; quorum sensing; 
antivirulence; agr 
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1. Introduction 
The marine environment is a rich and vastly underexplored resource in many aspects. Most of the 
Earth’s surface is covered by water, inhabited by an incredible diversity of species, many of which 
have yet to be discovered. Microbial species are an important source for marine chemodiversity and it 
is believed that marine microorganisms will provide valuable drug candidates in the future [1,2]. There 
are however certain challenges with respect to sampling and culturing, and the usually low yields of 
metabolites can hamper full structural characterization and biological explorations. 
A marine Photobacterium was selected from 500 bacterial strains collected during a global marine 
research cruise in 2006–2007 [3]. It was sampled from a mussel surface near the Solomon Islands and 
this bacterial strain was singled out as particularly interesting because of a two-pronged inhibitory 
effect of growth and quorum sensing (QS) in important human pathogens. The known pyrrothine 
antibiotic holomycin was responsible for the growth inhibition of V. anguillarum and S. aureus [4], 
while the solonamides were identified as the major contributors to the interference with agr quorum 
sensing in S. aureus [5]. Inhibition of virulence factor production and activity has been suggested as a 
new therapeutic approach suitable for antibiotic resistant pathogens [6]. In S. aureus, one of the 
possible targets is the agr quorum sensing system that in response to autoinducing peptide (AIP) 
accumulation at high cell densities induces expression of numerous extracellular toxins including hla 
encoding α-hemolysin while repressing expression of surface factors such as the spa encoded  
Protein A [7]. 
In this study, we report the identification of four cyclodepsipeptides in the 800–900 Da size range 
from the cell-associated (pellet) fraction of this marine Photobacterium that modulate expression of 
agr controlled virulence genes. The depsipeptides ngercheumicin F, G, H, and I are new additions to 
the structural family that initially constituted ngercheumicin A and B [8]. Three other depsipeptides 
ngercheumicin C, D, and E were isolated from the same bacterial strain as ngercheumicin A and B, but 
they are structurally different. All ngercheumicins reported to date have been isolated from 
Photobacterium spp. and a biological activity reported by Shizuri et al. for ngercheumicins A–E was 
against infections by Pseudovibrio denitrificans [8]. Like the solonamides [5], the ngercheumicins are 
16-membered macrocyclic depsipeptides with some structural resemblance to the AIPs of S. aureus. 
Generally, AIPs consist of a cyclopentapeptide moiety cyclized through a cysteine residue by a 
thiolactonization, and with an exocyclic peptide chain of variable length extended from the cysteine 
residue in the N-terminal direction [9]. The exocyclic chain appears to be closely related to agonistic 
activity as truncated AIPs are known to have antagonistic properties [10]. Structure-activity 
relationship studies by Mayville et al. [11] indicated that adjacent Leu and Phe residues are required 
for inhibitory activity; however, structural comparisons of 24 natural staphylococcal AIPs later showed 
that they consistently have bulky, hydrophobic amino acid side chains in the C-terminus [12]. This 
may instead be the structural requirement for activity. 
Here, we describe the isolation and structure elucidation of the four new ngercheumicins and 
discuss their role in QS. 
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2. Results and Discussion 
2.1. Isolation and Structure Elucidation of Ngercheumicins F–I 
The pellet of the Photobacterium sp. was extracted with organic solvents (see Experimental 
Section 3.2) and fractionated on a diol column. Mass spectrometric analysis revealed a series of 
peptide-like analogues which display good ionization in ESI
+
 MS and end absorption in UV 
spectroscopy. The fractions containing these analogues were pooled and subjected to further 
purification, first on a smaller diol column and then by preparative reversed phase HPLC, which gave 
four fractions of ngercheumicin F, G, H, and I, respectively. Ngercheumicins A and B were also 
detected by LC-MS, but they were not purified in sufficient amounts for structural or biological 
screening studies. The four new ngercheumicins were found to inhibit transcription of the regulatory 
rnaIII in S. aureus, which is the effector molecule of the agr QS system (See Section 2.2 and 
Supplementary Information).The ngercheumicins were isolated as white solids with the respective 
exact masses (HR-ESI-TOF) and molecular formulae: Ngercheumicin F (m/z: [M + H]
+
 853.5685, 
calculated for C43H77N6O11 as 853.5650), ngercheumicin G (m/z: [M + H]
+
 855.5907, calculated for 
C43H79N6O11 as 855.5807), ngercheumicin H (m/z: [M + H]
+
 881.6033, calculated for C45H81N6O11 as 
881.5963), and ngercheumicin I (m/z: [M + H]
+
 883.6255, calculated for C45H83N6O11 as 883.6120). 
Analysis of 1D and 2D nuclear magnetic resonance (NMR) spectroscopic data obtained for the four 
compounds characterized the structures as cyclodepsipeptides consisting of six amino acids and a  
3-hydroxy fatty acid (six NH signals and seven carbonyl resonances) (Figure 1). All four 
ngercheumicins were elucidated as having identical amino acid sequences, consisting of three leucines, 
two threonines, and one serine, as established by DQF-COSY, gHSQC, gHMBC, gH2BC, and 
TOCSY 2D NMR spectroscopic analyses. The closure of the macrocyclic ring through an ester linkage 
between the C-terminus and the hydroxyl group in one of the threonine residues was verified by the 
low field chemical shift of the β-proton of Thr2 (H26, Table 1) and a HMBC correlation between H26 
and the carbonyl (C1) of the C-terminal Leu
1
 residue (for HMBC and H2BC correlations, see 
Supplementary Information). This formed a 16-membered macrocycle with an exocyclic chain 
continuing in the N-terminal direction from Thr
2
, the chain constituting a Leu residue and a 3-hydroxy 
fatty acid (Figure 1). The structural difference between the four analogues was found in the length and 
saturation of the unbranched fatty acid chain. Ngercheumicin F and H each have one double bond in 
the 3-hydroxy fatty acid chain, whereas the fatty acids in ngercheumicin G and I are fully saturated, 
but with the same lengths as F and H, respectively. The previously isolated ngercheumicin A and B 
have a similar relationship, but with 12-carbon long fatty acid chains [8], whereas ngercheumicin F 
and H have fatty acid chains with 14 and 16 carbon atoms, respectively. The longer chains result in 
increasing overlap of 
1
H and 
13
C resonances in the aliphatic regions on both sides of the double bond. 
By thorough examination of HMBC and H2BC correlations in the chains, the structures of 
ngercheumicin F and H were elucidated and assigned as shown in Figure 1 and Table 1, respectively. 
The chemical shifts of ngercheumicin H were virtually symmetrical around the double bond because of 
the long chain, whereas there was a slight shift in ngercheumicin F, which has a shorter alkyl chain. 
The position of the double bond in ngercheumicin H was tentatively assigned based on the NMR data, 
as the data left an ambiguity of a CH2-group between position 41 and 47 due to the high degree of 
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symmetry and the overlapping resonances that 2D NMR was unable to resolve. However, assuming a 
correct assignment, a structural pattern emerged where ngercheumicin A, F, and H had their double 
bonds positioned seven carbon atoms from the end of the fatty acid chain, also known as n-7 fatty 
acids. Counting from the peptide-end of the fatty acid chain, the double bonds in ngercheumicin F and 
H are thus situated further into the fatty acid chains. 
Figure 1. Structures of ngercheumicin A, B, F, G, H, and I, where ngercheumicin A, F, 
and H have an unsaturation (cis) in the unbranched alkyl chain, R. 
 
Table 1. 
1
H and 
13
C NMR spectroscopic data (800 MHz, DMSO-d6) for ngercheumicins  
F–I. More elaborate NMR tables can be found in the Supplementary Information. 
 Ngercheumicin F Ngercheumicin G Ngercheumicin H Ngercheumicin I 
Position, Type δH (ppm) δC (ppm) δH (ppm) δC (ppm) δH (ppm) δC (ppm) δH (ppm) δC (ppm) 
Leu1         
1—CO − 170.8 − 170.8 − 170.8 − 170.8 
2—CHα 4.37 51.1 4.37 51.1 4.37 51.1 4.37 51.1 
3—CHβ 1.62, 1.55 40.4 1.61, 1.55 40.4 1.62, 1.56 40.4 1.61, 1.56 40.4 
4—CHγ 1.49 24.5 1.49 24.5 1.50 24.5 1.49 24.5 
5—CHδ,1 0.88 22.3 0.88 22.3 0.89 22.3 0.88 22.3 
6—CHδ,2 0.85 22.5 0.85 22.5 0.85 22.5 0.85 22.5 
7—NH 7.73 − 7.73 − 7.73 − 7.73 − 
Leu2         
8—CO − 171.0 − 171.0 − 171.0 − 171.0 
9—CHα 4.26 50.4 4.26 50.4 4.25 50.4 4.26 50.4 
10—CHβ 1.49 38.8 1.49 38.8 1.49 38.8 1.49 38.8 
11—CHγ 1.53 24.2 1.53 24.2 1.54 24.1 1.54 24.1 
12—CHδ,1 0.87 22.9 0.87 22.9 0.87 22.9 0.87 22.9 
13—CHδ,2 0.80 21.4 0.80 21.4 0.80 21.4 0.80 21.4 
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Table 1. Cont. 
14—NH 8.12 − 8.11 − 8.11 − 8.11 − 
L-allo-Thr1         
15—CO − 170.7 − 170.7 − 170.7 − 170.7 
16—CHα 3.86 59.9 3.86 59.9 3.86 59.9 3.86 59.9 
17—CHβ 3.88 65.1 3.88 65.1 3.88 65.1 3.87 65.1 
17—OH 4.70 − 4.69 − 4.69 − 4.69 − 
18—CHγ 1.03 20.0 1.03 20.1 1.03 20.1 1.03 20.1 
19—NH 8.09 − 8.09 − 8.09 − 8.09 − 
D-Ser         
20—CO − 170.0 − 170.0 − 170.0 − 170.0 
21—CHα 4.38 54.5 4.38 54.6 4.38 54.5 4.38 54.5 
22—CHβ 3.54 61.6 3.54 61.5 3.54 61.5 3.54 61.5 
22—OH 4.86 − 4.86 − 4.86 − 4.86 − 
23—NH 7.53 − 7.53 − 7.53 − 7.53 − 
L-allo-Thr2         
24—CO − 168.4 − 168.4 − 168.4 − 168.4 
25—CHα 4.40 56.2 4.39 56.2 4.39 56.2 4.39 56.2 
26—CHβ 5.35 69.6 5.34 69.6 5.34 69.6 5.35 69.6 
27—CHγ 1.10 17.0 1.10 17.0 1.10 16.9 1.10 17.0 
28—NH 8.40  8.39  8.39  8.39  
Leu3         
29—CO − 173.1 − 173.2 − 173.1 − 173.2 
30—CHα 4.37 51.7 4.37 51.8 4.37 51.8 4.37 51.8 
31—CHβ 1.48 40.3 1.48 40.2 1.48 40.2 1.48 40.2 
32—CHγ 1.62 24.2 1.62 24.2 1.62 24.2 1.63 24.2 
33—CHδ,1 0.92 22.6 0.92 22.6 0.91 22.6 0.92 22.6 
34—CHδ,2 0.87 21.9 0.87 21.9 0.87 21.9 0.87 21.9 
35—NH 8.20 − 8.20 − 8.20 − 8.20 − 
Fatty acid         
36—CO − 171.8 − 171.9 − 171.9 − 171.9 
37 ~2.24 43.3 2.24, 2.22 43.4 2.25, 2.22 43.4 2.25, 2.22 43.4 
38 3.78 67.4 3.77 67.5 3.78 67.5 3.78 67.5 
38—OH 4.62 − 4.60 − 4.60 − 4.59 − 
39 1.34, 1.30 36.2 1.31 36.6 1.32 36.6 1.32 36.6 
40 1.42, 1.28 25.1 1.34, 1.22 24.8 1.36, 1.23 24.8 1.35, 1.22 24.8 
41 1.96 26.6 1.23 ~29 ~1.2 ~29 1.23 29.1 
42 5.31 129.6 ~1.2 ~29 1.28 ~29 ~1.2 ~29 
43 5.31 129.6 ~1.2 ~29 1.97 26.6 ~1.2 ~29 
44 1.96 26.5 ~1.2 ~29 5.31 129.6 ~1.2 ~29 
45 1.28 29.0 ~1.2 ~29 5.31 129.6 ~1.2 ~29 
46 1.24 28.3 1.21 29.1 1.97 26.6 ~1.2 ~29 
47 1.22 31.1 1.22 31.3 1.28 ~29 ~1.2 ~29 
48 1.25 22.1 1.25 22.1 1.25 28.2 ~1.2 ~29 
49 0.84 13.9 0.84 13.9 1.22 31.1 1.22 31.3 
50     1.25 22.0 1.25 22.1 
51     0.84 13.9 0.84 13.9 
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The resonances originating from the double bond were very close in chemical shift, leading to 
severe second order effects in the 
1
H multiplet patterns. Due to the second order spin systems, it was 
not possible to determine the size of the J coupling constant, however the total span of the multiplets at 
5.31 ppm for both F and H was below 15 Hz, and assuming complete symmetry, a trans coupling 
seemed unlikely. The chemical shifts for the allylic carbons at 26.5–26.6 ppm are also consistent with 
cis configuration, as allylic carbons in trans fatty acids are about 5 ppm further downfield [13]. 
Therefore the double bonds in ngercheumicin F and H were assigned as cis. 
Attempts to obtain absolute stereochemical assignment of the amino acids were done by Marfey’s 
method, using existing methods for acid hydrolysis [14] and derivatization with Marfey’s reagent [15]. 
Complete stereochemical assignments were not obtained as Marfey’s method revealed the presence of 
both L- and D-Leu, and unambiguous resolution of the hydroxyamino acids Ser and Thr is known to be 
challenging [16]. Pure enantiomers of Leu, Ser and Thr were used to synthesise single diastereomers 
with Marfey’s reagent for comparison with the Marfey’s derivatives of the hydrolysed ngercheumicins. 
This also included allo-Thr. By comparison to the pure amino acid derivatives, L-Ser, D-Thr and  
D-allo-Thr were dismissed. Therefore the configuration of the Ser residue was firmly assigned as  
D-Ser. Although the peaks of L-Thr, D-Ser, and L-allo-Thr eluted within a narrow spectral window, the 
elution order together with MS detection verified the presence of L-allo-Thr and no L-Thr. This was 
supported by the size of the J coupling constant from Thr
2
 H26 to H25 and H27. The absolute 
configuration of the three Leu residues was ambiguous, however both L- and D-Leu were present. Due 
to the minute amounts available, (0.5–1.1 mg of each analogue) the configuration of the 3-hydroxy 
fatty acid was not determined. 
Organic synthesis could be a solution to the supply problem of these peptides, as synthesis of cyclic 
peptides is often a relatively straightforward procedure. Many cyclic peptides from marine microbial 
sources contain non-proteinogenic and D-amino acids as well as polyketide-derived structural motifs or 
fatty acids [17], which is also the case for the solonamides and the ngercheumicins. Undoubtedly, 
these traits complicate synthesis of both natural products and analogues. However, a study by  
Molhoek et al. showed that cyclization of a peptide antibiotic and substitution of L- with D-amino acids 
improved stability towards bacterial proteases (including those in S. aureus) and decreased cytotoxicity 
while retaining the antibacterial activity [18]. The ngercheumicin macrocycle is closed through an 
ester bond between the C-terminus and the side chain of a Thr residue. This is a common trait in 
depsipeptides, and e.g., the cyclodepsipeptide plitidepsin [2], which is undergoing clinical trials for 
treatment of several cancers, has this feature in common with the ngercheumicins. 
2.2. Ngercheumicins Interfere with agr 
Ngercheumicin F, G, H, and I were examined in the S. aureus lacZ reporter assays described by 
Nielsen et al. [19] monitoring transcriptional activity of the hla, spa, and P3 (rnaIII) promotors. All 
four ngercheumicins increased transcription of spa and reduced expression of hla and rnaIII, compared 
to a solvent control (see Supplementary Information). The inverse effect of the ngercheumicins on spa 
expression compared to rnaIII and hla indicates that the ngercheumicins interfere with agr activation. 
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To confirm these initial results, cultures of a highly virulent, community-acquired strain of  
S. aureus USA300 were exposed to ngercheumicins F–I and RNAIII expression was monitored in 
exponential and stationary growth phase by Northern blot analysis. Data confirmed that 
ngercheumicins reduced expression of rnaIII and thus interfere with agr in CA-MRSA strain USA300. 
At the ngercheumicin concentrations used in the culture samples for Northern blotting, there was a 
minor down regulation of rnaIII by ngercheumicin G and H at 5 µg mL
−1
 (see Supplementary 
Information). At 20 µg mL
−1
 (23 μM, see Figure 2), the rnaIII inhibiting effect was more pronounced 
for ngercheumicin G and H, but also F showed activity here and appeared to have the highest rnaIII 
inhibiting activity. Ngercheumicin I did not show any significant effect at either 5 or 20 µg mL
−1
. 
Figure 2. Northern blot of ngercheumicin F, G, H and I treated S. aureus USA300 wt 
(FPR3757) cells in stationary phase (OD600 = 3) at ngercheumicin concentration of  
20 µg mL
−1
. 
 
The ngercheumicins share structural traits with the AIPs of S. aureus. S. aureus strains express one 
of a least four variants of AIPs and each variant induces agr expression in strains of the same type but 
repress agr expression in strains of other types [20]. Interestingly, the ngercheumicins resemble the 
type II and III AIPs, whereas the solonamides resemble type I and II the most [21]. All have  
16-membered macrocyclic rings and flexible exocyclic chains (Figure 3). The AIPs have purely 
peptidic exocyclic chains, whereas the depsipeptides all contain fatty acid chains, but both the AIPs 
and the cyclodepsipeptides have variations in the length of the exocyclic chains, which perhaps relate 
to receptor specificity. Looking at the amino acid sequence of the ngercheumicins (Figure 3) starting at 
the C-terminus, the two Leu residues are also found in AIP-III, and the Thr-Ser sequence closely 
resembles the Ser-Ser sequence in AIP-II. It should be noted that this comparison is made without 
taking 3D configuration of the side chains into account, because only the 2D structures are known. It is 
however clear that part of the backbone structure is highly homologous to the native AIPs of S. aureus. 
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Figure 3. Schematic structures of S. aureus autoinducing peptides (AIPs) I–III, solonamide 
B and ngercheumicin G, with amino acid sequences and type of ring closure. AIP 
structures are reproduced from [21]. AIP-IV also exists, where the aspartic acid (D) of 
AIP-I is replaced by a tyrosine residue. 
 
Little is known about peptide signaling in the marine environment and whether other groups of 
peptide signal molecules exist there. It can be speculated that these depsipeptides interfere with QS 
pathways present in the marine environment or even act as alternative quorum sensing molecules. 
Existing QS systems include the N-acyl homoserine lactones in Gram-negative bacteria and the auto 
inducing peptides in the Gram-positive staphylococci [22]. That ngercheumicins F–I were isolated in 
low yields as intracellular metabolites, unlike the solonamides that were excreted in large amounts, 
could mean that they do not act as intercellular signaling molecules in the natural environment and 
therefore there could be an unexplored biological role for the ngercheumicins. Analyses of co-cultures 
of this Photobacterium with naturally co-occurring or competitive strains could provide further insight 
into the biological function of these compounds. 
3. Experimental Section 
3.1. Isolation and Identification of Strain s2753 
Bacterial strain s2753 was isolated from a mussel surface collected in the tropical Pacific (9.1° S 
156.8° E) during the Danish Galathea 3 expedition [3]. S2753 was assigned to the Vibrionaceae and 
sequence similarity of household genes identified it as a Photobacterium halotolerans as previously 
described [3–5]. 
Mar. Drugs 2013, 11 5059 
 
 
3.2. Isolation and Structure Elucidation of Four New Ngercheumicins 
S2753 was cultured in 10 L glass fermentors in 5 × 4 L SSS containing 0.4% glucose and 0.3% 
casamino acids in (25 °C, 72 h, 100 rpm). The liquid culture was centrifuged (15 min, 3500 × g) to 
isolate the pellet from the broth and Diaion HP20SS (12 g L
−1
) which was used to extract the bioactive 
compounds holomycin and solonamides A–B as previously described [4,5]. The pellet was extracted 
with 1 L 1:9 (v/v) MeOH/EtOAc (25 °C, 24 h, 100 rpm) and filtered off through a Watman 1 filter. 
The pellet extract was concentrated on a rotary evaporator and absorbed onto 5 g Isolute diol (Biotage, 
Uppsala, Sweden) for dry loading onto a 50 g SNAP column packed with Isolute diol and eluted on an 
Isolera automated flash system (Biotage, Uppsala, Sweden) using solvents ranging from heptane, 
dichloromethane, EtOAc to pure MeOH (30 mL min
−1
, 72 min). A total of 33 fractions were collected 
and subjected to LC-UV/MS. Fractions 7 to 10 (dichloromethane/EtOAc) were pooled and absorbed 
onto 1.5 g Isolute diol and further fractionated on a 10 g diol column run by gravity with heptanes, 
dichloromethane, EtOAc and MeOH as above. This yielded 10 fractions (again subjected to  
LC-UV/MS) of which fractions 6 and 7 (10%–30% MeOH in EtOAc) were purified on a Luna II 
column (5 μm C18, 250 × 10 mm ID, Phenomenex) in a Gilson 322 liquid chromatograph with a  
215 liquid handler/injector (BioLab, Risskov, Denmark) going from 70% to 100% aqueous MeCN,  
20 mM formic acid, over 10 min followed by 6 min isocratic elution. This yielded 12 fractions of 
which pure compounds were obtained directly: Ngercheumicin F (0.5 mg), Ngercheumicin G (1.0 mg), 
Ngercheumicin H (0.5 mg), and Ngercheumicin I (1.1 mg). Selected chromatograms are available in 
the Supplementary Information. 
LC-UV/MS analyses were performed on an Agilent 1100 HPLC system with a diode array detector 
coupled to an LCT TOF mass spectrometer (Micromass, Manchester, UK) using a Z-spray ESI source. 
Separation was performed at 40 °C with a Luna II C18 column (50 × 2 mm ID, 3 μm, Phenomenex, 
Torrance, CA, USA), applying a linear gradient of 15%–100% aqueous MeCN, 20 mM formic acid 
(LC-MS-grade), over 20 minutes at a flow rate of 0.3 mL/min. MS experiments were performed in 
ESI
+
 with a data acquisition range of m/z 100–2000. Accurate masses of ammonium adducts were 
measured for Ngercheumicin F (m/z: [M + NH4]
+
 870.5979, calculated for C43H80N7O11 as 870.5916), 
ngercheumicin G (m/z: [M + NH4]
+
 872.6206, calculated for C43H82N7O11 as 872.6072), 
ngercheumicin H (m/z: [M + NH4]
+
 898.6359, calculated for C45H84N7O11 as 898.6229), and 
ngercheumicin I (m/z: [M + NH4]
+
 900.6450, calculated for C45H86N7O11 as 900.6385). The [M + H]
+
 
adducts were reported in Section 2.1. 
To solve the absolute configuration of the amino acids Marfey’s method was applied: 100 μg of 
each cyclodepsipeptide was subjected to acid hydrolysis (200 μL 6 M HCl, 110 °C, 20 h), redissolved 
in 50 μL water and added 20 μL 1 M aqueous NaHCO3, then derivatised with 100 μL 1% w/v 
Marfey’s reagent in acetone (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA, Sigma-Aldrich, 
St. Louis, MO, USA) at 40 °C for 1 h as described by Bonnard et al. [15]. The reaction mixtures were 
neutralised with 10 μL 2 M aqueous HCl and diluted with 820 μL MeOH. Pure amino acid standards 
were derivatised by the same procedure using 50 μL 50 mM aqueous amino acid solution. Ultra-high 
performance liquid chromatography-diode array (UHPLC-DAD) separation and detection of the amino 
acid derivatives was done on a Dionex RSLC Ultimate 3000 (Dionex, Sunnyvale, CA, USA) equipped 
with a diode array detector. The separation was done in a Kinetex C18 column (150 × 2.10 mm,  
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2.6 μm, Phenomenex) at 60 °C with a flow rate of 0.8 mL min−1 using two different linear gradient 
methods. Method A included all L- and D-amino acids in the structure, whereas method B was run with 
shallow gradient and included L- and D-allo-Thr but not L- and D-Leu. This was an attempt to 
distinguish derivatives of D-Ser, L-Thr and L-allo-Thr which had very similar chromatographic 
properties on the column. 
Method A: From 8% to 15% aqueous MeCN, 0.65 mM TFA, over 22 min followed by an increase 
from 15% to 100% for 8.5 min. Retention times for the FDAA-amino acid derivatives were: L-Ser 
(4.21 min), L-Thr (5.46 min), D-Ser (5.56 min), D-Thr (12.38 min), L-Leu (25.23 min), D-Leu  
(26.00 min). Unreacted FDAA eluted at 11.0 min. 
Method B: From 8% to 10% aqueous MeCN, 0.65 mM TFA, over 25 min followed by an increase 
from 10% to 100% over 5.5 min. Retention times for the FDAA-amino acid derivatives were: L-Ser 
(4.46 min), L-Thr (5.90 min), D-Ser (5.97 min), L-allo-Thr (6.15 min), D-allo-Thr (10.28 min), D-Thr 
(15.82 min). Unreacted FDAA eluted at 10.4 min. 
NMR spectra were recorded on a Bruker Avance 800 MHz spectrometer equipped with a 5 mm TCI 
Cryoprobe using standard pulse sequences. The NMR data used for the structural assignments were 
acquired in DMSO-d6 (δH 2.49 ppm and δC 39.5 ppm). 
1
H and 
13
C NMR spectra are available in the 
Supplementary Information. 
3.3. Antivirulence Activity Testing and Northern Blotting 
The S. aureus lacZ reporter assays were performed as described by Nielsen et al. [19]. 
Ngercheumicin F, G, H, and I were dissolved in DMSO, and DMSO and H2O was included as negative 
controls in the assay. Pictures were taken after 11, 13 and 34 h of incubation for the rnaIII-, hla- and 
spa-reporter strains respectively (Supplementary Information). 
RNA for Northern blotting was purified from USA300 (FPR3757) samples from cultures grown in 
100 mL Erlenmeyer flasks containing 10 mL Tryptone Soya Broth (TSB, Oxoid, Greve, Denmark) 
shaking vigorously (200 rpm) in a water bath at 37 °C. Ngercheumicins (5 µg mL
−1
 and 20 µg mL
−1
) 
and DMSO (control) were added at OD600 = 0.4, and samples were taken at OD600 = 0.8 and 3.0. 
Northern blotting was performed as previously described [5] using an RNAIII-probe constructed using 
primer rnaIII forward (5′-GGG GAT CAC AGA GAT GTG ATG-3′), and rnaIII reverse (5′-GGG 
CAT AGC ACT GAG TCC AAG G-3′)(TAG Copenhagen A/S, Frederiksberg, Denmark). 
4. Conclusions 
Four new ngercheumicins were isolated on the mg-scale and their structure elucidated; however 
complete stereochemical assignments were not obtained. Although 20 L of bacterial culture was 
extracted, low isolated yields restricted the possibilities in both the structure elucidation and in the 
assessment of biological properties. Ngercheumicins were found to inhibit transcription of the 
regulatory rnaIII in S. aureus, the effector molecule of the agr QS system. These findings will aid in 
the future work to understand quorum sensing in bacteria, as more structural knowledge about QS 
inhibitors is valuable in the design of novel inhibitors. The cyclodepsipeptides isolated from this 
marine Photobacterium have some resemblance to the AIPs of S. aureus, and it can be speculated as to 
whether these molecules are a new class of peptide signaling molecules in the marine environment. 
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Figure S1. Detector response from HPLC purification of ngercheumicins, where fractions 
6, 8, 9 and 11 gave ngercheumicin F, G, H and I, respectively. Fraction size is not shown, 
as these are pooled fractions from the automatic fractionation. Fraction 7 and 10 contains 
isomers of ngercheumicin F and H. 
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Figure S2. Diode array detected (200–700 nm) chromatograms for purified samples of 
ngercheumicin F, G, H and I (from the top). 
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Figure S3. Selected region of the total ion chromatograms (TIC) of ngercheumicin F, G, H 
and I (from the top), showing [M + H]
+
, [M + NH4]
+
 and weak [M + Na]
+
 adducts. Outside 
the range are also [2M + NH4]
+
 at m/z 1723–1784. 
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Figure S4. 
1
H spectrum for ngercheumicin F. 
 
Figure S5. DQF-COSY for ngercheumicin F. 
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Figure S6. Multiplicity edited gHSQC for ngercheumicin F. 
 
Figure S7. gHMBC for ngercheumicin F. 
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Figure S8. 
1
H spectrum for ngercheumicin G. 
 
Figure S9. 
13
C spectrum for ngercheumicin G. 
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Figure S10. DQF-COSY for ngercheumicin G. 
 
Figure S11. Multiplicity edited gHSQC for ngercheumicin G. 
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Figure S12. gHMBC for ngercheumicin G. 
 
Figure S13. 
1
H spectrum for ngercheumicin H. 
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Figure S14. 
13
C spectrum for ngercheumicin H. 
  
Figure S15. DQF-COSY for ngercheumicin H. 
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Figure S16. Multiplicity edited gHSQC for ngercheumicin H. 
 
Figure S17. gHMBC for ngercheumicin H. 
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Figure S18. 
1
H spectrum for ngercheumicin I. 
 
Figure S19. 
13
C spectrum for ngercheumicin I. 
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Figure S20. DQF-COSY for ngercheumicin I. 
 
Figure S21. Multiplicity edited gHSQC for ngercheumicin I. 
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Figure S22. gHMBC for ngercheumicin I. 
 
Figure S23. Key HMBC and H2BC correlations in the fatty acid chain of Ngercheumicin F. 
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Figure S24. Northern blot results for ngercheumicin F, G, H and I in DMSO at 5 μg/mL  
(≈6 μM) and 20 μg/mL (≈23 μM) against S. aureus USA300/FPR3757 at OD600 = 0.8 and 
OD600 = 3.0. DMSO is used as negative control. 
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Figure S25. Plate assay results in the colorimetric S. aureus lacZ reporter assay with 
ngercheumicins F, G, H and I in DMSO at 1 mg/mL against S. aureus 8325-4. DMSO and 
water is used as negative controls. Inhibitors of the agr locus enhance transcription of spa 
and reduce expression of hla and rnaIII. 
 
Table S1. NMR table for Ngercheumicin F. 
Position, Type δH (ppm), #H, Multiplicity, J (Hz) δC (ppm) HMBC Connectivity H2BC Connectivity 
Leu
1
     
1—CO − 170.8 −  
2—CHα 4.37, 1H, m 51.1 1, 3  
3—CHβ 1.62, 1H, m 
1.55, 1H, m 
40.4 1, 2, 4, 5, 6  
4—CHγ 1.49, 1H, m 24.5 3  
5—CHδ,1 0.88, 3H, d, 6.5 22.3 3, 4, 6 4 
6—CHδ,2 0.85, 3H, d, 6.5 22.5 3, 4, 5 4 
7—NH 7.73, 1H, d, 6.5 − (2), 8 2 
Leu
2
     
8—CO − 171.0 −  
9—CHα 4.26, 1H, q, 8.0 50.4 8, 10 10 
10—CHβ 1.49, 2H, m 38.8 9, 11, 13 9 
11—CHγ 1.53, 1H, m 24.2  10 
12—CHδ,1 0.87, 3H, d, 6.5 22.9 10, 11, 13 11 
13—CHδ,2 0.80, 3H, d, 6.5 21.4 10, 11, 12 11 
14—NH 8.12, 1H, d, 8.5 − (9), 15 9 
Mar. Drugs 2013, 11 17 
 
 
Table S1. Cont. 
L-allo-Thr
1
     
15—CO − 170.7 −  
16—CHα 3.86, 1H, m 59.9 15, 17 17 
17—CHβ 3.88, 1H, m 65.1 (16) 16, 18 
17—OH 4.70, 1H, d, 4.6 − 16, 17, 18 17 
18—CHγ 1.03, 3H, d, 6.0 20.0 16, 17 17 
19—NH 8.09, 1H, d, 6.0 − (16), 20 16 
D-Ser     
20—CO − 170.0 −  
21—CHα 4.38, 1H, m 54.5 20, 22, 24 22 
22—CHβ 3.54, 2H, m 61.6 20, (21) 21 
22—OH 4.86, 1H, t, 6.0 − (21), 22 22 
23—NH 7.53, 1H, d, 8.0 − 24 21 
L-allo-Thr
2
     
24—CO − 168.4 −  
25—CHα 4.40, 1H, d, 9.0 56.2 24, 29  
26—CHβ 5.35, 1H, qd, 6.0, <1 69.6 1 27 
27—CHγ 1.10, 3H, d, 6.5 17.0 25, 26 26 
28—NH 8.40, 1H, d, 9.5  29 25 
Leu
3
     
29—CO − 173.1 −  
30—CHα 4.37, 1H, m 51.7 29, 31 31 
31—CHβ 1.48, 2H, m 40.3 29, 30, 32  
32—CHγ 1.62, 1H, m 24.2 33  
33—CHδ,1 0.92, 3H, d, 6.5 22.6 31, 32, 34 32 
34—CHδ,2 0.87, 3H, d, 6.5 21.9 31, 32, 33 32 
35—NH 8.20, 1H, d, 6.5 − 30, 31, 36 30 
Fatty acid     
36—CO − 171.8 −  
37 ~2.24, 2H, m 43.3 36, 38, (39) 38 
38 3.78, 1H, m 67.4  37 
38—OH 4.62, 1H, d, 5.0 − 37, 38, 39 38 
39 1.34, 1H, m 
1.30, 1H, m 
36.2 (38), 40 (38), 40 
40 1.42, 1H, m 
1.28, 1H, m 
25.1 41, 42 41 
41 1.96, 2H, m 26.6 43 (40), 42 
42 5.31, 1H, m 129.6 44 41, 43 
43 5.31, 1H, m 129.6 43 42, 44 
44 1.96, 2H, m 26.5 42 43, 45 
45 1.28, 2H, m 29.0  44 
46 1.24, 2H, m 28.3  47 
47 1.22, 2H, m 31.1 45 46 
48 1.25, 2H, m 22.1 47, 49 47, 49 
49 0.84, 3H, t, 7.0 13.9 47, 48 48 
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Table S2. NMR table for Ngercheumicin G. 
Position, Type δH (ppm), #H, Multiplicity, J (Hz) δC (ppm) HMBC Connectivity H2BC Connectivity 
Leu
1
     
1—CO − 170.8 −  
2—CHα 4.37, 1H, m 51.1 1, 3, 4, 8 3 
3—CHβ 1.61, 1H, m 
1.55, 1H, m 
40.4 1, 2, 4, 5, 6 2, 4 
4—CHγ 1.49, 1H, m 24.5 3, 5, 6 3 
5—CHδ,1 0.88, 3H, d, 6.5 22.3 3, 4, 6 4 
6—CHδ,2 0.85, 3H, d, 6.5 22.5 3, 4, 5 4 
7—NH 7.73, 1H, d, 6.5 − (1), 2, 3, 8 2 
Leu
2
     
8—CO − 171.0 −  
9—CHα 4.26, 1H, q, 8.0 50.4 8, 10, 11 10 
10—CHβ 1.49, 2H, m 38.8 9, 11, 12, 13 9, 11 
11—CHγ 1.53, 1H, m 24.2 (9), 10, 12, 13 10 
12—CHδ,1 0.87, 3H, d, 6.5 22.9 10, 11, 13 11 
13—CHδ,2 0.80, 3H, d, 6.5 21.4 10, 11, 12 11 
14—NH 8.11, 1H, d, 8.5 − 9, (10), 15 9 
L-allo-Thr
1
     
15—CO − 170.7 −  
16—CHα 3.86, 1H, m 59.9 15, 17, (18), 20 17 
17—CHβ 3.88, 1H, m 65.1 16 16, 18 
17—OH 4.69, 1H, d, 4.6 − 16, 17, 18 17 
18—CHγ 1.03, 3H, d, 6.0 20.1 16, 17 17 
19—NH 8.09, 1H, d, 6.0 − 16, 17, 20 16 
D-Ser     
20—CO − 170.0 −  
21—CHα 4.38, 1H, m 54.6 20, 22, (24) 22 
22—CHβ 3.54, 2H, m 61.5 20, 21 21 
22—OH 4.86, 1H, t, 6.0 − 21, 22 22 
23—NH 7.53, 1H, d, 8.0 − (20), 21, 22, 24 21 
L-allo-Thr
2
     
24—CO − 168.4 −  
25—CHα 4.39, 1H, d, 9.0 56.2 24, 26, 27, 29  
26—CHβ 5.34, 1H, qd, 6.0, <1 69.6 1, 24, 27 27 
27—CHγ 1.10, 3H, d, 6.5 17.0 25, 26 26 
28—NH 8.39, 1H, d, 9.5  25, (26), 29 25 
Leu
3
     
29—CO − 173.2 −  
30—CHα 4.37, 1H, m 51.8 29, 31, 32, 36 31 
31—CHβ 1.48, 2H, m 40.2 29, 30, 32, 33 30 
32—CHγ 1.62, 1H, m 24.2 31, 33 31, 33, 34 
33—CHδ,1 0.92, 3H, d, 6.5 22.6 31, 32, 34 32 
34—CHδ,2 0.87, 3H, d, 6.5 21.9 31, 32, 33 32 
35—NH 8.20, 1H, d, 6.5 − (29), 30, 31, 36 30 
Fatty acid     
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36—CO − 171.9 −  
37 2.24, 1H, dd, 14.0, 6.0 
2.22, dd, 14.0, 7.0 
43.4 36, 38, 39 38 
38 3.77, 1H, m 67.5 36, 40 37, 39 
38—OH 4.60, 1H, d, 5.0 − 37, 38, 39 38 
39 1.31, 2H, m 36.6 37, 38, 41 38, 40 
40 1.34, 1H, m 
1.22, 1H, m 
24.8   
41 1.23, 2H, m ~29   
42 ~1.2, 2H, m ~29   
43 ~1.2, 2H, m ~29   
44 ~1.2, 2H, m ~29   
45 ~1.2, 2H, m ~29   
46 1.21, 2H, m 29.1   
47 1.22, 2H, m 31.3  46, 48 
48 1.25, 2H, m 22.1 47, 49 47, 49 
49 0.84, 3H, t, 7.0 13.9 47, 48 48 
Table S3. NMR table for ngercheumicin H. 
Position, Type δH (ppm), #H, Multiplicity, J (Hz) δC (ppm) HMBC Connectivity H2BC Connectivity 
Leu
1
     
1—CO − 170.8 −  
2—CHα 4.37, 1H, m 51.1 1, 3, 4, 8  
3—CHβ 1.62, 1H, m 
1.56, 1H, m 
40.4 1, 2, 4, 5, 6  
4—CHγ 1.50, 1H, m 24.5 2, 3, 5, 6  
5—CHδ,1 0.89, 3H, d, 6.5 22.3 3, 4, 6 4 
6—CHδ,2 0.85, 3H, d, 6.5 22.5 3, 4, 5 4 
7—NH 7.73, 1H, d, 6.5 − (1), 2, 3, 8 2 
Leu
2
     
8—CO − 171.0 −  
9—CHα 4.25, 1H, q, 8.0 50.4 8, 10, 11 10 
10—CHβ 1.49, 2H, m 38.8 9, 11, 13 9, 11 
11—CHγ 1.54, 1H, m 24.1 9, 10, 13 10 
12—CHδ,1 0.87, 3H, d, 6.5 22.9 10, 11, 13 11 
13—CHδ,2 0.80, 3H, d, 6.5 21.4 10, 11, 12 11 
14—NH 8.11, 1H, d, 8.5 − 9, 10, 15 9 
L-allo-Thr
1
     
15—CO − 170.7 −  
16—CHα 3.86, 1H, m 59.9 15, 17, 18, 20 17 
17—CHβ 3.88, 1H, m 65.1 16 16, 18 
17—OH 4.69, 1H, d, 4.6 − 16, 17, 18 17 
18—CHγ 1.03, 3H, d, 6.0 20.1 16, 17 17 
19—NH 8.09, 1H, d, 6.0 − 16, 17, 20 16 
D-Ser     
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20—CO − 170.0 −  
21—CHα 4.38, 1H, m 54.5 20, 22, 24 22 
22—CHβ 3.54, 2H, m 61.5 20, 21 21 
22—OH 4.86, 1H, t, 6.0 − 21, 22 22 
23—NH 7.53, 1H, d, 8.0 − (20), 21, 22, 24 21 
L-allo-Thr
2
     
24—CO − 168.4 −  
25—CHα 4.39, 1H, d, 9.0 56.2 24, 26, 27, 29  
26—CHβ 5.34, 1H, qd, 6.0, <1 69.6 1, 24, 27 27 
27—CHγ 1.10, 3H, d, 6.5 16.9 25, 26 26 
28—NH 8.39, 1H, d, 9.5  25, 26, 29 25 
Leu
3
     
29—CO − 173.1 −  
30—CHα 4.37, 1H, m 51.8 29, 31, 32, 36 31 
31—CHβ 1.48, 2H, m 40.2 29, 30, 32, 33 30 
32—CHγ 1.62, 1H, m 24.2 30, 31, 34 31 
33—CHδ,1 0.91, 3H, d, 6.5 22.6 31, 32, 34 32 
34—CHδ,2 0.87, 3H, d, 6.5 21.9 31, 32, 33 32 
35—NH 8.20, 1H, d, 6.5 − (29), 30, 31, 36 30 
Fatty acid     
36—CO − 171.9 −  
37 2.25, 1H, dd, 14.0, 6.0 
2.22, 1H, dd, 14.0, 7.0 
43.4 36, 38, 39 38 
38 3.78, 1H, m 67.5 36, 40 37, 39 
38—OH 4.60, 1H, d, 5.0 − 37, 38, 39 38 
39 1.32, 2H, m 36.6 38, 41 38, 40 
40 1.36, 1H, m 
1.23, 1H, m 
24.8  39 
41 ~1.2, 2H, m ~29   
42 1.28, 2H, m ~29 44/45 43 
43 1.97, 2H, m 26.6 41? 42, 44 
44 5.31, 1H, m 129.6 43/46 43, 45 
45 5.31, 1H, m 129.6 43/46 44, 46 
46 1.97, 2H, m 26.6 48 45, 47 
47 1.28, 2H, m ~29 44/45 46 
48 1.25, 2H, m 28.2   
49 1.22, 2H, m 31.1 47, (51) 48, 50 
50 1.25, 2H, m 22.0 48, 49, 51 49, 51 
51 0.84, 3H, t, 7.0 13.9 49, 50 50 
Mar. Drugs 2013, 11 21 
 
 
Table S4. NMR table for ngercheumicin I. 
Position, Type δH (ppm), #H, Multiplicity, J (Hz) δC (ppm) HMBC Connectivity H2BC Connectivity 
Leu
1
     
1—CO − 170.8 −  
2—CHα 4.37, 1H, m 51.1 1, 3, 4, 8  
3—CHβ 1.61, 1H, m 
1.56, 1H, m 
40.4 1, 2, 4, 5, 6  
4—CHγ 1.49, 1H, m 24.5 2, 3, 5, 6  
5—CHδ,1 0.88, 3H, d, 6.5 22.3 3, 4, 6 4 
6—CHδ,2 0.85, 3H, d, 6.5 22.5 3, 4, 5 4 
7—NH 7.73, 1H, d, 6.5 − (1), 2, 3, 8 2 
Leu
2
     
8—CO − 171.0 −  
9—CHα 4.26, 1H, q, 8.0 50.4 8, 10, 11 10 
10—CHβ 1.49, 2H, m 38.8 9, 11, 13 9, 11 
11—CHγ 1.54, 1H, m 24.1 9, 10, 13 10 
12—CHδ,1 0.87, 3H, d, 6.5 22.9 10, 11, 13 11 
13—CHδ,2 0.80, 3H, d, 6.5 21.4 10, 11, 12 11 
14—NH 8.11, 1H, d, 8.5 − 9, 10, 15 9 
L-allo-Thr
1
     
15—CO − 170.7 −  
16—CHα 3.86, 1H, m 59.9 15, 17, 18, 20 17 
17—CHβ 3.87, 1H, m 65.1 16 16, 18 
17—OH 4.69, 1H, d, 4.6 − 16, 17, 18 17 
18—CHγ 1.03, 3H, d, 6.0 20.1 16, 17 17 
19—NH 8.09, 1H, d, 6.0 − 16, 17, 20 16 
D-Ser     
20—CO − 170.0 −  
21—CHα 4.38, 1H, m 54.5 20, 22, 24 22 
22—CHβ 3.54, 2H, m 61.5 20, 21 21 
22—OH 4.86, 1H, t, 6.0 − 21, 22 22 
23—NH 7.53, 1H, d, 8.0 − (20), 21, 22, 24 21 
L-allo-Thr
2
     
24—CO − 168.4 −  
25—CHα 4.39, 1H, d, 9.0 56.2 24, 26, 27, 29  
26—CHβ 5.35, 1H, qd, 6.0, <1 69.6 1, 24, 27 27 
27—CHγ 1.10, 3H, d, 6.5 17.0 25, 26 26 
28—NH 8.39, 1H, d, 9.5  25, 26, 29 25 
Leu
3
     
29—CO − 173.2 −  
30—CHα 4.37, 1H, m 51.8 29, 31, 32, 36 31 
31—CHβ 1.48, 2H, m 40.2 29, 30, 32, 33 30 
32—CHγ 1.63, 1H, m 24.2 30, 31, 34  
33—CHδ,1 0.92, 3H, d, 6.5 22.6 31, 32, 34 32 
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34—CHδ,2 0.87, 3H, d, 6.5 21.9 31, 32, 33 32 
35—NH 8.20, 1H, d, 6.5 − (29), 30, 31, 36 30 
Fatty acid     
36—CO − 171.9 −  
37 2.25, 1H, dd, 14.0, 7.0 2.22, 1H, dd, 
14.0, 6.0 
43.4 36, 38, 39 38 
38 3.78, 1H, m 67.5 36, 40 37, 39 
38—OH 4.59, 1H, d, 5.0 − 37, 38, 39 38 
39 1.32, 2H, m 36.6 38, 41 38, 40 
40 1.35, 1H, m 
1.22, 1H, m 
24.8   
41 1.23, 2H, m 29.1   
42 ~1.2, 2H, m ~29   
43 ~1.2, 2H, m ~29   
44 ~1.2, 2H, m ~29   
45 ~1.2, 2H, m ~29   
46 ~1.2, 2H, m ~29   
47 ~1.2, 2H, m ~29   
48 ~1.2, 2H, m ~29   
49 1.22, 2H, m 31.3  48, 50 
50 1.25, 2H, m 22.1 48, 49, 51 49, 51 
51 0.84, 3H, t, 7.0 13.9 49, 50 50 
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Enzyme catalysed production of sialylated
human milk oligosaccharides and
galactooligosaccharides by Trypanosoma
cruzi trans-sialidase
Jesper Holck1,5, Dorte M. Larsen1,5, Malwina Michalak1, Haiying Li2,
Louise Kjærulff3, Finn Kirpekar2, Charlotte H. Gotfredsen3, Sofia Forssten4,
Arthur C. Ouwehand4, Jørn D. Mikkelsen1 and Anne S. Meyer1
1Centre for BioProcess Engineering, Department of Chemical and Biochemical Engineering, Building 229, Technical University of Denmark,
2800 Kgs. Lyngby, Denmark
2Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense M, Denmark
3Department of Chemistry, Building 201, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
4DuPont Nutrition and Health, Active Nutrition, Sokeritehtaantie 20, 02460 Kantvik, Finland
A Trypanosoma cruzi trans-sialidase (E.C. 3.2.1.18) was cloned into Pichia pastoris and expressed. The pH
and temperature optimum of the enzyme was determined as pH 5.7 and 308C. Using casein
glycomacropeptide (CGMP) and lactose as sialyl-donor and acceptor respectively, the optimal donor/
acceptor ratio for the trans-sialidase catalysed 30-sialyllactose production was found to be 1:4.
Quantitative amounts of 30-sialyllactose were produced from CGMP and lactose at a yield of 40 mg/g
CGMP. The 30-sialyllactose obtained exerted a stimulatory effect on selected probiotic strains, including
different Bifidobacterium strains in single culture fermentations. The trans-sialidase also catalysed the
transfer of sialic acid from CGMP to galacto-oligosaccharides (GOS) and to the human milk
oligosaccharide (HMO) backbone lacto-N-tetraose (LNT) to produce 30-sialyl-GOS, including doubly
sialylated GOS products, and 30-sialyl-LNT, respectively. This work thus provides proof of the concept of
producing 30-sialyllactose and potentially other sialylated HMOs as well as sialylated GOS enzymatically
by trans-sialidase activity, while at the same time providing valorisation of CGMP, a co-processing
product from cheese manufacture.
Introduction
Human milk oligosaccharides (HMOs) are a group of complex
glycans that are abundant in human breast milk. With few excep-
tions, all known HMOs have a lactose core and are elongated via
linkage to one or more N-acetylglucosamine and galactose (N-
acetyllactosamine) moieties and can be decorated with sialic acid
(N-acetylneuraminic acid) and/or fucose residues [1]. Feeding of
breast milk to infants is linked to several beneficial effects, among
them promotion of bifidogenic growth [2,3], anti-adhesive
effects by blocking pathogens like Campylobacter jejuni [4] and
immunomodulatory effects [5]. The sialylated oligosaccharides
are a particularly interesting subgroup of HMOs. The sialylated
compounds constitute 28% of total oligo-saccharides in human
milk [6]. 30-Sialyllactose has been shown to induce growth of various
Bifidobacterium strains [7], inhibit the binding of cholera toxin in
vitro [8], and alter the gut microbiota in murine models [9], while
sialylated HMOs are moreover believed to be involved in infant
brain development [10]. Besides their presence in breast milk, HMOs
are in general not found in larger concentrations in nature or in
mammalian milk of other species and particularly not in bovine
milk, where only trace amounts are found [11]. The scarcity in
nature combined with the relatively expensive commercial 30-sia-
lyllactose (270s/g, www.carbosynth.com) and other sialylated
R
esearch
P
ap
er
Corresponding author: Meyer, A.S. (am@kt.dtu.dk)
5 These authors contributed equally.
156 www.elsevier.com/locate/nbt 1871-6784/$ - see front matter  2013 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.nbt.2013.11.006
HMOs and sialylated glycans, encourage the development of new
methods for economic large scale production of 30-sialyllactose,
both for further biological studies and commercial value.
Sialylated oligosaccharides can be produced enzymatically by
trans-sialidases, sialidases of sialyltransferases. Sialyltransferases
can transfer sialic acid from cytidine monophosphate-sialic acid
to an acceptor, but this process requires the activated CMP-sialic
acid [12]. Sialidases are hydrolytic enzymes that catalyse the
removal of sialic acid from a glycan residue. Under some condi-
tions or by mutation of the enzyme, their hydrolytic activity can
be repressed and sialic acid is transferred to an acceptor [13]. Trans-
sialidases are structurally related to sialidases, but lack the hydro-
lytic activity completely. The Trypanosoma cruzi trans-sialidase
(E.C. 3.2.1.18), an enzyme adapted from the parasite responsible
for Chagas disease [14], catalyses the transfer of a(2,3)-linked sialic
acid from one b-galactosyl residue to another [15]. Previous studies
have shown that sialidases and trans-sialidases can be used to
successfully transfer sialic acid from a sialic acid rich biopolymer
like whey protein or fetuin to a di- or oligosaccharide, for example
lactose, generating sialyllactose [16–18].
In this study, casein glycomacropeptide (CGMP), a dairy process
byproduct from cheese production with a sialic acid content of 4–
7% (w/w), was used as sialic acid donor for enzymatic synthesis of
30-sialyllactose. The primary objective of this study thus was to
assess the ability of the (cloned) Trypanozoma cruzi enzyme to
catalyse the trans-sialidase reaction and to optimise reaction para-
meters for an efficient production of gram quantities of 30-sialyl-
lactose from CGMP and lactose. By utilising an industrial, but food
grade, byproduct stream such as CGMP (and lactose), the costs can
be kept low and value is added to these byproducts from cheese
manufacture. In order also to specifically target novelty in relation
to enzymatic synthesis of other sialylated glycans, and based on
the hypothesis that the trans-sialidase might not be selective with
respect to the acceptor, an additional objective was to assess the
applicability of the enzyme also to catalyse the production of other
HMOs and potentially HMO-like compounds such as sialylated
lacto-N-tetraose (LNT) and sialylated galacto-oligosaccharides
(GOS) using CGMP as the sialyl-donor.
Materials and methods
Chemicals
Ammonium formate, citric acid, b-D-lactose, sodium acetate, and
sodium hydroxide were purchased from Sigma–Aldrich (Stein-
heim, Germany). 30- and 60-Sialyllactose (a(2,3)- and a(2,6)-sialyl-
lactose) standards were from Carbosynth Limited (Compton
Bershire, United Kingdom). LNT was purchased from Elicityl SA
(Crolles, France). GOS were purchased from Di Giovanni (Bologna,
Italy). SepharoseQ anion exchange resin and chromatography
columns were obtained from GE Healthcare Biosciences (Uppsala,
Sweden). All chemicals used were analytical grade.
Production of the trans-sialidase from T. cruzi (TcTS) in P.
pastoris
Vector and strain construction
The T. cruzi trans-sialidase amino acid sequence was obtained from
Uniprot, AC Q26966 [19]. For the cloning, the amino acid
sequence (Supplementary material, Fig. S1) was back-translated
into its gene sequence and the nucleotide sequence was optimised
for expression in Pichia pastoris by Geneart1 (Regensburg, Ger-
many) using the GeneOptimiser1 [20]. The codon-optimised
gene sequence, that is, the TcTS gene, was then cloned into the
pPICZalphaC vector (Invitrogen) using XbaI and XhoI restriction
sites. The final coding gene sequence consisted of (i) the yeast
alpha factor signal sequence, (ii) the TcTS gene, and (iii) the C-
terminal c-myc- and 6xhis-tag sequences (Supplementary mate-
rial, Fig. S2). pPICZalphaC_TcTS  was cloned into Escherichia coli
Top10 by electroporation and selected on low salt LB plates (20 g
agar, 5 g NaCl, 5 g yeast extract, 10 g tryptone and zeocin 25 mg
per liter). Colonies were checked by PCR using primers 50AOX
(50GACTGGTTCCAATTGACAAGC30) and 30AOX (50GCAAATG
GCATTCTGACATCC30). The target plasmid was purified from
5 mL of ON culture according to the protocol (Zyppo Plasmid
Miniprep kit, ZYMO Research, CA, USA). Linearisation of the
plasmid was performed using the restriction enzyme MssI accord-
ing to the manufacturer’s protocol (Fermentas, Germany) and the
plasmid was subsequently purified using a GFX column (GE
Healthcare, Uppsala, Sweden). The plasmid solution was concen-
trated at 608C to a final volume of 10 ml obtaining approximately
10 mg of plasmid. 5 ml was used for transformation. Transforma-
tion into P. pastoris X-33 and verification of the positive trans-
formants were performed according to the Invitrogen protocol
(Catalog V195-20, version E 2002) using the 30- and 50-AOX
primers described above. Selection was performed on YPD (10 g
yeast extract, 20 g peptone, 20 g dextrose) with 200 mg/ml and
500 mg/ml zeocin, respectively. Selective plates were incubated at
room temperature for four days before re-streaking on the same
selective media for another four days.
Screening, selection and production of P. pastoris transformants
with TcTS activity
14 re-streaked colonies were transferred to 250 mL flasks each
containing 40 mL BMGY (13.3 g YNB (yeast nitrogen base with
ammonium sulphate without amino acids)), 10 g glycerol, 10 g
yeast extract, 20 g peptone and 0.02 g biotin per liter and,
buffered to pH 6.0 with 100 mL 1 M potassium phosphate per
liter and incubated for 16 hours at 308C at 200 rpm. The cultures
were diluted into 15 mL BMMY (glycerol substituted with a final
concentration of 0.5% methanol) and incubated for 24 hours. A
final concentration of 0.5% methanol was added once a day for
two consecutive days, before the supernatants were harvested by
centrifugation and sterile filtered. Concentration was performed
using vivaspin20, 30 kDa cut-off concentrators according to the
protocol (GE Healthcare, Uppsala, Sweden). Purification of the
TcTS enzymes on affinity column chromatography and the SDS
silver staining was according to the procedure described by Silva
et al. [21]. Dot-blot was performed according to the protocol
from Abcam1 (Abcam, Cambridge, UK). Hydrolase activity was
measured in a reaction mixture containing 100 mM sodium
phosphate buffer (pH 7.0), 0.75 mM p-nitrophenol-N-acetyl
neuraminic acid (PNP-NeuAc) and enzyme. Reactions were
initiated by addition of PNP-NeuAc and colour development
was monitored by absorbance at 410 nm at 308C. Trans-sialidase
activity was assayed as described previously [22] but with several
modifications: 1 mM CGMP was used as the donor substrate, and
0.5 mM 4-methylumbelliferyl-b-D-galactopyranoside (MU-Gal)
was used as the acceptor.
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Fermentation of a P. pastoris clone expressing the TcTS enzyme
Based on the evaluation criteria described above, a P. pastoris strain
(TcTS27.200) expressing the TcTS enzyme in reasonable amounts
was selected for larger production in a 5 L Sartorius Biostat Aplus
fermentor (Sartorius, Company), principally as described pre-
viously [21], with the following modifications: the temperature
was 308C for the glycerol batch and glycerol fed-batch phases, but
was decreased to 288C during the induction of the methanol fed-
batch.
Sialic acid donor
CGMP (Lactoprodan, CGMP-20) was obtained from Arla Foods
Ingredients (VibyJ, Denmark). The sialic acid content was deter-
mined to be 5.7% (w/w), corresponding to 0.2 mmol/g dry matter,
by a fluorimetric quantification method using 30-sialyllactose as a
standard [23]. The distribution of (2,3) linked and (2,6) linked
sialic acid were estimated to be approximately 50:50 based on the
literature [24].
pH/temperature and donor/acceptor ratio optima
The temperature and pH optimum and the optimal donor/accep-
tor ratio were determined at the same time via a randomised,
quadratic central composite statistically designed experiment.
The design contained 24 different combinations of pH, tempera-
ture, donor- and acceptor concentrations, and three replications
of the centre point. The following factor limits were used: pH 5.5–
7.5, temperature 15–358C, CGMP concentration measured as
total sialic acid equivalents 0.18–4.6 mM (corresponding to 0.9–
23.4 g/L), and lactose concentration 1–25 mM (corresponding to
0.3–8.5 g/L). The pH was adjusted using a citric acid/disodium-
phosphate buffer system, having a final concentration in reac-
tions of 50 mM buffer capacity at each pH value. The enzyme
concentration was 1.1 g/L in all reactions. Temperature was main-
tained using an Eppendorf thermomixer with agitation at
700 rpm. After three hours reaction time, the reaction mixture
was transferred to Vivaspin 500 spin columns (GE Healthcare
Biosciences, Uppsala, Sweden), centrifuged at 15,000  g for
20 min for removal of CGMP, and the 30-sialyllactose concentra-
tion in the permeate was measured as response by HPAEC-PAD as
described below.
pH/temperature optimum improvement and level influence
The temperature and pH optimum and influence of different
levels of the optimal donor/acceptor ratio were determined at
the same time via a randomised, quadratic central composite
statistically designed experiment. The design included 15 dif-
ferent combinations of pH, temperature, concentration levels,
and three replications of the centre point. The factor limits of
pH and temperature were adjusted to fit the suggested optimal
conditions based on the initial study. The following factor limits
were used: pH 4.5–6.5, temperature 25–458C. Three different
concentration levels, all with the same ratio, were chosen based
on the optimal ratio determined in the first experiment. Level 1:
1.5 mM CGMP and 8 mM lactose. Level 2: 3.1 mM CGMP and
16 mM lactose. Level 3: 6.2 mM CGMP and 32 mM lactose (7.7,
15.8 and 31.5 g/L CGMP and 2.7, 5.5, 10.9 g/L lactose
respectively). Additional reaction parameters were as described
above.
Utilisation of alternative acceptors
The ability of the (cloned) T. cruzi enzyme to utilise LNT or GOS as
acceptor was investigated. Reaction conditions were maintained
from the lactose experiments which were 6.2 mM CGMP, 32 mM
LNT or GOS, 1.1 g/L enzyme, pH 6, temperature 308C. The average
molecular weight of the GOS was estimated to approximately
615 Da based on size distribution, measured by LC–MS. Reaction
times were two days and three hours for LNT and GOS respectively,
followed by removal of CGMP by spin column treatment as
described above.
Preparative scale production
The purpose of the preparative scale procedure was to produce
gram quantities of pure, well characterised 30-sialyllactose for
functional studies. The process involved enzymatic reaction, pur-
ification, structure verification, and functional analysis.
Enzymatic reaction
Prior to the enzymatic reaction the aqueous substrate solution
containing 7.5 mM CGMP (38.3 g/L) and 41.2 mM lactose (14.1 g/
L) was pasteurised in a steam heated, stirred batch reactor at 758C
for 2.5 min. A total volume of 5.8 L of the substrate solution was
transferred to a 6 L Sartorius Biostat Aplus fermentor (Goettingen,
Germany) equipped with monitors and controls for pH, agitator
speed, and temperature. The temperature was adjusted to 308C and
the pH was adjusted to 5.8 using citric acid. The reaction was
initiated by adding enzyme to a total of 0.7 g protein/L. The
reaction progressed for 22 hours.
Membrane separation
CGMP and enzyme were removed from residual lactose and 30-
sialyllactose by crossflow membrane separation using two sets of
Vivaflow 200 5 kDa MWCO Hydrosart (Sartorius, Goettingen Ger-
many) in parallel equipped with a Masterflex L/S peristaltic pump.
Filtration was maintained at room temperature with 1 bar pressure
for 22 hours. After reducing the reaction volume to approximately
30%, 2 L of water was added for diafiltration of the retentate. The
diafiltration was terminated after six hours.
Preparative ion exchange chromatography
Anion exchange chromatography for purification of 30-sialyllac-
tose from filtration permeate was performed at 238C with an A¨KTA
purifier 100 workstation equipped with a P-900 pump, P-960
sample pump, UV-900 monitor, pH/C monitor, and Frac-950
fraction collector, all controlled by UNICORN software. A HiScale
50 column with a 400 mL packed bed of SepharoseQ was used for
separation. All instruments, column material and software were
obtained from GE Healthcare Biosciences (Uppsala, Sweden). The
elution of the 30-sialyllactose was monitored by the UV absorption
at 210 nm. Elution was performed at a flow rate of 70 mL/min with
water and ammonium formate as eluents. Before injection the
column was equilibrated with water for 2 column volumes (CV).
After injection, unbound compounds were removed from the
column by washing with water for 2.5 CV, followed by isocratic
elution with 40 mM ammonium formate for 2.5 CV. After elution
the column was regenerated with 400 mM ammonium formate for
4 CV and with water for 2 CV. Fractionation was performed using
an elution volume as the fractionation parameter. The collected
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fractions containing 30-sialyllactose were pooled and lyophilized
repeatedly five times to remove water and ammonium formate
[25]. Residual ammonium formate was monitored using a Formic
Acid Assay kit from Megazyme.
30-Sialyllactose quantification
30-Sialyllactose concentrations were quantified on HPAEC-PAD
(High Performance Anion Exchange Chromatography with Pulsed
Amperometric Detection) using a DionexBioLC system (Dionex
Corp., Sunnyvale, CA) equipped with a DionexCarboPacTM PA20
analytical column (3 mm  150 mm). Lactose and 30-sialyllactose
were isocratically eluted using 16 mM sodium hydroxide and
55 mM sodium acetate. The following pulse potentials and dura-
tions were used for detection: E1 = 0.1 V, t1 = 400 ms; E2 = 2 V,
t2 = 20 ms; E3 = 0.6 V, m3 =10 ms; E4 = 0.1 V, t4 = 60 ms. Data
were collected and analyzed with the program Chromeleon 6.80
SP4 Build 2361 software (Dionex Corp., Sunnyvale, CA).
Capillary-LC/MS analyses
For liquid chromatography/mass spectrometry (LC/MS) analyses,
an Agilent 1100 LC/Agilent 6340 ion trap MS system was used.
Oligosaccharides were separated using a Hypercarb porous graphi-
tic carbon (PGC) column (0.32 mm  150 mm, 5 mm, Thermo
Scientific) at 308C. Samples in 10 mM ammonium bicarbonate
were loaded onto the column. Gradient elution was achieved
using a binary solvent system consisting of (A) 10 mM ammonium
bicarbonate, adjusted to pH 8.5 with ammonium hydroxide, and
(B) 100% acetonitrile at a flow rate of 5 mL/min. The gradient was
initially at 98:2 (% A:B) for 5 min, followed by a linear increase to
42:58 (% A:B) at 33 min. This concentration of B was held for
3 min. Subsequently the eluent was returned to 98:2 (% A:B) at
40 min and the system was allowed to equilibrate for 10 min prior
to the next injection. All solvents used were of the highest HPLC
grade. The mass spectrometry was performed in negative ion
mode, and was scanned in the range m/z 150-2200, followed by
data-dependent MS2 scans of the four most abundant ions in each
MS1 scan.
NMR spectroscopy
Nuclear magnetic resonance (NMR) spectra were recorded on
10 mg of 30-sialyllactose after anion exchange chromatography
and lyophilization in 500 mL D2O (99.9% D, Sigma–Aldrich) at
258C. Experiments were performed on a Bruker Avance 800 MHz
spectrometer with a 5 mm TCI cryoprobe, using standard 1D and
2D pulse sequences. External 1,4-dioxane was used as chemical
shift reference (dH 3.75 ppm and dC 67.4 ppm) and all spectra were
processed and analyzed using Topspin 3.0.
Functionality
The ability of the produced 30-sialyllactose to function as a sole
carbon source for seven probiotic strains and a potential pathogen
was assessed in a pure culture fermentation study. The tested
bacterial strains were Bifidobacterium longum subsp. longum
(Danisco Global Culture Collection DGCC 232), B. longum subsp.
infantis (DGCC 233), B. longum subsp. infantis (DGCC 1497), B.
longum subsp. infantis (DGCC 2238), Lactobacillus acidophilus
(NCFM, ATCC 700396), B. longum subsp. longum (Bl-05, DGCC
9917), Bifidobacterium lactis (HN019, DGCC 2013), and Clostridium
perfringens (ATCC 13124). The strains were pre-cultured from
stocks stored at 808C, in MRS media (de Man, Rogosa and Sharpe
medium, Lab M, Bury, United Kingdom) containing glucose for
24 hours at 378C. After pre-culturing, microbes were inoculated in
fresh MRS growth medium containing glucose for 24 hours at
378C. A cell suspension (1%, v/v) was prepared in MRS medium
without glucose and used immediately. Substrates sterilized by UV
radiation for 20 s were added to the cell suspension in a final
concentration of 1% (w/v). Bacterial growth was measured over
12 hours with the automatic Bioscreen C system as described by
Ma¨kela¨inen et al. [26] and measured as the area under the growth
curve (OD600  min) obtained from the Bioscreen data. Potato
galactan (Megazyme International Ltd., Bray Co., Wicklow, Ire-
land) was used as a bifidogenic control.
Statistical design and data analysis
For experimental designs the software MODDE Version 7.0.0.1
(UmetricsAB, Umea˚, Sweden) was used as an aid to design the
experimental template and to evaluate the effects and the inter-
actions by multiple linear regressions. All insignificant interac-
tions were removed from models, unless otherwise stated. For
single culture growth experiments one way analyses of variances
95% confidence intervals were compared as Tukey–Kramer inter-
vals calculated from pooled standard deviations (Minitab Statis-
tical Software, Addison-Weseley, Reading, MA, USA).
Results and discussion
The optimal reaction conditions, being pH, temperature, donor
and acceptor ratio, and substrate concentration were determined
after accomplishing two factorial designs. The first design was
performed to determine the preliminary pH/temperature opti-
mum and donor and acceptor ratio. The second design was per-
formed to determine the exact pH/temperature optimum and the
influence of substrate concentration.
pH/temperature optimum
From the available literature (Table 1), the exact pH/temperature
optimum for the T. cruzi trans-sialidase enzyme is unclear; the pH
at which enzyme assays have been run has generally been in the
range of 5–9, typically pH 7, whereas assay temperatures have
varied from 10 to 378C, including ‘room temperature’ (Table 1).
The experimental design was made to cover the mid-range of
reported assay conditions. With the factors in the first design
set at pH 5.5–7.5 and temperature 15–358C, the different experi-
ments gave yields in the range of 0.18–0.25 mM 30-sialyllactose.
Multiple linear regression analysis showed that both temperature
and pH had a significant influence on the 30-sialyllactose produc-
tion (Table 2). A lower pH and a higher temperature were favour-
able, with an apparent maximum at pH 5.5 and 35 8C, but it was
neither possible to determine a pH nor a temperature maximum,
since both the pH  pH and temperature  temperature quadratic
interactions were insignificant. The validity of the model was
confirmed by the value of the centre points (0.22  0.01) being
close to the coefficient of the constant (Table 2).
In the second factorial design, the experimental frame was
adjusted for better determination of pH and temperature opti-
mum. The intervals were adjusted to pH 4.5–6.5 and temperature
25–458C. The different experiments gave yields in the range of
New Biotechnology Volume 31, Number 2 March 2014 RESEARCH PAPER
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0.02–0.29 mM 30-sialyllactose. Multiple linear regression analysis
showed that both pH and temperature were significant factors
(Table 3). The validity of the model was confirmed by the value of
the centre points (0.22  0.02) being close to the coefficient of the
constant (Table 3). The pH  pH and temperature  temperature
quadratic interactions were also both significant, and pH and
temperature optima were identified as pH 5.8 and 29.58C respec-
tively (Fig. 1). The determined optima were included in the frame
of the first factorial design, but the data were inconclusive to
establish the optima. The temperature optimum at 29.58C was
in accordance with the temperatures ranging from room tempera-
ture to 378C previously reported for T. cruzi trans-sialidase (Table
1). The finding of the pH optimum at pH 5.8 was notably different
from the pH values previously reported, where the T. cruzi trans-
sialidase has usually been applied around pH 7 (Table 1).
Optimal donor/acceptor ratio
Apart from pH and temperature being factors in the first factorial
design, CGMP (as sialic acid equivalents) and lactose concentra-
tion, 0.18–4.60 mM and 1–25 mM, respectively, were also included
with yields in the range of 0.02–0.25 mM 30-sialyllactose. Multiple
linear regression analysis showed that the CGMP concentration
and the CGMP quadratic interaction were significant, with an
optimum at 3.5 mM (Table 2) (Fig. 2). The lactose concentration
was not found to be significant, but the significance of the quad-
ratic coefficient indicated the presence of an optimal lactose
concentration, estimated to 13.9 mM (Fig. 2). These results sug-
gested that the optimal donor/acceptor ratio was approximately
1:4. The tendency towards a higher acceptor concentration than
donor concentration does correspond well with previously
reported ratios, when the sialic acid donor is a glycoprotein type
[16,18,27], where the studied cases tend to have a higher donor
concentration. An opposite tendency is observed in cases invol-
ving radioactive labeled acceptors, where donor concentrations
are 100 times higher than acceptor concentrations [28–30], pre-
sumably due to the availability and costs of radioactive labeled
materials.
Optimal concentration levels
Like the pH and temperature, a second factorial design regarding
the donor and acceptor concentrations was established. While
maintaining the optimal donor/acceptor ratio determined in the
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TABLE 1
Donor and acceptor, ratios, pH, temperature and yields for Trypanosoma cruzi trans-sialidase reactions. Assay in yield indicates purpose
of reaction is screening
Donor Acceptor Ratio D:A (w/w%) pH Temperature Yield Reference
Whey Lactose 1:5 5–9 258C 25 mg/g DM [16]
Fetuin Lactose 1:4 7.0 308C 80 mol% [18]
Fetuin Lactose 1:3.3 7.4 378C Assay [27]
30-Sialyllactose MUgalb 2:1 7.0 208C Assay [47]
Fetuin Lactose derivativea 1.6:1 7.0 Room Assay [48]
30-Sialyllactose Lactose derivativea 1:1 7.0 Room Assay [48]
Sialyl-para-nitrophenol Branched a and b galactosides 1:6 6.0 308C 80–90% [49]
30-Sialyllactose [C14]N-acetyllactosamin 2:1 4.4–8.9, 7.9 optimum 378Cc 5–40 mol% [50]
30-Sialyllactose [C14]lactose 125:1 5–9.7 optimum Room Assay [28]
30-Sialyllactose [C14]lactose 83:1 7.6 258C Assay [30]
30-Sialyllactose [C14]lactose 135:1 7.0 10–298C Assay [29]
a Benzyl b-D-fucopyranosyl-(1 ! 6)-2-acetamido-2-deoxy-a-D-glucopyranoside.
b 4-Methyl-umbelliferyl-b-D-galactoside.
c But optimum was found to be 138C.
TABLE 2
Multiple linear regression results on the pH/temperature and
ratio. The validity of the model was confirmed by the value of the
centre points being close to the coefficient of the constant
Coefficient P*
Constant 0.2093 <0.0001
CGMP 0.0653 <0.0001
Lactose 0.0047 0.3488
Temperature 0.0233 0.0001
pH 0.0123 0.0200
CGMP  CGMP 0.0676 <0.0001
Lactose  lactose 0.0375 0.0085
Q2 = 0.91 and R2 = 0.95.
* P < 0.05 indicates significance at the 95% level.
TABLE 3
Multiple linear regression results on the pH/temperature
improvement and level
30-Sialyllactose Coefficient P*
Constant 0.217 <0.0001
Level 0.043 0.004
pH 0.030 0.030
Temperature 0.073 <0.0001
pH  pH 0.052 0.036
Temperature  temperature 0.067 0.011
Q2 = 0.69 and R2 = 0.89.
* P < 0.05 indicates significance at the 95% level.
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first factorial design, the impact of total substrate concentration
was investigated using three different levels, the initial concentra-
tions from the first design, 50% lower concentration and 100%
higher concentration, giving the levels: Level 1: 1.5 mM CGMP and
8 mM lactose. Level 2: 3.1 mM CGMP and 16 mM lactose. Level 3:
6.2 mM CGMP and 32 mM lactose. All with a maintained donor/
acceptor ratio. The formation of 30-sialyllactose went from
0.16 mM to 0.29 mM when substrate concentration was increased
from level 1 to level 3 (Fig. 3). Multiple linear regression analysis
confirmed that the substrate level was a significant factor (Table 3).
Even though an increased substrate level resulted in an increased
30-sialyllactose formation, the overall yield measured as sialic acid
transfer, or conversion, was decreased from 10.5% to 4.7% with an
increased substrate concentration from level 1 to level 3 (Fig. 3).
This controversy in product formation in relation to conversion
yield must be taken into account when large scale production of 30-
sialyllactose or other similar sialylated products is considered.
While the high substrate concentration, and hence high product
formation is favourable under circumstances where as much pro-
duct as possible is desirable, lower substrate concentrations, and
hence a higher conversion yield might be favourable if one or more
reactants are scarce or expensive.
Preparative scale production
The preparative scale reaction reached an approximate 30-sialyl-
lactose concentration of 2.4 mM corresponding to 1.54 g/L. 30-
Sialyllactose was purified from the ultrafiltration and dialysis
permeates by anionic exchange chromatography and the peak
of interest was detected by UV monitoring at 210 nm. Lactose was
eluted in pure water and 30-sialyllactose was eluted in 40 mM
ammonium formate. Fractions containing 30-sialyllactose from
repeated runs were collected, analyzed for 30-sialyllactose content,
and pooled. The fractions at around 35–40 min. were rich in 30-
sialyllactose and contained no traces of lactose. Typical injections
of 500 mL ultrafiltration permeate with 2.4 mM 30-sialyllactose
resulted in approximately 315 mL total fraction containing 3–
3.5 mM pure 30-sialyllactose resulting in a recovery for the anionic
exchange chromatography step at around 80–90%. The column
was loaded close to maximum capacity, since the lactose fraction
contained only trace amounts of 30-sialyllactose and increasing the
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FIGURE 1
pH/temperature optimum improvement. A response surface, based on data
of 15 different combinations of the 4 reaction factors pH, temperature, donor-
and acceptor concentration plus 3 replicated centrepoints, showing the
product formation given as 30-sialyllactose concentration in mM as a function
of pH and temperature.
FIGURE 2
Donor/acceptor ratio. A response surface, based on data of 24 different
combinations of the 4 reaction factors pH, temperature, donor- and acceptor
concentration plus 3 replicated centrepoints, showing the product formation
given as 30-sialyllactose concentration in mM as a function of lactose and
CGMP concentrations (both in mM).
FIGURE 3
30-Sialyllactose production and conversion percentages as a function of
substrate levels. Data are extracted from the second factorial design (15
factor combinations plus the centre point in triplicate). Data are represented
as means  standard deviation of two to three replicas. Means within same
category that do not share a letter are significantly different (P < 0.05).
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sample load with 50% did neither result in a notable increase in
the 30-sialyllactose fraction nor increased product concentration.
In turn, the amount of 30-sialyllactose found in the lactose fraction
was increased.
Addressing the overall yield based on mass, the final concentra-
tion of 30-sialyllactose was 1.54 g/L, corresponding to the yield of
approximately 40.2 mg/g CGMP. This yield exceeded the 30-sia-
lyllactose yield of 25 mg/g and 6 mg/g reported for mozzarella
whey and k-casein as sialic acid donors in a previously described
method using the T. cruzi trans-sialidase as enzymatic catalyst [16].
In a similar reaction scheme comprised of CGMP and lactose,
sialidases showing trans-sialidase activity from Arthrobacter urea-
faciens and Bifidobacterium infantis were investigated [17]. In three
hours the A. ureafaciens trans-sialidase reached a 30-sialyllactose
yield at 5.5 mg/g CGMP similar to the 5.8 mg/g CGMP (0.29 mM,
level 3 Fig. 3) obtained in this study after three hours. A drawback
of applying a sialidase was an observed reduction in the 30-sialyl-
lactose concentration caused by hydrolysis when the reaction time
exceeded three hours, hence a true trans-sialidase like the T. cruzi
trans-sialidase is superior due to the possibility of extended reac-
tion time and a consequently higher product formation.
The results showed that CGMP efficiently can be used as sialic
acid donor for production of gram quantities of 30-sialyllactose.
Since CGMP is the naturally sialyl-glycosylated peptide residue
which constitutes the soluble part of the bovine mile k-casein
molecule after chymosin-cleavage of the casein producing the
clotted cheese mass, the CGMP is an abundantly available food-
grade co-processing product from cheese production. Hence, opti-
misation of the reaction conditions on this substrate is important
in order for the process to be relevant for the prospective industrial
use of enzymatically produced 30-sialyllactose and other sialylated
HMOs as functional food ingredients. The final concentration of
2.4 mM 30-sialyllactose compared to the initial CGMP-bound sialic
acid of 7.5 mM resulted in a 32% conversion yield. Taking the
theoretical distribution of sialic acid linkages in CGMP into con-
sideration (50% 30 and 50% 60 [24]) the conversion yield was more
likely 64%, based on available 30 linkages. The excess of acceptor in
the reaction mixture was apparently not enough to drive the
reaction towards full conversion. This might be due to the rela-
tively large molecular structure of CGMP, where it can be assumed
that not every 30 linked sialic acid is physically available to the
trans-sialidase. Clarification demands further investigation of the
glycoside structure of CGMP.
Product characterisation
The structure and purity were confirmed by high performance
anionic exchange chromatography with pulsed amperometric
detection (HPAEC-PAD), liquid chromatography with mass spec-
trometry (LC–MS) and NMR spectroscopy. Initial HPAEC-PAD
analysis of the final product from ion exchange chromatography
showed identical retention time compared to commercial 30-sia-
lyllactose. Furthermore, the product had no traces of residual
lactose (data not shown). The structural configuration of the
produced 30-sialyllactose was identified by LC–MS in comparison
with commercial 30- and 60-sialyllactose. The LC–MS was per-
formed using a porous graphitic carbon column, which has been
shown efficient in separating isomeric structures of oligosacchar-
ides [31,32]. 30- and 60-sialyllactose isomers were eluted at different
retention times (dual peaks for each standard was due to the
mutarotation of sialyllactose in solution [32]) and fully resolved
(Fig. 4a). The sialyllactose product was identified as to be 30-
sialyllactose based on retention time and peak pattern (Fig. 4b).
The structure was further confirmed by 1H and 13C NMR assign-
ments using standard 1D and 2D NMR experiments. The spectral
assignment was in agreement with literature values for 30-sialyl-
lactose (Fig. 5) [33–35]. The spectral region between 3.5 and 4 ppm
holds the majority of the proton resonances for 30-sialyllactose,
which are elaborated in the NMR assignment table in the supple-
mentary material Figs. S3 and S4. The resonance from residual
solvent HDO at 4.78 ppm was suppressed by pre-saturation. As the
only major impurity the sample contained some ammonium
formate, present at 8.44 ppm in the 1H NMR spectrum (outside
spectral range (Fig. 5), see supplementary material Fig. S3) and at
171.8 ppm in the 13C NMR spectrum (supplementary material Fig.
S3). Apart from presence of ammonium formate in the sample the
purity was very high, estimated from 1D and 2D NMR. For full 1H
and 13C NMR spectra and assignments of 30-sialyllactose see the
supplementary material Figs. S3 and S4.
In addition to the product being 30-sialyllactose, it was con-
firmed that this T. cruzi trans-sialidase only possesses the transfer-
ase activity and not the hydrolytic activity reported both for T.
cruzi [29] and trans-sialidase enzymes from other organisms like T.
rangeli [13], since no free sialic acid was observed throughout the
analysis by neither HPEAC-PAD, LC–MS nor NMR spectroscopy.
Alternative acceptors
Besides lactose as acceptor, LNT and GOS were investigated. The
most abundant complex oligosaccharide in human milk (besides
lactose), is the tetramer LNT (Galb1-3/4GlcNacb1-3Galb1-4Glc),
and mono- and disialylated isomers of this molecule are the
second most predominant sialylated compounds next to sialyllac-
tose [36]. Even though GOS are not HMOs, GOS were chosen as an
easily accessible source of substrate that provides various chain
lengths and multiple C3 hydroxyl groups that might serve as trans-
sialidation (acceptor) sites. The acceptor specificity of the T. cruzi
trans-sialidase has been studied previously mainly to understand
the mechanism in relation to: (a) T. cruzi induced infection and
pathogenesis and how the organism evades host immune response
by trans-sialidase-catalysed sialylation of parasite cell surface
mucins [37], and (b) enzyme inhibitor development [38,39]. It
is thus well established that the T. cruzi trans-sialidase, including
the non-virulent recombinant T. cruzi trans-sialidase used in
synthesis [16,17,19] and as the basis for the present work, selec-
tively catalyses the transfer of a(2,3)-linked sialyl residues from
donor molecules to non-reducing terminal b-galactopyranosyl
units of acceptors. It is also known that the T. cruzi trans-sialidase
has relatively relaxed acceptor specificity, and that, for example,
the open-chain lactose derivatives lactitol and lactobionic acid are
good competitive inhibitors and thus good acceptors [38] and that
the enzyme also becomes partly inhibited by isomeric di-b-galac-
tosides and b-thiogalactosides (as judged by % enzyme activity
remaining in a radiochemical assay) [39]. The T. cruzi trans-siali-
dase has also been shown to catalyse the selective mono-sialyla-
tion of terminal b(1,3)-linked galactose-units when 30-sialyllactose
is used as donor as well as the synthesis of 30sialyl-N-acetyllacto-
samine using the non-natural methylumbelliferyl a-sialoside as
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donor [40]. However, to our knowledge neither LNT nor GOS have
been evaluated as acceptors for T. cruzi trans-sialidase catalysed
sialylation in relation to synthesis of HMOs or putative HMO-like
prebiotics. In the present study, by running the reactions under
similar conditions as for the production of 30-sialyllactose, it was
revealed that both LNT and GOS could serve as acceptors for the T.
cruzi trans-sialidase. The presence of sialyl-LNT and sialyl-GOS was
confirmed by LC–MS. Only qualitative verifications were per-
formed due to lack of standards. Only single sialylated LNT was
found, which is in compliance with the previously described
specificity of T. cruzi trans-sialidase towards terminal 30 linkages
[41]. Contrary, the MS/MS data (Fig. 6) on the sialyl-GOS fraction
purified by anion exchange chromatography, as described for
preparative production, revealed the presence of doubly sialylated
products with a GOS backbone of degree of polymerization (DP)
3–6, although only in minor amounts based on relative abun-
dances. The relative abundances of the different degrees of poly-
merizations in neutral oligosaccharides in the GOS mixture and
the resulting sialylated oligosaccharides were compared (Fig. 7). A
shift in the distribution towards shorter compounds was observed,
based on relatively more of sialylated DP2 and less of sialylated
DP4 and DP5 compared to the distribution in GOS, indicating
that the T. cruzi trans-sialidase has a higher affinity for shorter
acceptors.
Functionality
Single culture fermentations were performed as an initial test in
order to estimate the capability of 30-sialyllactose to induce growth
of seven common probiotic bacteria B. longum 232, B. longum Bl-
05, B. infantis 233, B. infantis 1497, B. infantis 2238, B. lactis HN019,
and L. acidophilus NCFM and one potential pathogen C. perfringens.
PCR screening revealed that the three B. infantis strains all con-
tained the constitutive sialidase Blon_2348 present in the HMO
utilisation cluster described by Sela et al. [42], whereas the two B.
longum strains did not (data not shown). The growth of the eight
strains were measured as OD  min for 12 hours using either
minimal MRS medium without glucose, the produced 30-sialyllac-
tose or galactan as substrate. The produced 30-sialyllactose was able
to induce statistically significant growth of B. longum 232, B.
infantis 233, B. infantis 1497 and B. lactis HN019 strains compared
to the pure media (Fig. 8). It was expected that all three B. infantis
strains would be able to utilise 30-sialyllactose, due to the presence
of the Blon_2348 sialidase encoding gene. Exo-a-sialidase activity
(EC 3.2.1.18) has previously been positively demonstrated in B.
longum subsp. infantis (ATCC15697 (=JCM1222)) and in two
strains of Bifidobacterium bifidum (JCM1254 and JCM7004) [43],
but it has previously been shown that some B. longum strains fail to
grow on neutral HMOs [2] and sialylated HMOs [44] as a sole
carbon source, which might explain the lack of induced growth of
B. longum BI-05. Contrary, 30-sialyllactose induced the growth of B.
longum 232 despite the lack of the Blon_2348 sialidase. Also B. lactis
HN019 was able to grow on 30-sialyllactose. Potato galactan, which
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FIGURE 4
Extracted ion chromatograms (EIC) of 30-sialyllactose ion [MH] at m/z 632.2. (a) 30- and 60-sialyllactose standards and (b) 30-sialyllactose purified by anion
exchange chromatography from preparative reaction.
FIGURE 5
1H NMR spectrum of the produced 30-sialyllactose in D2O with assignments of
distinctive and discriminative resonances. Insertion: structure of 30-
sialyllactose with selected atom numberings as used in the NMR
assignments.
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has previously shown bifidogenic effect [45] was only able to
induce growth of B. infantis 233 and B. infantis 1497, along with
L. acidophilus NCFM (Fig. 8). The lack of growth for the other
strains might be due to the difference of the galactan obtained
from Megazyme used in this study and the galactan extracted by
Thomassen et al. [45] and the fact that the bifidogenic effect was
obtained at species level in a mixed fermentation rather than at the
specific strain level.
The case that 30-sialyllactose was able to stimulate the growth of
C. perfringens, was expected based on the previously reported
presence of genes responsible for releasing and degradation of
sialic acid [46], but the extent of the induction was surprising
based on the limited growth by C. perfringens ATCC13124 on
neutral HMOs [3].
A common incident for the three strains with no growth induc-
tion, along with C. perfringens, was the relatively high background
growth on the MRS media without any added carbon source
(Fig. 8), which makes it more difficult to determine a significant
growth induction by the 30-sialyllactose and galactan. Using a
more suitable minimal medium, as described by Marcobal et al.
[3], would be beneficial for detecting small changes and might give
a more comprehensive conclusion.
Another aspect that might influence the results is the fact that
the individual cell suspensions were inoculated at a fixed inocula-
tion time, and not with respect to reaching the same OD. This
could mean that the strains were not in the same growth phase,
and hence responded differently to 30-sialyllactose.
Conclusions
A trans-sialidase from T. cruzi was successfully cloned and
expressed in P. pastoris. The pH and temperature optimum was
determined along with the optimal donor:acceptor ratio. A process
for production of gram quantities of 30-sialyllactose utilising a
dairy side stream as sialic acid donor was established, and the
enzyme was also shown to be able to catalyse sialyl-transfer from
CGMP to other acceptors, that is, GOS and LNT. The 30-sialyllac-
tose produced was able to induce the growth of selected Bifido-
bacterium strains, including some infant gut-related B. longum
subsp. infantis strains. The enzymatic method described here
provides a proof of concept and can serve as a benchmark for
production of gram quantities of 30-sialyllactose and other sialy-
lated oligosaccharides.
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FIGURE 6
MS/MS spectrum from LC–MS of a sialylated GOS tetramer with two sialic acid residues. Reaction conditions were 6.2 mM CGMP and 32 mM GOS at pH 6 and 308C
for three hours. The blue diamond indicates the precursor ion.
FIGURE 7
Relative abundances of neutral and sialylated GOS based on relative peak
areas from LC–MS. DP is referring to the length of the GOS backbone.
Reaction conditions were 6.2 mM CGMP and 32 mM GOS at pH 6 and 308C for
three hours.
FIGURE 8
Single culture bacterial growth expressed as area under the curve
[OD600  min]. Data are presented as means  standard deviations of three
to four replicas. Means within same bacterial strain that do not share a letter
are significantly different (P < 0.05).
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Supplementary material 
This supplement contains: 
Figure S1. Protein sequence of T. cruzi transsialidase. 
Figure S2. Gene sequence of T. cruzi transsialidase (with tags). 
Figure S3. 1H NMR spectrum of 3’-sialyllactose. 
Figure S4. 13C NMR spectrum of 3’-sialyllactose. 
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Figure S1. Protein sequence of T. cruzi transsialidase (without signal peptide, tags, and stop-codon). 
 
ATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTCCAGTCAACACTACAACAGAAGAT
GAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTCAGATTTAGAAGGGGATTTCGATGTTGCTGTTTTGCCATTTTC
CAACAGCACAAATAACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTCTCGAGA
AGAGAGAGGCTGAAGCAATGTTGGCTCCAGGTTCTTCCAGAGTCGAGTTGTTCAAGAGACAGTCCTCCAAGGTCCCATTCGAAAAGG
ACGGTAAGGTTACCGAGAGAGTTGTCCACTCCTTCAGATTGCCAGCCTTGGTTAACGTTGACGGTGTTATGGTTGCTATCGCTGACGCT
AGATACGAGACTTCTAACGACAACTCCCTGATCGACACCGTTGCTAAGTACTCTGTTGACGACGGTGAGACTTGGGAGACTCAGATTG
CTATCAAGAACTCCAGAGCCTCCTCCGTTTCCAGAGTTGTTGACCCAACCGTTATCGTCAAGGGTAACAAGTTGTACGTCCTGGTCGGT
TCTTACAACTCCTCCAGATCTTACTGGACTTCTCACGGTGATGCTAGAGACTGGGACATCTTGTTGGCTGTTGGTGAGGTTACTAAGTC
CACTGCTGGTGGTAAGATCACTGCTTCCATTAAGTGGGGTTCCCCAGTCTCCCTGAAAGAATTTTTCCCAGCCGAGATGGAAGGTATG
CACACTAACCAGTTCTTGGGTGGTGCTGGTGTTGCTATCGTTGCTTCTAACGGTAACCTGGTTTACCCAGTTCAGGTCACCAACAAGAA
GAAGCAGGTTTTCTCCAAGATCTTCTACTCCGAGGACGAGGGTAAGACTTGGAAGTTTGGTAAGGGTAGATCCGCCTTCGGTTGTTCT
GAACCAGTTGCTTTGGAGTGGGAGGGTAAGCTGATCATCAACACCAGAGTCGACTACAGAAGAAGATTGGTCTACGAGTCCTCCGAC
ATGGGTAACTCTTGGTTGGAAGCCGTTGGTACTTTGTCCAGAGTTTGGGGTCCATCCCCAAAGTCTAATCAACCAGGTTCCCAGTCCTC
CTTCACTGCTGTTACTATCGAGGGTATGAGAGTCATGCTGTTCACCCACCCATTGAACTTCAAGGGTAGATGGCTGAGAGACAGATTG
AACTTGTGGTTGACCGACAACCAGAGAATCTACAACGTCGGTCAGGTTTCCATCGGTGACGAAAACTCTGCTTACTCCTCCGTCTTGT
ACAAGGACGACAAGTTGTACTGCCTGCACGAGATTAACTCCAACGAGGTTTACTCCCTGGTTTTCGCCAGATTGGTCGGTGAGCTGAG
AATTATCAAGTCCGTCTTGCAGTCCTGGAAGAACTGGGATTCTCACTTGTCCTCCATCTGTACTCCAGCTGATCCAGCTGCTTCTTCAT
CTGAAAGAGGTTGCGGTCCAGCTGTTACTACCGTTGGTTTGGTTGGTTTCTTGTCCCACTCCGCTACTAAGACTGAATGGGAGGACGCC
TACAGATGTGTTAACGCTTCTACTGCTAACGCCGAGAGAGTTCCAAACGGTTTGAAGTTTGCCGGTGTTGGTGGTGGTGCTTTGTGGCC
AGTTTCTCAACAAGGTCAGAACCAGAGATACAGATTCGCTAACCACGCCTTCACCGTTGTTGCTTCCGTTACTATTCACGAGGTTCCAT
CCGTTGCTAGTCCTTTGTTGGGTGCTTCTTTGGACTCTTCCGGTGGTAAGAAGTTGTTGGGTTTGTCCTACGACGAGAGACACCAATGG
CAACCTATCTACGGTTCCACTCCAGTTACTCCAACTGGTTCTTGGGAGATGGGTAAGAGATACCACGTCGTTTTGACCATGGCCAACA
AGATTGGTTCCGAGTACATTGACGGTGAGCCATTGGAAGGTTCCGGTCAAACTGTTGTTCCAGACGAGAGAACTCCAGACATCTCCCA
CTTTTACGTCGGTGGTTACAAGAGATCCGACATGCCAACTATCTCCCACGTTACCGTCAACAACGTCCTGCTTTACAACAGACAGCTG
AACGCCGAAGAGATCAGAACCTTGTTCTTGTCCCAGGACCTGATTGGTACTGAAGCTCACATGGATTCCTCTTCCGACACTTCTGCTCT
AGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGA 
Figure S2. Gene sequence of T. cruzi transsialidase. Signal peptide (alpha factor signal sequence), T. cruzi 
transsialidase, [Alanine (GCT) and Leucine (CTA) insert before the c-myc epitope], c-myc tag and histidine-
tag and stop codon 
 
  
 
 
 
Figure S3. 1H NMR spectrum of 3’-sialyllactose. 1H NMR in D2O: 5.21 (d, J = 3.7 Hz, H1α), 4.65 (d, J = 8.0 Hz, 
H1β), 4.52 (d, J = 7.9 Hz, H1’), 4.10 (ddd, J = 3.0 Hz, 3.3 Hz, 9.9 Hz, H3’), 3.95 (m, H5α), 3.95 (m, H4’), 3.97 
(m, H6β), 3.92 (m, H6α), 3.88 (m, H8’’), 3.87 (m, H6α), 3.86 (m, H9’’), 3.84 (m, H5’’), 3.82 (m, H3α), 3.82 (m, 
H6β), 3.76 (m, H6’), 3.71 (m, H6’),  3.70 (m, H5’), 3.67 (m, H4α), 3.68 (m, H4’’), 3.65 (m, H4), 3.64 (m, H3β), 
3.64 (m, H9’’), 3.62 (m, H6’’), 3.59 (m, H5β), 3.59 (m, H7’’), 3.58 (m, H2α), 3.57 (m, H2’), 3.27 (dd, J = 8.1 Hz, 
9.3 Hz, H2β), 2.75 (dd, J = 4.7 Hz, 12.1 Hz, H3’’eq), 2.02 (s, Ac), 1.79 (dd, J = 11.7 Hz, 12.5 Hz, H3’’ax). 
  
 
Figure S4. 13C NMR spectrum of 3’-sialyllactose. 13C NMR in D2O: 175.8 (Ac), 174.7 (C1’’), 103.5 (C1’), 100.6 
(C2’’), 96.6 (C1β), 92.7 (C1α), 79.1 (C4α), 79.0 (C4), 76.3 (C3’), 76.0 (C5’), 75.6 (C5β), 75.2 (C3β), 74.6 (C2β), 
73.7 (C6’’), 72.6 (C8’’), 72.2 (C3α), 72.0 (C2α), 70.9 (C5α), 70.2 (C2’), 69.2 (C4’’), 68.9 (C7’’), 68.3 (C4’), 63.4 
(C9’’), 61.9 (C6’), 60.9 (C6β), 60.8 (C6α), 52.5 (C5’’), 40.5 (C3’’), 22.9 (Ac). 
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a  b  s  t  r  a  c  t
Casein  glycomacropeptide  (cGMP)  and  lactose,  which  are  puriﬁed  (or  semi-puriﬁed)  components
obtained  from  side streams  from  dairy  industry  operations,  were  used  as  substrates  for  enzyme  cat-
alyzed  production  of 3′-sialyllactose,  a model  case  compound  for human  milk  oligosaccharides  (HMOs).
The enzyme  employed  was  a mutated  sialidase,  Tr6,  derived  from  Trypanosoma  rangeli,  and  expressed
in  Pichia  pastoris  after  codon-optimization.  The  Tr6  contained  6  point  mutations  and  exhibited  trans-
sialidase  activity.  The  Tr6 trans-sialidase  reaction  conditions  were  tuned  for  maximizing  Tr6  catalyzed
3′-sialyllactose  production  by optimizing  pH,  temperature,  acceptor,  and  donor  concentrations  using
response  surface  designs.  At the  optimum  reaction  conditions,  the  Tr6 catalyzed  the  transfer  of  sialic
acid  from  cGMP  to lactose  at high  efﬁciency  without  substantial  hydrolysis  of the  3′-sialyllactose  prod-
uct.  The  robustness  of the  Tr6  catalyzed  reaction  was veriﬁed  at  5  L-scale  providing  a  yield  of  3.6  g
3′-sialyllactose  at an estimated  molar  trans-sialylation  yield  of 50%  on the  3′-sialyl  in cGMP.  Lacto-N-
tetraose  and  lacto-N-fucopentaoses  also  functioned  as acceptor  molecules  demonstrating  the  versatility
of the  Tr6  trans-sialidase  for  catalyzing  sialyl-transfer  for generating  different  HMOs.  The  data  signify  the
applicability  of  enzymatic  trans-sialylation  on  dairy  side-stream  components  for  production  of  human
milk  oligosaccharides.
© 2013  Elsevier  Ltd. All  rights  reserved.
1. Introduction
Human milk oligosaccharides (HMOs) appear to constitute an
innate immunologic mechanism by which human milk confers
breast-fed infants some level of protection against infections [1].
HMOs constitute the third most abundant component of human
milk after lactose and lipids, and levels of up to 8 g/L have been
reported [2], mainly during the ﬁrst days of lactation. The HMOs
function as soluble receptors that inhibit pathogens such as Campy-
lobacter jejuni and Escherichia coli K1 from adhering to their target
Abbreviations: cGMP, casein glycomacropeptide; HMOs, human milk oligosac-
charides; LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I, lacto-N-
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receptors on the mucosal surface of the host gastrointestinal tract,
and thereby help reduce the incidence of diarrhea and other dis-
eases in breast-fed infants [1,3]. HMO  molecules are also substrates
for probiotic gut bacteria, including Biﬁdobacterium longum subsp.
infantis [4] (previously known as Biﬁdobacterium infantis) and thus
seem to support the development of a healthy gut microﬂora in
breast-fed infants by acting as biﬁdogenic prebiotics [4].
All HMO  molecules contain lactose (Gal1-4Glc) at their reduc-
ing end and are built from sequential elongations via linkage
to one or more units of N-acetylglucosamine and galactose (N-
acetyllactosamine) and can be decorated with several sialic acid
(N-acetyl-neuraminic acid) and fucose residues [1,2,5]. Because
of the different backbone lengths, bonds, decorations via various
bond types, and different combinations of the basic building blocks
many different HMO  structures can exist. About 180 different HMO
species have thus been identiﬁed in a pooled human milk sample
from ﬁve individuals, and nearly 16% of the total oligosaccharide
abundances were found to correspond to sialylated oligosaccha-
rides [5]. Only a few HMOs are present in bovine milk and only at
low concentrations.
1359-5113/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.
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Biﬁdobacterium longum subsp. infantis (ATCC15697) is consid-
ered an “archetypical HMO-utilizing bacterium” [6], and has been
found to harbor genes for sialidase and fucosidase glycosyl hydro-
lases [6]. Exo--sialidase activity (EC 3.2.1.18) has also been
positively demonstrated in two strains of Biﬁdobacterium biﬁdum
(JCM1254 and JCM7004) [7].
Enzymatic synthesis (analytical scale) of sialylated oligosaccha-
rides by use of the trans-sialidase from the pathogenic parasite
Trypanosoma cruzi was reported already in 2000 [8]. The T. cruzi
trans-sialidase has been studied intensively due to its suggested
involvement in the mammalian host cell invasion process and
pathogenesis of T. cruzi leading to Chagas disease [9]. Hence, recom-
binant, catalytic domain forms of this enzyme have been expressed
in E. coli [10,11] and it has also been reported that the recombinant
enzyme can catalyze the sialylation of lactose derivatives such as
lactitol and lactobionic acid using 3′-sialyllactose (-Neu5Ac-(2-
3)-gal--(1-4)-glc) as donor [12]. The recombinant version of the
T. cruzi enzyme expressed in E. coli has also been used for prepar-
ative sialylation of a synthetic pentasaccharide from the mucins
of T. cruzi [13] and methods for enriching bovine milk with 3′-
sialyllactose employing the T. cruzi trans-sialidase and claims for
using a sialidase from other organisms have also been patented
[14,15]. The full T. cruzi dual-domain trans-sialidase enzyme is
considered a virulence factor for the invasive T. cruzi phenotype
[16], but the recombinant T. cruzi trans-sialidase used in synthesis
would not be virulent, and would moreover be inactivated when
heating and separation steps are included in the trans-sialylation
process. Nevertheless, due to its origin from a pathogenic organ-
ism it may  be difﬁcult to obtain approval and consumer acceptance
for using the T. cruzi trans-sialidase as an aid for producing
functional food ingredients for infant consumption. Regarding
catalysis facilitated by sialidases, i.e. sialidase glucosyl hydrolases
(neuraminidases) (EC 3.2.1.18), the problem is that the reaction
will invariably result in hydrolysis of the target 3′-sialyllactose
product.
However, mutants of the sialidase from the non-pathogenic Try-
panosoma rangeli have been reported to exhibit low trans-sialidase
activity (maximum 11% of the trans-sialidase activity of the T.
cruzi trans-sialidase) [17]. We  hypothesized that the use of such
a sialidase mutant from T. rangeli exhibiting trans-sialidase activ-
ity could provide an alternative route for enzymatic, biomimetic
in vitro synthesis of HMOs. The present study was  undertaken
to assess the catalytic ability of such a T. rangeli derived trans-
sialidase mutant for (i) enzymatic in vitro production of gram-levels
of 3′-sialyllactose, and (ii) enzymatic sialyl-transfer to other HMO
structures such as lacto-N-tetraose and lacto-N-fucopentaoses. An
additional objective was to utilize abundantly available food-grade
co-processing products from the dairy industry, i.e. lactose and
casein glycomacropeptide (cGMP), as substrates for the enzymatic
reaction to make the process relevant in relation to the prospective
use of sialylated HMOs as functional food ingredients.
2. Materials and methods
2.1. Substrates
-d-lactose and standard of N-acetylneuraminic acid (sialic acid) were pur-
chased from Sigma–Aldrich (Steinheim, Germany). Standards of 3′-sialyllactose
and 6′-sialyllactose were purchased from Carbosynth (Compton, United Kingdom).
Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), Lacto-N-fucopentaose I (LNFP
I),  and Lacto-N-fucopentaose V (LNFPV) were purchased from Elicityl SA (Crolles,
France). Casein glycomacropeptide (cGMP) in the form of the commercially available
product Lacprodan® CGMP-20 (intended for use in infant formulas and PKU-
products), containing a total of 5.7% (w/w), equivalent to 0.2 mmol/g dry matter,
of  covalently linked sialic acid was a gift from Arla Foods Ingredients amba (Viby,
Denmark). Before use, as a technical precaution in relation to HPAEC-analysis, low
molecular weight impurities in the cGMP solution were removed by ﬁltration on a
5  kDa membrane (Sartorius AG, Goettingen, Germany).
2.2. Vector and strain construction
A Trypanosoma rangeli sialidase gene (Genbank accession no. U83180.1) with
the  following mutations, M96V, A98P, S120Y, G249Y, Q284P and I37L [17] was
codon-optimized and synthesized by DNA 2.0 (Menlo Park, CA, USA). The gene
was  inserted into pPICZC  (Invitrogen, Life Technologies Corp. Carlsbad, CA, USA)
between the XbaI and XhoI restriction sites generating a translational fusion to the
-factor signal sequence and C-terminal c-myc and 6xHis tag. The vector was named
pPicZC Tr6 (the gene sequence is available in supplementary material Figure S1).
Transformation and selection of Pichia pastoris X-33 expressing the Tr6 gene were
carried out according to the manufacturer’s instructions. Zeocin resistant transfor-
mants were analyzed for protein expression by Western blot using a c-myc antibody
[18].
2.3. Production of the Tr6 enzyme in P. pastoris, puriﬁcation and characterization
The enzyme, Tr6, was produced in a 5 L Sartorius Biostat Aplus fermentation
of P. pastoris, in a fermentation run principally as detailed previously [19], with the
exception that the methanol fed-batch phase was done at 25 ◦C. The Tr6 enzyme
was  puriﬁed by Cu2+ afﬁnity column chromatography using a CIM® IDA-8f mL Tube
Monolithic Column (BIA Separations GmbH, Villach, Austria) [18]. The protein con-
centration was measured at 280 nm using Gene5TMTAKE3 module version 1.09
according to the manufacturer’s instructions (Biotek® Instruments, Inc.).
The purity of the Tr6 was evaluated by SDS-PAGE (BioRad, CA, US) using
Coomassie brilliant blue staining as described previously [18]. To test for N-
glycosylation the puriﬁed Tr6 was treated with endoglycosidase H (EndoH,
Medinova) for 1 h at 37 ◦C. Proteins treated with and without endoglycosidase H
were analyzed by Western blot, using monoclonal anti-poly-histidine–peroxidase
antibodies, principally as detailed previously [18].
2.4. Investigation of conditions for trans-sialylation by statistically designed
experiments
MODDE Version 7.0.0.1 (Umetrics AB, Umeå, Sweden) was used as a tool to
design the experimental frame, a quadratic central composite design, and to ﬁt and
analyze the data by multiple linear regression analysis. Lactose was used as an accep-
tor  and cGMP as donor of sialic acid. The buffer used in the reactions was 15 mM
phosphate-citrate buffer with pH values indicated below. Tr6 was incubated at a
concentration of 5.3 mg/L. Three pH regimes 5.5, 6.5 and 7.5 were tested. Incuba-
tion temperatures were 15, 20 and 25 ◦C. Lactose concentration varied from 0.34 to
351 mM and concentration of sialic acid residues bound in cGMP varied from 0.6
to  4.6 mM in the experimental design frame: lactose and cGMP were solubilized in
buffer and pre-incubated at speciﬁc temperatures, before the reactions were initi-
ated  by addition of enzyme. The biocatalysis process was  allowed to proceed for
20  min, and then stopped by heating for 10 min at 90 ◦C. Subsequently each sample
was  ﬁltered on a 5 kDa polyethersulfone membrane to remove cGMP (Vivaspin, Sar-
torius AG, Goettingen, Germany). Concentrations of 3′-sialyllactose and sialic acid
were determined by HPAEC and/or LC/MS as described below.
2.5. Time study of trans-sialylation catalyzed by Tr6 expressed in P. pastoris
Tr6 was incubated as described above at two different conditions: 25 ◦C, pH 5.5
with 36.8 mM lactose and 2.6 mM sialic acid bound in cGMP or with 117 mM lactose
and 4.6 mM sialic acid bound in cGMP. The reaction was followed for 100 min.
2.6. Enzymatic production of 3′-sialyllactose
The enzymatic trans-sialylation reaction was accomplished in a stirred reac-
tor  vessel in a total reaction volume of 5 L. 117 mM lactose and 4.6 mM sialic acid
linked to cGMP was  dissolved in 15 mM phosphate–citrate buffer (pH 5.5), and after
pre-incubation in the buffer at 25 ◦C for 10 min, 5.3 mg/L Tr6 was  added. The enzy-
matic catalysis lasted 20 min, then the reaction was terminated by inactivation of
the enzyme at 90 ◦C for 10 min. cGMP was removed from the reaction mixtures by
a  cross-ﬂow ﬁltration using a 5 kDa cutoff membrane (Sartorius AG, Goettingen,
Germany). The permeate containing 3′-sialyllactose, sialic acid, lactose and buffer
was collected and freeze-dried. After re-solubilization in water (775 mL) the reaction
products were separated by anion exchange chromatography using a HiScale 50/20
column (GE Healthcare) with a packed bed of Sepharose Q FF on an ÄKTA puriﬁer 100
work station. The elution was monitored at 210 nm.  Before injection the column was
equilibrated with 2 L of water. After injection of the sample, the column was  washed
with 1.2 L water and the products 3′-sialyllactose and sialic acid were then eluted
with 1.4 L of 40 mM ammonium formate. The products were lyophilized and residual
ammonium formate was removed by repeated solubilization and lyophilization.
2.7. Production and puriﬁcation of sialylated lacto-N-tetraoses and
lacto-N-fucopentaoses
The reactions were carried out at 5–100 mL scale employing the same reaction
conditions as described for 3′-sialyllactose production except that LNT, LNnT, LNFP
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Fig. 1. (a) Coomassie stained SDS-polyacrylamide gel. Lane 1: marker, lane 2: the Tr6 enzyme after IMAC puriﬁcation. (b) Western blot analysis of the produced Tr6 enzyme:
lane  1, crude protein; lane 2, protein after treatment with EndoH; lane 3, marker. For the Western blot proteins were incubated with monoclonal anti-poly-histidine-peroxidase
antibodies (Sigma–Aldrich) (as detailed in [18]).
I and LNFP V were used as acceptors instead of lactose. LNT was  used at 117 mM,
whereas LNnT, LNFP I and LNFP V were used at 25 mM.
2.8. High-performance anion exchange chromatography–pulsed amperometric
detection (HPAEC–PAD)
Separation and quantiﬁcation of 3′-sialyllactose and sialic acid were carried out
by  HPAEC–PAD analysis using a CarboPacTM PA1 (4 mm × 250 mm)  column and a
Dionex BioLC system. The eluent system comprised deionised water (A), 0.5 M NaOH
(B) and 1 M NaOAc (C) and the elution program was modiﬁed from the method
described in [20] as follows: For the ﬁrst 3 min  a ratio of 80: 20 (% A:B) was applied,
then a linear gradient from 80:20 (% A:B) to 60:20:20 (% A:B:C) was used during
3–27 min. Strongly retained anions were removed from the column by isocratic
elution at 40:20:40 (% A:B:C) from 27 to 31 min. Subsequently the column was  re-
equilibrated for 7 min  with 80:20 (% A:B).
2.9. Capillary liquid chromatography/mass spectrometry
For liquid chromatography/mass spectrometry (LC/MS) analyses, an Agilent
1100 LC/Agilent 6340 ion trap MS system was used. Oligosaccharides were sep-
arated using a Hypercarb porous graphitic carbon (PGC) column (0.32 × 150 mm,
5  m,  Thermo Scientiﬁc) at 30 ◦C. Samples (0.5 L) were loaded onto the column
in  10 mM ammonium bicarbonate. Gradient elution was achieved using a binary
solvent system consisting of (A) 10 mM ammonium bicarbonate, adjusted to pH 8.5
with ammonium hydroxide, and (B) 100% acetonitrile at a ﬂow rate of 5 L/min.
The gradient was  initially at 98:2 (% A:B) for 5 min, followed by a linear increase to
42:58 (% A:B) at 33 min. This concentration of B was  held for 3 min. Subsequently the
eluent was  returned to 98:2 (% A:B) at 40 min  and the system was allowed to equil-
ibrate for 10 min  prior to the next injection. All solvents used were of the highest
HPLC grade. The mass spectrometry was performed in negative ion mode, and was
scanned in the range m/z 150–2200 (2 microscans, maximum accumulation time of
150  ms,  an ion current count of 200,000) followed by data-dependent MS2  scans of
the  four most abundant ions in each MS1  scan.
2.10. Nuclear magnetic resonance (NMR) spectroscopy
NMR spectra were recorded in D2O (99.9% D, Sigma–Aldrich) at 25 ◦C on a Varian
Unity Inova 500 MHz  spectrometer equipped with a 5 mm probe, using standard
1D and 2D pulse sequences. 1,4-dioxane was  used as an external chemical shift
reference (ıH 3.75 ppm and ıC 67.4 ppm).
3. Results
3.1. Expression in P. pastoris and characterization of the
trans-sialidase Tr6
Since it is generally accepted that codon usage can affect (i.e.
decrease) recombinant protein yields [21] a synthetic gene with
a codon distribution optimized for P. pastoris expression [22] was
synthesized for the production of the T. rangeli sialidase Tr6. The
secreted Tr6 polypeptide comprised 663 amino acids including a 23
amino acid C-terminal c-myc and 6xHis tag (Supplementary mate-
rial, Figure S1) with a theoretical molecular weight of 73 kDa. A
positive transformant expressing the Tr6 enzyme was  selected and
used for enzyme production at a 5 L-scale. This production gave a
concentration of Tr6 of 1 g/L. After puriﬁcation, the enzyme had an
apparent molecular weight of about 80 kDa by SDS-PAGE (Fig. 1a),
but treatment of the Tr6 enzyme with EndoH followed by Western
blot analysis revealed that the expressed protein was  glycosylated
and the molecular weight of Tr6 was 75 kDa after deglycosylation
(Fig. 1 b).
3.2. Tuning of the Tr6 reaction conditions for maximizing
trans-sialidase activity
The wild type sialidase from T. rangeli and the derived Tr6
mutant enzyme have an inherent high level of sialidase activity, but
a relatively low level of trans-sialidase activity [17]. In the present
study we wanted to evaluate the relationship between Tr6 sialidase
and trans-sialidase activities and deﬁne the reaction conditions at
which the trans-sialidase activity would be maximal. For produc-
tion of 3′-sialyllactose, a systematic evaluation of the inﬂuence of
the reaction factors, notably the reaction temperature, pH, concen-
tration of the sialic acid donor (cGMP) and concentration of the
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Fig. 2. (a) Accumulation of 3′-sialyllactose and sialic acid over time (25 min) at low
concentration of lactose: 36.8 mM lactose, at 25 ◦C, pH 5.5, and 2.6 mM sialic acid
contained in cGMP; measured by HPAEC-PAD; 3′-sialyllactose; sialic acid. (b) Accu-
mulation of 3′-sialyllactose over time at high lactose, 117 mM lactose, 25 ◦C, pH 5.5,
and  4.6 mM sialic acid bound in cGMP; measured by LC/MS. No free sialic acid was
detected.
acceptor (lactose), revealed that increased temperature (from 15
to 25 ◦C) and decreased pH (from 7.5 to 5.5) gave rise to enhanced
yields of 3′-sialyllactose (Supplementary material, Figure S2), but
at the reaction optimum at pH 5.5 and 25 ◦C, at low concentration of
the acceptor, lactose (4 mM),  only low levels of 3′-sialyllactose were
produced, and free sialic acid was released simultaneously (Fig. 2a).
These data signiﬁed that the reaction conditions did not sufﬁciently
suppress the sialidase activity of the enzyme. The retainment of
some sialidase activity was, however, in agreement with previous
results reported for T. rangeli mutants expressed in E. coli [17]. Nev-
ertheless, when higher lactose concentrations (117–351 mM)  were
used, i.e. in effect a higher substrate acceptor:donor ration, the Tr6
enzyme was able to catalyze the production of high amounts of
3′-sialyllactose by trans-sialidase action without simultaneously
catalyzing release of free sialic acid (Fig. 2b). At this high accep-
tor concentration, and higher acceptor:donor ratio, the speciﬁc
activity of the Tr6 trans-sialidase activity was determined to be
16.2 mol  min−1 mg−1.
3.3. Enzymatic production, puriﬁcation and analysis of
3′-sialyllactose at 5 liter-scale
For the enzymatic production of 3′-sialyllactose 5.3 mg/L of Tr6
was incubated for 20 min  at the optimal reaction conditions of pH
5.5, 25 ◦C, using 117 mM lactose (equivalent to 40 g/L) and 4.6 mM
sialic acid residues bound in cGMP (equivalent to 26 g cGMP/L).
After deactivation of the enzyme, the 3′-sialyllactose product was
puriﬁed via a two-step down-stream process: the ﬁrst step was
ultraﬁltration to remove cGMP and Tr6. The permeate was  then
collected and after freeze-drying 180 g of dry product was  obtained
containing 3′-sialyllactose, unreacted lactose, sialic acid and buffer
used in the enzymatic process. In the second down-stream
processing step, the different compounds were then separated by
anion exchange chromatography using ammonium formate as the
eluent (Figure S3). The quality of the separation was conﬁrmed by
Fig. 3. (a) 1H NMR  spectrum of 3′-sialyllactose in D2O with assignments of distinc-
tive and discriminative resonances. The spectral region between 3.5 and 4 ppm holds
the remaining proton resonances for 3′-sialyllactose and besides a contamination
with formate the purity of the sample is very high. 1H NMR  and 13C NMR assign-
ment data of 3′-sialyllactose are given in Supplementary material S4. (b) Structure
of  3′-sialyllactose with selected atom numberings used in the NMR  assignment.
capillary LC/MS and NMR  spectroscopy (as discussed below).
In order to remove the ammonium formate, the samples were
lyophilized six times. The ﬁnal yield of 3′-sialyllactose was 3.6 g,
and the amount of free sialic acid was 133 mg.
Only approximately 50% of the sialic acid residues in the cGMP
are bound at the 3′-position, whereas the rest is bound at the
6′-position [23]. Since the Tr6 catalyzed the production of 3′-
sialyllactose, it can be assumed that only 3′-bound sialyl, i.e. ∼50%
of the total sialic acid in cGMP, was  available for this enzyme. There-
fore, the molar yield of 3′-sialyllactose was  ∼50% [47.74%] based on
the available 3′-sialic acid in cGMP.
The corresponding molar yield of the sialyllactose was  1% on the
lactose, and for the free sialic acid the yield was  ∼2% based on the
total sialyl-residues in the cGMP.
The identity of the 3′-sialyllactose product was conﬁrmed by
capillary LC/MS and NMR  (Fig. 3). 3′-Sialyllactose obtained from
the 5 L scale reaction eluted at the same time as the standard 3′-
sialyllactose (data not shown), indicating that the structure of the
compound produced was  3′-sialyllactose. Both 6′-sialyllactose and
3′-sialyllactose standards were fully resolved conﬁrming the ability
of the PGC column to provide good separation of different oligosac-
charides and stereoisomers [24]. No 6′-sialyllactose was detected
in the product proﬁle, only 3′-sialyllactose.
The 1H and 13C NMR  assignments obtained using 1D and 2D
NMR (Fig. 3 and supplementary material Figure S4) agreed with
literature values for 3′-sialyllactose [25,26]. Besides resonances of
3′-sialyllactose the 1H NMR  spectrum also showed a singlet reso-
nance at 8.44 ppm (data not shown), which resulted from residual
ammonium formate from the puriﬁcation buffer.
3.4. Enzymatic production of sialylated lacto-N-tetraose and
fuco-N-pentaoses
It was also demonstrated that the Tr6 was able to catalyze
the sialylation of lacto-N-tetraose and fuco-N-pentaoses, albeit the
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Fig. 4. Mass spectrum of ions eluted (at 17.6 and 18.8 min, respectively) in the post-reaction mixture of LNT incubated with cGMP and the Tr6 trans-sialidase: ion at m/z
706.3,  LNT; ion at m/z 997.3, sialylated LNT.
yields of the products were quite low; hence 5–12 mg  of sialylated
LNT, LNnT, LNFP I and LNFP V were obtained employing the opti-
mal  reactions conditions for the Tr6 (pH 5.5, 25 ◦C), and as high as
possible acceptor/donor ratio (see Section 2.7) (Figure S5). LC/MS
analysis showed the molecular species of LNT and sialylated-LNT
with the mass of sialylated-LNT at 997.3 (Fig. 4), corresponding to
the sum of the LNT ion (706.3) and dehydrated sialic acid (291) [27].
The mass of sialylated LNnT was also 997.3, whereas the masses for
sialylated LNFP I and LNFP V, respectively, were both determined
to be 1143 in agreement with the mass increment of 146 produced
by addition of fucose (data not shown). From the LC-MS results it
was evident that the sialylated products of LNT, LNnT, LNFP I and
LNFP V were predominantly singly sialylated (Figure S5).
4. Discussion
In the present study, the mutated T. rangeli sialidase, Tr6, was
codon optimized and expressed at a relatively high yield in P.
pastoris (1 g/L). In comparison, previously, only 5 mg/L of the trans-
sialidase from T. cruzi was produced in the same expression host,
P. pastoris [28]. This gene shared 67% homology to that of the wild
type gene from T. rangeli.  The relatively high yield of Tr6 in the
present study could be due to the codon optimization or the more
controlled conditions and higher cell density attained in a fer-
mentor as compared to shake ﬂasks. A high amount of Tr6 was
furthermore a prerequisite for a careful examination of the trans-
sialidase catalytic abilities of Tr6 at a range of process conditions
examined in the present study. At the optimal process conditions it
was observed, that the Tr6 sialidase from T. rangeli,  could be tuned
into an efﬁcient trans-sialidase with more than 93% trans-sialidase
activity and only 7% residual sialidase activity. These results dif-
fered from the trans-sialidase and sialidase activities recorded for
a Tr6 enzyme produced in E. coli, which showed relatively lower
trans-sialidase activity [17].
Whereas high substrate concentrations in general promote high
catalytic rates according to Michaelis–Menten kinetics, high accep-
tor:donor ratios are advantageous for promoting trans-sialidase
reactions, and generally used in T. cruzi trans-sialidase cataly-
sis studies [e.g. 8, 29] as well as in -galactosidase catalyzed
galacto-oligosaccharide synthesis reactions [30,31]. When lactose
is the acceptor for the trans-sialidase catalysis a high excess of
acceptor is not an economic problem, but once more expen-
sive tetra- and penta-saccharides are acceptors, measures such
as recycling of the unused acceptor may  have to be consid-
ered when comparing the application potential. Another issue
is enzyme re-use to improve biocatalytic productivity. A time
study performed at high lactose acceptor concentration was
used in the present work to determine the maximal, speciﬁc
trans-sialidase activity of Tr6. The speciﬁc Tr6 trans-sialidase activ-
ity was determined to 16.2 nmol min−1 per g of pure protein
(i.e. 16.2 mol  min−1 mg−1). This speciﬁc activity was in essence
equivalent to the apparent Vmax of 14.7 nmol min−1g−1 reported
for the similarly mutated T. rangeli sialidase expressed in E. coli
with 3′-sialyllactose as donor and lactose as acceptor substrate
[17], indicating that the maximal conversion rate found, was in
fact equal to the maximum catalytic rate of the Tr6 enzyme. It is
also interesting to note, that the speciﬁc Tr6 trans-sialidase activity
(of 16.2 mol  min−1 mg−1) was  ∼4 times higher than the reported
Vmax of the T. cruzi trans-sialidase (Vmax 3.8 nmol min−1g−1) mea-
sured using 3′-sialyllactose as the donor and lactose as the acceptor
[17], and ∼40,000 times higher than the maximal speciﬁc activity
(Vmax 0.41 nmol min−1 mg−1) reported by Agusti et al. [32] for T.
cruzi trans-sialidase catalyzed transfer of sialyl from 3′-sialyllactose
to terminal galactose in (synthetic) Galp(1 → 6)GlcNAc mucins of
the type involved in infection and pathogenesis of T. cruzi. With
cGMP as the donor (at 5 g/L) and lactose as the acceptor molecule (at
20 g/L) the rate of sialyllactose synthesis using the trans-sialidase
from T. cruzi occurs at a rate which is ∼450 times less than that
obtained in the present study with Tr6 [14]. As well, Biﬁdobacterium
infantis sialidase catalyzed trans-sialylation, employing high levels
of both cGMP and lactose [15], producing only a low level of sia-
lyllactose, took place at a rate which was 87-fold lower than that
obtained for Tr6 in the present study.
However, the speciﬁc Vmax rates reported recently for optimal
galactose transfer reactions for galacto-oligosaccharide synthesis
using sucrose as donor and lactose as acceptor, employing the
widely studied Bacillus circulans -galactosidase (commercially
known as Biolacta FN5′) may reach ∼2 mM min−1 [31]. This spe-
ciﬁc activity is ∼12 times higher than the speciﬁc trans-sialidase
activity of Tr6 of 16.2 nmol·min−1g−1 assuming an enzyme dos-
ing of the Biolacta FN5′ based on a para-nitrophenol galactoside
activity of the B. circulans -galactosidase of ∼1 U/mg [31,33].
In general it has been shown that a few hydrolases can carry out
a reverse reaction to synthesize organic molecules when the enzy-
matic process conditions have been optimized. This optimization
can be performed by changing the reaction conditions such as tem-
perature in the case of -galactosidase for galactooligosaccharide
production [34], glucose content in the case of the acyltrans-
ferase for production of glucose emulsiﬁers [35], and maltose level
in the case of generating isomaltooligosaccharides (IMO)  by glu-
coamylase [36]. These studies also showed that optimized process
conditions can have a profound, stimulating effect on the rate of
production and ﬁnal yield of the products. The latter is in agreement
with the present work whereby a sialidase with low trans-sialidase
has been tuned by favorable process conditions to exert a very
high trans-sialidase activity. The level of Tr6 produced in P. pas-
toris allowed a scaling of the enzymatic process to 5 L to establish
proof-of-concept for the Tr6 trans-sialidase productivity at scale,
providing 3.6 g of 3′-sialyllactose. To further validate the in vitro
concept with the new biocatalyst, LNT, LNnT, LNFP I and LNFP
V were also successfully decorated with sialic acid derived from
cGMP using the same procedure as employed for 3′-sialyllactose
production. The availability of optimized enzymes able to act on
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components from large scale side-streams from the agricultural
and dairy industries is a very important ﬁrst part of the decision
base for the food industry for developing competitive processes
for new functional food ingredients. The further interplay between
molecular evolution of the biocatalyst, i.e. Tr6, and biochemical
engineering optimization could further increase the yield of the
process developed here.
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Abstract 24 
This paper describes discovery of novel α-L-fucosidases for synthesis of various fucosylated 25 
oligosaccharides but also for hydrolysis of variably-linked α-L-fucose in selected plant materials. 26 
Several novel α-L-fucosidase-encoding genes were identified by functional screening of a soil-derived 27 
metagenomic library. In total, seven genes were expressed in E. coli as recombinant 6xHis-tagged 28 
proteins and were successfully produced and purified. All discovered enzymes can be classified in 29 
glycosyl hydrolase family 29 (GH-29). With exception of one, all enzymes were substrate-inhibited 30 
with Ki values ranging from 2.6 to 30.1 mM and were most hydrolytically active in pH range 6-7, when 31 
tested with p-nitrophenyl-α-L-fucose as the substrate. A difference in capability for hydrolysis of 32 
2’-fucosyllactose, 3-fucosyllactose and various plant materials was observed and appeared to correlate 33 
well with sequence similarity. Several enzymes were found to catalyse tranglycosylation either by self-34 
condensation or using lactose as acceptor and one exhibited an unusually high 35 
transglycosylation/hydrolysis ratio. 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
Keywords 44 
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1. Introduction 47 
L-Fucose (6-deoxy-L-galactose) is a monosaccharide with numerous biological roles and is observed in 48 
natural materials from various sources. In plant xyloglucans, which are often highly branched, L-fucose 49 
exists usually as terminal residue and is almost exclusively found in its α-anomeric configuration (1). 50 
Fucose can be O-methylated to various degrees in these materials (1, 2). Substantial amounts of 51 
sulfated fucose are found in fucoidan, a polysaccharide extracted from different species of brown algae 52 
(3). In addition, extracellular polysaccharides from various bacteria, fungi and micro-algae also contain 53 
L-fucose (1). 54 
Fucosylated glycoconjugates play a significant role in a wide range of biological processes such as 55 
defense in plants (4), receptor signaling, inflammation, metastasis and disease (fucosidosis) in 56 
mammals (5). The occurrence of fucose-containing compounds is well established in human milk 57 
oligosaccharides (2’-FL, 3-FL or lacto-N-fucopentaoses) (6, 7) blood group antigens (H, Lex, Lea, Leb 58 
determinants) (8) as well as at the non-reducing end of many glycan structures present on mammalian 59 
cells surfaces (1). The α-L-fucosyl residue is found α(1-2)-linked to D-galactose residues or α(1-3)-, 60 
α(1-4)-, or α(1-6)-linked to N-acetyl-D-glucosamine (9). Some of the more abundant fucosylated 61 
oligosaccharides in human milk, 2’-FL and 3-FL, not only stimulate the growth of bifidobacteria but 62 
also serve as antiadhesive antimicrobials (9). 63 
A widespread scientific interest in assessing biomedical properties of these fucosylated 64 
glycoconjugates, in particular oligosaccharides, stimulates efforts for their efficient and specific 65 
synthesis. Approaches include either chemical or enzymatic synthesis or combination of the two.  As 66 
compared with proteins, there is no universal mechanism for carbohydrate synthesis in living 67 
organisms. Moreover, enormous diversity of their stereochemistry makes it very difficult to automate 68 
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their synthesis. Although chemical methods have been developed, they are hampered by complexity of 69 
regio- and stereochemical control necessitating multiple protection and deprotection steps (10).  70 
The enzymatic synthesis can be accomplished by glycosyltransferases (GT) or glycoside hydrolases 71 
(GH). Mild conditions, higher specificity and simplicity of the enzymatic process are the advantage of 72 
this approach.  73 
GTs are responsible for the synthesis of glycoconjugates and oligosaccharides in all living organisms. 74 
They do not hydrolyze the product and are extremely efficient but their use is limited by expensive 75 
fucosyl nucleotide (GDP-Fuc) substrate, high specificity for natural donor and acceptor molecules and 76 
difficulty of enzyme purification (11). Attention has been devoted also to development of GT-based 77 
microbial systems with endogenous production of the activated sugar substrate intermediate (12). A 78 
maximum 2’-FL concentration of 1.23 g/l obtained from a batch fermentation with 14.5 g/l lactose was 79 
reported by Lee et al. (13). 80 
The other alternative for the enzymatic synthesis of fucosyl glyconjugates is the use of GHs in 81 
transglycosylation reactions. When the glycosyl-enzyme intermediate interacts with acceptor other than 82 
water, tranglycosylation reaction occurs (14). GHs that catalyze the hydrolysis of L-fucose are found in 83 
all three domains of life. Based on amino acid sequence similarity, all α-L-fucosidases hydrolyzing 84 
fucosyl derivatives with retention of the anomeric configuration are classified in CAZY (15) GH-29 85 
family, whereas inverting α-L-fucosidases are classified in family GH-95. The retaining GH-29 α-L-86 
fucosidases utilize a classical Koshland double displacement mechanism in which an aspartate residue 87 
is used as the catalytic nucleophile (16, 17). Under normal conditions these enzymes cleave glycosidic 88 
bonds in oligosaccharides and glycoconjugates. Glycosidases are attractive for oligosaccharide 89 
synthesis because glycoside substrates are relatively inexpensive, stable and some readily available. 90 
 5 
 
The usual promiscuity of GH binding sites enables glycosylation of a wide variety of acceptor 91 
molecules. 92 
Several α-L-fucosidases have been shown to exhibit transglycosylation properties. Examples include α-93 
L-fucosidases from Aspergillus niger, Corynebacterium sp., Penicillium multicolor (18), Pecten 94 
maximus (19), Alcaligenes sp. (20), Thermus sp. Y5 (21), and canines (19). Depending on enzyme 95 
source and reaction conditions, the final reaction yields remain moderate. 96 
Substantial advances in the discovery and engineering of these enzyme classes were thoroughly 97 
reviewed (22-24). α-fucosidase from Thermotoga maritima was successfully transformed into an α-98 
transfucosidase by directed evolution as reported by Osanjo et al (25). Moreover, much interest was 99 
devoted to glycosynthases - a new class of mutant glycosidases in which the active site nucleophile is 100 
replaced with a non-nucleophilic residue. (26) The mutation completely inactivates the enzyme but the 101 
activity can be restored in the presence of substrates with good leaving groups. This approach was 102 
successfully applied to Sulfolobus solfataricus α-L-fucosidase whose engineering led to yields as high 103 
as 91 % for selected acceptors and β-L-fucosyl azide as donor (27). 104 
Main challenges in applicability of GHs include enzyme mediated product degradation (hydrolysis) and 105 
low regiospecificity. Moreover, most studies focus on the use of relatively expensive fucose donors that 106 
limits the possibility of designing economically feasible processes. Selected high-fucose containing 107 
materials such as tragacanth, fucoidan or xyloglucan can offer interesting alternatives, if enzymes 108 
combining capability to synthesize various fucooligosaccharides and utilize such fucose donors are 109 
discovered.  110 
Functional screening of metagenomic libraries for discovery of novel enzymes has gained a lot of 111 
attention over the last years (28). It is an interesting alternative both to traditional culture-based 112 
methods and enzyme engineering for identification of novel variants of well-established enzyme 113 
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classes with new abilities. Despite challenges related to designing efficient and specific screening 114 
campaigns, several enzymes – including glycoside hydrolases – originating from various metagenomes 115 
have been identified and characterized (29).  116 
In this study we screened a soil metagenomic library for novel α-L-fucosidases. Relevant genes were 117 
identified and recombinant enzymes produced in E. coli. Subsequently, their hydrolytic activity and 118 
capability to synthesize various fucosylated oligosaccharides were investigated. The T. maritima α-L-119 
fucosidase and its L322P mutant which are relatively well characterized in scientific literature were 120 
used as benchmarks in this study (25). The use of α-L-fucosidases to synthesize the human milk fuco-121 
oligosaccharides 2’-FL and 3-FL was demonstrated. 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
 135 
 136 
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2. Materials and methods 137 
2.1 Substrates 138 
p-Nitrophenyl-α-L-fucose (pNP-Fuc) and 5-bromo-4-chloro-3-indolyl-α-L-fucose (X-Fuc) were 139 
purchased from from Carbosynth (Compton, United Kingdom). 2’-FL and 3-FL were obtained from 140 
Elicityl (Crolles, France).  β-lactose was purchased from Sigma-Aldrich (Steinheim, Germany). Fucose 141 
was supplied by DuPont Danisco (Denmark). Samples of fucoidan extracted from Fucus veniculosus, 142 
xyloglucan from citrus peel, and tragacanth gum from Astragalus gossypinus were kindly provided by 143 
Marcel Tutor Ale and Hassan Ahmadi Gavlighi from DTU Chemical Engineering (Kgs. Lyngby, 144 
Denmark). 145 
 146 
2.2 Strains and plasmids 147 
The E. coli ML297 strain is a ΔlacZYA derivative of EPI300™-T1R (Epicentre, USA) that was 148 
transformed with the heat-inducible lysis vector pEAS-1a (DualSystems Biotech, Switzerland). This 149 
strain was used for the maintenance and propagation of constructed metagenomic library. E. coli DH5α 150 
was used for subcloning and plasmid propagation. E. coli BL21(DE3) and OverExpress C41 (DE3) 151 
strains were used for production of recombinant α-L-fucosidases (Novagen and Lucigen, USA). 152 
 153 
2.3 Construction of metagenomic library 154 
Metagenomic DNA was extracted from 10 g of soil sample, using the PowerMax Soil DNA Isolation 155 
kit (Mobio Laboratories Inc.), using the manufacturer’s recommendations. Libraries of 40-50 kb 156 
metagenomic DNA in E. coli were created using the CopyControl Fosmid Library Production kit 157 
(Epicentre Biotechnologies). In brief, DNA was end-repaired and high molecular weight (40-50 kb) 158 
fragments were size selected and purified using 1 % low melting point-agarose gel electrophoresis 159 
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(overnight). 0.25 μg of metagenomic DNA was ligated with 0.5 μg of the linearized fosmid pCC1FOS 160 
vector and packaged using replication-deficient phage extract. E. coli strain ML297 was transfected 161 
with the resulting phages and library size was determined by plating serial dilutions on LB agar plates 162 
containing 12.5 μg/ml chloramphenicol and 100 μg/ml ampicillin. E. coli metagenomic DNA library 163 
was grown to mid-log phase for 8 h shaking at 30 °C in 50 ml LB supplemented with relevant 164 
antibiotics, and 2 ml aliquots with 15 % glycerol was stored frozen at -80 °C. Each frozen stock was 165 
subsequently confirmed to have about 50,000 colony forming units per ml. On the basis of the 166 
estimated library sizes, an average redundancy of about 1-2 clones per library aliquot could be inferred. 167 
2.4 Screening for α-L-fucosidase-bearing metagenomic clones 168 
To screen for novel α-L-fucosidase genes, a 1 Gbp soil metagenomic library was plated on standard 169 
size LB agar plates (10 cm in diameter) supplemented with 34 μg/ml chloramphenicol, 100 μg/ml 170 
ampicillin and 100 μg/ml of X-Fuc to a density of approximately 1,000 CFU. In total about 100,000 171 
colonies were cultivated for 3 days at 30 °C (to avoid heat-induced lysis) and colonies turning blue 172 
were selected. Fosmid material was isolated from liquid cultures of selected clones using 173 
FosmidMAX™ DNA Purification Kit (Epicentre, USA). Restriction analysis of fosmids with BamHI 174 
and PstI restriction was performed to find out the redundancy of all clones identified as positive.  175 
To facilitate further sequencing and gene identification, the fosmid DNA was digested with BamHI and 176 
further subcloned into BamHI-linearized and dephosphorylated pUC18 vector. 177 
Ligated DNA was used to transform electrocompetent cells of E. coli DH5α strain and resulting 178 
transformants were plated on LB agar plates supplemented with 100 μg/ml ampicillin and 100 μg/ml 179 
X-Fuc and incubated overnight at 37 °C.  Transformants degrading X-fuc contained fragments of the 180 
original fosmid with a functional α-L-fucosidase gene and were selected for further analysis. 181 
 182 
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2.5 Sequencing, identification and cloning of α-L-fucosidase genes 183 
pUC18-derivatives containing α-L-fucosidase-encoding genes were linearized using BamHI or PstI and 184 
gel-purified. These fragments were sequenced byIonTorrent PGM sequencing using 316 chip (DMAC, 185 
Lyngby, Denmark). Sequence reads were trimmed using clc_quality_trim script (CLC BIO, Aarhus, 186 
Denmark) and assembled using Ray Meta (30). BlastX (31) was used to search for closest homologs on 187 
protein level and to annotate all contigs. Primers were designed to close gaps between contigs 188 
containing truncated α-L-fucosidase-annotated genes at their 5’ or 3’ ends. For expression in E. coli, 189 
genes were PCR-amplified using specific primers (Table 1) and PCR products were restricted and 190 
inserted in the plasmid pETM10 between NcoI and KpnI. A gene encoding the α-L-fucosidase of 191 
Thermotoga maritima (Thma) was codon-optimized for E. coli and synthesized by GeneArt AG (Figure 192 
S3). The gene was PCR-amplified using relevant primers (Table 1), restricted and inserted in pETM10 193 
between NcoI and KpnI. The mutation L322P was introduced by PCR using overlapping primers. The 194 
resulting plasmids where used to transform E. coli BL21(DE3) or C41(DE3) strains. 195 
 196 
2.6 Expression and purification of α-L-fucosidases 197 
E. coli BL21(DE3) and C41(DE3) harboring recombinant plasmids were cultured in LB medium 198 
shaking at 30 °C prior to induction at OD600 0.6 with 0.2 mM or 1 mM IPTG. Expression was 199 
continued overnight at 25 °C with 180 rpm. The cell pellets were harvested by centrifugation and re-200 
suspended in binding buffer (20 mM phosphate-citrate buffer, 100 mM NaCl, 20 mM imidazole, pH 201 
7.4). Cells were lysed by sonication and centrifuged at 5,000 g for 20 min. The supernatant was 202 
subjected to sterile filtration through a 0.22 μm filter and subsequently loaded onto a Ni2+-sepharose 203 
HisTrap HP column (5 ml, GE healthcare). The purification was carried out using an ÄKTA purifier 204 
(GE healthcare). The column was equilibrated with binding buffer until UV and conductivity baselines 205 
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stabilized. After loading of the protein sample, unbound proteins were removed by washing with 10 CV 206 
of binding buffer, and the target recombinant enzyme was eluted with a linear gradient of 10 CV 207 
containing 20 to 500 mM of imidazole. The fractions containing 6xHis-tagged α-L-fucosidases were 208 
collected and desalted using PD-10 desalting columns (GE Healthcare) to remove imidazole. Protein 209 
concentrations were determined using the BCA protein assay (Thermo scientific) with BSA as the 210 
standard. 211 
 212 
2.7 Characterization of hydrolytic activity of novel α-L-fucosidases 213 
pH-dependence for hydrolysis was tested using 0.1 and 1.0 mM pNP-Fuc as substrate at 30 °C. The 214 
reactions were done in triplicates with the following buffers: 50 mM phosphate-citrate buffer (pH 3-8), 215 
50 mM tricine buffer (pH 8-9), 50 mM glycylglycine buffer (pH 8-9), 50 mM glycine-NaOH buffer 216 
(pH 9-10). Reactions with 0.1 mM pNP-Fuc were initiated by addition of enzyme at a final 217 
concentration of 0.2 μg/ml Mfuc1, 0.2 μg/ml Mfuc2, 0.6 μg/ml Mfuc3, 0.3 μg/ml Mfuc4, 0.2 μg/ml 218 
Mfuc5, 1.0 μg/ml Mfuc6, 0.2 μg/ml Mfuc7, 0.3 μg/ml Thma wild type, or 0.5 μg/ml Thma L322P. 219 
For reactions with 1.0 mM pNP-Fuc, with the exception of Mfuc2, the double concentration of enzyme 220 
was used. The release of p-nitrophenol (pNP) was followed by withdrawing samples at different time 221 
points (2, 4 and 8 min for 0.1 mM pNP-Fuc and 5, 10 and 20 min for 1.0 mM pNP-Fuc) and 222 
measurement of absorbance at 405nm after dilution with 0.5 M sodium carbonate. 223 
For a substrate saturation experiment, reactions were set up as described for the pH-dependence 224 
experiment (0.1 mM pNP-Fuc) except that reactions were done at respective optimum pH and with 0.1, 225 
0.25, 0.5, 1.0, 2.5, and 5 mM pNP-Fuc, and in case of Mfuc2 0.3 μg/ml of enzyme was used. Samples 226 
were withdrawn at 2.5, 5 and 10 min. Reactions were done in triplicate and kinetic data for Mfuc6 were 227 
fitted using allosteric model and the data for remaining enzymes with substrate inhibiton model. Non-228 
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linear regression analysis was performed with the use of GraphPad Prism (GraphPad Software, USA). 229 
For estimation of the temperature stability, the enzymes were incubated in 5 mM buffer at optimal pH 230 
at a concentration of 0.8 μg/ml Mfuc1, 0.4 μg/ml Mfuc2, 1.2 μg/ml Mfuc3, 0.9 μg/ml Mfuc4, 0.7 μg/ml 231 
Mfuc5, 3.9 μg/ml Mfuc6, 0.5 μg/ml Mfuc7, 0.9 μg/ml Thma wild type, or 1.5 μg/ml Thma L322P for 232 
10, 20, 30 and 40 min at various temperatures as indicated (30-100 °C). Residual enzyme activity was 233 
measured in a continuous assay using 1 mM pNP-Fuc with 50 mM buffer (pH 7) and 10 % of the 234 
enzyme concentration stated above and following release of pNP spectrophotometrically at 405 nm. 235 
The substrate specificity of purified enzymes was analyzed at 30 °C using 1 mM of the following 236 
chromogenic substrates in 50 mM phosphate-citrate buffer (pH 7.0): pNP-β-D-Gal, pNP-β-D-Glc, 237 
pNP-β-D-Lac using enzyme concentrations stated above. The release of pNP was followed 238 
spectrophotometrically at 405 nm in continuous assays. 239 
The hydrolysis of 2’-FL, 3-FL and fucose containing polymers, citrus peel xyloglucan, tracacanth and 240 
fucoidan was performed in duplicates in 96-deep well plates in total volume of 500 μl, at 30 °C and 241 
enzyme loading of 10 μg (except 20 μg for Mfuc7). Initial concentration of 1 mM and 150 min-reaction 242 
time for FLs were used. For polymer substrates the initial concentration of substrates was chosen to 243 
correspond to a final fucose content of 0.25 mM. The reactions were carried out for 240 min and post-244 
reaction mixtures were filtered using AcroPrep™ Advance 96-Well Omega Filter and ultrafiltered using 245 
Ultrafilter (10 kDa MWCO) plates, respectively (Pall, USA). Diluted permeates were analyzed by 246 
HPAEC-PAD. 247 
 248 
2.8 Immuno-glycan microarray analysis of fucosylated xyloglucan cleavage  249 
The extraction of cell wall components and subsequent analysis was performed essentially as described 250 
before (32). 4 M NaOH (containing 0.1 % NaBH4) extracts from the different plant species were 251 
 12 
 
spotted using a microarray robot (Sprint, Arrayjet, Roslin, UK). Each extracted sample was printed as a 252 
two-fold dilution followed by 3 five-fold dilutions. All sample dilutions were performed in printing 253 
buffer (55.2 % glycerol, 44 % water, 0.8 % Triton X-100). The samples were printed onto nitrocellulose 254 
membrane with a pore size of 0.45 μm (Whatman, Maidstone, UK). Once printed, arrays were blocked 255 
with PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.5) containing 5 % 256 
w/v low fat milk powder (M-PBS) for 1 hour. Hereafter, they were washed in PBS and incubated with 257 
or without 10 μg of tested α-L-fucosidases at 30 °C at optimal pH. After incubation, arrays were 258 
washed thoroughly with PBS, followed by 2 hours incubation with xyloglucan-specific monoclonal 259 
antibodies LM15 (PlantProbes, Leeds University, UK) diluted 10-fold or the antibody CCRC-M1 260 
specific for fucosylated xyloglucan (Complex Carbohydrate Research Center) diluted 250-fold in M-261 
PBS. Subsequently, arrays were washed in PBS and incubated with anti-rat or anti-mouse secondary 262 
antibody respectively conjugated to alkaline phosphatase (Sigma, Poole, UK) diluted 1/5000 in M-PBS. 263 
After washing with PBS and dH2O, arrays were developed in a solution containing 5-bromo-4-chloro-264 
3-indolylphosphate and nitro blue tetrazolium in alkaline phosphatase buffer (100 mM NaCl, 5 mM 265 
MgCl2, 100 mM diethanolamine, pH 9.5). Developed microarrays were scanned at 2400 dpi (CanoScan 266 
8800F, Canon, Søborg, Denmark) and converted to TIFFs. Antibody signals were measured using 267 
appropriate software (Array-Pro Analyzer 6.3, Media Cybernetics, Rockville, USA). Data were 268 
presented as two datasets where maximal spot signal was set to 100 and all other values normalized 269 
accordingly. Color intensity is correlated to mean spot signal value and a cut-off of 5 was applied. 270 
 271 
2.9 Identification of selected reaction products by nuclear magnetic resonance (NMR). 272 
For initial identification of trans-fucosylation products, non-buffered reactions were performed using 273 
20 mM pNP-Fuc as the donor and 25 mM lactose as the acceptor at 30 °C for 50 min. 500 μl reactions 274 
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were started by the addition of enzymes to final concentration of 42 μg/ml Mfuc1, 12 μg/ml Mfuc2, 41 275 
μg/ml Mfuc3, 34 μg/ml Mfuc4, 18 μg/ml Mfuc5, 65 μg/ml Mfuc7, 17 μg/ml Mfuc6, 51 μg/ml Thma 276 
wild type, and 58 μg/ml Thma L322P. The enzymes were removed using Vivaspin 500 filters with a 5 277 
kDa cut-off (Sartorius, Germany) at 4 °C. The permeate was freeze-dried and NMR spectra were 278 
acquired in 500 μL D2O (99.9 % D, Sigma-Aldrich) at 25 °C on a Varian Unity Inova 500 MHz 279 
spectrometer equipped with a 5 mm probe or a Bruker Ascend 400 MHz spectrometer with a 5 mm 280 
Prodigy cryoprobe using standard pulse sequences. External standard of 1,4-dioxane was used as 281 
chemical shift reference (δH 3.75 ppm and δC 67.4 ppm). Structure elucidation was achieved by full 1H 282 
and 13C NMR assignments using standard 1D and 2D homo- and heteronuclear NMR experiments (33, 283 
34). Chemical shifts of compounds annotated in this study are presented in the Supplementary material 284 
(Figure S7). 285 
 286 
2.10 High-performance anion exchange chromatography (HPAEC-PAD) and reverse phase 287 
chromatography (RP-HPLC) 288 
A Dionex ICS-5000 system consisting of DP-5000 gradient pump, ED-5000 electrochemical (pulsed 289 
amperometric) detector coupled to an AS-AP autosampler (Dionex Corp., CA) was used for HPAEC-290 
PAD analysis. The separation was accomplished using a CarboPac PA1 analytical column (4 mm × 250 291 
mm) with CarboPac PA1 guard column (4 mm × 50 mm) (Dionex Corp.) at 30 °C with a flow rate of 1 292 
ml/min. Hydrolysis products of 2’-FL, 3-FL and high-molecular substrates were analyzed with the 293 
following programme: 0-16 min at 75 mM NaOH, 17-21 min at 250 mM NaOH and regeneration 22-35 294 
min at 75 mM NaOH. For analysis of products in transfucosylation reactions, a 40 min isocratic 295 
separation using 75 mM NaOH as eluent was performed.  296 
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To analyse peak identities of individual p-nitrophenyl α-L-fucosyl-α-L-fucose products (pNP-Fuc-Fuc), 297 
transfucosylation reactions were performed as described in section 2.11 with the use of Mfuc6 and 298 
Mfuc7. After enzyme removal, compounds in the 20 μl permeate samples were separated by RP-HPLC  299 
using a ODS-L Optimal column (250 mm x 4.6 mm) at 30 °C and with a flow rate of 1 ml/min. A two-300 
solvent system consisting of acetonitrile (A) and water (B) was used with a linear gradient from 3 to 301 
30 % A for 40 min and regeneration at 3 % A for 15 min. The individual pNP-containing compounds 302 
were detected by UV spectrophotometry at 225 nm and collected into separate fractions. The procedure 303 
was repeated three times using each of the post-reaction mixtures, fractions corresponding to individual 304 
peaks were pooled and freeze-dried. The fractions were analysed by 1H NMR and HPAEC-PAD as 305 
detailed above. 306 
 307 
2.11 Time course of transglycosylation with selected enzymes 308 
Transfucosylation with selected enzymes was evaluated in a time-course experiments using 25 mM 309 
pNP-Fuc as donor and 100 mM lactose as acceptor, at 30 °C and pH optimum (as determined for 310 
hydrolysis of pNP-Fuc). The final enzyme concentrations were as for the transfucosylation experiment 311 
mentioned above (methods 2.9). The reactions were carried out in duplicates in 96-well deep well 312 
microtiter plates. 30 μl samples were withdrawn at indicated time points and diluted 10-fold with ice-313 
cold milliQ water. The post-reaction mixtures were filtered using AcroPrep™ Advance 96-Well Omega 314 
Filter and ultrafiltered using Ultrafilter (10 kDa MWCO) plates, respectively (Pall, USA). The 315 
permeates were further diluted for determination of pNP content by spectrophotometry at 410 nm and 316 
HPAEC-PAD analysis. 317 
 318 
 319 
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2.12 Accession numbers 320 
The complete nucleotide sequences of novel α-L-fucosidase encoding genes are available in GenBank 321 
under the following accession numbers: KJ626336 (mfuc1), KJ626337 (mfuc2), KJ626338 (mfuc3), 322 
KJ626339 (mfuc4), KJ626340 (mfuc5), KJ626341 (mfuc6), and KJ626342 (mfuc7). 323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
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3 Results 343 
3.1 Screening for α-L-fucosidases, subcloning and identification of gene sequences 344 
In this study a soil metagenomic library was used to screen for novel α-L-fucosidases. Of 345 
approximately 100.000 colonies screened using the chromogenic substrate 5-bromo-4-chloro-3-indolyl-346 
α-L-fucose (X-Fuc), α-L-fucosidase activity was detected in 40 clones. From these clones, fosmids 347 
were isolated and subjected to restriction analysis resulting in identification of 16 non-redundant 348 
clones.  Fosmid inserts of about 50 kb were digested with BamHI or PstI and the smaller restriction 349 
products were inserted in the vector pUC18 and screened on X-Fuc yielding 7 positive clones. After 350 
sequencing by Ion Torrent, subsequent annotation and ORF analysis revealed 9 contigs containing full-351 
length (5 contigs) or partial sequences of α-L-fucosidase genes. Analysis of the putative promoters and 352 
ribosomal binding sites allowed identification of translation starts and stops and missing sequences 353 
were determined by PCR using primers annealing up-  and downstream of each α-L-fucosidase gene. 354 
The 7 identified α-L-fucosidase-encoding genes were denoted mfuc1, 2, 3, 4, 5, 6 and 7. 355 
 356 
3.2 Sequence analysis 357 
An overview of the genes identified in this study is presented in Table 2. Based on BLAST analysis all 358 
enzymes, with exception of Mfuc3 showed sequence similarity with α-L-fucosidases with sequence 359 
identity to best hit ranging from 56-76 % (Table 2). Mfuc3 shares 41 % with the closest homolog 360 
identified by BlastX – β-galactosidase trimerisation domain-containing protein. It is also the least 361 
similar (32 % identity) when α-L-fucosidases reported in this work are compared (not shown). The 362 
genes had a GC-content ranging from 58.5 to 65.4 and most of the α-L-fucosidases had a theoretical 363 
molecular weight between 47.3 and 52.2 kDa while Mfuc3 was larger with a molecular weight of 75.6 364 
kDa. The sequences were analysed using the NCBI Conserved Domain software (35) and all sequences 365 
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except Mfuc3 were found to contain an α-L-fucosidase domain (pfam01120). Significant hits for 366 
Mfuc3 were to GHL6 (pfam14871) a family of hypothetical glycosyl hydrolases and to A4 beta-367 
galactosidase middle domain. Using the sequence-based annotation tool in the CAZYmes Analysis 368 
Toolkit (36), all identified enzymes, were classified in GH 29. Mfuc1-7 and some of the most 369 
established representatives of GH-29 family are presented in a phylogram (Figure 1). It has been shown 370 
that the catalytic nucleophile in GH-29 enzymes is a conserved aspartate residue (16). This residue was 371 
also identified in each of the α-L-fucosidases reported here by multiple alignment. 372 
 373 
3.3 Production of recombinant α-L-fucosidases in E. coli 374 
The seven metagenomic α-L-fucosidase genes were inserted in the pETM10 vector and were expressed 375 
in E. coli BL21(DE3) and C41(DE3). The highest yields of recombinant proteins as judged by SDS-376 
PAGE, were obtained for Mfuc1, 2 and 4 when expressed in E. coli BL21(DE3) and Mfuc3, 5, 6 and 7 377 
expressed in E. coli C41(DE3) (data not shown). SDS-PAGE of purified 6xHis-tagged α-L-fucosidases 378 
verified the expected size of enzymes (Figure 2). 379 
 380 
3.4 Termostability, pH optimum, and apparent kinetics of pNP-Fuc hydrolysis. 381 
Substantially, all the seven enzymes were able to hydrolyze the pNP-Fuc substrate. The specificity for 382 
hydrolysis of other non-fucose pNP-glycosides was also evaluated. However, none of the enzymes 383 
tested exhibited detectable activity. The physicochemical properties of the enzymes were characterized 384 
using pNP-Fuc as substrate. Most enzymes were active in a relatively broad pH ranges and exhibited 385 
maximum activity at pH 6-7 (Table 3). Mfuc6 hydrolyzed pNP-Fuc optimally at pH 9. Also the 386 
thermostability of the enzymes was tested and although some differences were observed, all enzymes 387 
had a half-life of less than 5 min at 60 °C and can be categorized as mesophilic. In contrast, the 388 
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benchmark enzyme from T. maritima had a half-life of about 48 min at 100 °C. The complete data sets 389 
recorded for each enzyme are shown in supplementary Figures S1 and S2. 390 
Next, we determined the dependence of initial reaction rate on the substrate concentration in the range 391 
from 0.1 to 5 mM of pNP-Fuc and found that the Km values ranged from 68 μM to 308 μM (Table 4). 392 
All enzymes except Mfuc6 exhibited some level of substrate inhibition with Ki values ranging between 393 
2.6 and 30.1 mM (Table 4; Figure S5). Interestingly, for Mfuc6 the substrate-saturation data was best 394 
modeled using an allosteric sigmoidal model, and the Hill coefficient of 0.40 indicates a negative 395 
cooperativity in substrate binding. 396 
 397 
3.5 Substrate specificity 398 
After characterizing the enzymes using the artificial substrate pNP-Fuc, we wanted to analyse the 399 
specificity towards various fucose-containing compounds of natural origin. First, we tested the activity 400 
of the enzymes towards two human milk fucose-oligosaccharides – 2’-FL and 3-FL  in which fucose is 401 
α(1-2)-linked to galactose and α(1-3)-linked to glucose, respectively (Table 4). The enzymes Mfuc3 402 
and 6 expressed no activity on these substrates. The other enzymes degraded 2’-FL, but only Mfuc5 403 
and to a lesser extent Mfuc1 and 7 were able to hydrolyze 3-FL. Xyloglucan extracted from citrus peel 404 
- containing 27 mg fucose/g was tested but only Mfuc5 exhibited substantial activity on this polymer 405 
and released 39 ± 2 % of total fucose (data not shown).  To further examine this observation, we used 406 
glycan arrays to investigate the activity on fucosylated xyloglucan originating from two flowering 407 
plants Arabidopsis thaliana and Sambucus nigra. The presence of fucose in these plant cell wall 408 
materials was monitored by binding of monoclonal antibody CCRC-M1 that is specific for fucose-409 
containing xyloglucan structures (37). Four enzymes, Mfuc1, 2, 4, and 5 were able to catalyse 410 
hydrolysis of fucosylated xyloglucans from the plants as shown by complete loss of CCRC-M1 411 
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antibody labelling (Figure 3). Less pronounced activity was observed for Mfuc7. As a control, binding 412 
of monoclonal antibody LM15 was shown to not be influenced by the action of the tested α-L-413 
fucosidases. This antibody is specific for xyloglucan epitopes XXX(G) and XLX(G)/XXL(G) that are 414 
not attacked by α-L-fucosidases (38, 39).  415 
Finally, we tested whether the enzymes were able to act on fucoidan from Fucus veniculosus, a 416 
polymer containing α(1-2)-linked sulphated fucose (40) and on tragacanth gum from Astragalus 417 
gossypinus a fucose-rich pectin-like structure where fucose is thought to be α(1-2)-linked to xylose side 418 
chains (41).. However none of the enzymes were able to release fucose from these polymers. 419 
 420 
3.6 Transfucosylation activity of metagenomic α-L-fucosidases  421 
For initial evaluation of transglycosylation properties we set up reactions using 20 mM pNP-Fuc as 422 
donor and 25 mM lactose as acceptor. The formation of transglycosylation products was evaluated by 423 
HPAEC-PAD and NMR. When evaluated using HPAEC-PAD Thma wild type and its L322P mutant 424 
produced 0,1 mM of 2’-FL that corresponds to 1 % yield based on donor substrate (Table 6). 425 
Production of 0,1mM of 3-FL was catalyzed by Mfuc5, corresponding to 1 % yield. The remaining 426 
enzymes produced no or lower amounts of FLs. Interestingly, other products were detected.  Three 427 
different self-condensation products were identified by NMR, corresponding to p-nitrophenyl α-L-428 
fucosyl-(1-2)-α-L-fucose as well as the (1-3)- and (1-4)-linked pNP-Fuc-Fuc glycosides (Figure 6). 429 
Linkage positions were determined by strong and unambiguous heteronuclear multiple bond 430 
correlations (HMBC) across the glycosidic bonds between the respective fucose residues, as well as 431 
from Fuc H1 to C1 of pNP. Nuclear Overhauser effect spectroscopy (NOESY) connectivities were used 432 
to confirm the structures. Selected NMR spectra and chemical shifts of compounds characterized in this 433 
study are collected in supplementary Figures S6 and S7. 2’-FL and 3-FL were present in insufficient 434 
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amounts for definitive confirmation by NMR. Due to very low yield we were not able to identify all of 435 
the products formed in the reaction that were detected by HPAEC-PAD (Figure 5). RP-HPLC 436 
separation of individual α-linked pNP-Fuc-Fuc compounds from reaction mixtures of Mfuc6 and 437 
Mfuc7 enabled the identification of the respective HPAEC-PAD peaks (Figure 5) by 1H NMR 438 
spectroscopy. Higher DP oligosaccharides were not detected when analyzing 1H NMR spectra. The 439 
concentrations of detected condensation products were estimated by comparison of characteristic non-440 
overlapping 1H NMR signals and these of fucose in each sample and are presented in Table 6. 441 
Predominantly, pNP-Fuc-(1-2)-Fuc was produced in the reaction catalyzed by Mfuc6 at 5.7 mM 442 
corresponding to a yield of 34 % based on the donor.  The total concentration of pNP-Fuc-Fuc products 443 
was in this case 6.8 mM. pNP-Fuc-(1-2)-Fuc was also the predominant self-condensation product and 444 
only Mfuc7 produced preferentially pNP-Fuc-(1-3)-Fuc.  445 
It has been demonstrated for other hydrolases that high concentration of acceptor can improve 446 
transglycosylation yields (42). We therefore set up reactions with a higher acceptor:donor ratio (100 447 
mM lactose as acceptor and 25 mM pNP-Fuc as donor) and followed the reactions in time course-448 
experiments (Figure 4 and S4). The transient maximum yield of 3-FL present in the reaction catalyzed 449 
by Mfuc5 was 0.9 mM whereas 1.6 mM of 2’-FL was produced in the reaction with Thma L322P. 450 
Throughout the course of the reaction catalyzed by Mfuc6, fucose concentration remained very low 451 
compared to concentration of pNP released. Formation of other products was observed, albeit not 452 
quantified due to lack of external standards.  453 
 454 
 455 
 456 
 457 
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4. Discussion 458 
4.1 Identification of novel α-L-fucosidases from metagenomic libraries 459 
This paper reports the identification and characterisation of seven novel α-L-fucosidases present in the 460 
soil metagenome with respect to both hydrolysis and transfucosylation.  461 
E. coli was used as a heterologous host for both functional screening of the metagenomic library and 462 
the expression of discovered genes. This imposes a bias towards prokaryotic genes compatible with E. 463 
coli transcription and translation machinery (43). Several solutions for enhancing the number of 464 
heterologously expressed genes in E. coli exist, but no universal way of expressing the full set of 465 
enzymatic activities from given metagenome has yet been proposed (44). A key element in a successful 466 
screening campaign is the choice of assay. It is a prerequisite that it allows high-throughput screening 467 
without compromising the selectivity and sensitivity towards the desired activity (45).  In contrast to 468 
several high throughput screens developed for glycosidases, assaying the transfer activity is extremely 469 
challenging as no obvious change in fluorescence or absorbance is associated with the reaction.  Thus, 470 
in this study we searched for enzymes with α-L-fucosidase activity and subsequently evaluated the 471 
possibility for transfucosylation using lactose as an acceptor. A similar approach has been applied for 472 
screening of mutagenesis libraries for enzymes with improved transfucosylation activity (25, 46). 473 
Evidently, α-L-fucosidases that do not act on X-Fuc or whose hydrolytic activity is minimal under the 474 
conditions in the E. coli cytoplasm may not be detected. Further, enzymes having a strong preference 475 
for trans-glycosylation with very limited hydrolase activities such as e.g. the trans-sialidase found in 476 
Trypanosoma cruzi (47) would likely not be identified by this approach. 477 
 478 
 479 
 480 
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4.2 Sequence analysis of novel α-L-fucosidases 481 
α-L-fucosidases are currently classified in the two glycoside hydrolase families GH-29 and GH-95. 482 
Based on amino acid sequence, all seven α-L-fucosidases reported in this work could be classified in 483 
the GH-29 family. This family uses an Asp as catalytic nucleophile that was also present in the seven 484 
new fucosidases. In T. maritima α-L-fucosidase, Glu 266 was identified as the general acid/base 485 
nucleophile (48). Despite structural conservation, this residue is not fully sequence-conserved in the 486 
GH29 family(49) and in agreement with this, only for a subset of the α-L-fucosidases, a Glu was found 487 
to align with Thma Glu266 in multiple sequence alignment. 488 
Recently, the GH-29 family was divided into two groups based on substrate specificity and 489 
phylogenetic clustering (50). According to this classification the α-L-fucosidases identified in this 490 
study belong to subfamily GH-29A. As observed in the phylogram with some of the best characterised 491 
representatives of this family (Figure 1), Mfuc1, 2, 4, 5, and 7 formed a new clade indicating relatively 492 
close evolutionary relationship. Mfuc3 was more distantly related to the other α-L-fucosidases. 493 
 494 
4.3 Hydrolase activity of novel α-L-fucosidases 495 
To characterise the enzymes, we tested their kinetic properties, as well as pH optimum and 496 
thermostability. Most of the enzymes were found to be substrate inhibited. In case of Mfuc6 the 497 
substrate-saturation data was best modeled using an allosteric sigmoidal model which suggests the 498 
presence of allosteric substrate-binding site, and the Hill coefficient of 0.394 indicated a negative 499 
cooperativity in substrate binding. Allosteric substrate binding was not reported for α-L-fucosidases 500 
before whereas the substrate inhibition behaviour with Michaelis-Menten kinetics is usually observed. 501 
When analyzing thermostability, it was observed that most enzymes were mesophilic, and for most 502 
enzymes pH optimum was in the range of pH 6-7. A number of characterized α-L-fucosidases also were 503 
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reported to have pH optimum in this range (51). In contrast Mfuc6 was most active at pH 9. According 504 
to the Brenda Enzyme database (52) containing 252 α-L-fucosidase entries at the time of writing, 505 
Mfuc6 have the highest pH optimum reported to date. 506 
To test the substrate specificity, we measured hydrolase activity on a variety of substrates. These 507 
included the two human milk oligosaccharides 2’-FL and 3-FL where fucose is α(1-2)-linked to 508 
galactose and α(1-3)-linked to glucose respectively. They were also tested on xyloglucan from 509 
Arabidopsis thaliana in which fucose is α(1-2)-linked to galactose (53) and xyloglucan from Sambucus 510 
niara. Most of the enzymes were able to degrade 2’-FL to various extents, whereas there appeared to be 511 
a correlation between sequence conservation and substrate specificity. In the phylogram, a clade 512 
consisting of Mfuc1, 2, 4, 5, and 7 was observed (Figure 1). Although with different efficiency these 513 
five enzymes were the only enzymes able to release fucose from 3-FL and xyloglucan. The ability of 514 
some α-L-fucosidases to catalyze such reactions has been demonstrated previously (54). Finally we 515 
tested the enzymes against fucoidan from Fucus veniculosus and tragacanth gum from Astragalus 516 
gossypinus but none of the enzymes were active on these substrates. Fucoidan is a fucose polymer with 517 
α(1-2)-linkage containing sulphate in the 4th position (3) and tragacanth gum contains fucose residues 518 
α(1-2)-linked to xylose side chains (41). So far, no enzymes have been reported to release fucose from 519 
tragacanth. In contrast, several α-L-fucosidases were reported to hydrolyze various fucoidan 520 
preparations (55).  521 
Although both Mfuc3 and 6 efficiently cleaved pNP-Fuc, they did not act on other substrates tested 522 
here. It remains to be determined what their native activity is. 523 
 524 
 525 
 526 
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4.4 Trans-α-L-fucosidase activity of novel α-L-fucosidases 527 
Due to the functional properties of fucosylated compounds, their specific synthesis is receiving 528 
increasing interest. Enzymatically, this can be done by employing α-L-fucosidases in transfucosylation 529 
reactions. 2’-FL and 3-FL are some of the dominant fucosylated/neutral oligosaccharides in human 530 
milk (56, 57) and have been shown to have specific biological functions. We therefore made a 531 
preliminary assessment of the potential of using the  metagenomic α-L-fucosidases for synthesis of 532 
these compounds. As a benchmark, we included one of the mutants of T. maritima α-L-fucosidase 533 
reported to exhibit increased transfucosylation activity (25). Using pNP-Fuc as donor and lactose as 534 
acceptor (acceptor:donor ratio 1.25) we analysed the samples by both HPAEC-PAD and 1H and 13C 535 
NMR spectroscopy. The transfucosylation products 2’-FL and 3-FL were observed by HPAEC-PAD 536 
analysis although they were present in insufficient amounts for definitive identification by NMR. 537 
Under the experimental conditions applied, the benchmark enzyme Thma wild type exhibited the 538 
highest capability for formation of 2’-FL and Mfuc5 for formation of 3-FL (Table 6). Since in most 539 
cases, the transfucosylation products are also substrates for the enzyme, it is paramount to control 540 
reaction time. Further, it has been demonstrated for some hydrolases that increasing the acceptor 541 
concentration can result in increased yields (per donor). We therefore used an acceptor:donor ratio of 4 542 
in a time course experiment and observed a maximum 2’-FL concentration of 1.5 mM, corresponding 543 
to 7.5 % yield based on substrate, when reaction was catalyzed by  Thma L322P (Figure 4). Thma 544 
L322P was reported to yield about 4-fold more transfucosylation product as compared to Thma wild 545 
type (25). When using higher acceptor concentration, this trend was confirmed also in this study, where 546 
Thma wildtype had a maximal transient yield of 4.5 % 2’-FL, that is 0.9 mM. α-L-fucosidases from 547 
various sources such as Alcaligenes sp. have been reported to catalyse transfucosylation with higher 548 
yields than reported here (42). However with the functional importance of e.g. FL it is surprising that in 549 
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most reported studies artificial acceptor molecules such as various pNP-glycosides have been used. In 550 
fact is has been observed for most glycosidases, including α-L-fucosidases, that the +2 acceptor binding 551 
site exhibits a  preference for pNP or an aromatic aglycon part likely related to a high density of 552 
aromatic residues (25). In one study (42), lactose was used as acceptor in reactions with porcine and 553 
Alcaligenes sp. α-L-fucosidase. With a yield of 34 %, Alcaligenes sp. α-L-fucosidase was able to 554 
fucosylate lactose to produce 3’-FL. In contrast, we here demonstrated the use of α-L-fucosidases to 555 
synthesize the basic human milk fuco-oligosaccharides 2’-FL and 3-FL.  556 
It was previously shown that many glycosidases are able to produce tranglycosylation products using 557 
the same molecule as donor and acceptor, leading to formation of self-condensation products (i.e., 558 
disaccharides linked to a nitrophenyl group). By NMR analysis it was concluded that all the α-L-559 
fucosidases made self-condensation products to various degrees. Three different pNP-Fuc-Fuc products 560 
were identified, corresponding to p-nitrophenyl α-L-fucosyl-(1-2)-α-L-fucose as well as the α(1-3)- and 561 
α(1-4)-linked pNP-Fuc-Fuc glycosides. Literature data for the (1-2)- and (1-4)-linked glycosides by 562 
Benešová et al. (58) were comparable to our observation, however with minor discrepancies on the 563 
chemical shift values, which may result from pH effects. Osanjo et al. reported NMR data for the (1-3)-564 
linked glycoside in pyridine-d5 (25). Mfuc6 that was unable to hydrolyze any of the substrates tested in 565 
this study, did not produce FL but demonstrated the highest yield of self-condensation products 566 
(33.7 %). For Thma the main self-condensation product was reported to be pNP-Fuc-(1-3)-Fuc (25), 567 
whereas under our experimental conditions we observed mainly the formation of α(1-2)- linkages. This 568 
discrepancy might be due to difference in reaction conditions. This indicates that careful selection of 569 
transfucosylation reaction conditions might be a route to modulate regioselectivity.  570 
Attention was not paid to the optimization of yields and therefore strategies such as addition of organic 571 
solvents, optimization of acceptor:donor ratio, enzyme load or ionic strength may lead to significant 572 
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improvement in the yields of the final products during transglycosylation reaction (59, 60).  573 
 574 
4.5 Concluding remarks 575 
In conclusion, our results further substantiate that functional mining of metagenome can lead to 576 
successful discovery of diverse glycoside hydrolases, specifically α-L-fucosidases. Using recombinant 577 
enzymes under experimental conditions applied we were able to perform the synthesis of fucosyllactose 578 
and cleave fucose from various plant polymer structures. Results obtained in this study cannot be 579 
directly applicable for efficient synthesis of fucosylated oligosaccharides. Biocatalysts discovered in 580 
this work, however, constitute a good starting point for further enzyme and reaction engineering 581 
towards this goal. 582 
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Tables 756 
Table 1. 757 
Name Sequence Restriction site 
mfuc1_fw TAGCGGTCTCACATGTTGAAACCCAAACCGACCACC  BsaI 
mfuc1_rv TAGCGGATCCTTACTTCAAAGTCAACTCAATCACC BamHI 
mfuc2_fw TAGCGGTCTCACATGCAACACCAAGCGGCAG BsaI 
mfuc2_rv TAGCGGATCCTTACTTCAGGAACAGCTCGATCACTG BamHI 
mfuc3_fw TAGCGGTCTCACATGGAAACACTTCCCTTTAGACAGGTC BsaI 
mfuc3_rv TAGCGGATCCTTATTCTCTAGCGGCGCCCTG BamHI 
mfuc4_fw TAGCGGTCTCACATGTACACACCCAAACCGACGC BsaI 
mfuc4_rv TAGCGAATTCCTACTCTTTCAGCTCCAGCTCGATG EcoRI 
mfuc5_fw TAGCGGTCTCACATGAATAACGATCGAATGCAGTGG BsaI 
mfuc5_rv TAGCGAATTCTCATTTCAACACCAGCTCCACG EcoRI 
mfuc6_fw TAGCGGTCTCACATGAAAAAAACCAACACCTGGTTCG BsaI 
mfuc6_rv TAGCGAATTCTCAAGCCACGTCGATCGC EcoRI 
mfuc7_fw TAGCGAAGACACCATGACAAGCTATGTGACCCGCAAAAC BbsI 
mfuc7_rv TAGCGAATTCTTACTTCAGAAAAAGCTCAATGACCG EcoRI 
Thma_fw ATCGGGTCTCCCATGATTTCAATGAAACCGCGTTATAAACC BsaI 
Thma_rv 
L322P_fw 
L322P_rv 
CGGGGTACCTTATTCCTCGACTGCTTCCAGAACC 
CGGAAATCTGTTGCTGAATGTTGGACCGAAAGGC 
CAACATTCAGCAACAGATTTCCGCCTTTGCTAAC 
KpnI 
 
 
 758 
 759 
  760 
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Table 2. 761 
  Gene names nt .length GC content Identity (similarity, %) Best hit (accession no.) Organism name (best hit) 
 
mfuc1 
1281 58.5 % 67 (81) α-L-fucosidase (YP_001278245) Roseiflexus sp. RS-1 
mfuc2 1290 65.4 % 73 (83) α-L-fucosidase (YP_003323631.1|) Thermobaculum terrenum 
mfuc3 2025 60.6 % 41 (57) 
beta-galactosidase trimerisation domain-
containing protein YP_004464268.1| 
Mahella australiensis 
mfuc4 1287 61.3 % 70 (81) α-L-fucosidase (YP_001278245) Roseiflexus sp. RS-1 
mfuc5 1260 60.4 % 74 (85) Putative α-L-fucosidase YP_004173881.1 Anaerolinea thermophila 
mfuc6 1251 65.4 % 65 (81) α-L-fucosidase YP_007147579.1| Cylindrospermum stagnale 
mfuc7 1323 60.7 % 76 (86) α-L-fucosidase WP_009252575.1| Lachnospiraceae bacterium 
 762 
 763 
 764 
Table 3. 765 
 Mfuc1 Mfuc2 Mfuc3 Mfuc4 Mfuc5 Mfuc6 Mfuc7 Thma WT 
 
pH opt 7 7 6 7 7 9 6 7 1 
pH interval 2 6-9 6-10 6-8 6-9 5-8 6-10 6-7 4-9 
Temperature stability, T1/2         
30 °C > 2 h > 2 h > 2 h > 2 h > 2 h > 2 h ~98 min > 2 h 
40 °C > 2 h > 2 h > 2 h > 2 h > 2 h ~56 min ~28 min > 2 h 
50 °C > 2 h ~9 min ~67 min > 2 h < 2 min ~14 min ~8 min > 2 h 
60 °C < 2 min < 2 min ~4 min < 2 min < 2 min < 2 min < 2 min > 2 h 
70 °C ND ND ND ND ND ND ND > 2 h 
90 °C ND ND ND ND ND ND ND > 2 h 
100 °C ND ND ND ND ND ND ND ~48 min 
 766 
 767 
768 
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Table 4. 769 
 Mfuc1 Mfuc2 Mfuc3 Mfuc4 Mfuc5 Mfuc7 TmαFuc L322P  Mfuc6   
 
Vmax 1.6±0.0 2.3 ±0.081 1.6 ±0.090 0.77±0.017 1.9 ±0.04 2.2 ±0.16 0.67 ±0.02 0.47 ±0.01 Vmax 0.56 ±0.05 
  
Km 0.11±0.01 0.14 ±0.01 0.31 ±0.03 0.071 ±0.01 0.13 ±0.01 0.28 ±0.05 0.06 ±0.01 0.07 ±0.01 H 0.40 ±0.05   
Ki 7.1±0.6 7.1 ±0.9 2.6 ±0.3 30 ±6.8 12±1.2 12 ±3.4 22 ±4.9 32±9.5 Kprime 0.74±0.16   
 770 
 771 
Table 5. 772 
 Mfuc1 Mfuc2 Mfuc3 Mfuc4 Mfuc5 Mfuc6 Mfuc7 Thma WT 
2’-FL 76 ±1 % 88±1 % 2 ±1 % 47±1 % 87±1 % 2 ±2 % 94±1 % 71±1 % 
3-FL 11 ±2 % 4±2 % 0 ±2 % 3 ±2 % 34 ±3 % 0 ±2 % 12 ±2 % 1 ±2 % 
 773 
 774 
Table 6. 775 
Amount (mM)  
 pNP-Fuc-( 1-2)-α-L-fuc* 
Enzyme pNP-Fuc* fuc 2’-FL 3-FL α( 1-2) α( 1-3) α( 1-4) 
Mfuc1 0.1 20.3 0.0 0.1 0.1 0.0 0.0 
Mfuc2 0.1 17.9 0.1 0.1 0.6 0.0 0.0 
Mfuc3 0.0 18.3 0.0 0.0 0.1 0.0 0.0 
Mfuc4 0.4 18.3 0.0 0.0 0.2 0.0 0.0 
Mfuc5 0.5 12.9 0.0 0.2 0.5 0.2 0.0 
Mfuc6 1.2 7.3 0.0 0.0 5.7 0.3 0.8 
Mfuc7 4.6 12.3 0.0 0.0 1.2 2.0 0.0 
Thma 1.0 13.9 0.2 0.0 3.4 0.1 0.1 
L322P 1.3 13.0 0.1 0.0 3.1 0.0 0.1 
 776 
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Figures  777 
Figure 1. 778 
 779 
 780 
Figure 2 781 
 782 
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Figure 3.  783 
 784 
 785 
 786 
Figure 4.  787 
 788 
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 Figure 5.  789 
 790 
 791 
Figure 6.  792 
 793 
  794 
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Table legends 795 
Table 1.  List of primers used for amplification of α-L-fucosidase-encoding genes. Restriction sites are 796 
underlined, start and stop codons are indicated in bold, and mutagenic codon in bold and underlined.  797 
Table  2. Properties of E. coli functional α-L-fucosidase genes identified from soil metagenomic library 798 
Table 3. Properties of α-L-fucosidases derived from metagenomic library screening as well as α-L-fucosidase 799 
from Thermotoga maritima. 800 
1
 pH optimum was measured with 0.1 and 1 mM substrate; for Thma two optima (pH 4 and 7) were observed 801 
with 1 mM substrate. 802 
2
 pH  interval where enzymes displayed more than 20 % of maximal enzyme activity. 803 
Table 4. Kinetic parameters of pNP-α-Fuc hydrolysis with metagenomic α-L-fucosidases at 30 °C and optimal 804 
pH as determined for pNP-Fuc. Kinetic constants were determined from the time-dependent release of pNP at 805 
405 nm. Kinetic data for Mfuc6 were fitted using allosteric model (Y=Vmax*X
h/(Kprime + X
h)) and the data for 806 
remaining enzymes with substrate inhibiton model Y=Vmax*X/(Km + X*(1+X/Ki (61). Kprime is related to but 807 
not equal to Km. h is the Hill slope indicating the measure of cooperativity in substrate binding. 808 
Table 5. Demonstration of hydrolytic regiospecificity of metagenome-derived α-L-fucosidases. The numbers 809 
represent the percentage of 1 mM initial substrate hydrolysed with 10μg of α-L-fucosidase within 150 min at 30 810 
°C at optimal pH (50 mM phosphate-citrate buffer or glycine-NaOH for Mfuc6). 811 
Table  6. Concentrations (mM) of substrates and products as determined using HPAEC-PAD and NMR. 812 
*Concentrations (mM) estimated by comparison of characteristic non-overlapping 1H NMR signals and that of 813 
L-fucose. L-Fucose concentration in each sample was determined by HPAEC-PAD 814 
 815 
 816 
Figure legends 817 
Figure 1.  A phylogenetic analysis of discovered α-L-fucosidase sequences and selected representatives of GH-818 
29 family.  Neighbor-Joining method (62) was used to infer the phylogeny and evolutionary analyses were 819 
 42 
 
conducted in MEGA6 (63). All positions containing gaps and missing data were eliminated. There were a total 820 
of 136 AA positions in the alignment. The percentage of replicate trees in which the associated taxa clustered 821 
together in the bootstrap test (1000 replicates) are shown next to the branches (64).  822 
Figure 2.  SDS-PAGE of metagenome-derived (lanes 2-8) and benchmark α-L-fucosidases (lanes 9-10), all 823 
expressed in E. coli and purified by IMAC. Marker – lane 1. 824 
Figure 3. Release of fucose from xyloglucans of selected plant species by α-L-fucosidases. As a control, 825 
xyloglucan was measured with the antiobody LM15, while fucosylated xyloglucan was measured using the 826 
antibody CCRC-M1. 827 
Figure 4. Time course concentrations of L-fucose (squares), pNP (circles), pNP-Fuc (triangles facing down), 3-828 
FL (diamonds), 2’-FL (triangles) in the transfucosylation reactions catalyzed by Mfuc5, and 6 as well as Thma 829 
wild type and L322P mutant. Reactions were done using 25 mM pNP-Fuc as donor and 100 mM lactose as 830 
acceptor at 30 °C and optimal pH.  831 
Figure 5. HPAEC analysis of transfucosylation catalyzed with Mfuc5. The identity of pNP-Fuc-Fuc compounds 832 
was successfully determined after reverse phase mode separation into individual fractions and annotation by 833 
NMR and HPAEC-PAD. 834 
Figure 6. Transglycosylation reactions catalyzed by tested metagenomic α-L-fucosidases and α-L-fucosidase 835 
from T. maritima. Additionally to hydrolysis products: L-fucose and 4-nitrophenol, the formation of self-836 
condensation products 1: pNP-Fuc-(1-2)-Fuc, 2: pNP-Fuc-(1-3)-Fuc, 3: pNP-Fuc-(1-4)-Fuc and fucosyllactoses 837 
was catalyzed by α-L-fucosidases to various degree. 838 
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Figure S1. pH optimum for metagenomic fucosidases. The activity of the enzymes was tested at indicated pH and initial 
reaction rates were measured. The buffers used were 50 mM of phosphate-citrate (pH 3-8; blue diamonds), tricine (pH 8-9; 
red squares); glycylglycine (pH 8-9; green triangles), and glycine-NaOH (pH 9-10; purple crosses). Enzyme concentrations 
used in assays with 0.1 mM substrate were as follows: 0,2 μg/mL Mfuc1, 0,2 μg/mL Mfuc2, 0,6 μg/mL Mfuc3, 0,3 μg/mL 
Mfuc4, 0,2 μg/mL Mfuc5, 1,0 μg/mL Mfuc6, 0,2 μg/mL Mfuc7, 0,3 μg/mL Thma fucosidase, 0,5 μg/mL Thma L322P. With 
exception of Mfuc2, the double concentration of enzyme was used in assays with 1 mM substrate. All reactions were done at 
30 °C. 
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Figure S2. Thermostability of metagenomic fucosidases. The enzymes were diluted in a 5 mM pH buffer 
reflecting pH optimum and incubated at indicated temperatures and periods of time after which residual activity 
was measured in a continuous assay at pH 7 at 30 °C. Enzyme concentrations used in assays with 0.1 mM 
substrate were as follows: 0.8 μg/mL Mfuc1, 0.4 μg/mL Mfuc2, 1.2 μg/mL Mfuc3, 0.9 μg/mL Mfuc4, 0.7 μg/mL 
Mfuc5, 3.9 μg/mL Mfuc6, 0.5 μg/mL Mfuc7, 0.9 μg/mL Thma fucosidase, 1.5 μg/mL Thma L322P Activities were 
normalized on basis of enzyme activity with no heat treatment.  
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>Thma_Bsopt 
ATGATTTCAATGAAACCGCGTTATAAACCGGATTGGGAATCACTGAGAGAACATACAGTTCCGAAATGGTTTG
ATAAAGCGAAATTTGGCATTTTTATCCATTGGGGCATCTATTCAGTTCCGGGATGGGCAACACCGACAGGCGA
ACTGGGCAAAGTTCCGATGGATGCATGGTTTTTTCAAAATCCGTATGCGGAATGGTATGAAAATAGCCTGCGC
ATTAAAGAATCACCGACATGGGAATATCATGTCAAAACATATGGCGAAAACTTTGAATATGAAAAATTTGCGG
ATCTTTTTACAGCGGAAAAATGGGATCCGCAAGAATGGGCAGATTTGTTCAAAAAAGCAGGCGCAAAATATGT
CATCCCGACAACAAAACATCATGATGGCTTTTGCCTGTGGGGCACGAAGTATACAGATTTTAACAGCGTCAAA
CGCGGACCGAAAAGAGATCTGGTTGGCGATCTGGCAAAAGCAGTTAGAGAAGCAGGCCTGAGATTTGGCGTCT
ATTATTCAGGCGGACTGGATTGGAGATTTACAACAGAACCGATTCGCTATCCGGAAGATCTGTCATATATTAG
ACCGAACACATATGAATATGCGGATTATGCGTATAAACAGGTTATGGAACTGGTCGATCTGTATCTGCCGGAT
GTTCTGTGGAATGATATGGGCTGGCCTGAAAAAGGCAAAGAAGATCTGAAATATCTTTTTGCGTATTACTATA
ACAAACATCCGGAAGGCAGCGTCAATGATAGATGGGGAGTTCCGCATTGGGATTTCAAAACAGCAGAATATCA
TGTGAACTATCCTGGCGATCTTCCGGGATATAAATGGGAATTTACAAGAGGCATTGGCCTTAGCTTTGGCTAT
AATAGAAATGAAGGACCGGAACATATGCTGTCAGTTGAACAACTGGTTTATACACTGGTTGATGTTGTTAGCA
AAGGCGGAAATCTGCTGCTGAATGTTGGACCGAAAGGCGATGGCACAATTCCGGATCTGCAAAAAGAAAGACT
GCTGGGCCTGGGCGAATGGCTGAGAAAATATGGAGATGCAATTTATGGCACAAGCGTTTGGGAAAGATGCTGC
GCAAAAACAGAAGATGGCACAGAAATTCGCTTTACAAGAAAATGCAACCGCATTTTTGTCATCTTTCTGGGCA
TTCCTACAGGCGAAAAAATTGTTATTGAAGATCTTAATCTGAGCGCAGGCACAGTTCGCCATTTTCTGACAGG
CGAAAGACTGAGCTTTAAAAACGTTGGCAAAAACCTGGAAATCACGGTTCCGAAAAAACTGCTGGAAACGGAT
TCAATTACACTGGTTCTGGAAGCAGTCGAGGAA 
 
 
Figure S3. Sequence of E. coli codon optimized sequence of Thermotoga maritima α-L-fucosidase gene used in 
this study 
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Figure S4. Time course of reactions catalyzed by metagenome-derived fucosidases where 25mM of pNP-α-L-
fucose was used as donor and 100mM of lactose as acceptor. L-fucose (squares), pNP (circles), pNP-Fuc (triangles 
facing down), 3-FL (diamonds), 2’-FL (triangles). 
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Figure S5. Substrate saturation curves for metagenomic fucosidases along with non-linear regression fits with 
sigmoidal allosteric (Mfuc8; Y=Vmax*X
h/(Kprime + X
h)) and substrate inhibiton (all except Mfuc6, 
Y=Vmax*X/(Km + X*(1+X/Ki))) model. The various enzymes were assayed at 30 °C at their identified optimum 
pH. In case of of Thma WT, the optimum pH was 7 at 0.1 mM pNP-Fuc while two optima (pH 4 and 7) were 
observed at 1 mM pNP-Fuc, consequently substrate saturation was tested at both pH.  Enzyme concentrations 
used were as follows: 0.2 μg/mL Mfuc1, 0.03 μg/mL Mfuc2, 0.6 μg/mL Mfuc3, 0.3 μg/mL Mfuc4, 0.2 μg/mL 
Mfuc5, 1.0 μg/mL Mfuc6, 0.2 μg/mL Mfuc7, 0.3 μg/mL Thma fucosidase, 0.5 μg/mL Thma L322P The 
concentrations pf pNP-Fuc tested were 0.1, 0.25, 0.5, 1.0, 2.5, and 5.0 mM 
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Figure S6. Selected 1H NMR spectra acquired in this study 
 
 
 
Figure 6.1. 1H NMR spectrum (D2O, 400 MHz) of p-nitrophenyl α-L-fucose.  
 
Figure 6.1. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc1 enzyme with 
 12 
 
expansion of the α-anomeric region.  
 
 
Figure 6.2. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc2 enzyme with 
expansion of the α-anomeric region.  
 
Figure 6.3. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc3 enzyme with 
expansion of the α-anomeric region.  
 
 13 
 
 
Figure 6.4. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc4 enzyme with 
expansion of the α-anomeric region.  
 
 
Figure 5.6. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc5 enzyme with 
expansion of the α-anomeric region.  
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Figure 6.6. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc6 enzyme with 
expansion of the α-anomeric region. The residual solvent signal was removed by presaturation. 
 
 
Figure 6.7. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by Mfuc7 enzyme with 
expansion of the α-anomeric region. The residual solvent signal was removed by presaturation. 
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Figure 6.8. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by T. maritima wildtype 
enzyme with expansion of the α-anomeric region.  
 
 
Figure 6.9. 1H NMR spectrum (D2O, 500 MHz) of post-enzymatic reaction mixture by the T. maritima L322P 
enzyme with expansion of the α-anomeric region. 
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Figure  6.10. 1H NMR spectra (D2O, 400 MHz) of individual self-condensation products separated by HPLC and 
comparison with products of selected enzymatic reactions. From the top: p-nitrophenyl α-L-fucosyl-(1-4)-α-L-
fucose, p-nitrophenyl α-L-fucosyl-(1-3)-α-L-fucose, p-nitrophenyl α-L-fucosyl-(1-2)-α-L-fucose, reaction 
catalyzed by Mfuc7, and reaction catalyzed by Mfuc6. The residual solvent signals were (partially) removed by 
presaturation.  
 
 
 
p-nitrophenyl α-L-fucosyl-(1-2)-α-L-fucose 
1H NMR: δ 8.26 (d, 2H, J = 8.8 Hz, H3’’), 7.28 (d, 2H, J = 8.8 Hz, H2’’), 5.84 (d, 1H, J = 2.8 Hz, 
H1), 5.11 (d, 1H, J = 3.9 Hz, H1’), 4.34 (br. q, 1H, J = 6.5 Hz, H5’), 4.14 (m, 1H, H2),4.13 (m, 1H, 
H5), 4.11 (m, 1H, H3), 4.08 (m, 1H, H4), 3.97 (dd, 1H, J = 3.5 Hz, 10.5 Hz, H3’), 3.83 (m, 1H, 
H4’), 3.82 (m, 1H, H2’), 1.23 (d, 3H, J = 6.5 Hz, H6’), 1.15 (d, 3H, J = 6.7 Hz, H6). 13C NMR 
derived from gHSQC and gHMBC: δ 162.2 (C1’’), 143.0 (C4’’), 126.9 (2*C3’’), 117.6 (2*C2’’), 
97.6 (C1), 96.3 (C1’), 75.3 (C2), 72.7 (C4’), 70.3 (C3’), 68.7 (C4), 68.8 (C2’), 68.6 (C3), 67.9 
(C5’), 66.7 (C5), 16.3 (C6’), 16.2 (C6). 
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p-nitrophenyl α-L-fucosyl-(1-3)-α-L-fucose 
1H NMR: δ 8.26 (d, 2H, J = 9.0 Hz, H3’’), 7.28 (d, 2H, J = 9.0 Hz, H2’’), 5.98 (d, 1H, J = 3.5 Hz, 
H1), 5.04 (d, 1H, J = 4.0 Hz, H1’), 4.28 (br. q, 1H, J = 6.7 Hz, H5’), 4.21 (dd, 1H, J = 3.4 Hz, 10.4 
Hz, H3), 4.14 (br. q, 1H, J = 6.7 Hz, H5), 4.04 (dd, 1H, J = 3.5 Hz, 10.4 Hz, H2), 3.92 (m, 1H, 
H3’), 3.91 (m, 1H, H4), 3.80 (br. d, 1H, J = 3.3 Hz, H4’), 3.72 (dd, 1H, J = 4.0 Hz, 10.2 Hz, H2’), 
1.21 (d, 3H, J = 6.7 Hz, H6’), 1.15 (d, 3H, J = 6.7 Hz, H6). 13C NMR derived from gHSQC and 
gHMBC: δ 162.5 (C1’’), 143.2 (C4’’), 126.9 (2*C3’’), 117.7 (2*C2’’), 97.0 (C1’), 95.1 (C1), 72.7 
(C2), 72.5 (C4), 72.3 (C4’), 70.1 (C3’), 68.8 (C3), 68.6 (C2’), 67.9 (C5’), 66.7 (C5), 16.3 (C6’), 
16.1 (C6). 
p-nitrophenyl α-L-fucosyl-(1-4)-α-L-fucose 
1H NMR: δ 8.26 (d, 2H, J = 9.2 Hz, H3’’), 7.27 (d, 2H, J = 9.2 Hz, H2’’), 5.83 (d, 1H, J = 3.9 Hz, 
H1), 4.95 (d, 1H, J = 4.0 Hz, H1’), 4.54 (br. q, 1H, J = 6.6 Hz, H5), 4.20 (m, 1H, H3), 4.18 (m, 1H, 
H5’), 4.04 (dd, 1H, J = 3.9 Hz, 10.6 Hz, H2), 3.94 (dd, 1H, J = 3.0 Hz, 10.8 Hz, H3’), 3.90 (br. d, 
1H, J = 3.0 Hz, H4’), 3.83 (br. d, 1H, J = 3.0 Hz, H4), 3.80 (dd, 1H, J = 4.0 Hz, 10.8 Hz, H2’), 1.23 
(d, 3H, J ~ 7 Hz, H6’), 1.17 (d, 3H, J = 6.6 Hz, H6). 13C NMR derived from gHSQC and gHMBC: 
δ 162.3 (C1’’), 143.1 (C4’’), 126.8 (2*C3’’), 117.6 (2*C2’’), 101.3 (C1’), 97.7 (C1), 80.5 (C4’), 
70.2 (C3’), 69.7 (C3), 69.5 (C2’), 69.5 (C5’), 68.8 (C4), 68.4 (C2), 67.7 (C5), 16.2 (C6’), 16.2 (C6). 
 
Figure 7. NMR chemical shifts of selected compounds characterized in this study. 
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Figure 8. Comparison of 1H NMR integrals for reaction mixtures of the different enzymes. Representative 
integrals of selected molecules were used to compare relative amounts within the NMR samples. For all samples 
the Gal anomeric resonance in lactose was calibrated to 1, which enables some comparison between samples, 
however with relatively high uncertainty. Anomeric resonances were used for integration. For the pNP-Fuc-Fuc 
products (1-2-, 1-3-, and 1-4-linked) the anomeric signal at the reducing end was used, for Fuc, the α- and β-
anomeric resonances were added together.  
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